
<html lang="en"     class="pb-page"  data-request-id="904100cb-03ab-4d88-86be-27b263a2e1aa"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.0c01882;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-7;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion" /></meta><meta name="dc.Creator" content="G. Stuart  Cockerill" /></meta><meta name="dc.Creator" content="Richard M.  Angell" /></meta><meta name="dc.Creator" content="Alexandre  Bedernjak" /></meta><meta name="dc.Creator" content="Irina  Chuckowree" /></meta><meta name="dc.Creator" content="Ian  Fraser" /></meta><meta name="dc.Creator" content="Jose  Gascon-Simorte" /></meta><meta name="dc.Creator" content="Morgan S. A.  Gilman" /></meta><meta name="dc.Creator" content="James A. D.  Good" /></meta><meta name="dc.Creator" content="Rachel  Harland" /></meta><meta name="dc.Creator" content="Sara M.  Johnson" /></meta><meta name="dc.Creator" content="John H  Ludes-Meyers" /></meta><meta name="dc.Creator" content="Edward  Littler" /></meta><meta name="dc.Creator" content="James  Lumley" /></meta><meta name="dc.Creator" content="Graham  Lunn" /></meta><meta name="dc.Creator" content="Neil  Mathews" /></meta><meta name="dc.Creator" content="Jason S.  McLellan" /></meta><meta name="dc.Creator" content="Michael  Paradowski" /></meta><meta name="dc.Creator" content="Mark E.  Peeples" /></meta><meta name="dc.Creator" content="Claire  Scott" /></meta><meta name="dc.Creator" content="Dereck  Tait" /></meta><meta name="dc.Creator" content="Geraldine  Taylor" /></meta><meta name="dc.Creator" content="Michelle  Thom" /></meta><meta name="dc.Creator" content="Elaine  Thomas" /></meta><meta name="dc.Creator" content="Carol  Villalonga Barber" /></meta><meta name="dc.Creator" content="Simon E.  Ward" /></meta><meta name="dc.Creator" content="Daniel  Watterson" /></meta><meta name="dc.Creator" content="Gareth  Williams" /></meta><meta name="dc.Creator" content="Paul  Young" /></meta><meta name="dc.Creator" content="Kenneth  Powell" /></meta><meta name="dc.Description" content="RV521 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was identified after a lead optimization process based upon hits that originated from a physical property ..." /></meta><meta name="Description" content="RV521 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was identified after a lead optimization process based upon hits that originated from a physical property ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 17, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01882" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01882" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01882" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01882" /></link>
        
    
    

<title>Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01882" /></meta><meta property="og:title" content="Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0023.jpeg" /></meta><meta property="og:description" content="RV521 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was identified after a lead optimization process based upon hits that originated from a physical property directed hit profiling exercise at Reviral. This exercise encompassed collaborations with a number of contract organizations with collaborative medicinal chemistry and virology during the optimization phase in addition to those utilized as the compound proceeded through preclinical and clinical evaluation. RV521 exhibited a mean IC50 of 1.2 nM against a panel of RSV A and B laboratory strains and clinical isolates with antiviral efficacy in the Balb/C mouse model of RSV infection. Oral bioavailability in preclinical species ranged from 42 to &gt;100% with evidence of highly efficient penetration into lung tissue. In healthy adult human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a significant reduction in viral load and symptoms compared to placebo." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01882"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01882">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-8/abseba.2021.7.issue-8/20210809/abseba.2021.7.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-15/accacs.2021.11.issue-15/20210806/accacs.2021.11.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-31/acsodf.2021.6.issue-31/20210810/acsodf.2021.6.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-31/ascecg.2021.9.issue-31/20210809/ascecg.2021.9.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-31/ancham.2021.93.issue-31/20210810/ancham.2021.93.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-31/bichaw.2021.60.issue-31/20210810/bichaw.2021.60.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-8/bomaf6.2021.22.issue-8/20210809/bomaf6.2021.22.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-29/cgeabj.2021.99.issue-29/20210809-01/cgeabj.2021.99.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-15/cmatex.2021.33.issue-15/20210810/cmatex.2021.33.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-15/enfuem.2021.35.issue-15/20210805/enfuem.2021.35.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-8/estlcu.2021.8.issue-8/20210810/estlcu.2021.8.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-8/jceda8.2021.98.issue-8/20210810/jceda8.2021.98.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-8/jctcce.2021.17.issue-8/20210810/jctcce.2021.17.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-15/joceah.2021.86.issue-15/20210806/joceah.2021.86.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-30/jpcafh.2021.125.issue-30/20210805/jpcafh.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-30/jpcbfk.2021.125.issue-30/20210805/jpcbfk.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-30/jpccck.2021.125.issue-30/20210805/jpccck.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-30/jpclcd.2021.12.issue-30/20210805/jpclcd.2021.12.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-8/jprobs.2021.20.issue-8/20210806/jprobs.2021.20.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-31/langd5.2021.37.issue-31/20210810/langd5.2021.37.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-15/mamobx.2021.54.issue-15/20210810/mamobx.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-15/orlef7.2021.23.issue-15/20210806/orlef7.2021.23.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-15/orgnd7.2021.40.issue-15/20210809/orgnd7.2021.40.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01882&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01882&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01882&amp;href=/doi/10.1021/acs.jmedchem.0c01882" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3658-3676</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00208" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.0c01826" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">G. Stuart Cockerill</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">G. Stuart Cockerill</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Reviral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +44 (0) 1740 625250; Email: <a href="/cdn-cgi/l/email-protection#ee9d8d818d858b9c878282ae9c8b98879c8f82c08d81c09b85"><span class="__cf_email__" data-cfemail="84f7e7ebe7efe1f6ede8e8c4f6e1f2edf6e5e8aae7ebaaf1ef">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=G.+Stuart++Cockerill">G. Stuart Cockerill</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6340-0808" title="Orcid link">http://orcid.org/0000-0002-6340-0808</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard M. Angell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard M. Angell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sussex Drug Discovery Centre, University of Sussex, Brighton, England BN1 9QJ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard+M.++Angell">Richard M. Angell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alexandre Bedernjak</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alexandre Bedernjak</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Reviral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alexandre++Bedernjak">Alexandre Bedernjak</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Irina Chuckowree</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Irina Chuckowree</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sussex Drug Discovery Centre, University of Sussex, Brighton, England BN1 9QJ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Irina++Chuckowree">Irina Chuckowree</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ian Fraser</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ian Fraser</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Reviral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ian++Fraser">Ian Fraser</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jose Gascon-Simorte</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jose Gascon-Simorte</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sussex Drug Discovery Centre, University of Sussex, Brighton, England BN1 9QJ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jose++Gascon-Simorte">Jose Gascon-Simorte</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Morgan S. A. Gilman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Morgan S. A. Gilman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas 78712, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Morgan+S.+A.++Gilman">Morgan S. A. Gilman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James A. D. Good</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James A. D. Good</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Reviral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+A.+D.++Good">James A. D. Good</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rachel Harland</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rachel Harland</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Reviral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rachel++Harland">Rachel Harland</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sara M. Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sara M. Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Vaccines and Immunity, The Research Institute at Nationwide Children’s Hospital, and Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio 43205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sara+M.++Johnson">Sara M. Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John H Ludes-Meyers</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John H Ludes-Meyers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas 78712, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+H++Ludes-Meyers">John H Ludes-Meyers</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Edward Littler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Edward Littler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Reviral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Edward++Littler">Edward Littler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James Lumley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James Lumley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Reviral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++Lumley">James Lumley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Graham Lunn</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Graham Lunn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sussex Drug Discovery Centre, University of Sussex, Brighton, England BN1 9QJ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Graham++Lunn">Graham Lunn</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Neil Mathews</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neil Mathews</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Reviral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neil++Mathews">Neil Mathews</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason S. McLellan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason S. McLellan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas 78712, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason+S.++McLellan">Jason S. McLellan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Paradowski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Paradowski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicines Discovery Institute, Cardiff University, Cardiff, Wales CF10 3AT, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Paradowski">Michael Paradowski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark E. Peeples</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark E. Peeples</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Vaccines and Immunity, The Research Institute at Nationwide Children’s Hospital, and Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio 43205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark+E.++Peeples">Mark E. Peeples</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Claire Scott</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Claire Scott</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Reviral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Claire++Scott">Claire Scott</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dereck Tait</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dereck Tait</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Reviral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dereck++Tait">Dereck Tait</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Geraldine Taylor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Geraldine Taylor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Pirbright Institute, Ash Road, Pirbright, Surrey GU24 0NF, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Geraldine++Taylor">Geraldine Taylor</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michelle Thom</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michelle Thom</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Pirbright Institute, Ash Road, Pirbright, Surrey GU24 0NF, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michelle++Thom">Michelle Thom</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elaine Thomas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elaine Thomas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Reviral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elaine++Thomas">Elaine Thomas</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carol Villalonga Barber</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carol Villalonga Barber</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sussex Drug Discovery Centre, University of Sussex, Brighton, England BN1 9QJ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carol++Villalonga+Barber">Carol Villalonga Barber</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simon E. Ward</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon E. Ward</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicines Discovery Institute, Cardiff University, Cardiff, Wales CF10 3AT, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon+E.++Ward">Simon E. Ward</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8745-8377" title="Orcid link">http://orcid.org/0000-0002-8745-8377</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel Watterson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel Watterson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland 4072, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Watterson">Daniel Watterson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gareth Williams</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gareth Williams</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sussex Drug Discovery Centre, University of Sussex, Brighton, England BN1 9QJ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gareth++Williams">Gareth Williams</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul Young</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Young</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland 4072, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Young">Paul Young</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Kenneth Powell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kenneth Powell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Reviral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth++Powell">Kenneth Powell</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01882&amp;href=/doi/10.1021%2Facs.jmedchem.0c01882" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3658–3676</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 17, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 October 2020</li><li><span class="item_label"><b>Published</b> online</span>17 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01882" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01882</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3658%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DG.%2BStuart%2BCockerill%252C%2BRichard%2BM.%2BAngell%252C%2BAlexandre%2BBedernjak%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D7%26contentID%3Dacs.jmedchem.0c01882%26title%3DDiscovery%2Bof%2BSisunatovir%2B%2528RV521%2529%252C%2Ban%2BInhibitor%2Bof%2BRespiratory%2BSyncytial%2BVirus%2BFusion%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3676%26publicationDate%3DApril%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01882"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1724</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01882" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;G.&quot;,&quot;last_name&quot;:&quot;Stuart Cockerill&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;M. Angell&quot;},{&quot;first_name&quot;:&quot;Alexandre&quot;,&quot;last_name&quot;:&quot;Bedernjak&quot;},{&quot;first_name&quot;:&quot;Irina&quot;,&quot;last_name&quot;:&quot;Chuckowree&quot;},{&quot;first_name&quot;:&quot;Ian&quot;,&quot;last_name&quot;:&quot;Fraser&quot;},{&quot;first_name&quot;:&quot;Jose&quot;,&quot;last_name&quot;:&quot;Gascon-Simorte&quot;},{&quot;first_name&quot;:&quot;Morgan&quot;,&quot;last_name&quot;:&quot;S. A. Gilman&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;A. D. Good&quot;},{&quot;first_name&quot;:&quot;Rachel&quot;,&quot;last_name&quot;:&quot;Harland&quot;},{&quot;first_name&quot;:&quot;Sara&quot;,&quot;last_name&quot;:&quot;M. Johnson&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;H Ludes-Meyers&quot;},{&quot;first_name&quot;:&quot;Edward&quot;,&quot;last_name&quot;:&quot;Littler&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Lumley&quot;},{&quot;first_name&quot;:&quot;Graham&quot;,&quot;last_name&quot;:&quot;Lunn&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;Mathews&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;S. McLellan&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Paradowski&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;E. Peeples&quot;},{&quot;first_name&quot;:&quot;Claire&quot;,&quot;last_name&quot;:&quot;Scott&quot;},{&quot;first_name&quot;:&quot;Dereck&quot;,&quot;last_name&quot;:&quot;Tait&quot;},{&quot;first_name&quot;:&quot;Geraldine&quot;,&quot;last_name&quot;:&quot;Taylor&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;Thom&quot;},{&quot;first_name&quot;:&quot;Elaine&quot;,&quot;last_name&quot;:&quot;Thomas&quot;},{&quot;first_name&quot;:&quot;Carol&quot;,&quot;last_name&quot;:&quot;Villalonga Barber&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;E. Ward&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Watterson&quot;},{&quot;first_name&quot;:&quot;Gareth&quot;,&quot;last_name&quot;:&quot;Williams&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Young&quot;},{&quot;first_name&quot;:&quot;Kenneth&quot;,&quot;last_name&quot;:&quot;Powell&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;3658-3676&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01882&quot;},&quot;abstract&quot;:&quot;RV521 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was identified after a lead optimization process based upon hits that originated from a physical property directed hit profiling exercise at Reviral. This exercise encompassed collaborations with a number of contract organizations with collaborative medicinal chemistry and virology during the optimization phase in addition to those utilized as the compound proceeded through preclinical and clinical evaluation. RV521 exhibited a mean IC50 of 1.2 nM against a panel of RSV A and B laboratory strains and clinical isolates with antiviral efficacy in the Balb/C mouse model of RSV infection. Oral bioavailability in preclinical species ranged from 42 to &gt;100% with evidence of highly efficient penetration into lung tissue. In healthy adult human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a significant reduction in viral load and symptoms compared to placebo.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01882&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01882" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01882&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01882" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01882&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01882" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01882&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01882&amp;href=/doi/10.1021/acs.jmedchem.0c01882" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01882" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01882" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01882%26sid%3Dliteratum%253Aachs%26pmid%3D33729773%26genre%3Darticle%26aulast%3DCockerill%26date%3D2021%26atitle%3DDiscovery%2Bof%2BSisunatovir%2B%2528RV521%2529%252C%2Ban%2BInhibitor%2Bof%2BRespiratory%2BSyncytial%2BVirus%2BFusion%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D7%26spage%3D3658%26epage%3D3676%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291567" title="Oxindoles">Oxindoles</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291411" title="Pharmacokinetics">Pharmacokinetics</a>,</li><li><a href="/action/doSearch?ConceptID=292504" title="Permeability">Permeability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/jmcmar.2021.64.issue-7/20210408/jmcmar.2021.64.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">RV521 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was identified after a lead optimization process based upon hits that originated from a physical property directed hit profiling exercise at Reviral. This exercise encompassed collaborations with a number of contract organizations with collaborative medicinal chemistry and virology during the optimization phase in addition to those utilized as the compound proceeded through preclinical and clinical evaluation. RV521 exhibited a mean IC<sub>50</sub> of 1.2 nM against a panel of RSV A and B laboratory strains and clinical isolates with antiviral efficacy in the Balb/C mouse model of RSV infection. Oral bioavailability in preclinical species ranged from 42 to >100% with evidence of highly efficient penetration into lung tissue. In healthy adult human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a significant reduction in viral load and symptoms compared to placebo.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06853" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06853" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Respiratory syncytial virus (RSV) is an RNA virus of the <i>Pneumoviridae</i> family and is responsible for a seasonal and global respiratory tract infection. Patient populations most at risk of severe disease from RSV are specifically patients with weakened immune function due to old age or immature immune and physical development.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Populations at risk are premature infants, immunocompromised adults, COPD (chronic obstructive pulmonary disease) and CHF (chronic heart failure) patients, and the elderly. The viral infection can progress to lower respiratory tract infection (LRTI) and result in airway inflammation, bronchiolitis, pneumonia, and in extreme cases, respiratory failure. Premature infants and young children with underlying heart disease or pulmonary dysplasia have the highest risk of severe disease resulting from RSV LRTI.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> RSV is associated with significantly more deaths and infant hospitalizations than influenza,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> parainfluenza, or human metapneumovirus. Additionally, severe RSV infection in infancy is linked to the later development of asthma.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">Despite the clear impact of the virus and associated economic burden, limited treatments exist for RSV disease. No licensed vaccine exists, and only palivizumab,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> a monoclonal antibody (mAb) approved for prophylaxis, and ribavirin, a broad-spectrum nucleoside antiviral drug of low efficacy, have been approved. The standard of care for RSV-infected patients remains supportive, including fluids and oxygen.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p last">RSV contains a single stranded linear RNA genome with 10 genes encoding 11 proteins.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Proteins of interest to drug discovery programs have been L (RNA polymerase), N (nucleoprotein), M (matrix protein), M2.1 (essential cofactor for the polymerase complex), and F (fusion protein). This paper describes our approach to inhibitors of the fusion protein, given its fundamental importance in viral infectivity and also its conserved nature.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27168" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27168" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A perspective on the position of anti-RSV drug discovery in 2018 described the progression of several direct acting antivirals for the treatment of RSV into clinical trials, targeting both fusion and replication.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> When this particular project was initiated in 2011, the field was far less mature; indeed, only RSV604, an RSV nucleocapsid protein inhibitor, had demonstrated efficacy, and that in a subanalysis of stem cell transplant patient data.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Recently, data have been disclosed for both presatovir<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a><b>1</b> and JNJ-53718678<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a><b>2</b> in adult and pediatric patient populations, respectively. Additionally, an inhibitor of RSV fusion, ziresovir<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a><b>3</b>, and EDP-938,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> an N protein inhibitor (structure not disclosed), have progressed into the human challenge model and phase 2 trials (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Clinical stage RSV fusion inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Hit Identification</h3><div class="NLM_p">We focused our attention on the fusion target, not least because in addition to its key role in the infectivity process, there were small molecule fusion templates that possessed inherent developability advantages, specifically in terms of molecular size, physical properties, and potency that could lead to a hit compound worthy of progression. We focused our attention on a cyclic urea/benzimidazole scaffold previously described.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> This series looked to have beneficial optimization properties over other fusion archetypes known at that time. Although it was unclear why compounds had failed to progress in 2011, subsequent summaries have appeared.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> As part of our analysis, we looked at the physical properties of compounds prepared in this series from a number of sources. A typical output is shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. We examined a number of patents pertaining to RSV fusion inhibitors<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a> and identified a clear trend toward higher clogP values, with the majority of compounds possessing values greater than 3.5. The detrimental effects of higher clogP values have been documented.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> Our intention was to focus our modifications to restrict our clogP figure to less than 3.5 to enhance the development potential of any candidate clinical compound.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. A plot of numbers of compounds disclosed in three benzimidazole patents against clogP.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> clogP figures represent the central point of each bin covering clogP values ±0.25. clogP values were calculated using Biobyte version 5.4 (<a href="http://www.biobyte.com/index.html" class="extLink">http://www.biobyte.com/index.html</a>). Patent example data were extracted from Surechembl (<a href="https://www.surechembl.org/search/" class="extLink">https://www.surechembl.org/search/</a>). Examples with a molecular weight outside of the range 300–700 were removed, and structures were checked manually with reactive compounds removed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In what was an increasingly complex patent space,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> structural novelty was a key consideration. Despite this complexity, we had analyzed the patent space associated with the area and identified spirocyclic systems as possessing the required novelty. We therefore focused our initial synthetic program on a novel range of spirocyclic ring containing heterocycles by constructing spirocyclic systems anchored to a bicyclic oxindole or the corresponding tetrahydroquinolinone component of the fusion inhibitor (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Summary of spirocyclic structural scan, with cores A–G used in the initial hit finding exercise. The five and six membered lactam cores are shown in red, and the proposed three to five membered spirocycles are shown in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This limited structural scan of three to five membered ring containing spiro systems allowed the observation of a structure activity pattern, which was most apparent with an amino methylene benzimidazole scaffold (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, R═CH<sub>2</sub>NH<sub>2</sub>, and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Potency against the virus was measured using an RSV A2 strain plaque reduction assay (PRA) in Vero cells with cellular cytotoxicity measured in parallel. Significant potency was observed with a 6,5 oxindole containing a spirocyclopropyl (compound <b>6</b>), while oxindoles containing larger spirocyclic ring systems (<b>4</b>, <b>5</b>, and <b>7</b>) were less potent in this smaller oxindole system. The larger 6,6 systems, either tetrahydroquinolinone or tetrahydropyranone <b>8</b>–<b>10</b>, were observed to be markedly less potent (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). A comparative study with unsubstituted benzimidazole series demonstrated analogous trends but with poorer activities generally (data not shown); in this less active series, the corresponding spirocyclobutyl oxindole was the most potent analogue (EC<sub>50</sub> = 7.5 μM). We were encouraged that the structure activity trends were in line with our physicochemical targets; clogP and clogD values were acceptable at this stage, particularly for the smaller ring sizes.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Spirocyclic Compounds Prepared during the Hit Finding Exercise<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0017.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">core</th><th class="colsep0 rowsep0" align="center" char=".">RSV A2 PRA EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">CC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">cLogD<sub>7.4</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="char" char=".">580</td><td class="colsep0 rowsep0" align="char" char=".">9.94</td><td class="colsep0 rowsep0" align="char" char=".">2.84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="char" char=".">240</td><td class="colsep0 rowsep0" align="char" char=".">13.75</td><td class="colsep0 rowsep0" align="char" char=".">2.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">15.29</td><td class="colsep0 rowsep0" align="char" char=".">1.95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">D</td><td class="colsep0 rowsep0" align="char" char=".">310</td><td class="colsep0 rowsep0" align="char" char=".">23.11</td><td class="colsep0 rowsep0" align="char" char=".">1.62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">E</td><td class="colsep0 rowsep0" align="char" char=".">14 000</td><td class="colsep0 rowsep0" align="char" char=".">11.54</td><td class="colsep0 rowsep0" align="char" char=".">3.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">3400</td><td class="colsep0 rowsep0" align="char" char=".">33.4</td><td class="colsep0 rowsep0" align="char" char=".">2.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">G</td><td class="colsep0 rowsep0" align="char" char=".">1700</td><td class="colsep0 rowsep0" align="char" char=".">22.7</td><td class="colsep0 rowsep0" align="char" char=".">1.69</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">Cores and R group as defined in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. The plaque reduction assay (PRA) was performed in Vero cells with the RSV A2 strain. CC<sub>50</sub> refers to Vero cell cytotoxicity and was assessed by MTT staining. EC<sub>50</sub> and CC<sub>50</sub> values are an average of at least two testing occasions. clogD<sub>7.4</sub> values were calculated using Marvin software 18.16.0, 2018, ChemAxon (<a href="http://www.chemaxon.com" class="extLink">http://www.chemaxon.com</a>.).</p></div></div></div><div class="NLM_p">Profiling of leading compounds <b>6</b> and <b>7</b> from this exercise in an <i>in vitro</i> ADME and physicochemical screen showed compounds with good solubility, permeability, and plasma protein binding unbound fractions (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>a). Clearance data were acceptable in rodent and dog microsomes, although half-lives were low in human microsomes. We progressed the most potent compound <b>6</b> into a mouse <i>in vivo</i> pharmacokinetic study. We observed a low level of exposure (F, 4%, <i>C</i><sub>max</sub> 6 ng/mL) with high clearance (98 mL/min/kg). In light of this high clearance, we employed a microsomal ID study in rat and human microsomes to investigate the metabolic susceptibility of the molecule. In this study, the lead compound <b>6</b> was incubated at 10 μM with microsomes isolated from liver hepatocytes, and sites of metabolism were subsequently proposed from mass spectral analysis of fragmentation patterns (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Significantly, greater turnover was observed in incubations with human microsomes than the rat system. This correlated with the previously observed microsomal clearance data (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>a). Most interestingly, both human specific metabolites and those observed in both species were confined structurally to the cyclopropyl oxindole fragment of the molecule.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Although hydroxylation metabolites were proposed in the rat microsomal incubation, a specific monohydroxylation metabolite was far more prevalent in human microsomes, and double hydroxylation metabolites were only observed in the human incubation (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_002.pdf" class="ext-link">Supporting Information</a>). This focused our attention on the cyclopropyl oxindole.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. (a) <i>In Vitro</i> and (b) <i>in Vivo</i> Pharmacokinetic Data for Leading Compounds from the Hit Finding Exercise</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="6" align="center">(a) <i>In Vitro</i> Pharmacokinetic Data</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">kinetic solubility<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (μM)</th><th class="colsep0 rowsep0" align="center" char="."><i>P</i><sub>app</sub><a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> (10<sup>–6</sup> cm s<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center">PPB <i>F</i><sub>u</sub> (%) rat, dog, human</th><th class="colsep0 rowsep0" align="center">microsomal CL<sub>int</sub> (μL/min/μg protein) rat, dog, human</th><th class="colsep0 rowsep0" align="center">microsomal <i>t</i><sub>1/2</sub> (min) rat, dog, human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="char" char=".">155</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="left">10, 10, 7</td><td class="colsep0 rowsep0" align="left"><19, <28, 592</td><td class="colsep0 rowsep0" align="left">>95, >100, 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="char" char=".">160</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="left">24, 14, 17</td><td class="colsep0 rowsep0" align="left"><31, <28, 488</td><td class="colsep0 rowsep0" align="left">>89, >100, 6</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="5" align="center">(b) <i>In Vivo</i> Pharmacokinetic Data</th></tr><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="5" align="center">mouse pharmacokinetics for compound <b>6</b><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (oral) (ng/mL)</th><th class="colsep0 rowsep0" align="center">clearance (i.v.) (mL/min/kg)</th><th class="colsep0 rowsep0" align="center">Vd<sub>ss</sub> (i.v.) (L/kg)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">98</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Kinetic solubility was determined by the addition of the compound in DMSO to 0.1 M PBS at pH 7.4; precipitation of the compound was measured at a range of concentrations.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Apparent permeability (<i>P</i><sub>app</sub>) in a wild-type unidirectional MDCK cell assay.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">The compound was dosed as a suspension of the amorphous solid at 1 mg/kg i.v. and 5 mg/kg p.o.</p></div></div></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Summary of metabolite ID study for compound <b>6</b> following incubation with microsomes derived from rat and human liver cells. The most likely sites of metabolism are indicated by arrows.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">This point in time represented a key moment for the project and Reviral; we had identified a potent hit compound with pharmacokinetic properties that demonstrated some level of oral bioavailability, albeit with the aforementioned metabolic liability (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>a and b). This series of compounds we believed possessed potential for good oral absorption properties.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Additionally, a high volume of distribution was observed in this compound <i>in vivo</i>. The link between compound distribution and clearance could not be ignored. Indeed, a positively distributing compound would be expected to attain higher concentrations in target tissue than those observed in the plasma compartment,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> with a potential beneficial effect for efficacy studies. The metabolite study itself provided us with a clear plan and the potential for a productive optimization process. Initial studies in the next phase of the project were directed toward blocking metabolism on the oxindole.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Lead Optimization</h3><div class="NLM_p">The project employed a design, make, and test framework whereby compounds were tested initially in an RSV fusion reporter-based cell–cell fusion assay (in human embryonic kidney 293T cells) before subsequent antiviral evaluation in the whole virus RSV A2 plaque assay (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). This fusion assay<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> was a higher throughput assay that allowed an efficient generation of initial activity data and, importantly for us, was colocated with the medicinal chemistry group. We progressed compounds with fusion IC<sub>50</sub> ≤ 5 nM into the plaque assay which was run at distance by a collaborator. Compounds were then evaluated in physicochemical and pharmacokinetic assays on contract. Some changes took place at this point, specifically the contractor supplying <i>in vitro</i> ADME/physical property determination assays. At a later stage in the project, the development of a company “in house” antiviral capability led to the use of additional cell lines. For example, HepG2 cells and Hep2 cells were added in the cell toxicity screen. Where this affects data in this paper, the alternate cell lines used are indicated. Despite these changes, toxicity data for compounds retained a consistent profile in these assays.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Project flowchart depicting the design, make, and test cycle for compounds prepared in the project. The design, make, and test cycle allowed a progression to <i>in vivo</i> evaluation in the mouse BalbC model. Detailed virology and toxicity analysis prior to progression into preclinical evaluation followed. Generalized progression criteria are shown in italics below or alongside each assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds satisfying our basic criteria for progression would progress into two key antiviral assays: the human airway epithelial (HAE) model,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> whereby differentiated human epithelial cell cultures were infected with a luciferase expressing RSV, and the use of the Balb/C mouse RSV infection model to study <i>in vivo</i> efficacy (<i>vide infra</i>).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">Detailed analysis followed for a compound satisfying our potency and pharmacokinetic requirements; principally, this comprised testing against a range of RSV A and B laboratory strains and low passage clinical isolates of RSV A and B. Consistent activity against these strains was an important requirement for any compound to progress given that RSV A and B strains cocirculate during an infectious season. Additionally, there was now a longer-term commitment to perform experiments to raise and subsequently sequence the RNA of resistant mutants to such a compound. The complexity of these later-stage virology studies restricted them to the analysis of a compound moving toward clinical evaluation and were performed as an integral part of the company’s in-house capability as it evolved.</div><div class="NLM_p">The medicinal chemistry strategy employed during this phase of the project was to target three key areas of the lead compound <b>6</b> depicted in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>. An initial focus on introduction of substituents into the oxindole portion of the molecule to help block metabolism was followed by targeted modifications of the chain substituting the benzimidazole and modifications to the basic aminomethylene functionality. Approaches to analogues of the aza-oxindole <b>7</b> were of lower priority within the research team due to the lower potency of this lead compound and practical issues associated with the synthesis of the spirocyclic aza-oxindole fragment at this stage in the project. Compounds subsequently derived from lead <b>7</b> are reviewed briefly at the end of this section (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0006.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structural modification strategies employed in the lead optimization of hit <b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0007.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Spirocyclopropyl aza-oxindoles and heterocyclic spirocyclic oxindoles identified at Reviral Ltd.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Spirocyclopropyl Oxindole Ring Modification</h3><div class="NLM_p">The initial LO studies were aimed at the introduction of stabilizing groups into the oxindole portion of the lead compound as directed by our earlier metabolite ID study. <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> shows a selection of substituents that were successfully introduced as part of this exercise. The emphasis at this stage was focused on small halogen substituents that would represent as small a physical property change as possible while functioning in a metabolic blocking role. Potency could be retained for 5- and 6-chlorine substituted compounds (<b>13</b> and <b>15</b><a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) relative to compound (<b>6</b>); 4- and 7-chlorine substitution had a deleterious effect (<b>11</b> and <b>16</b>), whereas 5- and 6-fluorine substitution produced the most potent analogues (<b>12</b> and <b>14</b>) with the synthetically more accessible 6-regioisomer <b>14</b> marginally more potent. Cell assay variability has to be taken into account with these data, and it was seen that the fusion assay grouped analogues into tighter groups of potent and less potent modifications. In the light of the later crystal structure of RV521 bound to the trimeric prehairpin binding pocket (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KQD">7KQD</a>); the binding of the oxindole component into a small well-defined pocket is evident (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, particularly panel b). One would suspect a chlorine substituent would explore the steric limitations of this pocket with direct ligand protein steric effects and conformational effects upon the ligand itself (particularly in the 7 position). 6-Fluoro substitution direct ligand/protein interactions are harder to discern, but there could be beneficial binding effects.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Lead Optimization of Hit Spirocycle (<b>6</b>): Antiviral Activity and Cell Toxicity for Compounds Prepared as a Result of the Metabolite ID Study<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0018.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">substituent R</th><th class="colsep0 rowsep0" align="center" char=".">RSV fusion IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">RSV A2 plaque EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">CC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">15 290</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="char" char=".">11.1</td><td class="colsep0 rowsep0" align="char" char=".">180.7</td><td class="colsep0 rowsep0" align="char" char=".">5200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">5-F</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">7600</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">5-Cl</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char=".">25.4</td><td class="colsep0 rowsep0" align="char" char=".">710</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">6-F</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="char" char=".">3000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">6-Cl</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">6.7</td><td class="colsep0 rowsep0" align="char" char=".">4500</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">7-Cl</td><td class="colsep0 rowsep0" align="char" char=".">46.7</td><td class="colsep0 rowsep0" align="char" char=".">2384.3</td><td class="colsep0 rowsep0" align="char" char=".">21 700</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">7-F</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">40.8</td><td class="colsep0 rowsep0" align="char" char=".">31 100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup><sup>a</sup></sup><p class="last">The RSV cell fusion assay was performed in human embryonic kidney 293T cells cotransfected with RSV F protein from the RSV A2 strain or an expression plasmid encoding a transcriptional transactivator fusion protein. The plaque reduction assay (PRA) was performed in Vero cells with the RSV A2 strain. CC<sub>50</sub> refers to Vero cell cytotoxicity and was assessed by MTT staining. IC<sub>50</sub>, EC<sub>50</sub>, and CC<sub>50</sub> values are an average of at least two testing occasions.</p></div></div></div><div class="NLM_p">The evaluation of compounds in <i>in vitro</i> ADME studies (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) provided new data for us at this stage. The permeability assay was changed to a bidirectional assay in MDCK cells, as opposed to the previously employed unidirectional system in the same cell line. Additionally, the solubility assay method was changed to assess thermodynamic solubility; amorphous solid compound was now administered to aqueous buffer and solubility assessed over 24 h as opposed to an administration of compound in DMSO to buffer. The lead compound 14 demonstrated both good thermodynamic solubility and reasonable fraction unbound (fu) in the protein binding assay (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>a). They were profiled alongside the 7-fluorine substituted regioisomer <b>17</b>. There was some variability observable in unbound fraction between species for these compounds, and microsomal clearance was still significant.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. (a) <i>In Vitro</i> and (b) <i>in Vivo</i> Pharmacokinetic Data for Leading Compounds from Lead Optimization of the Oxindole</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="6" align="center">In Vitro Pharmacokinetic Data</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">thermodynamic solubility<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (μM)</th><th class="colsep0 rowsep0" align="center"><i>P</i><sub>app</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> (10<sup>–6</sup> cm s<sup>–1</sup>) A<sub>2</sub>B/B<sub>2</sub>A; ER</th><th class="colsep0 rowsep0" align="center">PPB <i>F</i><sub>u</sub> (%) rat, dog, human</th><th class="colsep0 rowsep0" align="center">microsomal CL<sub>int</sub> (μL/min/μg protein) rat, dog, human</th><th class="colsep0 rowsep0" align="center">rat liver hepatocyte CL<sub>int</sub> (μL/min/10<sup>6</sup> cells)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">155</td><td class="colsep0 rowsep0" align="left">(12)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">10, 10, 7</td><td class="colsep0 rowsep0" align="left"><19, <28, 592</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">(7.3)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">19, 15, 11</td><td class="colsep0 rowsep0" align="left"><29, <29, 344</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">176.3</td><td class="colsep0 rowsep0" align="left">0.75/65.6; 88</td><td class="colsep0 rowsep0" align="left">33.3, 15.1, 18.4</td><td class="colsep0 rowsep0" align="left">45, 6.23, 50.7</td><td class="colsep0 rowsep0" align="left">43.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">1230</td><td class="colsep0 rowsep0" align="left">0.19/42.1; 227</td><td class="colsep0 rowsep0" align="left">10.4, 14.7, 42</td><td class="colsep0 rowsep0" align="left">37.8, 2.23, 7.0</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="5" align="center">In Vivo Pharmacokinetic Data</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">Rat Pharmacokinetic properties <i>in vivo</i><a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (oral) (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">clearance (i.v.)(mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Vd<sub>ss</sub> (i.v.) (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="char" char=".">44.2</td><td class="colsep0 rowsep0" align="char" char=".">174.0</td><td class="colsep0 rowsep0" align="char" char=".">54.3</td><td class="colsep0 rowsep0" align="char" char=".">25.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="char" char=".">31.3</td><td class="colsep0 rowsep0" align="char" char=".">107.7</td><td class="colsep0 rowsep0" align="char" char=".">11.9</td><td class="colsep0 rowsep0" align="char" char=".">8.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Thermodynamic solubility at pH 7.4 was determined by addition of aqueous solvent to solid compound and mixed overnight. The saturated solution was filtered and quantified against a DMSO stock solution using LC-UV.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Permeability assay in MDCK (MDR1) cells. Direction is indicated by A<sub>2</sub>B or B<sub>2</sub>A. ER denotes efflux ratio.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Permeability data from a wild-type unidirectional MDCK cell assay.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Compounds were dosed as a suspension of the amorphous solid at 1 mg/kg i.v. and 5 mg/kg p.o.</p></div></div></div><div class="NLM_p last">The permeability of the 7-fluoro example <b>17</b> was low, and both of these regioisomeric compounds <b>14</b> and <b>17</b> exhibited significant efflux ratios. No advantage was observed with the 5-fluoro analogue <b>12</b> as this compound exhibited a very high clearance in human microsomes and a low to moderate permeability in the unidirectional permeability assay (CL<sub>int</sub>: 344 μL/min/μg protein, <i>t</i><sub>1/2</sub> = 8 min; <i>P</i><sub>app</sub> = 7.3 × 10<sup>–6</sup> cms<sup>–1</sup>). When evaluated in <i>in vivo</i> pharmacokinetic studies (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>b), the 6-fluoro compound <b>14</b> was more promising with a bioavailability of 25% versus 8.8% for <b>17</b> in rats (10 mg/kg oral, 1 mg/kg (iv), however clearance remained high. The disconnect observable between <i>in vitro</i> microsomal clearances and the <i>in vivo</i> clearance for all of these compounds has to be taken in context with the large volumes of distribution observable for these compounds (<b>6</b>, <b>14</b>, and <b>17</b>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>b). The consensus at this point was that we were indeed in a position whereby we had modified the metabolic lability of the compounds; however, the distributive properties of the compounds clouded the overall picture. A high volume of distribution, because it relates the total body concentration of drug to the drug plasma concentration, would actually be reflected in enhanced clearance figures.<a onclick="showRef(event, 'cit23a'); return false;" href="javascript:void(0);" class="ref cit23a">(23a)</a> We progressed the optimization of these compounds with the view that retaining good distribution properties was a favorable characteristic; indeed, the presystemic extraction of drugs that can be classed as lipophilic amines in organs such as the lung is documented.<a onclick="showRef(event, 'cit23b'); return false;" href="javascript:void(0);" class="ref cit23b">(23b)</a> This strategy was borne out ultimately in the properties of RV521 (<b>20</b>, <i>vide infra</i>). At this point, we turned our attention to chain modifications.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Benzimidazole Chain Modifications</h3><div class="NLM_p">The benzimidazole chain substituent was a major lipophilic component of the structure; in addition, there was some level of evidence for this chain as a target of metabolism (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Our strategy was to reduce the lipophilicity of this chain substituent without a significant increase in polar surface area. This approach would allow us to reduce the overall lipophilicity with the benefit of improving solubility and the metabolic profile while retaining the acceptable permeability observed thus far.</div><div class="NLM_p">In general, as observed in other reported inhibitors of RSV F protein,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> chains with four to five atoms were acceptable in terms of potency and, most interestingly, cyclic systems such as cyclohexanol (<b>22</b>) or pyran (<b>23</b>) were also potent in the RSV plaque and fusion assays (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). In the case of the pharmacokinetics of cyclohexanol <b>22</b> (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Tables <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>), low permeability and low clearance were observed <i>in vitro</i> (<i>P</i><sub>app</sub> MDCK-MDR1A2B/B2A; ER 0.13/2.8; 21 × 10<sup>–6</sup> cm s<sup>–1</sup>, 0.13 mL/min/mg protein in rat microsomes), and high clearance and low bioavailability were observed in mice (82.7 mL/min/kg, <i>F</i> 4.4%).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Chain Modification Antiviral Activity and Calculated Physicochemical Properties<a class="ref internalNav" href="#tbl5-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0019.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0020.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl5-fn1"><div class="footnote" id="tbl5-fn1"><sup><sup>a</sup></sup><p class="last">The plaque reduction assay (PRA) was performed in Huh-7 cells with the RSV A2 strain. IC<sub>50</sub> and EC<sub>50</sub> values are an average of at least two testing occasions. CC<sub>50</sub> refers to cell cytotoxicity measured in HepG2 cells.</p></div><div class="footnote" id="t5fn1"><sup><sup>b</sup></sup><p class="last">ΔclogD<sub>7.4</sub> values are calculated by comparison with the parent iso-pentyl substituent compounds <b>14</b> and <b>17</b> (clogD<sub>7.4</sub> 2.09 for both compounds). Values were calculated for ClogD<sub>7.4</sub> and PSA using Marvin (Marvin 16.5.16.0, 2016, ChemAxon (<a href="http://www.chemaxon.com" class="extLink">http://www.chemaxon.com</a>).</p></div><div class="footnote" id="t5fn2"><sup><sup>c</sup></sup><p class="last">clogD<sub>7.4</sub> for compound <b>20</b> is 2.00.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. <i>In Vitro</i> ADME Data for Selected Examples Prepared as Part of the Chain Modification Process</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">thermodynamic solubility<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> (μM)</th><th class="colsep0 rowsep0" align="center"><i>P</i><sub>app</sub><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a> (10<sup>–6</sup> cm s<sup>–1</sup>) A<sub>2</sub>B/B<sub>2</sub>A; ER</th><th class="colsep0 rowsep0" align="center">PPB<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a><i>F</i><sub>u</sub> (%) r/d/h</th><th class="colsep0 rowsep0" align="center">microsomal<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> CL<sub>int</sub> (μL/min/μg protein) r/d/h</th><th class="colsep0 rowsep0" align="center">microsomal <i>t</i><sub>1/2</sub> (min) r/d/h</th><th class="colsep0 rowsep0" align="center">hepatocyte<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> CL<sub>int</sub> (μL/min/10<sup>6</sup> cells) r/d/h</th><th class="colsep0 rowsep0" align="center">hepatocyte <i>t</i><sub>1/2</sub> (min) r/d/h</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">2595</td><td class="colsep0 rowsep0" align="left">0.24/0.79; 3.26</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">3.63/5.34/3.78</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">417</td><td class="colsep0 rowsep0" align="left">0.5/73; 146</td><td class="colsep0 rowsep0" align="left">52/27/67</td><td class="colsep0 rowsep0" align="left">17/2.6/44</td><td class="colsep0 rowsep0" align="left">80/532/32</td><td class="colsep0 rowsep0" align="left">14.8/2.4/6.58</td><td class="colsep0 rowsep0" align="left">93/580/211</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">1178</td><td class="colsep0 rowsep0" align="left">0.4/2.7; 7.5</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">0.7/2.0/2.9</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">313</td><td class="colsep0 rowsep0" align="left">0.1/2.8; 21</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">9.4/5.02/4.6</td><td class="colsep0 rowsep0" align="left">147/276/300</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">1270</td><td class="colsep0 rowsep0" align="left">0.4/40.6; 94</td><td class="colsep0 rowsep0" align="left">39.9/49.7/54.8</td><td class="colsep0 rowsep0" align="left">5.2/0.4/66.4</td><td class="colsep0 rowsep0" align="left">246/3350/20.9</td><td class="colsep0 rowsep0" align="left">21.2/0.8/7.1</td><td class="colsep0 rowsep0" align="left">61.4/>1000/197</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">0/0.14: ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">71.3/328/177</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">0/0.1:ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">328.0/71.3/177.0</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Thermodynamic solubility at pH 7.4 was determined by addition of aqueous solvent to solid amorphous compound and mixed overnight. The saturated solution was filtered and quantified against a DMSO stock solution using LC-UV.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Permeability assay in MDCK (MDR1) cells. Direction is indicated by A<sub>2</sub>B or B<sub>2</sub>A. ER denotes efflux ratio. ND denotes not determined.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">r/d/h denotes rat, dog, or human derived plasma protein/microsomes/hepatocytes, respectively.</p></div></div></div><div class="NLM_p">Low permeabilities were observed with the methylsulfonylpropyl chain compound <b>18</b>, perhaps as a result of increased polar surface area and lowered clogP. This low permeability was reflected in poor pharmacokinetics in the mouse; no oral exposure was seen for this compound (data not shown). The introduction of either the pyran or trifluorobutyl chain provided acceptable permeabilities in addition to reduced clogP values for the pyran (<b>23</b>) and a polar surface area figure below 70 A<sup>2</sup> for the trifluorobutyl substituted systems (<b>20</b>) and (<b>21</b>). Conventionally viewed as a lipophilic substituent, the trifluorobutyl system can be viewed from a different perspective. A matched pair analysis reported by Böhm et al. described the contextual dependence of the fluorine as a logP lowering or raising substituent. They described how the polarity increase of the fluorine atoms overcompensated for their lipophilic nature functioning as logP lowering substituents in their study.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p last">The trifluorobutyl <b>20</b> and pyran <b>23</b> both exhibited acceptable permeability and microsomal half-lives (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). In the case of compound <b>20</b>, acceptable hepatocyte half-lives were observed in all species. Unbound protein fractions were good for both compounds, and thermodynamic solubility was improved versus the iso-pentyl <b>14</b>. As a result, both of these compounds were progressed into <i>in vivo</i> pharmacokinetic evaluation, these data are shown in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a><i>vide infra</i>. The trifluorobutyl substituted 7-fluorooxindole system <b>21</b> has shown favorable <i>in vitro</i> ADME properties and acceptable potency (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). In this case, low oral bioavailability was observed in both mouse and rat (12.9 and 14%, respectively, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). The high clearance in mice and rats for <b>21</b> was not predicted by the <i>in vitro</i> data. Compound <b>20</b> showed lower clearances in mice and dogs indicative of an improved metabolic stability in these species. High volumes of distribution were observed for both compounds <b>20</b> and <b>21</b>.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Aminomethylene Substituent Modifications</h3><div class="NLM_p">To complete the investigation into substituent effects in this system, a range of modifications was introduced at the 6-position of the benzimidazole. Polar, nonpolar, basic, and acidic groups were all investigated at this position (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). The potential for the interaction of this group in this class of molecule to bind to target site acidic amino acid residues has been highlighted in earlier publications.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Our strategy at this stage was to investigate alternatives to the aminomethylene, mostly with hydrogen bonding potential that could be associated with a different pharmacokinetic absorption or stability profile. To summarize the output from this program of work, the structure activity pattern observed within our system clearly demonstrated that basic groups, such as a simple amine or the strongly basic amidine functionality, were the most potent (e.g., <b>25</b>) and potency in the fusion assay for these compounds was maintained in the plaque assay. Neutral groups such as amide and methanesulphonyl (<b>28</b> and <b>30</b>) demonstrated significantly poorer levels of activity, while acidic groups were inactive in this specific scaffold (<b>29</b>). In the case of the 6-chlorine substituted analogue <b>33</b>, reduced potency in the plaque assay was compounded by low permeability and high clearance in microsomes (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). In addition, there was a clear trend for simplicity of substituent, with the introduction of alkyl groups into the amidine functionality either as a spacer group or nitrogen substituent negatively impacting upon activity (<b>26</b> and <b>27</b>).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The potency of the amidine containing analogue was counteracted by the low absorption characteristics of this strongly basic group:<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> permeability was low in both directions (<b>25</b>: MDCK (MDR1) A<sub>2</sub>B:B<sub>2</sub>A <i>P</i><sub>app</sub> = 0.413:0.876 × 10<sup>–6</sup> cm s<sup>–1</sup>). Subsequently, the potential for interaction of such basic functionality with a hydrophilic region within the fusion protein was supported by the crystal structure obtained for our clinical compound (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Antiviral Activity and Cell Cytotoxicity Data for 6-Substituted Benzimidazoles<a class="ref internalNav" href="#tbl7-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0021.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0022.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl7-fn1"><div class="footnote" id="tbl7-fn1"><sup><sup>a</sup></sup><p class="last">The plaque reduction assay (PRA) was performed in Vero cells or Hep2 cells* with the RSV A2 strain. CC<sub>50</sub> refers to cell cytotoxicity in HepG2 cells and was assessed by MTT staining. Alternatively, compound cell toxicity was performed in either Hep2 cells* or Vero cells** as described earlier. IC<sub>50</sub>, EC<sub>50</sub>, and CC<sub>50</sub> values are an average of at least two testing occasions.</p></div></div><div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Aza-Oxindoles and Heterocyclic Spiro-Oxindole Systems</h3><div class="NLM_p">Introduction of nitrogen into the oxindole system had been of interest through this optimization period due to an expectation of improved potency associated with the cyclopropyl variant of <b>7</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) that was identified as a lead compound during the hit finding exercise. Synthesis of useful quantities of material to allow full profiling of compounds containing this substructure proved difficult and these difficulties relegated the priority of this work within the optimization program. Two exemplary aza-oxindoles (<b>34</b> and <b>35</b>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) were prepared which demonstrated potency in plaque assays (<b>34</b>: EC<sub>50</sub> = 2.1 nM and <b>35</b>: EC<sub>50</sub> = 4.1 nM). Compound <b>35</b> displayed a low intrinsic permeability (MDCK (MDR1) <i>P</i><sub>app</sub> A<sub>2</sub>B:B<sub>2</sub>A = 0.1:0.0 × 10<sup>–6</sup> cms<sup>–1</sup>) and high clearance (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) that translated to low bioavailability in the mouse (18%) with high clearance (81 mL min<sup>–1</sup> kg<sup>–1</sup>, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>).</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. <i>In Vivo</i> Pharmacokinetic Data for Leading Compounds in Multiple Species<a class="ref internalNav" href="#tbl8-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">dose; i.v./p.o., (mg/kg)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (p.o./i.v., h)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>max</sub> (h) p.o.</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> p.o. (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">Cl (i.v.) (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Vd<sub>ss</sub> (i.v.) (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">1/10</td><td class="colsep0 rowsep0" align="left">4.2/3.1</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">224</td><td class="colsep0 rowsep0" align="char" char=".">47.9</td><td class="colsep0 rowsep0" align="char" char=".">17.5</td><td class="colsep0 rowsep0" align="char" char=".">46.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">1/10</td><td class="colsep0 rowsep0" align="left">1.8/9.9</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">74.2</td><td class="colsep0 rowsep0" align="char" char=".">164</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">102</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">NT/50</td><td class="colsep0 rowsep0" align="left">ND/5.9</td><td class="colsep0 rowsep0" align="char" char=".">5.3</td><td class="colsep0 rowsep0" align="char" char=".">475</td><td class="colsep0 rowsep0" align="char" char=".">ND</td><td class="colsep0 rowsep0" align="char" char=".">ND</td><td class="colsep0 rowsep0" align="char" char=".">132</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">0.3/3</td><td class="colsep0 rowsep0" align="left">12.3/7.4</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">82.4</td><td class="colsep0 rowsep0" align="char" char=".">17.8</td><td class="colsep0 rowsep0" align="char" char=".">17.6</td><td class="colsep0 rowsep0" align="char" char=".">44.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">1/5</td><td class="colsep0 rowsep0" align="left">2.4/ND</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">110</td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="char" char=".">11.3</td><td class="colsep0 rowsep0" align="char" char=".">12.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">1/10</td><td class="colsep0 rowsep0" align="left">ND/0.8</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">44.3</td><td class="colsep0 rowsep0" align="char" char=".">209</td><td class="colsep0 rowsep0" align="char" char=".">11.0</td><td class="colsep0 rowsep0" align="char" char=".">13.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">1/10</td><td class="colsep0 rowsep0" align="left">ND/0.9</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">47.8</td><td class="colsep0 rowsep0" align="char" char=".">82.7</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">1/10</td><td class="colsep0 rowsep0" align="left">1.7/1.4</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">450</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="char" char=".">39.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">0.3/3</td><td class="colsep0 rowsep0" align="left">5.2/3.1</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">505</td><td class="colsep0 rowsep0" align="char" char=".">19.2</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char=".">163</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">1/10</td><td class="colsep0 rowsep0" align="left">ND/1.0</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">200</td><td class="colsep0 rowsep0" align="char" char=".">81.1</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char=".">18.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl8-fn1"><div class="footnote" id="tbl8-fn1"><sup><sup>a</sup></sup><p class="last">ND indicates not determined; NT indicates not tested. The compound was dosed as a suspension of the amorphous solid at the doses indicated i.v. and p.o.</p></div></div></div><div class="NLM_p last">Our program strategy had from the start utilized the structurally novel approach of incorporating a spirocyclic ring system into a bicyclic template (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Although this annotation has focused on the spirocyclopropyl output from this exercise, a number of other substituted spirocyclic ring systems were prepared and evaluated in this project, and single figure nanomolar potency was achievable with heterospirocycles of a variety of ring sizes. Azetidine and pyran lead compounds <b>36</b> and <b>37</b> that arose from this work are shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>. Subsequent patent filings by others dictated that we move away from optimization of these compounds.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The SAR and synthetic approaches to these compounds are described elsewhere.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> RV521 Evaluation</h3><div class="NLM_p">Compound <b>20</b> (RV521) and subsequently its related pyran analogue <b>23</b> were evaluated in rodent and dog pharmacokinetic studies (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). RV521 preceded its pyran analogue <b>23</b> through the project evaluation process by several months and although <b>23</b> demonstrated similar pharmacokinetic properties, it was never in a position to catch up and overtake the evaluation of RV521. As such the compound was held as a short-term back up compound in the event of issues occurring with RV521. The remainder of the discussion will focus on the properties of RV521.</div><div class="NLM_p">RV521 showed a moderate to long intravenous half-life (4.2 h in mice, 1.8 h in rats, and 12.3 h in dogs) with variable clearance in these species, approximately 53–61% of hepatic blood flow in mice and dogs and in contrast, approximately 200% of hepatic blood flow in rats. The compound had a large volume of distribution in all the species tested, suggestive of extensive tissue distribution. Subsequently, the relevance of this property of RV521, and other molecules in this series, was reinforced by repeat oral dosing studies in rats that showed a high lung to plasma ratio for RV521 (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_002.pdf" class="ext-link">Supporting Information</a>). Lung and plasma samples were taken on day seven (4 and 24 h time points) of a repeat dosing study, QD at 43.5 mg/kg. Analysis of these samples showed a 100-fold and 500-fold lung to plasma ratio. RV521 was present in the lung at a concentration of 11.8 mg/g at this dose at the 24-h time point on day 7.</div><div class="NLM_p">Oral exposure was demonstrated in rats at doses of 10 and 50 mg/kg with bioavailability at 102 and 132%, respectively: the apparent availability >100% most likely due to dose-dependent nonlinear kinetics. Plasma concentrations in rats declined with a half-life of 3.1 h, and the compound was absorbed relatively slowly with a <i>t</i><sub>max</sub> of 5.3 h. When dogs were dosed at 3 mg/kg, the bioavailability was shown to be 44.2% with an oral <i>t</i><sub>1/2</sub> of 12.3 h, and the compound was absorbed relatively slowly with a <i>t</i><sub>max</sub> of 4 h. An evaluation of metabolism in primary hepatocytes suggested that hepatic metabolism was a major pathway of elimination across all of these species.</div><div class="NLM_p">The activity of RV521 in the RSV plaque assay was evaluated against a panel of laboratory strains and low passage clinical isolates of RSV A and B strains. RV521 showed potent activity with an average IC<sub>50</sub> of 1.4 nM for RSV A (<i>n</i> = 20) and 1.0 nM for RSV B (<i>n</i> = 16) (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_002.pdf" class="ext-link">Supporting Information</a> for strains tested against and IC<sub>50</sub> values).</div><div class="NLM_p">The inhibition of RSV by RV521 was further investigated in an <i>in vitro</i> primary human airway epithelial cell (HAE) infectivity model.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The use of HAE cells provided a closer clinical context for RSV evaluation than that possible by standard plaque assay formats in continuous cell lines. Further, the use of trans-well plate inserts in this system allows for apical infection of the system with virus while allowing dosing the compound basolaterally, a system reflective of systemic exposure (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Differentiated HAE cell cultures mimic certain aspects of infection pathology and, unlike rodent models which are only semipermissive to infection, retain replicative capacity. This model has been used previously in the testing of RSV N protein inhibitors.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Recently, the differential activities of RSV inhibitors in the human airway epithelium model have been reported.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0008.jpeg" id="GRAPHIC-d7e2679-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (a) RV521 inhibition of RSV infection of HAE cells. Treatment of HAE cells with 10 nM RV521 2 h prior to infection (shaded bars) with recombinant luciferase-expressing RSV reduced the titer (as measured by luminescence) at 7 and 8 days postinfection versus untreated controls (white bars). Data are presented as mean ± SD (<i>n</i> = 3). (b) Representation of the inset cell system that allows viral infection to and sampling of the apical surface of the epithelial layer and compound administration (blue arrows) to the basolateral surface of the cells via the cell nutrient (salmon).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Treatment of HAE cells with 10 nM of RV521 resulted in a significant reduction in RSV shed from the apical surface compared to untreated controls. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, 2.30 log<sub>10</sub> and 2.35 log<sub>10</sub> reductions in RSV titer compared with untreated controls were observed on day 7 and day 8 post infection, respectively. Histological analysis of the control and compound treated HAE cell cultures, at 8 days post infection, revealed that control and compound treated cells retained tight junctions, suggestive of a healthy epithelial cell layer and RV521 treatment did not elicit any apparent change in cell morphology or viability.</div><div class="NLM_p">To characterize the mode of action of RV521 and to identify the viral determinants conferring reduced susceptibility to RV521, we performed an <i>in vitro</i> resistance selection study.</div><div class="NLM_p">An RSV stock resistant to RV521 was generated by serial passage of RSV in increasing concentrations of RV521. We utilized Hep-2 cell cultures inoculated with RSV strain Memphis 37b in the presence of RV521 (at EC<sub>50</sub> concentration) or no inhibitor (control). Once an 80–90% cytopathic effect was observed, or after a maximum of 7 days, RSV was passaged into fresh HEp2 cells and the concentration of RV521 increased 2-fold. Serial passaging in the presence of increasing concentrations of RV521 was continued for ten passages. The resistant RSV stocks were used for EC<sub>50</sub> determinations by plaque assay, and RNA was extracted for RSV F gene sequencing. This identified an amino acid substitution at position 489 in the RSV F protein, aspartic acid (D) to tyrosine (Y) (D489Y) with resistance to RV521. EC<sub>50</sub> values for RV521 against the RV521 resistant virus and passage control virus were 88.98 and 1.18 nM, respectively, representing a 76-fold shift in EC<sub>50</sub> in response to the acquisition of viral resistance to RV521.</div><div class="NLM_p">D489Y is a mutation in the RSV F protein observed in <i>in vitro</i> resistance studies with other RSV fusion inhibitors,<a onclick="showRef(event, 'ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37">(35−37)</a> and cross resistance with these inhibitors of RSV fusion was observed (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_002.pdf" class="ext-link">Supporting Information</a>). The resistant virus remained sensitive to treatment with known RSV replication inhibitors, the N-protein inhibitor RSV604 and the nucleoside pro-drug ALS-8112. However, most importantly, RSV containing D489Y has shown to have reduced fitness, with the virus exhibiting poor growth characteristics, in culture.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a></div><div class="NLM_p">We were able to obtain a crystal structure of RV521 bound to the prefusion conformation of the F protein (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). This structure placed the compound into the central binding region defined by subunits of the trimeric protein as described for other fusion inhibitors, notably that described for JNJ-53718678.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Key interactions observed are π interactions with the three key phenylalanine residues in this trimer defined pocket. Phe140 and Phe488 from one monomer shown in gold in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>a and Phe140 from a second monomer define these interactions. The aminomethylene functionality was observed to form a potential H bond with Thr397 from the third monomer (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>b). The mutable aspartic acid D489 was observed as a close neighbor of the amino group of RV521 with an N-<i>H</i> to C═O distance of around 2.6 Å. This observation was strongly supportive of the requirement for basic group in the inhibitor.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0009.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Crystal structure of RV521 bound to the F-protein (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KQD">7KQD</a>) in its trimeric prefusion conformation. Views are shown of the binding site created by the trimer. Amino acid residues are shown as gold, pink, or green filled sticks with the backbone shown as a ribbon in the corresponding color. Each colored region corresponds to each individual monomer. (a) Binding mode in a top-down view of RV521 depicting π-bonding interactions with phenylalanine 488 and 140 of the gold monomer. (b) Binding mode showing the orientation of the aminomethylene into a hydrophilic region created by Asp489 and Thr397 with the H bonding interaction with Threonine 397 backbone carbonyl indicated by the dotted line. The proximity of the mutable Asp489 is depicted most clearly in panel b. Amino acid residue labels are shown in the color of the monomer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Final support for the progression of the compound to the clinic was provided by an <i>in vivo</i> efficacy evaluation of RV521 in Balb/C mice inoculated with RSV A2 (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). A number of animal models exist for this evaluation of compounds <i>in vivo</i> however they are of varying utility, most notably in terms of compound requirement.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In our case, mice received two oral doses of RV521 (0, 1, 10, or 50 mg/kg) 2 h pre- and 24 h postintranasal inoculation with RSV strain A2. Animals were euthanized 5 days post-RSV inoculation, and lung homogenates were prepared. Viral titers in lung homogenates were evaluated by plaque assay on Vero cells. Virus titers in the lungs of mice treated with 50, 10, and 1 mg/mL RV521, compared to the control group, were reduced by 1.6 log<sub>10</sub> (98% reduction), 1.09 log<sub>10</sub> (92% reduction), and 0.67 log<sub>10</sub> (79% reduction), respectively. Concentrations of RV521 were measured in plasma samples taken 5 h after the first dose and immediately prior to the second dose of the compound. Concentrations of RV521 measured in the plasma were vastly in excess of EC<sub>50</sub> figures (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_002.pdf" class="ext-link">Supporting Information</a>) except at the lowest dose. The activity of the compound observed in this model at the 1 mg/kg dose has to be taken in the context of the distributive properties of the compound <i>vide infra</i>.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0010.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. RV521 reduced lung virus titers in a Balb/C mouse model of RSV infection. Balb/C mice were treated with RV521 (1, 10, or 50 mg/kg) 2 h pre- and 24 h postintranasal inoculation with RSV strain A2. RSV viral titers in lung homogenates were measured 5 days postinfection. Data are expressed as a percentage of control group and shown as mean ± sd (<i>n</i> = 6 animals per group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Synthesis Overview</h3><div class="NLM_p">In general, compounds prepared within this program utilized the same convergent synthetic strategy with benzimidazole and spirocyclic oxindole fragments prepared as key intermediates (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). These two fragments were then linked via alkylation of the spirocyclic lactam.</div><figure id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0012.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Disconnection of Generalized Target Compound Structure into Chlorobenzimidazole and Spirocyclic Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Blue and red rings indicate variable sized spirocyclic ring systems. X = F, Cl, H. Y = H, CH<sub>2</sub>NHBoc, Cl, CN. R is a variable alkyl chain.</p></p></figure><div class="NLM_p">The discovery phase synthesis of RV521 is representative of the route employed for the preparation of the benzimidazole intermediates (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> and <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). This proceeded via an established sequence which started with an S<sub>N</sub>Ar displacement of the chlorine of 4-chloronitrobenzonitrile <b>38</b> by trifluorobutylamine. Nitro reduction, benzimidazole formation with the chloroacetyl chloride and acetate hydrolysis provided nitrile <b>40</b>. Nitrile reduction and subsequent chlorination provided the key chloromethyl intermediate <b>41</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Cyclopropanation of 6-fluorooxindole <b>42</b> was performed utilizing lithium diisopropylamide as base in an alkylation methodology with 1,2-dibromoethane to provide the spirocyclopropyl oxindole <b>43</b>. Both halves of the molecule (<b>41</b> and <b>43</b>) were then linked via a simple displacement reaction (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Removal of the BOC protecting group and hydrochloride salt formation afforded a clean preparation of the HCl salt of RV521.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><figure id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Benzimidazole Intermediate for RV521<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 4,4,4-trifluorobutan-1-amine, NEt<sub>3</sub>, MeCN, rt, 16 h, 92%. (ii) Pd/C, H<sub>2</sub>, rt, 16 h, 88%. (iii) acetoxyacetyl chloride, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h, then AcOH, 80 °C, 16 h, 69%. (iv) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 1 h, 91%. (v) Pd(OH)<sub>2</sub>/C, HCl, H<sub>2</sub>, MeOH/THF, rt, 16 h, then BOC anhydride, DIPEA,CH<sub>2</sub>Cl<sub>2</sub>, rt, 3 h, 83%. (vi) MsCl, DIPEA, THF, rt, 16 h, 96%.</p></p></figure><figure id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0014.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Sequence Used in the Preparation of RV521<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <i>n</i>-BuLi, diisopropylamine, 1,2-dibromoethane, −40 to 18 °C, 47%. (ii) NaH, DMF, rt, 16 h, 75%. (iii) HCl (2 M in Et<sub>2</sub>O), CH<sub>2</sub>Cl<sub>2</sub>, rt, 6 h, then aq. NaHCO<sub>3</sub> workup, 63%. (iv) HCl (2 M in Et<sub>2</sub>O), CH<sub>2</sub>Cl<sub>2</sub>, 30 min, 81%.</p></p></figure><div class="NLM_p">Other benzimidazole precursors were prepared via an analogous sequence to that shown for the synthesis of <b>20</b> (and are detailed in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_002.pdf" class="ext-link">Supporting Information</a>), while the spirocyclic lactams employed in the hit finding exercise could be prepared via an alkylation methodology to construct the exocyclic ring last, with a complementary approach enabling preparation of a spirocyclic 6,6-system (details in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_002.pdf" class="ext-link">Supporting Information</a>).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Recently developed cyclopropanation methodologies have been reported that enable facile one-pot access to the spirocyclopropyl oxindoles of compounds <b>11</b>–<b>17</b> and <b>35</b> without N-protection.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> Of particular note, the nucleophilic alkylation methodology of Andreasson et al. was exploited to enable construction of the spirocyclopropyl azaoxindole <b>49</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Addition of a methylene to the pyridyl acetoacetate <b>46</b> afforded <b>47</b>. Subsequent cyclopropanation to <b>48</b> was followed by nitro reduction and ring closure to give the target oxindole <b>49</b>. 6-Substituted benzimidazole target compounds were assembled either directly from <b>20</b> or via manipulation of the 6-cyano analogue <b>24</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0015.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Spirocyclic Azaoxindole <b>49</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) ethylchoroacetate, KO<sup>t</sup>Bu, 0 °C to rt, 2.5 h, 80%. (ii) K<sub>2</sub>CO<sub>3</sub>, benzyltriethylammonium chloride, paraformaldehyde, toluene, 90 °C, 1.25 h, 77%. (iii) DBU, trimethylsulfoxonium chloride, CH<sub>3</sub>CN, 60 °C, 45 min, 59%. (iv) Pd/C, EtOH, H<sub>2</sub>, 16 h. (v) 1,5,7-Triazabicyclo[4.4.0]dec-5-ene, 80 °C, 1 h, 90%.</p></p></figure><figure id="sch5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0016.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 6-Aminomethylene Derivatives from 6-Cyanobenzimidazole <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Synthesis is described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_002.pdf" class="ext-link">Supporting Information</a>). Reagents and conditions: <b>25</b>: (i) acetyl chloride, EtOH, rt, 16 h. (ii) NH<sub>3</sub>, methanol, rt, 48 h, 21%. <b>26</b>: (iii) acetyl chloride, EtOH, rt, 16 h. (iv) EtNH<sub>2</sub>, methanol, rt, 16 h, 57%. <b>27</b>: (v) 5% Pd/C, H<sub>2</sub>, HCl/MeOH, 77%. vi) (BocN)<sub>2</sub>C═N(SO<sub>2</sub>CF<sub>3</sub>), Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 23 h. (vii) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 19 h, 78%. <b>28</b>: (viii) NaOH, dioxane, reflux, 36%. <b>31</b>: (ix) 5% Pd/C, H<sub>2</sub>, HCl/MeOH, 77%. (x) acetyl chloride, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 71%.</p></p></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> RSV521 Progression into Clinical Trials</h3><div class="NLM_p">RV521 progressed into the preclinical evaluation phase, utilizing a virtual development model employing external contract synthesis, pharmacology and toxicology. In summary, <i>in vitro</i> broad receptor pharmacology was acceptable, and the cardiotoxicology profile exhibited no QT effects in an anesthetized guinea pig model or subsequently in any <i>in vivo</i> (dog telemetry) studies. Ames and rat micronucleus tests were negative. Single dose safety pharmacology showed no evidence of any adverse findings and repeat dose toxicity studies determined a NOAEL that gave an acceptable safety margin. Events observed at the highest dose were reversible and could be readily monitored in the clinic. Repeat dose toxicity studies were performed for 28 days in both rats and dogs, and subsequent studies in juvenile animals enabled the clinical program to progress to pediatric studies. The dose predictions for the first study in man were based on <i>in vitro</i> clearance values in rat. On this basis, and assuming a one-compartment first-order absorption model, daily oral doses of 50 mg were predicted to achieve steady state trough concentrations equivalent to a 3-fold margin above the <i>in vitro</i> EC<sub>90</sub> value for total (free and bound) plasma concentration of RV521.</div><div class="NLM_p">Subsequent evaluation of PK from the initial Phase 1 study in healthy volunteers indicated that the predictions based on rat clearance overestimated RV521 plasma exposure, and doses of 200 and 350 mg BID were required to meet or exceed the target of a 3-fold margin above the <i>in vitro</i> EC<sub>90</sub> value.</div><div class="NLM_p">The path through the initial stages of clinical development has become established for inhibitors of RSV primarily because of the availability of an RSV challenge virus. In general, small-molecule inhibitors of RSV have progressed through the clinic according to draft EMEA guidelines.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> In general, after Phase 1 single and multiple ascending dose studies in healthy volunteers to demonstrate safety, tolerability, and indicate pharmacokinetics, clinical compounds have entered a Phase 2a proof of concept study in the human challenge model. This is a trial whereby cohorts of healthy volunteers are quarantined in a specialist unit and intranasally infected with RSV strain Memphis 37b, the only GMP quality RSV virus currently available for human challenge. Viral load, as assessed by assay of nasal washes, has been shown to correlate with disease severity in the challenge model,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> and treatment is delayed until volunteers are shedding virus; this model therefore formed a basis whereby the effect of antiviral agents can be studied in a well-controlled patient group.</div><div class="NLM_p">Data from RSV fusion inhibitors studied in this clinical model have been published. Presatovir and JNJ-53718678 (<b>1</b> and <b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) were shown to effectively reduce viral load and symptom scores.<a onclick="showRef(event, 'ref11 ref47'); return false;" href="javascript:void(0);" class="ref ref11 ref47">(11,47)</a> Subsequently with this proof of concept in hand, inhibitors have moved into patient population studies. The initial patient studies being in pediatric populations, targeting infants up to the age of 24 months. In cases where the properties of a compound have not supported progression in infants,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> the next stage of evaluation has been in vulnerable adult populations such as hematopoietic cell transplant (HCT) recipients with RSV infections of the upper or lower respiratory tract (URTI or LRTI), lung transplant patients with RSV infection and adults hospitalized with RSV infections.<a onclick="showRef(event, 'ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51">(49−51)</a></div><div class="NLM_p">Significant challenges are associated with both of these clinical evaluation routes. The recruitment of adult populations has to be achieved at an early stage in infection. Pediatric clinical studies require a revisiting of ascending dose studies prior to any patient study, and the disease course in pediatric patients is quite different to that in adults. Essentially, infants struggle to control primary RSV infections, and lower age trends toward slower viral clearance and a greater viral load, as measured by viral AUC.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><div class="NLM_p">RV521 progressed through phase 1 single ascending and multiple ascending dose studies in a total of 76 healthy volunteers. At doses between 175 and 350 mg, exposures could be achieved that provided trough levels greater than a multiple of three times the plasma protein adjusted EC<sub>90</sub>. (this was the median EC<sub>90</sub> from multiple (<i>n</i> = 16) RSV plaque assays with RSV strain A2). No serious adverse events were reported at the doses investigated and this allowed the dosing regimen to be formulated for the progression of the compound into the human challenge model.</div><div class="NLM_p">The Phase 2a clinical study<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> was performed to establish proof-of-concept for the antiviral activity of RV521 in the treatment of RSV, using a virus challenge model per regulatory guidance. Additional aims for this study were to determine the safety, tolerability, and pharmacokinetic profile of RV521 and to perform mutation detection analyses to test for potential development of RSV resistance to RV521.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div class="NLM_p">The study was conducted in healthy male or female adult volunteers (aged between 18 and 45 years) with low serum levels of pre-existing specific antibodies to RSV, which indicated that the subject would be sensitive to RSV infection and would likely become infected following inoculation with the challenge virus. This challenge virus was the RSV-A Memphis 37b strain, and approximately 4 log<sub>10</sub> plaque forming units (PFU) were administered on day zero. Subjects were then randomly assigned to 3 equivalently sized groups and dosed with 200 or 350 mg of RV521 or placebo twice daily for 5 days following confirmation of infection.</div><div class="NLM_p">Nasal wash samples were taken twice daily from day 2 through to discharge (day 12) to allow measurement of viral load via reverse transcriptase quantitative RT-qPCR and a cell-based infectivity assay.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The occurrence and severity of symptoms were reported, and nasal mucus was weighed. Pharmacokinetic assessments were based on venous blood samples taken from day zero through to discharge. Safety assessments, including electrocardiogram recordings, physical examination, and urinalysis, were taken at prespecified time points throughout the study. Adverse events were monitored daily.</div><div class="NLM_p">Efficacy data for mean viral loads versus time are shown in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>a and b. There was a significant reduction in the mean AUC of viral load as assessed by RT-qPCR and cell-based infectivity assay with RV521 versus placebo for both doses of RV521. The percentage reduction highlighted the scale of this effect with the mean reductions in RT-qPCR AUC for RV521 at 200 and 350 mg relative to placebo calculated at 55.25 and 63.05%, respectively, and 76.42 and 68.60% reduction by cell-based infectivity assay. RV521 at these doses significantly reduced the AUC of total symptom score compared with placebo and a posthoc analysis of nasal mucus weight data showed that the mean daily nasal mucus weight was significantly lower in the RV521 treatment groups relative to the placebo group. Target group mean trough levels (3 × plasma protein adjusted <i>in vitro</i> EC<sub>90</sub>) were achieved and maintained at a level equivalent or greater than this for the duration of the study. The target exposure level was achieved in both dose groups with no significant differences in efficacy observed between the 200 and 350 mg dose groups, although it should be noted that the study was not designed to assess differences in treatment effect between the two doses. The most common treatment-emergent adverse events (nausea and diarrhea) were mild, transient, and resolved. No treatment-related serious adverse events were observed. In summary, this clinical human challenge study demonstrated proof of concept for clinical efficacy of RV521.</div><figure id="fig11" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0011.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Mean viral load by nasal wash RT-qPCR (A) and by nasal wash cell-based infectivity assay (B) by day relative to dosing. Once RSV infection was confirmed, treatment was initiated at 200 or 350 mg BID. Viral load (RT-qPCR) appeared to rebound after day 8.5 in the placebo arm. However, this apparent increase resulted from the staggered randomization of subjects (the mean viral load at day 9 was calculated from just four subjects, three of whom had consistently high viral loads throughout the study). Figure reprinted under a Creative Commons Attribution 4.0 International License (CC BY 4.0).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Reprinted from DeVincenzo, J.; Tait, D.; Efthimiou, J.; Mori, J.; Kim, Y.-I.; Thomas, E.; Wilson, L.; Harland, R.; Mathews, N.; Cockerill, S.; Powell, K.; Littler, E. A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein. Antimicrob. Agents Chemother. 2020, 64, e01884–19. Copyright 2020 American Society of Microbiology.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67762" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67762" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Herein, we have described the properties of and process behind the identification of <b>20</b>, known as RV521 and subsequently named sisunatovir, as a potent and clinically efficacious inhibitor of RSV fusion in the human challenge model of RSV infection.</div><div class="NLM_p">RSV521 was shown to be potent against a panel of RSV A and B clinical isolates. Resistance studies confirmed the mode of action with key mutations identified and <i>in vivo</i> antiviral efficacy was demonstrated in the Balb/C mouse model of RSV infection at levels comparable with those seen for other inhibitors.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Additionally, an effective demonstration of activity was seen in human airway epithelial cells. Oral bioavailability in preclinical species ranged from 42 to >100% with evidence of efficient penetration into lung tissue. Following a successful preclinical phase, the compound progressed through phase 1 healthy volunteer single and multiple dose studies. In healthy human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a significant reduction in viral load and reduction in symptoms compared to placebo. In conclusion, a potent, oral RSV fusion inhibitor with the potential to treat RSV infection in infants and adults is reported.</div><div class="NLM_p last">This program to identify RV521 has been core to the progress of Reviral Ltd. and was supported by a number of funding initiatives. A discussion of the background to the process is of some worth at this stage in the article. The plans for the project were laid by the founding team of Reviral, and this led to the initial lead compound <b>6</b>. The properties of this compound were sufficient, in terms of absorption and distribution particularly, to allow progression into the lead optimization phase. Identification of RV521 was supported by Reviral and allowed the elevation of the compound into full clinical evaluation. As the compound continues to move through clinical evaluation, the company has continued to grow, building a pipeline of projects in addition to this initial flagship project.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64767" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64767" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> General Synthetic Protocols</h3><div class="NLM_p last">All reagents were purchased from commercial suppliers and were of the highest available purity. Unless otherwise stated, chemicals were used as supplied without further purification. Anhydrous solvents were purchased from Acros (AcroSeal) or Sigma-Aldrich (SureSeal) and were stored under nitrogen. Petroleum ether refers to the fraction with a boiling point between 40 and 60 °C. All reactions were carried out under a nitrogen atmosphere unless otherwise specified. Flash column chromatography was performed using an automated chromatography system on silica gel. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were typically recorded on a Varian VNMRS 500 MHz spectrometer at 30 °C using residual isotopic solvent as an internal reference. The chemical shift data for each signal are given as δ in units of parts per million (ppm). LC-MS data were recorded on a Shimadzu Prominence Series coupled to a LCMS-2020 ESI mass spectrometer. Samples were eluted through a Phenomenex Gemini C18 (pore size: 110 Å; particle size: 5 μm; dimensions: 250 × 4.6 mm column) using water and acetonitrile acidified by 0.1% formic acid at 1 mL/min, a run time of 7 min unless otherwise noted, and detection at 254 nm. HRMS (ESI) was recorded on either a Bruker Daltonics, Apex III, ESI source: Apollo ESI, with methanol as spray solvent or a QToF Premier, Waters machine (diode array detection: 210–500 nm, oven temperature: 40 °C, MassLynx v4.1 data handling) equipped with a Waters BEH C18 column (particle size: 1.7 μm; 2.1 × 100 mm) eluting with 0.1% formic acid in water and methanol gradient. Only molecular ions, fractions from molecular ions, and other major peaks are reported as <i>m</i>/<i>z</i> ratios. The purity of final compounds was determined to be >95% using UHPLC analyses performed on a Waters Acquity UPLC system with a Kinetex C18 column (pore size: 100 Å; particle size: 1.7 μm; dimensions: 2.1 × 50 mm).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 3-Amino-4-(4,4,4-trifluorobutylamino) Benzonitrile (<b>39</b>)</h3><div class="NLM_p">A solution of 4-chloro-3-nitro-benzonitrile (10 g, 54.78 mmol), 4,4,4-trifluorobutan-1-amine (6.91 mL, 60.25 mmol), and NEt<sub>3</sub> (9.16 mL, 65.73 mmol) in MeCN (130 mL) was stirred at rt for 16 h. Further 4,4,4-trifluorobutan-1-amine (0.6 mL, 5.23 mmol) and NEt<sub>3</sub> (0.9 mL, 6.46 mmol) were added, and the reaction was stirred at rt for 5 h. The volatiles were removed <i>in vacuo</i>; the residue was taken up in water, and the resultant precipitate filtered, washed with water, and dried. Trituration with petroleum ether afforded 3-nitro-4-(4,4,4-trifluorobutylamino) benzonitrile as a bright yellow solid (13.71 g, 92%) which was used without further purification. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.54 (d, <i>J</i> = 2.1 Hz, 1H), 8.41 (s, 1H), 7.65 (dd, <i>J</i> = 9.0, 2.1 Hz, 1H), 6.92 (d, <i>J</i> = 8.9 Hz, 1H), 3.49 (q, <i>J</i> = 6.7 Hz, 2H), 2.28 (ddt, <i>J</i> = 15.3, 10.6, 5.5 Hz, 2H), 2.05 (p, <i>J</i> = 7.5 Hz, 2H).</div><div class="NLM_p last">A solution of 3-nitro-4-(4,4,4-trifluorobutylamino) benzonitrile (13.71 g, 50.18 mmol) in MeOH (250 mL) was flushed with N<sub>2</sub>, charged with 10 wt % palladium on carbon (534 mg, 0.50 mmol) and purged with hydrogen. The reaction mixture was stirred under an atmosphere of hydrogen (balloon) at rt overnight. The reaction mixture was filtered through a pad of Celite and washed with MeOH until the filtrate was colorless. The filtrate was evaporated <i>in vacuo</i> to give the crude product as a dark solid (12.6 g). Recrystallization from EtOAc/petroleum ether afforded 2× batches of product as a gray solid (batch 1:2.56 g; batch 2:2.17 g). The filtrate from the recrystallization was evaporated under reduced pressure and purified (SiO<sub>2</sub>, 40–70% EtOAc in petroleum ether) to afford a purplish dark gray solid (6.02 g). Combined yield: 10.75 g, 88%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.19 (dd, <i>J</i> = 8.3, 1.8 Hz, 1H), 7.02 (d, <i>J</i> = 1.8 Hz, 1H), 6.60 (d, <i>J</i> = 8.3 Hz, 1H), 3.27 (t, <i>J</i> = 7.1 Hz, 2H), 2.24 (tdt, <i>J</i> = 16.0, 10.7, 5.7 Hz, 2H), 1.95 (p, <i>J</i> = 7.2 Hz, 2H). LCMS (ESI+) <i>m</i>/<i>z</i> 244.3 [M + H]<sup>+</sup> at 3.28 min.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> [5-Cyano-1-(4,4,4-trifluorobutyl)benzimidazol-2-yl]methyl Acetate</h3><div class="NLM_p last">Acetoxyacetyl chloride (2.21 mL, 20.56 mmol) was added dropwise via a syringe to a stirred and cooled (0 °C) solution of 3-amino-4-(4,4,4-trifluorobutylamino) benzonitrile (5.0 g, 20.56 mmol) and NEt<sub>3</sub> (5.73 mL, 41.11 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (75 mL). The reaction mixture was allowed to attain rt and stirred for 2 h. The volatiles were removed <i>in vacuo</i>, and the residue was dissolved in acetic acid (30 mL) and stirred at 80 °C for 16 h. The volatiles were removed under reduced pressure; the residue was taken up in CH<sub>2</sub>Cl<sub>2</sub> (200 mL) and then washed with saturated solution of Na<sub>2</sub>CO<sub>3</sub> (3× 100 mL) and dried (MgSO<sub>4</sub>), and the solvent removed under reduced pressure. Purification by flash chromatography (SiO<sub>2</sub>, 40–80% EtOAc in petroleum ether) followed by trituration afforded an off-white solid (4.61 g, 69%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27–8.15 (m, 1H), 7.89 (dd, <i>J</i> = 8.4, 0.7 Hz, 1H), 7.71 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 5.37 (s, 2H), 4.40 (t, <i>J</i> = 7.7 Hz, 2H), 2.46–2.32 (m, 2H), 2.09 (s, 3H), 2.05–1.90 (m, 2H). LCMS (ESI+) <i>m</i>/<i>z</i> 326.1 [M + H]<sup>+</sup> at 3.26 min.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 2-(Hydroxymethyl)-1-(4,4,4-trifluorobutyl)benzimidazole-5-carbonitrile (<b>40</b>)</h3><div class="NLM_p last">A suspension of [5-cyano-1-(4,4,4-trifluorobutyl)benzimidazol-2-yl]methyl acetate (7.44 g, 22.87 mmol) and potassium carbonate (6.32 g, 45.74 mmol) in MeOH (120 mL) was stirred at rt for 1 h. The reaction mixture was concentrated <i>in vacuo</i>; CH<sub>2</sub>Cl<sub>2</sub> (200 mL) was added, and the mixture stirred for 10 min, then filtered, and washed with CH<sub>2</sub>Cl<sub>2</sub>. The filtrate concentrated <i>in vacuo</i>. Purification by flash chromatography (SiO<sub>2</sub>, 0–5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) followed by trituration with Et<sub>2</sub>O afforded a white solid (3.90 g). The Et<sub>2</sub>O triturate was concentrated <i>in vacuo</i> and purified by flash chromatography (SiO<sub>2</sub>, 0–5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford a second crop of product (2.02 g, pink solid). Combined yield: 5.92 g, 91%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.14 (dd, <i>J</i> = 1.5, 0.7 Hz, 1H), 7.84 (dd, <i>J</i> = 8.4, 0.7 Hz, 1H), 7.66 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 5.80–5.70 (m, 1H), 4.75 (d, <i>J</i> = 5.4 Hz, 2H), 4.40 (t, <i>J</i> = 7.6 Hz, 2H), 2.44–2.28 (m, 2H), 2.00 (dq, <i>J</i> = 12.0, 7.8 Hz, 2H). LCMS (ESI+) <i>m</i>/<i>z</i> 284.2 [M + H]<sup>+</sup> at 2.06 min.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>tert</i>-Butyl <i>N</i>-[[2-(Hydroxymethyl)-1-(4,4,4-trifluorobutyl)benzimidazol-5-yl]methyl]carbamate</h3><div class="NLM_p">Palladium hydroxide on activated carbon (20 wt %; 773 mg, 5.51 mmol) was added to a solution of 2-(hydroxymethyl)-1-(4,4,4-trifluorobutyl)benzimidazole-5-carbonitrile (4.33 g, 15.29 mmol) in MeOH (150 mL) and THF (77 mL). The reaction was purged with H<sub>2</sub>; hydrogen chloride (0.4 M solution in water; 37 mL, 15.26 mmol) was added, and the solution was stirred under an atmosphere of hydrogen via a balloon at rt overnight. The reaction was filtered through a pad of Celite and washed with MeOH (3× 30 mL), and the filtrate was concentrated <i>in vacuo</i>. The residue was diluted with water (50 mL) and basified to pH ≈ 9.5 with saturated aqueous Na<sub>2</sub>CO<sub>3</sub> solution. The resulting suspension was then concentrated to dryness under reduced pressure. The residue was suspended in MeCN/Et<sub>2</sub>O (1:1, 2× 50 mL) and filtered. The precipitate was washed with EtOH (6× 50 mL), and the solvent was removed under reduced pressure to afford a white solid (4 g). The precipitate was washed further with EtOH (3× 30 mL), and the solvent was removed under reduced pressure. The filtrate from the MeCN/Et<sub>2</sub>O wash was also concentrated under reduced pressure, and the combined residues were purified by flash chromatography [SiO<sub>2</sub>, eluting with CH<sub>2</sub>Cl<sub>2</sub>:MeOH:NH<sub>3</sub> (100:0:0 to 90:10:2)], which afforded a further 380 mg of off-white solid. The combined material (∼4.38 g) was taken to the next step without further purification.</div><div class="NLM_p last">Di<i>tert</i>-butyl dicarbonate (3.26 g, 14.92 mmol) was added portionwise to a solution of crude 5-(aminomethyl)-1-(4,4,4-trifluorobutyl)benzimidazol-2-yl]methanol (4.38 g, 15.25 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (4.82 mL, 27.67 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (150 mL) under N<sub>2</sub>, and the reaction was stirred at rt for 3 h. The volatiles were removed under reduced pressure, and the crude was suspended in petroleum ether:EtOAc (∼8:2; 50 mL) and filtered. The precipitate was washed with petroleum ether:EtOAc (∼8:2; 3 × 50 mL), and the filtrate was discarded. The precipitate was washed with water H<sub>2</sub>O (2× 50 mL) and dried in a vacuum oven. The solid was then triturated with MeOH (30 mL) and dried to afford a white solid (4.93 g, 83%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.52 (d, <i>J</i> = 8.4 Hz, 1H), 7.44 (s, 1H), 7.39–7.32 (m, 1H), 7.14 (d, <i>J</i> = 8.3 Hz, 1H), 5.60 (t, <i>J</i> = 5.7 Hz, 1H), 4.70 (d, <i>J</i> = 5.5 Hz, 2H), 4.33 (t, <i>J</i> = 7.4 Hz, 2H), 4.20 (d, <i>J</i> = 6.2 Hz, 2H), 2.43–2.26 (m, 3H), 2.00 (p, <i>J</i> = 7.6 Hz, 2H), 1.39 (s, 9H). LCMS (ESI+) <i>m</i>/<i>z</i> 388.1 [M + H]<sup>+</sup> at 0.57 min.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>tert</i>-Butyl <i>N</i>-[[2-(Chloromethyl)-1-(4,4,4-trifluorobutyl)benzimidazol-5-yl]methyl]carbamate (<b>41</b>)</h3><div class="NLM_p last">Methanesulfonyl chloride (193 μL, 2.50 mmol) was added dropwise via syringe to a cooled (0 °C) solution of <i>tert</i>-butyl <i>N</i>-[[2-(hydroxymethyl)-1-(4,4,4-trifluorobutyl)benzimidazol-5-yl]methyl]carbamate (0.88 g, 2.27 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (1.19 mL, 6.81 mmol) in THF (15 mL). The reaction mixture was allowed to warm to rt and stirred overnight. The reaction was quenched with water (10 mL), and the volatiles were removed under reduced pressure. The residue was diluted with water (25 mL) and extracted with EtOAc (2 × 25 mL). The combined organic extracts were washed with saturated citric acid solution, then saturated aqueous NaHCO<sub>3</sub> solution, and dried (MgSO<sub>4</sub>), and the solvent was removed under reduced pressure to afford a light orange oil (880 mg, 96%) which was used without further purification. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.58 (d, <i>J</i> = 8.3 Hz, 1H), 7.48 (s, 1H), 7.38 (t, <i>J</i> = 6.4 Hz, 1H), 7.21 (d, <i>J</i> = 8.3 Hz, 1H), 5.06 (s, 2H), 4.36 (t, <i>J</i> = 7.6 Hz, 2H), 4.21 (d, <i>J</i> = 6.3 Hz, 2H), 2.38 (ddt, <i>J</i> = 14.8, 8.6, 3.2 Hz, 2H), 2.06–1.98 (m, 2H), 1.39 (s, 9H). LCMS (ESI+) <i>m</i>/<i>z</i> 406.0 [M + H]<sup>+</sup> at 3.74 min. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>24</sub>ClF<sub>3</sub>N<sub>3</sub>O<sub>2</sub> 406.1504, found 406.1503.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 6′-Fluoro-1′,2′-dihydrospiro[cyclopropane-1,3′-indole]-2′-one (<b>43</b>)</h3><div class="NLM_p last">A solution of 6-fluoroindolin-2-one (1.63 g, 10.79 mmol) and diisopropylamine (3.17 mL, 22.65 mmol) in anhydrous tetrahydrofuran (18 mL) under N<sub>2</sub> was cooled at −40 °C using a dry ice/acetonitrile bath. <i>n</i>-Butyllithium solution (2.5 M in hexanes; 17.26 mL, 43.14 mmol) was added dropwise via syringe over 15 min. Upon complete addition, the dry ice/acetonitrile bath was changed for an ice bath, and the reaction allowed to warm to 0 °C. A solution of 1,2-dibromoethane (2.79 mL, 32.35 mmol) in THF (7 mL) was then added dropwise, and the reaction mixture was stirred at rt overnight. The reaction was quenched with saturated aq. NH<sub>4</sub>Cl (60 mL) and diluted with EtOAc (100 mL), and the phases separated. The aqueous layer was extracted with EtOAc (50 mL); the combined organic layers were extracted with brine (2× 75 mL) and dried (MgSO<sub>4</sub>), and the solvent was removed under reduced pressure. The crude was purified by flash chromatography (SiO<sub>2</sub>, 0–100% EtOAc in petroleum ether) to afford an orange solid (902 mg, 47%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.49 (s, 1H), 6.79–6.67 (m, 3H), 1.76 (q, <i>J</i> = 3.9 Hz, 2H), 1.53 (q, <i>J</i> = 4.2 Hz, 2H). LCMS (ESI+) <i>m</i>/<i>z</i> 178.2 [M + H]<sup>+</sup> at 1.31 min.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>tert</i>-Butyl <i>N</i>-([2-((6′-Fluoro-2′-oxo-1′,2′-dihydrospiro[cyclopropane-1,3′-indole]-1′-yl)methyl)-1-(4,4,4-trifluorobutyl)-1<i>H</i>-1,3-benzodiazol-5-yl]methyl)carbamate (<b>44</b>)</h3><div class="NLM_p last">Sodium hydride (60% dispersion in mineral oil; 0.11 mL, 2.75 mmol) was added in one portion to a cooled (0 °C) solution of 6′-fluoro-1,2-spiro[cyclopropane-1,3′-indole]-2′-one (487 mg, 2.75 mmol) in DMF (10 mL) under nitrogen. The reaction was allowed to attain rt and stirred for 1 h. A solution of crude <i>N</i>-[[2-(chloromethyl)-1-(4,4,4-trifluorobutyl)-1<i>H</i>-1,3-benzodiazol-5-yl]methyl]carbamate (1.01 g, 2.48 mmol) in DMF (4 mL) was then added by dropwise addition over 5 min, and the reaction mixture was stirred at rt for 16 h. The reaction was quenched with water (100 mL) and extracted with EtOAc (3× 75 mL). The combined organics were washed with water (100 mL) and brine (120 mL) and then dried (MgSO<sub>4</sub>) and evaporated under reduced pressure. The crude oil was purified by flash chromatography (SiO<sub>2</sub>, 0–100% EtOAc in petroleum ether) followed by trituration with petroleum ether/EtOAc (4:1; 10 mL) to afford a yellow solid (1030 mg, 75%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.74–7.70 (m, 1H), 7.34 (dd, <i>J</i> = 9.1, 2.1 Hz, 1H), 6.77–6.66 (m, 2H), 5.30–5.26 (m, 2H), 4.91 (s, 1H), 4.45 (d, 2H), 4.33 (t, <i>J</i> = 7.9 Hz, 2H), 2.20–2.06 (m, 2H), 1.91–1.81 (m, 2H), 1.81–1.72 (m, 2H), 1.63 (d, <i>J</i> = 1.0 Hz, 1H), 1.59–1.53 (m, 2H), 1.48 (s, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 177.1, 162.3 (d, <i>J</i><sub>CF</sub> = 245 Hz), 148.4, 143.1 (d, <i>J</i><sub>CF</sub> = 12 Hz), 142.6, 134.5, 133.8, 127.0, 125.3, 123.5, 119.1 (d, <i>J</i><sub>CF</sub> = 9 Hz), 118.96, 109.6, 109.1 (d, <i>J</i><sub>CF</sub> = 23 Hz), 99.6 (d, <i>J</i><sub>CF</sub> = 30 Hz), 77.2, 42.7, 38.2, 31.1 (q, <i>J</i><sub>CF</sub> = 28 Hz), 26.7, 22.7, 22.6, 22.58, 19.6. LCMS <i>m</i>/<i>z</i> [M+ H]<sup>+</sup> 547.2 at 4.55 min.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 1′-([5-(Aminomethyl)-1-(4,4,4-trifluorobutyl)-1<i>H</i>-1,3-benzodiazol-2-yl]methyl)-6′fluoro-1′,2′-dihydrospiro[cyclopropane-1,3′-indole]-2′-one (<b>20</b>)</h3><div class="NLM_p">To a solution of <i>tert</i>-butyl <i>N</i>-[(2-[(6′-fluoro-2′-oxo-1′,2′-dihydro[spirocyclopropane-1,3′-indole]-1′-ylmethyl]-1-(4,4,4-trifluorobutyl)-1<i>H</i>-1,3-benzodiazyl)methyl]carbamate (1030 mg, 1.88 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3.5 mL) under nitrogen was added hydrogen chloride solution (2 M in Et<sub>2</sub>O; 12.54 mL, 25.08 mmol). A pink/white solid precipitate formed almost immediately, and the mixture was stirred at rt for 6 h. The reaction mixture was concentrated under reduced pressure at ambient temperature and azeotroping with CH<sub>2</sub>Cl<sub>2</sub> (3× 20 mL) to avoid HCl concentration. The crude product was sonicated and triturated with Et<sub>2</sub>O (2 × 15 mL, then 4 × 10 mL). The mixture was filtered, washed with (Et<sub>2</sub>O (3× 10 mL), and dried in a vacuum oven to give the crude HCl salt of the desired product as an off-white solid (851 mg, 89% crude yield).</div><div class="NLM_p last">The crude HCl salt was partitioned between EtOAc (80 mL) and saturated aqueous NaHCO<sub>3</sub> solution (80 mL). The organic phase was separated, and the aqueous layer was extracted with EtOAc (3 × 30 mL). The organics were combined, dried (MgSO<sub>4</sub>), and concentrated under reduced pressure. The residue was triturated with Et<sub>2</sub>O (15 mL) and then purified by flash chromatography on [SiO<sub>2</sub>, 0–50% CH<sub>2</sub>Cl<sub>2</sub>:MeOH:NH<sub>3</sub> (9:1:0.2) in CH<sub>2</sub>Cl<sub>2</sub>] to afford the free base as a white solid (539 mg, 63%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.58 (d, <i>J</i> = 1.5 Hz, 1H), 7.54 (d, <i>J</i> = 8.3 Hz, 1H), 7.24 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 7.17 (dd, <i>J</i> = 9.6, 2.4 Hz, 1H), 7.06 (dd, <i>J</i> = 8.3, 5.4 Hz, 1H), 6.81 (ddd, <i>J</i> = 10.5, 8.2, 2.4 Hz, 1H), 5.29 (s, 2H), 4.36 (t, <i>J</i> = 7.7 Hz, 2H), 3.79 (s, 2H), 2.39–2.26 (m,, 2H), 1.88–1.80 (m,, 2H), 1.67 (q, <i>J</i> = 4.1, 3.4 Hz, 2H), 1.59 (q, <i>J</i> = 4.5, 3.9 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.3, 161.4 (d, <i>J</i><sub>CF</sub> = 239.7 Hz), 148.8, 143.65 (d, <i>J</i><sub>CF</sub> = 12.2 Hz), 142.0, 137.7, 133.9, 127.2 (q, <i>J</i><sub>CF</sub> = 276.7 Hz), 125.6 (d, <i>J</i><sub>CF</sub> = 2.4 Hz), 122.5, 120.2 (d, <i>J</i><sub>CF</sub> = 9.7 Hz), 117.4, 109.8,, 108.0 (d, <i>J</i><sub>CF</sub> = 22.5 Hz), 98.2 (d, <i>J</i> = 28.2 Hz), 45.7, 41.9, 37.2, 30.1 (q, <i>J</i><sub>CF</sub> = 28.4 Hz), 26.3, 22.2, 19.9. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>23</sub>N<sub>4</sub>OF<sub>4</sub>: 447.1808, found: 447.1816. LCMS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> 447.3 at 0.58 min.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 1′-([5-(Aminomethyl)-1-(4,4,4-trifluorobutyl)-1<i>H</i>-1,3-benzodiazol-2-yl]methyl)-6′fluoro-1′,2′-dihydrospiro[cyclopropane-1,3′-indole]-2′-one hydrochloride (<b>20</b>·HCl)</h3><div class="NLM_p last">HCl (2.0 M in Et<sub>2</sub>O; 0.6 mL, 1.21 mmol) was added dropwise to a solution of 1′-([5-(aminomethyl)-1-(4,4,4-trifluorobutyl)-1<i>H</i>-1,3-benzodiazol-2-yl]methyl)-6′fluoro-1′,2′-dihydrospiro[cyclopropane-1,3′-indole]-2′-one (539 mg, 1.21 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL), and the reaction mixture was stirred for 30 min. The solvent was then evaporated under vacuum. The residue was dissolved in MeOH (20 mL), concentrated under vacuum at rt, and dried further in a vacuum oven at 40 °C, affording the hydrochloride salt as a white solid (480 mg, 81%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.39 (br. s, 3H), 7.75 (d, <i>J</i> = 1.5 Hz, 1H), 7.68 (d, <i>J</i> = 8.3 Hz, 1H), 7.40 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 7.14 (dd, <i>J</i> = 9.6, 2.4 Hz, 1H), 7.08 (dd, <i>J</i> = 8.3, 5.4 Hz, 1H), 6.82 (ddd, <i>J</i> = 10.3, 8.3, 2.4 Hz, 1H), 5.33 (s, 2H), 4.40 (t, <i>J</i> = 7.7 Hz, 2H), 2.40–2.27 (m, 2H), 1.88–1.83 (m, 2H), 1.69 (q, <i>J</i> = 3.9 Hz, 2H), 1.58 (q, <i>J</i> = 3.8 Hz, 2H)). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.35, 161.4 (d, <i>J</i> = 240 Hz), 149.8, 143.6 (d, <i>J</i> = 12 Hz), 141.8, 135.1, 127.2 (q, <i>J</i> = 276 Hz), 127.8, 125.65 (d, <i>J</i> = 2 Hz), 123.8, 120.3 (d, <i>J</i> = 10 Hz), 120.0, 110.4, 108.05 (d, <i>J</i> = 22.5 Hz), 98.1 (d, <i>J</i> = 28 Hz), 42.6, 42.0, 37.2, 30.0 (q, <i>J</i> = 28 Hz), 26.35, 22.2, 18.9. HRMS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>23</sub>N<sub>4</sub>OF<sub>4</sub>: 447.1808, found: 447.1805.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> RSV Fusion Assay</h3><div class="NLM_p last">The inhibition of RSV F protein mediated cell–cell fusion was investigated in an <i>in vitro</i> RSV F protein cell–cell fusion assay based on the method of Branigan et al.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Briefly, human embryonic kidney 293T cells (ATCC, CRL-11268) were cotransfected with an expression plasmid encoding the RSV F protein from the RSV A2 strain (pCDNA3.1-A2-F; codon optimized F protein sequence from RSV strain A2 was synthesized (GeneArt) and subcloned into pCDNA3.1(+) (Invitrogen, V79020) and a reporter plasmid containing the luciferase gene under the control of a GAL4 responsive promoter (pFR-Luc, Stratagene 219050). A second set of 293T cells was transfected with an expression plasmid encoding a transcriptional transactivator fusion protein consisting of the GAL4 DNA binding domain fused to the activation domain of NF-κB (pCDNA3.1 GAL4/NFκB: GAL4-NF-κB sequence was synthesized (Genscript) and subcloned into pCDNA3.1(+) (Invitrogen, V79020). After 24 h, the two cell populations were mixed in the presence of threefold serial dilutions of test compound, and the RSV F protein-mediated fusion between the two cell populations was measured by quantifying the luciferase activity induced by the colocalization of the GAL4-NF-κB transactivator fusion protein and the GAL 4 responsive luciferase reporter expression plasmid after 24 h.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Plaque Reduction Assay</h3><div class="NLM_p last">The inhibition of RSV infection of cells was investigated in an <i>in vitro</i> RSV plaque assay. African green monkey kidney (Vero) or HepG2 cell cultures were infected with the RSV strain A2 or low passage clinical strains of RSV for 48 h in the presence of a range of test compound concentrations (0.01 nM to 100 μM) prior to detection of distinct foci of infection (plaques) by immunostaining.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Cell Cytotoxicity Assay</h3><div class="NLM_p last">Cell cytotoxicity was assessed in parallel to plaque reduction assays. African green monkey kidney (Vero), HepG2, or Hep2 cells were cultured in the presence of a range of test compound concentrations (0.01 nM to 100 μM) prior to measurement of cell viability by the addition of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), CellTox green (Promega), or CellTiter-Glo (Promega).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Inhibition of RSV in Primary Human Airway Epithelial Cells</h3><div class="NLM_p last">The inhibition of RSV was investigated in an <i>in vitro</i> primary HAE cell infectivity model.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Briefly, HAE cells were differentiated on Type IV collagen coated trans-well plate inserts for 61 days. Differentiated HAE cell cultures (<i>n</i> = 3) were preincubated with compound (10 nM) for 2 h prior to apical inoculation with 4 × 10<sup>5</sup> plaque forming units (pfu) of recombinant luciferase-expressing RSV (lucRSV). Samples of lucRSV shed by the infected HAE cells were obtained daily for eight consecutive days by washing the HAE apical cell surface for 2 h. Analysis of RSV yield in the HAE apical samples was conducted by infecting human lung epithelial A549 cells and determining the luciferase activity 24 h post infection (pi). On day 8 pi, the HAE cells were fixed and stained with H&E for histological examination.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Animal Experiments</h3><div class="NLM_p last">All animal experimentation was covered under the UK Animals (Scientific Procedures) Act (1986) and EU directive 86/609/EEC. All such work was monitored by regular inspections of procedures and facilities by the on-site Veterinarian and UK Home Office inspectors.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>In Vivo</i> Pharmacokinetics</h3><div class="NLM_p">The pharmacokinetics of the compounds were studied <i>in vivo</i> in male Sprague–Dawley rats at doses of 1 mg/kg (IV) and 10 mg/kg (PO). Sprague–Dawley rats were treated with experimental compounds via intravenous and oral administration. Three animals for each route of administration were used with serial blood sampling at ten time points post dosing of compound.</div><div class="NLM_p">An intravenous bolus was administered at a dose of 1 mg/kg and at a concentration of 1 mg/mL in 40:60 dimethylacetamide/saline (0.9% <i>w/v</i> saline). Animals were weighed and used if between 200 and 250 g. Serial blood samples were collected at 0.02, 0.08, 0.25, 0.50, 1, 2, 4, 6, 8, and 24 h postdosing. Animals were observed for any overt clinical signs or symptoms. Blood samples were delivered into an anticoagulant (sodium heparin) and centrifuged at 4 °C. Plasma samples were subsequently stored frozen at less than −20 °C prior to analysis.</div><div class="NLM_p">Following protein precipitation with acetonitrile, samples were analyzed with tandem liquid chromatography/mass spectrometry using electrospray ionization. A full matrix curve with internal standards was employed, and PK parameters were calculated.</div><div class="NLM_p">In a similar manner, oral administration was performed by gavage at doses of 5 or 10 mg/kg at a concentration of 5 mg/mL in 1% methyl cellulose (Sigma M7140), 0.1% Tween 80 in water. Serial samples were taken as described above.</div><div class="NLM_p">Acclimatized male CD-1 mice were group-housed in a temperature and light controlled facility on a 12-h light/dark cycle with food and water available <i>ad libitum</i>. Mice included in the study were individually housed until completion. All animals were subjected to health monitoring in accordance with the above guidelines by the onsite Home Office registered veterinarian.</div><div class="NLM_p">Animals were anaesthetized, and terminal blood samples were collected by cardiac puncture. Samples were transferred into heparinized polypropylene tubes on wet ice and centrifuged at 4 °C within 15 min to yield plasma which was snap-frozen and stored at −20 °C. Sampling time points were 2, 5, 15 min and 1, 2, 4, 8, 12, 24 h for the <i>in vitro</i> arm and 5, 15, 30 min, 1, 1.5, 2, 4, 6, 8, 12, and 24 h for the <i>oral</i> arm. Samples were analyzed using an UHPLC-TOF instrument that comprised an Agilent 1290 HPLC pump with an Agilent 1290 autosampler coupled with an Agilent 6550 quadrupole-TOF mass spectrometer. The system was controlled by MassHunter software vB.05.01</div><div class="NLM_p">Six male Beagle dogs (non-naive, 12–13 kg) were housed in pairs and acclimatized in a temperature and light controlled on a 12-h light/dark cycle with food offered each morning and water available <i>ad libitum</i>. On dosing days, dogs were fed 2 h after dose administration with water available <i>ad libitum</i>. Prior to commencement of each dosing session, each dog was examined by a qualified Veterinary Surgeon for suitability for the study.</div><div class="NLM_p">Serial blood samples were collected into heparinized polypropylene tubes and immediately centrifuged at 4 °C for 10 min at 3000<i>g</i> to yield plasma which was snap-frozen and stored at −20 °C. Sampling times were 2, 5, and 15 min and 1, 2, 4, 8, 12, and 24 h for the <i>in vitro</i> arm and 15 and 30 min and 1, 1.5, 2, 4, 6, 8, 12, and 24 h for the <i>oral</i> arm.</div><div class="NLM_p last">Samples were analyzed using an UHPLC-TOF instrument that comprised an Agilent 1290 HPLC pump with an Agilent 1290 autosampler, coupled with an Agilent 6550 quadrupole-TOF mass spectrometer. The system was controlled by MassHunter software vB.05.01</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Efficacy in a Balb/C Mouse Model of RSV</h3><div class="NLM_p last">Briefly, Balb/C mice (6 per treatment group, 7–8-week-old females) received two PO doses of compound (0, 1, 10, or 50 mg/mL) 2 h pre- and 24 h postintranasal inoculation with 5 × 10<sup>6</sup> pfu of RSV strain A2. Animals were euthanized 5 days post-RSV inoculation, and lung homogenates were prepared. RSV titers in lung homogenates were evaluated by plaque assay on Vero cells.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01882" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18215" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18215" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01882?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01882</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular data strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Procedures for <i>in vitro</i> ADME assays, additional ADME data, metabolite identification data, virology data, crystallographic data, synthetic procedures, and characterization of all other compounds and key intermediates (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_001.csv">jm0c01882_si_001.csv (8.91 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_002.pdf">jm0c01882_si_002.pdf (2.02 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01882" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87200" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87200" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">G. Stuart Cockerill</span> - <span class="hlFld-Affiliation affiliation">Reviral
Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6340-0808" title="Orcid link">http://orcid.org/0000-0002-6340-0808</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#681b0b070b030d1a010404281a0d1e011a0904460b07461d03"><span class="__cf_email__" data-cfemail="1e6d7d717d757b6c7772725e6c7b68776c7f72307d71306b75">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard M. Angell</span> - <span class="hlFld-Affiliation affiliation">Sussex
Drug Discovery Centre, University of Sussex, Brighton, England BN1 9QJ, U.K.</span>; 
    <span>Present Address:
                        R.A.: Drug Discovery Group, Translational Research Office, School of Pharmacy, University College London, 9–39 Brunswick Square, London WC1N 1AX, U.K</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexandre Bedernjak</span> - <span class="hlFld-Affiliation affiliation">Reviral
Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Irina Chuckowree</span> - <span class="hlFld-Affiliation affiliation">Sussex
Drug Discovery Centre, University of Sussex, Brighton, England BN1 9QJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ian Fraser</span> - <span class="hlFld-Affiliation affiliation">Reviral
Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</span>; 
    <span>Present Address:
                        I.F.: CRL, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, U.K</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jose Gascon-Simorte</span> - <span class="hlFld-Affiliation affiliation">Sussex
Drug Discovery Centre, University of Sussex, Brighton, England BN1 9QJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Morgan S. A. Gilman</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Biosciences, The University
of Texas at Austin, Austin, Texas 78712, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James A. D. Good</span> - <span class="hlFld-Affiliation affiliation">Reviral
Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rachel Harland</span> - <span class="hlFld-Affiliation affiliation">Reviral
Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sara M. Johnson</span> - <span class="hlFld-Affiliation affiliation">Center
for Vaccines and Immunity, The Research Institute at Nationwide Children’s
Hospital, and Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio 43205, United States</span>; 
    <span>Present Address:
                        S.M.J.: Office of Research, University of Michigan Medical School, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John H Ludes-Meyers</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Biosciences, The University
of Texas at Austin, Austin, Texas 78712, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edward Littler</span> - <span class="hlFld-Affiliation affiliation">Reviral
Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Lumley</span> - <span class="hlFld-Affiliation affiliation">Reviral
Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</span>; 
    <span>Present Address:
                        J.L.: Molecular Design, Data and Computational Sciences, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Graham Lunn</span> - <span class="hlFld-Affiliation affiliation">Sussex
Drug Discovery Centre, University of Sussex, Brighton, England BN1 9QJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil Mathews</span> - <span class="hlFld-Affiliation affiliation">Reviral
Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason S. McLellan</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Biosciences, The University
of Texas at Austin, Austin, Texas 78712, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Paradowski</span> - <span class="hlFld-Affiliation affiliation">Medicines
Discovery Institute, Cardiff University, Cardiff, Wales CF10 3AT, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark E. Peeples</span> - <span class="hlFld-Affiliation affiliation">Center
for Vaccines and Immunity, The Research Institute at Nationwide Children’s
Hospital, and Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio 43205, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claire Scott</span> - <span class="hlFld-Affiliation affiliation">Reviral
Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</span>; 
    <span>Present Address:
                        C.S.: Covance, Springfield House, Hyde Street, Leeds LS2 9LH, U.K</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dereck Tait</span> - <span class="hlFld-Affiliation affiliation">Reviral
Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Geraldine Taylor</span> - <span class="hlFld-Affiliation affiliation">The Pirbright
Institute, Ash Road, Pirbright, Surrey GU24 0NF, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle Thom</span> - <span class="hlFld-Affiliation affiliation">The Pirbright
Institute, Ash Road, Pirbright, Surrey GU24 0NF, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elaine Thomas</span> - <span class="hlFld-Affiliation affiliation">Reviral
Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carol Villalonga Barber</span> - <span class="hlFld-Affiliation affiliation">Sussex
Drug Discovery Centre, University of Sussex, Brighton, England BN1 9QJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon E. Ward</span> - <span class="hlFld-Affiliation affiliation">Medicines
Discovery Institute, Cardiff University, Cardiff, Wales CF10 3AT, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8745-8377" title="Orcid link">http://orcid.org/0000-0002-8745-8377</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Watterson</span> - <span class="hlFld-Affiliation affiliation">School
of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland 4072, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gareth Williams</span> - <span class="hlFld-Affiliation affiliation">Sussex
Drug Discovery Centre, University of Sussex, Brighton, England BN1 9QJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Young</span> - <span class="hlFld-Affiliation affiliation">School
of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland 4072, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth Powell</span> - <span class="hlFld-Affiliation affiliation">Reviral
Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, U.K.</span></div></li></ul></li><li></li><li><span class="author-information-subsection-header">Funding</span><p>Funding of the work described herein was provided initially by a self-funding initiative of the founders of Reviral Ltd. Subsequently the project was progressed via a Wellcome Trust Seeding Drug Discovery Award (WT100544) with Professor Simon Ward, then of the University of Sussex as coapplicant. Subsequent funding was provided by Reviral Ltd., supported both from “angel” investor sources and blue-chip venture capital.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">For PDB code 7KQD (RSV Fusion protein with compound 20 bound), the authors will release the atomic coordinates and experimental data upon article publication.<br /></br>The authors declare the following competing financial interest(s): G.S.C., A.B., J.A.D.G., R.H., E.L., N.M., E.T., and K.P. are employees and shareholders in Reviral Ltd. R.M.A., I.F., J.L., and C.S. are shareholders in Reviral Ltd. M.E.P. has received fees for participation in an advisory board from Reviral. In addition research grants from the NIH (Grants AI112524, AI095684, and AI093848), the Cystic Fibrosis Foundation, Pfizer, and Janssen. D.T. reports receiving personal fees from Reviral outside the submitted work.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e4343-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68138" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68138" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Desmond O’Connor and Mohammad Avalijeh of Pharmidex UK for supporting the pharmacokinetic studies and Alan Kenwright, Jackie Mosely, and Juan Aquilar-Malavia of Durham University analytical department for NMR and MS support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">A<sub>2</sub>B, B<sub>2</sub>A</td><td class="NLM_def"><p class="first last">direction of compound permeability</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">twice daily dosing</p></td></tr><tr><td class="NLM_term">CHF</td><td class="NLM_def"><p class="first last">chronic heart failure</p></td></tr><tr><td class="NLM_term">Cl<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">ERD</td><td class="NLM_def"><p class="first last">enhanced respiratory disease</p></td></tr><tr><td class="NLM_term"><i>f</i><sub>u</sub></td><td class="NLM_def"><p class="first last">fraction unbound</p></td></tr><tr><td class="NLM_term">ΔclogD<sub>7.4</sub></td><td class="NLM_def"><p class="first last">change in calculated log D at pH 7.4</p></td></tr><tr><td class="NLM_term">ΔtPSA</td><td class="NLM_def"><p class="first last">change in total polar surface area</p></td></tr><tr><td class="NLM_term">ERD</td><td class="NLM_def"><p class="first last">enhanced respiratory disease</p></td></tr><tr><td class="NLM_term">F protein</td><td class="NLM_def"><p class="first last">fusion protein</p></td></tr><tr><td class="NLM_term">GLP</td><td class="NLM_def"><p class="first last">good laboratory practice</p></td></tr><tr><td class="NLM_term">G protein</td><td class="NLM_def"><p class="first last">glycoprotein</p></td></tr><tr><td class="NLM_term">HAE</td><td class="NLM_def"><p class="first last">human airway epithelial</p></td></tr><tr><td class="NLM_term">HBSS</td><td class="NLM_def"><p class="first last">Hanks balanced salt solution</p></td></tr><tr><td class="NLM_term">HCT</td><td class="NLM_def"><p class="first last">hematopoietic cell transplant</p></td></tr><tr><td class="NLM_term">Hep2</td><td class="NLM_def"><p class="first last">human epithelial type 2 cells</p></td></tr><tr><td class="NLM_term">lucRSV</td><td class="NLM_def"><p class="first last">luciferase expressing respiratory syncytial virus</p></td></tr><tr><td class="NLM_term">LO</td><td class="NLM_def"><p class="first last">lead optimization</p></td></tr><tr><td class="NLM_term">mAb</td><td class="NLM_def"><p class="first last">monoclonal antibody</p></td></tr><tr><td class="NLM_term">LRTI</td><td class="NLM_def"><p class="first last">lower respiratory tract infection</p></td></tr><tr><td class="NLM_term">M protein</td><td class="NLM_def"><p class="first last">matrix protein</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">NOAEL</td><td class="NLM_def"><p class="first last">no observed adverse event level</p></td></tr><tr><td class="NLM_term">N protein</td><td class="NLM_def"><p class="first last">nucleoprotein</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub></td><td class="NLM_def"><p class="first last">apparent permeability</p></td></tr><tr><td class="NLM_term">P protein</td><td class="NLM_def"><p class="first last">phosphoprotein</p></td></tr><tr><td class="NLM_term">pi</td><td class="NLM_def"><p class="first last">postinfection</p></td></tr><tr><td class="NLM_term">PFU</td><td class="NLM_def"><p class="first last">plaque forming units</p></td></tr><tr><td class="NLM_term">PRA</td><td class="NLM_def"><p class="first last">plaque reduction assay</p></td></tr><tr><td class="NLM_term">RSV</td><td class="NLM_def"><p class="first last">respiratory syncytial virus</p></td></tr><tr><td class="NLM_term">RSV A2</td><td class="NLM_def"><p class="first last">respiratory syncytial virus A2 strain</p></td></tr><tr><td class="NLM_term">SAD</td><td class="NLM_def"><p class="first last">single ascending dose</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>max</sub></td><td class="NLM_def"><p class="first last">time to maximum absorption</p></td></tr><tr><td class="NLM_term">URTI</td><td class="NLM_def"><p class="first last">upper respiratory tract infection</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06751" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06751" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 53 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falsey, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessey, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Formica, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, E. E.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus infection in the elderly and high-risk adults</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1749</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa043951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1056%2FNEJMoa043951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=15858184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1749-1759&author=A.+R.+Falseyauthor=P.+A.+Hennesseyauthor=M.+A.+Formicaauthor=C.+Coxauthor=E.+E.+Walsh&title=Respiratory+syncytial+virus+infection+in+the+elderly+and+high-risk+adults&doi=10.1056%2FNEJMoa043951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus infection in elderly and high-risk adults</span></div><div class="casAuthors">Falsey, Ann R.; Hennessey, Patricia A.; Formica, Maria A.; Cox, Christopher; Walsh, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1749-1759</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Respiratory syncytial virus (RSV) is an increasingly recognized cause of illness in adults.  Data on the epidemiol. and clin. effects in community-dwelling elderly persons and high-risk adults can help in assessing the need for vaccine development.  METHODS During four consecutive winters, we evaluated all respiratory illnesses in prospective cohorts of healthy elderly patients (≥65 years of age) and high-risk adults (those with chronic heart or lung disease) and in patients hospitalized with acute cardiopulmonary conditions.  RSV infection and influenza A were diagnosed on the basis of culture, reverse-transcriptase polymerase chain reaction, and serol. studies.  RESULTS A total of 608 healthy elderly patients and 540 high-risk adults were enrolled in prospective surveillance, and 1388 hospitalized patients were enrolled.  A total of 2514 illnesses were evaluated.  RSV infection was identified in 102 patients in the prospective cohorts and 142 hospitalized patients, and influenza A was diagnosed in 44 patients in the prospective cohorts and 154 hospitalized patients.  RSV infection developed annually in 3 to 7 percent of healthy elderly patients and in 4 to 10 percent of high-risk adults.  Among healthy elderly patients, RSV infection generated fewer office visits than influenza; however, the use of health care services by high-risk adults was similar in the two groups.  In the hospitalized cohort, RSV infection and influenza A resulted in similar lengths of stay, rates of use of intensive care (15 percent and 12 percent, resp.), and mortality (8 percent and 7 percent, resp.).  On the basis of the diagnostic codes of the International Classification of Diseases, 9th Revision, Clin. Modification at discharge, RSV infection accounted for 10.6 percent of hospitalizations for pneumonia, 11.4 percent for chronic obstructive pulmonary disease, 5.4 percent for congestive heart failure, and 7.2 percent for asthma.  CONCLUSIONS RSV infection is an important illness in elderly and high-risk adults, with a disease burden similar to that of nonpandemic influenza A in a population in which the prevalence of vaccination for influenza is high.  An effective RSV vaccine may offer benefits for these adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC4DLnaPCjP7Vg90H21EOLACvtfcHk0ljjJewO_2t7QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsr8%253D&md5=84051565564c0794974fde0b28a0e887</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa043951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa043951%26sid%3Dliteratum%253Aachs%26aulast%3DFalsey%26aufirst%3DA.%2BR.%26aulast%3DHennessey%26aufirst%3DP.%2BA.%26aulast%3DFormica%26aufirst%3DM.%2BA.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DWalsh%26aufirst%3DE.%2BE.%26atitle%3DRespiratory%2520syncytial%2520virus%2520infection%2520in%2520the%2520elderly%2520and%2520high-risk%2520adults%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D1749%26epage%3D1759%26doi%3D10.1056%2FNEJMoa043951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simoes, E. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessner, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polack, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balsells, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acacio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguayo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alassani, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awori, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azziz-Baumgartner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggett, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmaseda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barahona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basnet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassat, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basualdo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigogo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bont, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breiman, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carosone-Link, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chipeta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clara, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Cuellar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, D.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash-yandag, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deloria-Knoll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dherani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eap, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebruke, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echavarria, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Freitas Lázaro Emediato, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasce, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feikin, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groome, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halasa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirve, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homaira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howie, S. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jara, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jroundi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartasasmita, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khuri-Bulos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotloff, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucero, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucion, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupisan, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcone, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCracken, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mejia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moisi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraleda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munywoki, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutyara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicol, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nokes, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nymadawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Costa Oliveira, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshitani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranhos-Baccalà, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picot, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakoto-Andrianarivelo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russomando, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salimi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawatwong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheltema, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweiger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidenberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strand, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutanto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapia, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamthitiwat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waicharoen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watthanaworawit, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, L.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zar, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, H.</span></span> <span> </span><span class="NLM_article-title">Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">946</span>– <span class="NLM_lpage">958</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)30938-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2FS0140-6736%2817%2930938-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=28689664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BC1cjlslKluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=946-958&author=T.+Shiauthor=D.+A.+McAllisterauthor=K.+L.+O%E2%80%99Brienauthor=E.+A.+F.+Simoesauthor=S.+A.+Madhiauthor=B.+D.+Gessnerauthor=F.+P.+Polackauthor=E.+Balsellsauthor=S.+Acacioauthor=C.+Aguayoauthor=I.+Alassaniauthor=A.+Aliauthor=M.+Antonioauthor=S.+Awasthiauthor=J.+O.+Aworiauthor=E.+Azziz-Baumgartnerauthor=H.+C.+Baggettauthor=V.+L.+Baillieauthor=A.+Balmasedaauthor=A.+Barahonaauthor=S.+Basnetauthor=Q.+Bassatauthor=W.+Basualdoauthor=G.+Bigogoauthor=L.+Bontauthor=R.+F.+Breimanauthor=W.+A.+Brooksauthor=S.+Broorauthor=N.+Bruceauthor=D.+Brudenauthor=P.+Buchyauthor=S.+Campbellauthor=P.+Carosone-Linkauthor=M.+Chadhaauthor=J.+Chipetaauthor=M.+Chouauthor=W.+Claraauthor=C.+Cohenauthor=E.+de+Cuellarauthor=D.-A.+Dangauthor=B.+Dash-yandagauthor=M.+Deloria-Knollauthor=M.+Dheraniauthor=T.+Eapauthor=B.+E.+Ebrukeauthor=M.+Echavarriaauthor=C.+C.+de+Freitas+L%C3%A1zaro+Emediatoauthor=R.+A.+Fasceauthor=D.+R.+Feikinauthor=L.+Fengauthor=A.+Gentileauthor=A.+Gordonauthor=D.+Goswamiauthor=S.+Goyetauthor=M.+Groomeauthor=N.+Halasaauthor=S.+Hirveauthor=N.+Homairaauthor=S.+R.+C.+Howieauthor=J.+Jaraauthor=I.+Jroundiauthor=C.+B.+Kartasasmitaauthor=N.+Khuri-Bulosauthor=K.+L.+Kotloffauthor=A.+Krishnanauthor=R.+Libsterauthor=O.+Lopezauthor=M.+G.+Luceroauthor=F.+Lucionauthor=S.+P.+Lupisanauthor=D.+N.+Marconeauthor=J.+P.+McCrackenauthor=M.+Mejiaauthor=J.+C.+Moisiauthor=J.+M.+Montgomeryauthor=D.+P.+Mooreauthor=C.+Moraledaauthor=J.+Moyesauthor=P.+Munywokiauthor=K.+Mutyaraauthor=M.+P.+Nicolauthor=D.+J.+Nokesauthor=P.+Nymadawaauthor=M.+T.+da+Costa+Oliveiraauthor=H.+Oshitaniauthor=N.+Pandeyauthor=G.+Paranhos-Baccal%C3%A0author=L.+N.+Phillipsauthor=V.+S.+Picotauthor=M.+Rahmanauthor=M.+Rakoto-Andrianariveloauthor=Z.+A.+Rasmussenauthor=B.+A.+Rathauthor=A.+Robinsonauthor=C.+Romeroauthor=G.+Russomandoauthor=V.+Salimiauthor=P.+Sawatwongauthor=N.+Scheltemaauthor=B.+Schweigerauthor=J.+A.+G.+Scottauthor=P.+Seidenbergauthor=K.+Shenauthor=R.+Singletonauthor=V.+Sotomayorauthor=T.+A.+Strandauthor=A.+Sutantoauthor=M.+Syllaauthor=M.+D.+Tapiaauthor=S.+Thamthitiwatauthor=E.+D.+Thomasauthor=R.+Tokarzauthor=C.+Turnerauthor=M.+Venterauthor=S.+Waicharoenauthor=J.+Wangauthor=W.+Watthanaworawitauthor=L.-M.+Yoshidaauthor=H.+Yuauthor=H.+J.+Zarauthor=H.+Campbellauthor=H.+Nair&title=Global%2C+regional%2C+and+national+disease+burden+estimates+of+acute+lower+respiratory+infections+due+to+respiratory+syncytial+virus+in+young+children+in+2015%3A+a+systematic+review+and+modelling+study&doi=10.1016%2FS0140-6736%2817%2930938-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study</span></div><div class="casAuthors">Shi Ting; Balsells Evelyn; Campbell Stuart; Campbell Harry; McAllister David A; O'Brien Katherine L; Deloria-Knoll Maria; Simoes Eric A F; Madhi Shabir A; Groome Michelle; Moore David P; Gessner Bradford D; Moisi Jennifer C; Polack Fernando P; Acacio Sozinho; Aguayo Claudia; Sotomayor Viviana; Alassani Issifou; Ali Asad; Antonio Martin; Ebruke Bernard E; Awasthi Shally; Pandey Nitin; Awori Juliet O; Azziz-Baumgartner Eduardo; Baggett Henry C; Baillie Vicky L; Balmaseda Angel; Barahona Alfredo; Basnet Sudha; Bassat Quique; Basualdo Wilma; Bigogo Godfrey; Bont Louis; Scheltema Nienke; Breiman Robert F; Brooks W Abdullah; Goswami Doli; Broor Shobha; Krishnan Anand; Bruce Nigel; Dherani Mukesh; Bruden Dana; Buchy Philippe; Carosone-Link Phyllis; Chadha Mandeep; Chipeta James; Chou Monidarin; Clara Wilfrido; Cohen Cheryl; Moyes Jocelyn; de Cuellar Elizabeth; Dang Duc-Anh; Dash-Yandag Budragchaagiin; Eap Tekchheng; Echavarria Marcela; Marcone Debora N; de Freitas Lazaro Emediato Carla Cecilia; da Costa Oliveira Maria Tereza; Fasce Rodrigo A; Feikin Daniel R; Feng Luzhao; Yu Hongjie; Gentile Angela; Lucion Florencia; Gordon Aubree; Goyet Sophie; Halasa Natasha; Hirve Siddhivinayak; Homaira Nusrat; Howie Stephen R C; Jara Jorge; McCracken John P; Jroundi Imane; Kartasasmita Cissy B; Mutyara Kuswandewi; Khuri-Bulos Najwa; Kotloff Karen L; Tapia Milagritos D; Libster Romina; Lopez Olga; Lucero Marilla G; Lupisan Socorro P; Mejia Mario; Montgomery Joel M; Moraleda Cinta; Munywoki Patrick; Nicol Mark P; Nokes D James; Nymadawa Pagbajabyn; Oshitani Histoshi; Paranhos-Baccala Glaucia; Picot Valentina Sanchez; Phillips Lia N; Rahman Mustafizur; Rakoto-Andrianarivelo Mala; Rasmussen Zeba A; Thomas Elizabeth D; Rath Barbara A; Robinson Annick; Romero Candice; Russomando Graciela; Salimi Vahid; Sawatwong Pongpun; Thamthitiwat Somsak; Schweiger Brunhilde; Scott J Anthony G; Seidenberg Phil; Shen Kunling; Singleton Rosalyn; Strand Tor A; Sutanto Agustinus; Sylla Mariam; Tokarz Rafal; Turner Claudia; Watthanaworawit Wanitda; Venter Marietjie; Waicharoen Sunthareeya; Wang Jianwei; Yoshida Lay-Myint; Zar Heather J; Nair Harish</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">390</span>
        (<span class="NLM_cas:issue">10098</span>),
    <span class="NLM_cas:pages">946-958</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  We have previously estimated that respiratory syncytial virus (RSV) was associated with 22% of all episodes of (severe) acute lower respiratory infection (ALRI) resulting in 55 000 to 199 000 deaths in children younger than 5 years in 2005.  In the past 5 years, major research activity on RSV has yielded substantial new data from developing countries.  With a considerably expanded dataset from a large international collaboration, we aimed to estimate the global incidence, hospital admission rate, and mortality from RSV-ALRI episodes in young children in 2015.  METHODS:  We estimated the incidence and hospital admission rate of RSV-associated ALRI (RSV-ALRI) in children younger than 5 years stratified by age and World Bank income regions from a systematic review of studies published between Jan 1, 1995, and Dec 31, 2016, and unpublished data from 76 high quality population-based studies.  We estimated the RSV-ALRI incidence for 132 developing countries using a risk factor-based model and 2015 population estimates.  We estimated the in-hospital RSV-ALRI mortality by combining in-hospital case fatality ratios with hospital admission estimates from hospital-based (published and unpublished) studies.  We also estimated overall RSV-ALRI mortality by identifying studies reporting monthly data for ALRI mortality in the community and RSV activity.  FINDINGS:  We estimated that globally in 2015, 33·1 million (uncertainty range [UR] 21·6-50·3) episodes of RSV-ALRI, resulted in about 3·2 million (2·7-3·8) hospital admissions, and 59 600 (48 000-74 500) in-hospital deaths in children younger than 5 years.  In children younger than 6 months, 1·4 million (UR 1·2-1·7) hospital admissions, and 27 300 (UR 20 700-36 200) in-hospital deaths were due to RSV-ALRI.  We also estimated that the overall RSV-ALRI mortality could be as high as 118 200 (UR 94 600-149 400).  Incidence and mortality varied substantially from year to year in any given population.  INTERPRETATION:  Globally, RSV is a common cause of childhood ALRI and a major cause of hospital admissions in young children, resulting in a substantial burden on health-care services.  About 45% of hospital admissions and in-hospital deaths due to RSV-ALRI occur in children younger than 6 months.  An effective maternal RSV vaccine or monoclonal antibody could have a substantial effect on disease burden in this age group.  FUNDING:  The Bill & Melinda Gates Foundation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT1wEfflojsmwxyojvcjibhfW6udTcc2eYvQD4Nc0WcNLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjlslKluw%253D%253D&md5=e31889022b79f89577df68e5c4fa2788</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2930938-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252930938-8%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DT.%26aulast%3DMcAllister%26aufirst%3DD.%2BA.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DK.%2BL.%26aulast%3DSimoes%26aufirst%3DE.%2BA.%2BF.%26aulast%3DMadhi%26aufirst%3DS.%2BA.%26aulast%3DGessner%26aufirst%3DB.%2BD.%26aulast%3DPolack%26aufirst%3DF.%2BP.%26aulast%3DBalsells%26aufirst%3DE.%26aulast%3DAcacio%26aufirst%3DS.%26aulast%3DAguayo%26aufirst%3DC.%26aulast%3DAlassani%26aufirst%3DI.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DAntonio%26aufirst%3DM.%26aulast%3DAwasthi%26aufirst%3DS.%26aulast%3DAwori%26aufirst%3DJ.%2BO.%26aulast%3DAzziz-Baumgartner%26aufirst%3DE.%26aulast%3DBaggett%26aufirst%3DH.%2BC.%26aulast%3DBaillie%26aufirst%3DV.%2BL.%26aulast%3DBalmaseda%26aufirst%3DA.%26aulast%3DBarahona%26aufirst%3DA.%26aulast%3DBasnet%26aufirst%3DS.%26aulast%3DBassat%26aufirst%3DQ.%26aulast%3DBasualdo%26aufirst%3DW.%26aulast%3DBigogo%26aufirst%3DG.%26aulast%3DBont%26aufirst%3DL.%26aulast%3DBreiman%26aufirst%3DR.%2BF.%26aulast%3DBrooks%26aufirst%3DW.%2BA.%26aulast%3DBroor%26aufirst%3DS.%26aulast%3DBruce%26aufirst%3DN.%26aulast%3DBruden%26aufirst%3DD.%26aulast%3DBuchy%26aufirst%3DP.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DCarosone-Link%26aufirst%3DP.%26aulast%3DChadha%26aufirst%3DM.%26aulast%3DChipeta%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DM.%26aulast%3DClara%26aufirst%3DW.%26aulast%3DCohen%26aufirst%3DC.%26aulast%3Dde%2BCuellar%26aufirst%3DE.%26aulast%3DDang%26aufirst%3DD.-A.%26aulast%3DDash-yandag%26aufirst%3DB.%26aulast%3DDeloria-Knoll%26aufirst%3DM.%26aulast%3DDherani%26aufirst%3DM.%26aulast%3DEap%26aufirst%3DT.%26aulast%3DEbruke%26aufirst%3DB.%2BE.%26aulast%3DEchavarria%26aufirst%3DM.%26aulast%3Dde%2BFreitas%2BL%25C3%25A1zaro%2BEmediato%26aufirst%3DC.%2BC.%26aulast%3DFasce%26aufirst%3DR.%2BA.%26aulast%3DFeikin%26aufirst%3DD.%2BR.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DGentile%26aufirst%3DA.%26aulast%3DGordon%26aufirst%3DA.%26aulast%3DGoswami%26aufirst%3DD.%26aulast%3DGoyet%26aufirst%3DS.%26aulast%3DGroome%26aufirst%3DM.%26aulast%3DHalasa%26aufirst%3DN.%26aulast%3DHirve%26aufirst%3DS.%26aulast%3DHomaira%26aufirst%3DN.%26aulast%3DHowie%26aufirst%3DS.%2BR.%2BC.%26aulast%3DJara%26aufirst%3DJ.%26aulast%3DJroundi%26aufirst%3DI.%26aulast%3DKartasasmita%26aufirst%3DC.%2BB.%26aulast%3DKhuri-Bulos%26aufirst%3DN.%26aulast%3DKotloff%26aufirst%3DK.%2BL.%26aulast%3DKrishnan%26aufirst%3DA.%26aulast%3DLibster%26aufirst%3DR.%26aulast%3DLopez%26aufirst%3DO.%26aulast%3DLucero%26aufirst%3DM.%2BG.%26aulast%3DLucion%26aufirst%3DF.%26aulast%3DLupisan%26aufirst%3DS.%2BP.%26aulast%3DMarcone%26aufirst%3DD.%2BN.%26aulast%3DMcCracken%26aufirst%3DJ.%2BP.%26aulast%3DMejia%26aufirst%3DM.%26aulast%3DMoisi%26aufirst%3DJ.%2BC.%26aulast%3DMontgomery%26aufirst%3DJ.%2BM.%26aulast%3DMoore%26aufirst%3DD.%2BP.%26aulast%3DMoraleda%26aufirst%3DC.%26aulast%3DMoyes%26aufirst%3DJ.%26aulast%3DMunywoki%26aufirst%3DP.%26aulast%3DMutyara%26aufirst%3DK.%26aulast%3DNicol%26aufirst%3DM.%2BP.%26aulast%3DNokes%26aufirst%3DD.%2BJ.%26aulast%3DNymadawa%26aufirst%3DP.%26aulast%3Dda%2BCosta%2BOliveira%26aufirst%3DM.%2BT.%26aulast%3DOshitani%26aufirst%3DH.%26aulast%3DPandey%26aufirst%3DN.%26aulast%3DParanhos-Baccal%25C3%25A0%26aufirst%3DG.%26aulast%3DPhillips%26aufirst%3DL.%2BN.%26aulast%3DPicot%26aufirst%3DV.%2BS.%26aulast%3DRahman%26aufirst%3DM.%26aulast%3DRakoto-Andrianarivelo%26aufirst%3DM.%26aulast%3DRasmussen%26aufirst%3DZ.%2BA.%26aulast%3DRath%26aufirst%3DB.%2BA.%26aulast%3DRobinson%26aufirst%3DA.%26aulast%3DRomero%26aufirst%3DC.%26aulast%3DRussomando%26aufirst%3DG.%26aulast%3DSalimi%26aufirst%3DV.%26aulast%3DSawatwong%26aufirst%3DP.%26aulast%3DScheltema%26aufirst%3DN.%26aulast%3DSchweiger%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DJ.%2BA.%2BG.%26aulast%3DSeidenberg%26aufirst%3DP.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DSingleton%26aufirst%3DR.%26aulast%3DSotomayor%26aufirst%3DV.%26aulast%3DStrand%26aufirst%3DT.%2BA.%26aulast%3DSutanto%26aufirst%3DA.%26aulast%3DSylla%26aufirst%3DM.%26aulast%3DTapia%26aufirst%3DM.%2BD.%26aulast%3DThamthitiwat%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DE.%2BD.%26aulast%3DTokarz%26aufirst%3DR.%26aulast%3DTurner%26aufirst%3DC.%26aulast%3DVenter%26aufirst%3DM.%26aulast%3DWaicharoen%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWatthanaworawit%26aufirst%3DW.%26aulast%3DYoshida%26aufirst%3DL.-M.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DZar%26aufirst%3DH.%2BJ.%26aulast%3DCampbell%26aufirst%3DH.%26aulast%3DNair%26aufirst%3DH.%26atitle%3DGlobal%252C%2520regional%252C%2520and%2520national%2520disease%2520burden%2520estimates%2520of%2520acute%2520lower%2520respiratory%2520infections%2520due%2520to%2520respiratory%2520syncytial%2520virus%2520in%2520young%2520children%2520in%25202015%253A%2520a%2520systematic%2520review%2520and%2520modelling%2520study%26jtitle%3DLancet%26date%3D2017%26volume%3D390%26spage%3D946%26epage%3D958%26doi%3D10.1016%2FS0140-6736%2817%2930938-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Feltes, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondheimer, H. M.</span></span> <span> </span><span class="NLM_article-title">Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1471</span>– <span class="NLM_lpage">1480</span>, <span class="refDoi"> DOI: 10.1517/14712598.7.9.1471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1517%2F14712598.7.9.1471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=17727335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2sXps1Wnsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1471-1480&issue=9&author=T.+F.+Feltesauthor=H.+M.+Sondheimer&title=Palivizumab+and+the+prevention+of+respiratory+syncytial+virus+illness+in+pediatric+patients+with+congenital+heart+disease&doi=10.1517%2F14712598.7.9.1471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease</span></div><div class="casAuthors">Feltes, Timothy F.; Sondheimer, Henry M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1471-1480</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Respiratory syncytial virus (RSV) is a significant pathogen for infants and children with congenital heart disease.  Non-sustained immunity and failure to develop an effective vaccine has steered RSV management toward a passive immunotherapy strategy in at-risk children.  Palivizumab is a humanized murine monoclonal antibody targeting the RSV envelope F glycoprotein.  In a Phase III clin. trial palivizumab significantly reduced RSV hospitalization in children with significant congenital heart disease and was proven to be safe.  Palivizumab is one of the first monoclonal antibodies to significantly impact a pediatric disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYl03zv6kWuLVg90H21EOLACvtfcHk0li7Njq9Osq__g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXps1Wnsb8%253D&md5=48c600df4bf1fbd64e784d794e1af2a3</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1517%2F14712598.7.9.1471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.7.9.1471%26sid%3Dliteratum%253Aachs%26aulast%3DFeltes%26aufirst%3DT.%2BF.%26aulast%3DSondheimer%26aufirst%3DH.%2BM.%26atitle%3DPalivizumab%2520and%2520the%2520prevention%2520of%2520respiratory%2520syncytial%2520virus%2520illness%2520in%2520pediatric%2520patients%2520with%2520congenital%2520heart%2520disease%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2007%26volume%3D7%26issue%3D9%26spage%3D1471%26epage%3D1480%26doi%3D10.1517%2F14712598.7.9.1471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viboud, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringholz, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abedi, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brammer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shay, D. K.</span></span> <span> </span><span class="NLM_article-title">Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1427</span>– <span class="NLM_lpage">1436</span>, <span class="refDoi"> DOI: 10.1093/cid/cis211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1093%2Fcid%2Fcis211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=22495079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BC38rkt1GitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2012&pages=1427-1436&author=H.+Zhouauthor=W.+W.+Thompsonauthor=C.+G.+Viboudauthor=C.+M.+Ringholzauthor=P.-Y.+Chengauthor=C.+Steinerauthor=G.+R.+Abediauthor=L.+J.+Andersonauthor=L.+Brammerauthor=D.+K.+Shay&title=Hospitalizations+associated+with+influenza+and+respiratory+syncytial+virus+in+the+United+States%2C+1993%E2%80%932008&doi=10.1093%2Fcid%2Fcis211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008</span></div><div class="casAuthors">Zhou Hong; Thompson William W; Viboud Cecile G; Ringholz Corinne M; Cheng Po-Yung; Steiner Claudia; Abedi Glen R; Anderson Larry J; Brammer Lynnette; Shay David K</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1427-36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Age-specific comparisons of influenza and respiratory syncytial virus (RSV) hospitalization rates can inform prevention efforts, including vaccine development plans.  Previous US studies have not estimated jointly the burden of these viruses using similar data sources and over many seasons.  METHODS:  We estimated influenza and RSV hospitalizations in 5 age categories (<1, 1-4, 5-49, 50-64, and ≥65 years) with data for 13 states from 1993-1994 through 2007-2008.  For each state and age group, we estimated the contribution of influenza and RSV to hospitalizations for respiratory and circulatory disease by using negative binomial regression models that incorporated weekly influenza and RSV surveillance data as covariates.  RESULTS:  Mean rates of influenza and RSV hospitalizations were 63.5 (95% confidence interval [CI], 37.5-237) and 55.3 (95% CI, 44.4-107) per 100000 person-years, respectively.  The highest hospitalization rates for influenza were among persons aged ≥65 years (309/100000; 95% CI, 186-1100) and those aged <1 year (151/100000; 95% CI, 151-660).  For RSV, children aged <1 year had the highest hospitalization rate (2350/100000; 95% CI, 2220-2520) followed by those aged 1-4 years (178/100000; 95% CI, 155-230).  Age-standardized annual rates per 100000 person-years varied substantially for influenza (33-100) but less for RSV (42-77).  CONCLUSIONS:  Overall US hospitalization rates for influenza and RSV are similar; however, their age-specific burdens differ dramatically.  Our estimates are consistent with those from previous studies focusing either on influenza or RSV.  Our approach provides robust national comparisons of hospitalizations associated with these 2 viral respiratory pathogens by age group and over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzhkrglS1cIxWfpMXQLRstfW6udTcc2eaX2Wh9t6RoTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rkt1GitA%253D%253D&md5=0cd99de3701b6283121ecfcbdf49ce1e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcis211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcis211%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DW.%2BW.%26aulast%3DViboud%26aufirst%3DC.%2BG.%26aulast%3DRingholz%26aufirst%3DC.%2BM.%26aulast%3DCheng%26aufirst%3DP.-Y.%26aulast%3DSteiner%26aufirst%3DC.%26aulast%3DAbedi%26aufirst%3DG.%2BR.%26aulast%3DAnderson%26aufirst%3DL.%2BJ.%26aulast%3DBrammer%26aufirst%3DL.%26aulast%3DShay%26aufirst%3DD.%2BK.%26atitle%3DHospitalizations%2520associated%2520with%2520influenza%2520and%2520respiratory%2520syncytial%2520virus%2520in%2520the%2520United%2520States%252C%25201993%25E2%2580%25932008%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D54%26spage%3D1427%26epage%3D1436%26doi%3D10.1093%2Fcid%2Fcis211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Yarza, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mejias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramilo, O.</span></span> <span> </span><span class="NLM_article-title">The association between respiratory syncytial virus infection and the development of childhood asthma</span>. <i>Journal of Pediatric Infectious Disease</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1097/INF.0b013e3180618c42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1097%2FINF.0b013e3180618c42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=17848887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BD2srjvVSnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=733-739&author=E.+G.+Perez-Yarzaauthor=A.+Morenoauthor=P.+Lazaroauthor=A.+Mejiasauthor=O.+Ramilo&title=The+association+between+respiratory+syncytial+virus+infection+and+the+development+of+childhood+asthma&doi=10.1097%2FINF.0b013e3180618c42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature</span></div><div class="casAuthors">Perez-Yarza Eduardo G; Moreno Antonio; Lazaro Pablo; Mejias Asuncion; Ramilo Octavio</div><div class="citationInfo"><span class="NLM_cas:title">The Pediatric infectious disease journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">733-9</span>
        ISSN:<span class="NLM_cas:issn">0891-3668</span>.
    </div><div class="casAbstract">BACKGROUND:  The relation between early respiratory syncytial virus (RSV) infection and later emergence of episodes of wheezing/asthma remains a subject of debate.  We carried out a systematic review of studies of the association between RSV infection in the first 36 months of life and the subsequent development of asthma/bronchial hyperreactivity.  METHODS:  A literature search for original studies on RSV respiratory infection published in English or Spanish over the last 21 years was conducted in the bibliographic databases Medline, Embase, and Indice Medico Espanol, and in the Cochrane library.  Articles were included if they described original studies of confirmed RSV infection in children under 3 years of age, and had defined outcome variables.  The methodologic quality of articles included in the review was evaluated according to the Hadorn criteria.  RESULTS:  The review included 12 original articles that respond to the research question.  The studies evaluated showed that RSV lower respiratory tract infection is associated with an increased risk for subsequent development of asthma/recurrent wheezing, and that this association becomes progressively smaller with increasing age.  CONCLUSION:  On the basis of this systematic review of the literature, it can be concluded that a significant association exists between RSV infection in childhood and the long-term development of subsequent episodes of recurrent wheezing or asthma.  However, the methodologic quality of the articles evaluated is limited, and hence additional studies are needed, ideally, with specific therapeutic interventions aimed at reducing RSV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFb2bX3_5oohpyrDyM_m9cfW6udTcc2eaX2Wh9t6RoTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srjvVSnug%253D%253D&md5=e89f361d225f377e9ec63f9847f56262</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1097%2FINF.0b013e3180618c42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FINF.0b013e3180618c42%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Yarza%26aufirst%3DE.%2BG.%26aulast%3DMoreno%26aufirst%3DA.%26aulast%3DLazaro%26aufirst%3DP.%26aulast%3DMejias%26aufirst%3DA.%26aulast%3DRamilo%26aufirst%3DO.%26atitle%3DThe%2520association%2520between%2520respiratory%2520syncytial%2520virus%2520infection%2520and%2520the%2520development%2520of%2520childhood%2520asthma%26jtitle%3DJournal%2520of%2520Pediatric%2520Infectious%2520Disease%26date%3D2007%26volume%3D26%26spage%3D733%26epage%3D739%26doi%3D10.1097%2FINF.0b013e3180618c42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mac, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchesne-Belanger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, B.</span></span> <span> </span><span class="NLM_article-title">Cost-effectiveness of palivizumab for respiratory syncytial irus: a systematic review</span>. <i>Pediatrics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>143</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e20184064</span>, <span class="refDoi"> DOI: 10.1542/peds.2018-4064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1542%2Fpeds.2018-4064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=31040196" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2019&pages=e20184064&issue=5&author=S.+Macauthor=A.+Sumnerauthor=S.+Duchesne-Belangerauthor=R.+Stirlingauthor=M.+Tunisauthor=B.+Sander&title=Cost-effectiveness+of+palivizumab+for+respiratory+syncytial+irus%3A+a+systematic+review&doi=10.1542%2Fpeds.2018-4064"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1542%2Fpeds.2018-4064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1542%252Fpeds.2018-4064%26sid%3Dliteratum%253Aachs%26aulast%3DMac%26aufirst%3DS.%26aulast%3DSumner%26aufirst%3DA.%26aulast%3DDuchesne-Belanger%26aufirst%3DS.%26aulast%3DStirling%26aufirst%3DR.%26aulast%3DTunis%26aufirst%3DM.%26aulast%3DSander%26aufirst%3DB.%26atitle%3DCost-effectiveness%2520of%2520palivizumab%2520for%2520respiratory%2520syncytial%2520irus%253A%2520a%2520systematic%2520review%26jtitle%3DPediatrics%26date%3D2019%26volume%3D143%26issue%3D5%26spage%3De20184064%26doi%3D10.1542%2Fpeds.2018-4064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wainwright, C.</span></span> <span> </span><span class="NLM_article-title">Acute viral bronchiolitis in children – a very common condition with few therapeutic options</span>. <i>Paediatr. Respir. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.prrv.2009.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2Fj.prrv.2009.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=20113991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252Fotlyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=39-45&issue=1&author=C.+Wainwright&title=Acute+viral+bronchiolitis+in+children+%E2%80%93+a+very+common+condition+with+few+therapeutic+options&doi=10.1016%2Fj.prrv.2009.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Acute viral bronchiolitis in children- a very common condition with few therapeutic options</span></div><div class="casAuthors">Wainwright Claire</div><div class="citationInfo"><span class="NLM_cas:title">Paediatric respiratory reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-45; quiz 45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute viral bronchiolitis remains a cause of substantial morbidity and health care costs in young infants.  It is the most common lower respiratory tract condition and most common reason for admission to hospital in infants.  Many respiratory viruses have been associated with acute viral bronchiolitis although respiratory syncytial virus (RSV) remains the most frequently identified virus.  Most infants have a mild self limiting illness while others have more severe illness and require hospital admission and some will need ventilatory support.  Differences in innate immune function in response to the respiratory viral insult as well as differences in the geometry of the airways may explain some of the variability in clinical pattern.  Young age and history of prematurity remain the most important risk factors although male gender, indigenous status, exposure to tobacco smoke, poor socioeconomic factors and associated co-morbidities such as chronic lung disease and congenital heart disease increase the risks of more severe illness.  Supportive therapy remains the major treatment option as no specific treatments to date have been shown to provide clinically important benefits except for inhaled hypertonic saline.  Prophylaxis of high risk infants with palivizumab should be considered although the cost effectiveness is still unclear.  Many questions remain regarding optimal management approaches for infants requiring hospitalisation with bronchiolitis including use of nasogastric feeding, the optimal role of supplemental oxygen, optimal use of hypertonic saline and the role of combinations of therapies, the use of heliox or modern physiotherapy approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjYoMkmkNtP-Lt9HypzAgQfW6udTcc2eaX2Wh9t6RoTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252Fotlyhsw%253D%253D&md5=ef94d9327375911261d3d3cf730c66bd</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2Fj.prrv.2009.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prrv.2009.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DWainwright%26aufirst%3DC.%26atitle%3DAcute%2520viral%2520bronchiolitis%2520in%2520children%2520%25E2%2580%2593%2520a%2520very%2520common%2520condition%2520with%2520few%2520therapeutic%2520options%26jtitle%3DPaediatr.%2520Respir.%2520Rev.%26date%3D2010%26volume%3D11%26issue%3D1%26spage%3D39%26epage%3D45%26doi%3D10.1016%2Fj.prrv.2009.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Empey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peebles, R. S.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolls, J. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic advances in the treatment and prevention of respiratory syncytial virus</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1258</span>– <span class="NLM_lpage">1267</span>, <span class="refDoi"> DOI: 10.1086/651603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1086%2F651603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=20235830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVehtL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=1258-1267&issue=9&author=K.+M.+Empeyauthor=R.+S.+Peeblesauthor=J.+K.+Kolls&title=Pharmacologic+advances+in+the+treatment+and+prevention+of+respiratory+syncytial+virus&doi=10.1086%2F651603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic advances in the treatment and prevention of respiratory syncytial virus</span></div><div class="casAuthors">Empey, Kerry M.; Peebles, R. Stokes, Jr.; Kolls, Jay K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1258-1267</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">A review.  Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus (RSV).  Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children.  Ribavirin is approved for treatment of severe RSV disease; however, its effectiveness in improving outcomes is questionable.  During the past 40 years, many obstacles have delayed the development of safe and effective vaccines and treatment regimens.  This article reviews these obstacles and presents the novel development strategies used to overcome many of them.  Also discussed are promising new antiviral treatment candidates and their assocd. mechanism of action, the significant advances made in vaccine development, and exciting, new studies directed at improving outcomes through pharmacol. manipulation of the host response to RSV disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowVNHvx4G3Z7Vg90H21EOLACvtfcHk0lhA4ZtlU9is2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVehtL3N&md5=f5b23cc6db487b8e50ceb7379cdd107f</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1086%2F651603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F651603%26sid%3Dliteratum%253Aachs%26aulast%3DEmpey%26aufirst%3DK.%2BM.%26aulast%3DPeebles%26aufirst%3DR.%2BS.%26aulast%3DKolls%26aufirst%3DJ.%2BK.%26atitle%3DPharmacologic%2520advances%2520in%2520the%2520treatment%2520and%2520prevention%2520of%2520respiratory%2520syncytial%2520virus%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2010%26volume%3D50%26issue%3D9%26spage%3D1258%26epage%3D1267%26doi%3D10.1086%2F651603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collins, P. L.</span></span> <span> </span><span class="NLM_article-title">Respiratory Syncytial Virus—Human (Paramyxoviridae)</span>. In  <i>Encyclopedia of Virology</i>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, G.</span>, <span class="NLM_string-name">Robert, G. W.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Oxford, U.K.</span>, <span class="NLM_year">1999</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1006%2Frwvi.1999.0246" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&author=P.+L.+Collinsauthor=G.+Allan&author=G.+W.+Robert&title=Encyclopedia+of+Virology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1006%2Frwvi.1999.0246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1006%252Frwvi.1999.0246%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DP.%2BL.%26atitle%3DRespiratory%2520Syncytial%2520Virus%25E2%2580%2594Human%2520%2528Paramyxoviridae%2529%26btitle%3DEncyclopedia%2520of%2520Virology%26aulast%3DAllan%26aufirst%3DG.%26pub%3DElsevier%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hacking, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hull, J.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus--viral biology and the host response</span>. <i>J. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1053/jinf.2002.1015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1053%2Fjinf.2002.1015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=12217726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BD38vlvFKqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=18-24&author=D.+Hackingauthor=J.+Hull&title=Respiratory+syncytial+virus%2D%2Dviral+biology+and+the+host+response&doi=10.1053%2Fjinf.2002.1015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus--viral biology and the host response</span></div><div class="casAuthors">Hacking D; Hull J</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of infection</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-24</span>
        ISSN:<span class="NLM_cas:issn">0163-4453</span>.
    </div><div class="casAbstract">Respiratory syncytial virus (RSV) is the most important cause of respiratory tract infection in infants.  We have an incomplete understanding of the reasons why some infants are more severely affected by RSV than others.  There is no effective antiviral treatment for the infection.  Advances in our understanding of the biology of RSV, particularly in relation to the attachment protein G and the fusion protein F, have revealed potential targets for new antiviral therapies and vaccine development.  In response to RSV infection an intense inflammatory response is triggered, mediated initially by the infected airway epithelial cells.  Cell mediated responses are important in controlling the extent of infection and in viral clearance.  Humoral responses are important in protection.  There is early evidence that genetic variation of the host response can influence the outcome of RSV-induced bronchiolitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSLUItxgiDFScuCWE5mhx1RfW6udTcc2eZFOTTYsBGdBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vlvFKqtw%253D%253D&md5=d6cb630e5400cdec66aca9d1b0026573</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1053%2Fjinf.2002.1015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fjinf.2002.1015%26sid%3Dliteratum%253Aachs%26aulast%3DHacking%26aufirst%3DD.%26aulast%3DHull%26aufirst%3DJ.%26atitle%3DRespiratory%2520syncytial%2520virus--viral%2520biology%2520and%2520the%2520host%2520response%26jtitle%3DJ.%2520Infect.%26date%3D2002%26volume%3D45%26spage%3D18%26epage%3D24%26doi%3D10.1053%2Fjinf.2002.1015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cockerill, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, J. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, N.</span></span> <span> </span><span class="NLM_article-title">State of the art in respiratory syncytial virus drug discovery and development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3206</span>– <span class="NLM_lpage">3227</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01361</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01361" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFeisrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3206-3227&author=G.+S.+Cockerillauthor=J.+A.+D.+Goodauthor=N.+Mathews&title=State+of+the+art+in+respiratory+syncytial+virus+drug+discovery+and+development&doi=10.1021%2Facs.jmedchem.8b01361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">State of the Art in Respiratory Syncytial Virus Drug Discovery and Development</span></div><div class="casAuthors">Cockerill, G. Stuart; Good, James A. D.; Mathews, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3206-3227</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Respiratory syncytial virus (RSV) is a globally prevalent viral infection with limited treatment options which hospitalizes millions each year.  Treatment options have been limited to palivizumab, a monoclonal antibody, approved for prophylaxis in high-risk infants and ribavirin with very limited efficacy and significant safety concerns.  This Perspective surveys the range of direct acting antiviral agents (DAAs) that target key steps in the viral life cycle.  A no. of approaches to DAAs have produced landmark clin. studies over the past few years, notably in fusion and nucleoside inhibitors, and an update of the clin. status of these compds. is provided.  Non-nucleoside inhibitors of replication are reviewed in addn. to inhibitors of other mechanisms, notably the RSV N and G proteins.  This article will provide an informative perspective of the current status of drug discovery targeted at providing an effective therapy for RSV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogooGT67MNJLVg90H21EOLACvtfcHk0lhA4ZtlU9is2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFeisrnP&md5=b52538dbb8d747951846fc831eb67c1c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01361%26sid%3Dliteratum%253Aachs%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DGood%26aufirst%3DJ.%2BA.%2BD.%26aulast%3DMathews%26aufirst%3DN.%26atitle%3DState%2520of%2520the%2520art%2520in%2520respiratory%2520syncytial%2520virus%2520drug%2520discovery%2520and%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3206%26epage%3D3227%26doi%3D10.1021%2Facs.jmedchem.8b01361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, J.</span>; <span class="NLM_string-name">Cockerill, S. G.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of RSV604</span>. In  <i>Antiviral Drugs: From Basic Discovery Through Clinical Trials</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmierski, W. M.</span></span>, Ed.; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1002%2F9780470929353.ch26" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Chapman&author=S.+G.+Cockerillauthor=W.+M.+Kazmierski&title=Antiviral+Drugs%3A+From+Basic+Discovery+Through+Clinical+Trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2F9780470929353.ch26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470929353.ch26%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520RSV604%26btitle%3DAntiviral%2520Drugs%253A%2520From%2520Basic%2520Discovery%2520Through%2520Clinical%2520Trials%26aulast%3DKazmierski%26aufirst%3DW.%2BM.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaglioni-Weinlich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambkin-Williams, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Riordan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toback, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span> <span> </span><span class="NLM_article-title">Oral GS-5806 Activity in a respiratory syncytial virus challenge study</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1401184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1056%2FNEJMoa1401184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=25140957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Cjsb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=711-722&author=J.+P.+DeVincenzoauthor=R.+J.+Whitleyauthor=R.+L.+Mackmanauthor=C.+Scaglioni-Weinlichauthor=L.+Harrisonauthor=E.+Farrellauthor=S.+McBrideauthor=R.+Lambkin-Williamsauthor=R.+Jordanauthor=Y.+Xinauthor=S.+Ramanathanauthor=T.+O%E2%80%99Riordanauthor=S.+A.+Lewisauthor=X.+Liauthor=S.+L.+Tobackauthor=S.-L.+Linauthor=J.+W.+Chien&title=Oral+GS-5806+Activity+in+a+respiratory+syncytial+virus+challenge+study&doi=10.1056%2FNEJMoa1401184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Oral GS-5806 activity in a respiratory syncytial virus challenge study</span></div><div class="casAuthors">DeVincenzo, John P.; Whitley, Richard J.; Mackman, Richard L.; Scaglioni-Weinlich, Cecilia; Harrison, Lisa; Farrell, Eric; McBride, Stephen; Lambkin-Williams, Robert; Jordan, Robert; Xin, Yan; Ramanathan, Srini; O'Riordan, Thomas; Lewis, Sandra A.; Li, Xiaoming; Toback, Seth L.; Lin, Shao-Lee; Chien, Jason W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-722, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Respiratory syncytial virus (RSV) is a common cause of infant hospitalizations and is increasingly recognized as a cause of considerable morbidity and mortality.  No accepted antiviral treatment exists.  Methods: We conducted a double-blind, placebo-controlled study of GS-5806, an oral RSV-entry inhibitor, in healthy adults who received a clin. challenge strain of RSV intranasally.  Participants were monitored for 12 days.  At the time of a pos. test for RSV infection or 5 days after inoculation, whichever occurred first, participants were randomly assigned to receive GS-5806 or placebo in one of seven sequential cohorts.  Cohorts 1 to 4 received a first dose of 50 mg of GS-5806 and then 25 mg daily for the next 4 days, cohort 5 received a first dose of 50 mg and then 25 mg daily for the next 2 days, cohort 6 received one 100-mg dose, and cohort 7 received a first dose of 10 mg and then 5 mg daily for the next 4 days.  Dose selection for cohorts 5, 6, and 7 occurred after an interim anal. of data for cohorts 1 to 4.  The primary end point was the area under the curve (AUC) for the viral load, which was assessed after administration of the first dose through the 12th day after inoculation.  Secondary end points were mucus wt. and symptom scores.  Results: Among the 54 participants in cohorts 1 to 4 who were infected with RSV, active treatment was assocd. with a lower viral load (adjusted mean, 250.7 vs. 757.7 log10 plaque-forming-unit equiv. [PFUe] × hours per mL; P<0.001), lower total mucus wt. (mean, 6.9 g vs. 15.1 g; P = 0.03), and a lower AUC for the change from baseline in symptom scores (adjusted mean, -20.2 vs. 204.9 × hours; P = 0.005).  The results were similar in cohorts 5, 6, and 7.  Adverse events, including low neutrophil counts and increased levels of alanine aminotransferase, were more common among participants receiving GS-5806.  Conclusions: Treatment with GS-5806 reduced the viral load and the severity of clin. disease in a challenge study of healthy adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqxDrIVO5aQLVg90H21EOLACvtfcHk0liboIUUcCQprA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Cjsb7O&md5=72276739a80d55a732269359e338fb95</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1401184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1401184%26sid%3Dliteratum%253Aachs%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26aulast%3DWhitley%26aufirst%3DR.%2BJ.%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DScaglioni-Weinlich%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DL.%26aulast%3DFarrell%26aufirst%3DE.%26aulast%3DMcBride%26aufirst%3DS.%26aulast%3DLambkin-Williams%26aufirst%3DR.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DXin%26aufirst%3DY.%26aulast%3DRamanathan%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DS.%2BA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DToback%26aufirst%3DS.%2BL.%26aulast%3DLin%26aufirst%3DS.-L.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26atitle%3DOral%2520GS-5806%2520Activity%2520in%2520a%2520respiratory%2520syncytial%2520virus%2520challenge%2520study%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D711%26epage%3D722%26doi%3D10.1056%2FNEJMoa1401184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinón-Torres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntjens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remmerie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vingerhoets, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrero, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epalza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, safety and antiviral effects of multiple doses of the respiratory syncytial virus fusion protein inhibitor, JNJ-53718678, in infants hospitalized with RSV infection: A randomized phase 1b study</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">e594</span>– <span class="NLM_lpage">e603</span>, <span class="refDoi"> DOI: 10.1093/cid/ciaa283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1093%2Fcid%2Fciaa283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=32201897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnvFCiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2020&pages=e594-e603&author=F.+Martin%C3%B3n-Torresauthor=S.+Ruschauthor=D.+Huntjensauthor=B.+Remmerieauthor=J.+Vingerhoetsauthor=K.+McFadyenauthor=F.+Ferreroauthor=E.+Baraldiauthor=P.+Rojoauthor=C.+Epalzaauthor=M.+Stevens&title=Pharmacokinetics%2C+safety+and+antiviral+effects+of+multiple+doses+of+the+respiratory+syncytial+virus+fusion+protein+inhibitor%2C+JNJ-53718678%2C+in+infants+hospitalized+with+RSV+infection%3A+A+randomized+phase+1b+study&doi=10.1093%2Fcid%2Fciaa283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics, safety, and antiviral effects of multiple doses of the respiratory syncytial virus (RSV) fusion protein inhibitor, JNJ-53718678, in infants hospitalized with RSV infection: a randomized phase 1b study</span></div><div class="casAuthors">Martinon-Torres, Federico; Rusch, Sarah; Huntjens, Dymphy; Remmerie, Bart; Vingerhoets, Johan; McFadyen, Katie; Ferrero, Fernando; Baraldi, Eugenio; Rojo, Pablo; Epalza, Cristina; Stevens, Marita</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e594-e603</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">This phase 1b study evaluated the pharmacokinetics, safety, and antiviral effects of the respiratory syncytial virus (RSV)-specific fusion inhibitor JNJ-53718678 (JNJ-8678) in hospitalized RSV-infected patients aged > 1 to ≤24 mo.  Patients categorized by age (cohort 1: ≥6 to ≤24 mo; cohort 2: ≥3 to < 6 mo; cohort 3: > 1 to < 3 mo) were randomized to oral JNJ-8678 or placebo once daily for 7 days.  Dose increases followed data review committee recommendations (cohort 1: 2/6/8/9 mg/kg; cohort 2: 1.5/4.5/6 mg/kg; cohort 3: 1/3/5 mg/kg).  Cohort 1 included a 9 mg/kg dose, as target exposures were not reached at lower doses.  Sparse pharmacokinetic samples were assessed using population pharmacokinetics modeling.  Safety was assessed by adverse events (AEs), lab. tests, and electrocardiograms.  To assess antiviral effects, RSV RNA viral load from nasal swabs was quantified over time using reverse-transcription quant. polymerase chain reaction.  Patients received JNJ-8678 (n = 37) or placebo (n = 7).  Pharmacokinetic parameters were similar at the highest doses for cohorts 1-3 (area under the plasma concn.-time curve from time of administration up to 24 h postdosing at day 7: 35 840, 34 980, and 39 627 ng × hour/mL, resp.).  Two grade 3 AEs were reported (both bronchiolitis; 1 JNJ-8678, 1 placebo), reported as serious AEs; all other AEs were grade 1 or 2.  Two addnl. serious AEs were reported (rhinitis [JNJ-8678]; pneumonia [placebo]).  No deaths, grade 4 AEs, or AEs leading to discontinuation were reported.  Median RSV viral load change from baseline in JNJ-8678 vs placebo by day 3 was -1.98 vs -0.32 log10 copies/mL.  In RSV-infected infants, JNJ-8678 was well tolerated.  Target exposures were reached and antiviral activity was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX-d7X2g1ye7Vg90H21EOLACvtfcHk0lgx9qMXW6ekZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnvFCiug%253D%253D&md5=aa4018755fbc161c817b0abf56a2de8a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciaa283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciaa283%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%25C3%25B3n-Torres%26aufirst%3DF.%26aulast%3DRusch%26aufirst%3DS.%26aulast%3DHuntjens%26aufirst%3DD.%26aulast%3DRemmerie%26aufirst%3DB.%26aulast%3DVingerhoets%26aufirst%3DJ.%26aulast%3DMcFadyen%26aufirst%3DK.%26aulast%3DFerrero%26aufirst%3DF.%26aulast%3DBaraldi%26aufirst%3DE.%26aulast%3DRojo%26aufirst%3DP.%26aulast%3DEpalza%26aufirst%3DC.%26aulast%3DStevens%26aufirst%3DM.%26atitle%3DPharmacokinetics%252C%2520safety%2520and%2520antiviral%2520effects%2520of%2520multiple%2520doses%2520of%2520the%2520respiratory%2520syncytial%2520virus%2520fusion%2520protein%2520inhibitor%252C%2520JNJ-53718678%252C%2520in%2520infants%2520hospitalized%2520with%2520RSV%2520infection%253A%2520A%2520randomized%2520phase%25201b%2520study%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2020%26volume%3D71%26spage%3De594%26epage%3De603%26doi%3D10.1093%2Fcid%2Fciaa283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of ziresovir as a potent, selective, and orally bioavailable respiratory syncytial virus fusion protein inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6003</span>– <span class="NLM_lpage">6014</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00654</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00654" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKksb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6003-6014&author=X.+Zhengauthor=L.+Gaoauthor=L.+Wangauthor=C.+Liangauthor=B.+Wangauthor=Y.+Liuauthor=S.+Fengauthor=B.+Zhangauthor=M.+Zhouauthor=X.+Yuauthor=K.+Xiangauthor=L.+Chenauthor=T.+Guoauthor=H.+C.+Shenauthor=G.+Zouauthor=J.+Z.+Wuauthor=H.+Yun&title=Discovery+of+ziresovir+as+a+potent%2C+selective%2C+and+orally+bioavailable+respiratory+syncytial+virus+fusion+protein+inhibitor&doi=10.1021%2Facs.jmedchem.9b00654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor</span></div><div class="casAuthors">Zheng, Xiufang; Gao, Lu; Wang, Lisha; Liang, Chungen; Wang, Baoxia; Liu, Yongfu; Feng, Song; Zhang, Bo; Zhou, Mingwei; Yu, Xin; Xiang, Kunlun; Chen, Li; Guo, Tao; Shen, Hong C.; Zou, Gang; Wu, Jim Zhen; Yun, Hongying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6003-6014</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ziresovir (RO-0529, AK0529) is reported here for the first time as a promising respiratory syncytial virus (RSV) fusion (F) protein inhibitor that currently is in advanced clin. trials.  This article reports the discovery of ziresovir as a potent, selective and orally bioavailable RSV F protein inhibitor, and highlights the efforts of rational drug design, lead optimization, improvement of in vitro and in vivo anti-RSV activities and pharmacokinetics in animal species.  Ziresovir demonstrates single-digit nM EC50 potency against lab. strains as well as clin. isolates of RSV in cellular assays, and more than one log viral load redn. in BALB/c mouse model of RSV viral infection.  Ziresovir was proven to be a specific RSV F protein inhibitor by identification of drug resistant mutations of D486N, D489V, and D489Y in RSV F protein and the inhibition of RSV F protein-induced cell-cell fusion in cellular assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon6vNioogRRrVg90H21EOLACvtfcHk0lgx9qMXW6ekZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKksb7K&md5=6d21370486436746fff2710b9a38b545</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00654%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DZou%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DYun%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520ziresovir%2520as%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520respiratory%2520syncytial%2520virus%2520fusion%2520protein%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6003%26epage%3D6014%26doi%3D10.1021%2Facs.jmedchem.9b00654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coakley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenhoor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eze, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noulin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvathova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adda, N.</span></span> <span> </span><span class="NLM_article-title">LB6. EDP-938, a novel RSV N-inhibitor, administered once or twice daily was safe and demonstrated robust antiviral and clinical efficacy in a healthy volunteer challenge study</span>. <i>Open Forum Infectious Diseases</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">S995</span>, <span class="refDoi"> DOI: 10.1093/ofid/ofz415.2489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1093%2Fofid%2Fofz415.2489" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=S995&author=E.+Coakleyauthor=A.+Ahmadauthor=K.+Larsonauthor=T.+McClureauthor=K.+Linauthor=K.+Linauthor=K.+Tenhoorauthor=K.+Ezeauthor=N.+Noulinauthor=V.+Horvathovaauthor=B.+Murrayauthor=M.+Bailletauthor=J.+Moriauthor=N.+Adda&title=LB6.+EDP-938%2C+a+novel+RSV+N-inhibitor%2C+administered+once+or+twice+daily+was+safe+and+demonstrated+robust+antiviral+and+clinical+efficacy+in+a+healthy+volunteer+challenge+study&doi=10.1093%2Fofid%2Fofz415.2489"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fofid%2Fofz415.2489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fofid%252Fofz415.2489%26sid%3Dliteratum%253Aachs%26aulast%3DCoakley%26aufirst%3DE.%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DLarson%26aufirst%3DK.%26aulast%3DMcClure%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DTenhoor%26aufirst%3DK.%26aulast%3DEze%26aufirst%3DK.%26aulast%3DNoulin%26aufirst%3DN.%26aulast%3DHorvathova%26aufirst%3DV.%26aulast%3DMurray%26aufirst%3DB.%26aulast%3DBaillet%26aufirst%3DM.%26aulast%3DMori%26aufirst%3DJ.%26aulast%3DAdda%26aufirst%3DN.%26atitle%3DLB6.%2520EDP-938%252C%2520a%2520novel%2520RSV%2520N-inhibitor%252C%2520administered%2520once%2520or%2520twice%2520daily%2520was%2520safe%2520and%2520demonstrated%2520robust%2520antiviral%2520and%2520clinical%2520efficacy%2520in%2520a%2520healthy%2520volunteer%2520challenge%2520study%26jtitle%3DOpen%2520Forum%2520Infectious%2520Diseases%26date%3D2019%26volume%3D6%26spage%3DS995%26doi%3D10.1093%2Fofid%2Fofz415.2489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combrink, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiello, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovesi, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venables, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulgeze, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trehan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span> <span> </span><span class="NLM_article-title">Orally active fusion inhibitor of respiratory syncytial virus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1128/AAC.48.2.413-422.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1128%2FAAC.48.2.413-422.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=14742189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFGls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=413-422&author=C.+Cianciauthor=K.+L.+Yuauthor=K.+Combrinkauthor=N.+Sinauthor=B.+Pearceauthor=A.+Wangauthor=R.+Civielloauthor=S.+Vossauthor=G.+Luoauthor=K.+Kadowauthor=E.+V.+Genovesiauthor=B.+Venablesauthor=H.+Gulgezeauthor=A.+Trehanauthor=J.+Jamesauthor=L.+Lambauthor=I.+Medinaauthor=J.+Roachauthor=Z.+Yangauthor=L.+Zadjuraauthor=R.+Colonnoauthor=J.+Clarkauthor=N.+Meanwellauthor=M.+Krystal&title=Orally+active+fusion+inhibitor+of+respiratory+syncytial+virus&doi=10.1128%2FAAC.48.2.413-422.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Orally active fusion inhibitor of respiratory syncytial virus</span></div><div class="casAuthors">Cianci, Christopher; Yu, Kuo-Long; Combrink, Keith; Sin, Ny; Pearce, Bradley; Wang, Alan; Civiello, Rita; Voss, Stacey; Luo, Guangxiang; Kadow, Kathy; Genovesi, Eugene V.; Venables, Brian; Gulgeze, Hatice; Trehan, Ashok; James, Jennifer; Lamb, Lucinda; Medina, Ivette; Roach, Julia; Yang, Zheng; Zadjura, Lisa; Colonno, Richard; Clark, Junius; Meanwell, Nicholas; Krystal, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">413-422</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">BMS-433771 was a potent inhibitor of respiratory syncytial virus (RSV) replication in vitro.  It exhibited excellent potency against multiple lab. and clin. isolates of both group A and B viruses, with an av. 50% effective concn. of 20 nM.  Mechanism-of-action studies demonstrated that BMS-433771 inhibits the fusion of lipid membranes during both the early virus entry stage and late-stage syncytium formation.  After isolation of resistant viruses, resistance was mapped to a series of single amino acid mutations in the F1 subunit of the fusion protein.  Upon oral administration, BMS-433771 was able to reduce viral titers in the lungs of mice infected with RSV.  This new class of orally active RSV fusion inhibitors offers potential for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR6fq_vRrsObVg90H21EOLACvtfcHk0lg0CksWAG8Kig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFGls7Y%253D&md5=790547babc0dcd1a87b628897ac68663</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.2.413-422.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.2.413-422.2004%26sid%3Dliteratum%253Aachs%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DK.%2BL.%26aulast%3DCombrink%26aufirst%3DK.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DPearce%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DCiviello%26aufirst%3DR.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DKadow%26aufirst%3DK.%26aulast%3DGenovesi%26aufirst%3DE.%2BV.%26aulast%3DVenables%26aufirst%3DB.%26aulast%3DGulgeze%26aufirst%3DH.%26aulast%3DTrehan%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DRoach%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DOrally%2520active%2520fusion%2520inhibitor%2520of%2520respiratory%2520syncytial%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D413%26epage%3D422%26doi%3D10.1128%2FAAC.48.2.413-422.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vendeville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooymans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwanten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Berg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battles, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raboisson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonckers, T. H. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2- yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3- dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a potent and orally bioavailable fusion inhibitor of respiratory syncytial virus</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8046</span>– <span class="NLM_lpage">8058</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00226</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00226" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsVCqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8046-8058&author=S.+Vendevilleauthor=A.+Tahriauthor=L.+Huauthor=S.+Deminauthor=L.+Cooymansauthor=A.+Vosauthor=L.+Kwantenauthor=J.+Van+den%0ABergauthor=M.+B.+Battlesauthor=J.+S.+McLellanauthor=A.+Koulauthor=P.+Raboissonauthor=D.+Roymansauthor=T.+H.+M.+Jonckers&title=Discovery+of+3-%28%7B5-chloro-1-%5B3-%28methylsulfonyl%29propyl%5D-1H-indol-2-+yl%7Dmethyl%29-1-%282%2C2%2C2-trifluoroethyl%29-1%2C3-+dihydro-2H-imidazo%5B4%2C5-c%5Dpyridin-2-one+%28JNJ-53718678%29%2C+a+potent+and+orally+bioavailable+fusion+inhibitor+of+respiratory+syncytial+virus&doi=10.1021%2Facs.jmedchem.0c00226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus</span></div><div class="casAuthors">Vendeville, Sandrine; Tahri, Abdellah; Hu, Lili; Demin, Samuel; Cooymans, Ludwig; Vos, Ann; Kwanten, Leen; Van den Berg, Joke; Battles, Michael B.; McLellan, Jason S.; Koul, Anil; Raboisson, Pierre; Roymans, Dirk; Jonckers, Tim H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8046-8058</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a seasonal virus that infects the lungs and airways of 64 million children and adults every year.  It is a major cause of acute lower respiratory tract infection and is assocd. with significant morbidity and mortality.  Despite the large medical and economic burden, treatment options for RSV-assocd. bronchiolitis and pneumonia are limited and mainly consist of supportive care.  This publication covers the medicinal chem. efforts resulting in the identification of JNJ-53718678 (I), an orally bioavailable RSV inhibitor that was shown to be efficacious in a phase 2a challenge study in healthy adult subjects and that is currently being evaluated in hospitalized infants and adults.  Cocrystal structures of several new derivs. helped in rationalizing some of the structure-activity relationship (SAR) trends obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Q5vkPwsLFLVg90H21EOLACvtfcHk0lg0CksWAG8Kig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsVCqtr0%253D&md5=cf57029d4262a269c1afeab3db55d4b2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00226%26sid%3Dliteratum%253Aachs%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DDemin%26aufirst%3DS.%26aulast%3DCooymans%26aufirst%3DL.%26aulast%3DVos%26aufirst%3DA.%26aulast%3DKwanten%26aufirst%3DL.%26aulast%3DVan%2Bden%2BBerg%26aufirst%3DJ.%26aulast%3DBattles%26aufirst%3DM.%2BB.%26aulast%3DMcLellan%26aufirst%3DJ.%2BS.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DJonckers%26aufirst%3DT.%2BH.%2BM.%26atitle%3DDiscovery%2520of%25203-%2528%257B5-chloro-1-%255B3-%2528methylsulfonyl%2529propyl%255D-1H-indol-2-%2520yl%257Dmethyl%2529-1-%25282%252C2%252C2-trifluoroethyl%2529-1%252C3-%2520dihydro-2H-imidazo%255B4%252C5-c%255Dpyridin-2-one%2520%2528JNJ-53718678%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520fusion%2520inhibitor%2520of%2520respiratory%2520syncytial%2520virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8046%26epage%3D8058%26doi%3D10.1021%2Facs.jmedchem.0c00226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-L.</span>; <span class="NLM_string-name">Civiello, R. L.</span>; <span class="NLM_string-name">Combrink, K. D.</span>; <span class="NLM_string-name">Gulgeze, H. B.</span>; <span class="NLM_string-name">Sin, N.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Meanwell, N.</span>; <span class="NLM_string-name">Venables, B. L.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Pearce, B. C.</span>; <span class="NLM_string-name">Yin, Z.</span>; <span class="NLM_string-name">Thuring, J. W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Substituted 2-Methyl-benzimidazole Antiviral Agents</span>. <span class="NLM_patent">WO/2002/062290</span>, Nov 21, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=K.-L.+Yu&author=R.+L.+Civiello&author=K.+D.+Combrink&author=H.+B.+Gulgeze&author=N.+Sin&author=X.+Wang&author=N.+Meanwell&author=B.+L.+Venables&author=Y.+Zhang&author=B.+C.+Pearce&author=Z.+Yin&author=J.+W.+Thuring&title=Heterocyclic+Substituted+2-Methyl-benzimidazole+Antiviral+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.-L.%26atitle%3DHeterocyclic%2520Substituted%25202-Methyl-benzimidazole%2520Antiviral%2520Agents%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-L.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Sun, Y.</span>; <span class="NLM_string-name">Cianci, C.</span>; <span class="NLM_string-name">Thuring, J. W.</span>; <span class="NLM_string-name">Combrink, K.</span>; <span class="NLM_string-name">Meanwell, N.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Civiello, R. L.</span></span> <span> </span><span class="NLM_article-title">Substituted 2-Methyl-benzimidazole Respiratory Syncytial Virus Antiviral Agents</span>. <span class="NLM_patent">WO/2003/053344</span>, July 03, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=K.-L.+Yu&author=X.+Wang&author=Y.+Sun&author=C.+Cianci&author=J.+W.+Thuring&author=K.+Combrink&author=N.+Meanwell&author=Y.+Zhang&author=R.+L.+Civiello&title=Substituted+2-Methyl-benzimidazole+Respiratory+Syncytial+Virus+Antiviral+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.-L.%26atitle%3DSubstituted%25202-Methyl-benzimidazole%2520Respiratory%2520Syncytial%2520Virus%2520Antiviral%2520Agents%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blade, H.</span>; <span class="NLM_string-name">Carron, E.</span>; <span class="NLM_string-name">Jackson, H.</span>; <span class="NLM_string-name">Lumley, J.</span>; <span class="NLM_string-name">Pilkington, C.</span>; <span class="NLM_string-name">Tomkinson, G.</span>; <span class="NLM_string-name">Thomas, A.</span>; <span class="NLM_string-name">Warne, J.</span></span> <span> </span><span class="NLM_article-title">Benzimidazole Derivatives and their use as Antiviral Agents</span>. <span class="NLM_patent">WO/2010/103306</span>, Sep 17, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=H.+Blade&author=E.+Carron&author=H.+Jackson&author=J.+Lumley&author=C.+Pilkington&author=G.+Tomkinson&author=A.+Thomas&author=J.+Warne&title=Benzimidazole+Derivatives+and+their+use+as+Antiviral+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlade%26aufirst%3DH.%26atitle%3DBenzimidazole%2520Derivatives%2520and%2520their%2520use%2520as%2520Antiviral%2520Agents%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lj4cKZC4KGhKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span>; <span class="NLM_string-name">Price, D. A.</span></span> <span> </span><span class="NLM_article-title">Chapter 23: Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks</span>. In  <i>Annu. Rep. Med. Chem.</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>, <span class="NLM_year">2010</span>; Vol.  <span class="NLM_volume">45</span>, pp  <span class="NLM_fpage">380</span>– <span class="NLM_lpage">391</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=380-391&author=M.+P.+Edwards&author=D.+A.+Priceauthor=J.+E.+Macor&title=Annu.+Rep.+Med.+Chem."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DChapter%252023%253A%2520Role%2520of%2520Physicochemical%2520Properties%2520and%2520Ligand%2520Lipophilicity%2520Efficiency%2520in%2520Addressing%2520Drug%2520Safety%2520Risks%26btitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26pub%3DAcademic%2520Press%26date%3D2010%26volume%3D45%26spage%3D380%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span> For a comparable study
in the benzimidazolone series of fusion inhibitors, see:<span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiello, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combrink, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulgeze, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venables, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalterio, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dando, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovesi, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.11.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2Fj.bmcl.2006.11.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=17169560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12rtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=895-901&author=K.-L.+Yuauthor=N.+Sinauthor=R.+L.+Civielloauthor=X.+A.+Wangauthor=K.+D.+Combrinkauthor=H.+B.+Gulgezeauthor=B.+L.+Venablesauthor=J.J.+K.+Wrightauthor=R.+A.+Dalterioauthor=L.+Zadjuraauthor=A.+Marinoauthor=S.+Dandoauthor=C.+D%E2%80%99Arienzoauthor=K.+F.+Kadowauthor=C.+W.+Cianciauthor=Z.+Liauthor=J.+Clarkeauthor=E.+V.+Genovesiauthor=I.+Medinaauthor=L.+Lambauthor=R.+J.+Colonnoauthor=Z.+Yangauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Respiratory+syncytial+virus+fusion+inhibitors.+Part+4%3A+Optimization+for+oral+bioavailability&doi=10.1016%2Fj.bmcl.2006.11.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability</span></div><div class="casAuthors">Yu, Kuo-Long; Sin, Ny; Civiello, Rita L.; Wang, X. Alan; Combrink, Keith D.; Gulgeze, H. Belgin; Venables, Brian L.; Wright, J. J. Kim; Dalterio, Richard A.; Zadjura, Lisa; Marino, Anthony; Dando, Sandra; D'Arienzo, Celia; Kadow, Kathleen F.; Cianci, Christopher W.; Li, Zhufang; Clarke, Junius; Genovesi, Eugene V.; Medina, Ivette; Lamb, Lucinda; Colonno, Richard J.; Yang, Zheng; Krystal, Mark; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-901</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of benzimidazole-based inhibitors of respiratory syncytial virus (RSV) fusion were optimized for antiviral potency, membrane permeability and metabolic stability in human liver microsomes.  1-Cyclopropyl-1,3-dihydro-3-[[1-(4-hydroxybutyl)-1H-benzimidazol-2-yl]methyl]-2H-imidazo[4,5-c]pyridin-2-one (I, BMS-433771) was identified as a potent RSV inhibitor demonstrating good bioavailability in the mouse, rat, dog and cynomolgus monkey that demonstrated antiviral activity in the BALB/c and cotton rat models of infection following oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwTTCqYL_6iLVg90H21EOLACvtfcHk0lj4cKZC4KGhKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12rtLc%253D&md5=1df6d784bda1cabee0b57b799f1f165e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.11.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.11.063%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BA.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DGulgeze%26aufirst%3DH.%2BB.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DWright%26aufirst%3DJ.J.%2BK.%26aulast%3DDalterio%26aufirst%3DR.%2BA.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DDando%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DCianci%26aufirst%3DC.%2BW.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DClarke%26aufirst%3DJ.%26aulast%3DGenovesi%26aufirst%3DE.%2BV.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DRespiratory%2520syncytial%2520virus%2520fusion%2520inhibitors.%2520Part%25204%253A%2520Optimization%2520for%2520oral%2520bioavailability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D895%26epage%3D901%26doi%3D10.1016%2Fj.bmcl.2006.11.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mansoor, A.</span>; <span class="NLM_string-name">Mahabadi, N.</span></span> Vol. of Distribution. [Updated 2020 Jul 27]. In: StatPearls [Internet]. <span class="NLM_publisher-name">StatPearls Publishing</span>: <span class="NLM_publisher-loc">Treasure Island, FL</span>, <span class="NLM_year">2020</span>. Available from: <a href="https://www.ncbi.nlm.nih.gov/books/NBK545280/" class="extLink">https://www.ncbi.nlm.nih.gov/books/NBK545280/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Mansoor%2C+A.%3B+Mahabadi%2C+N.+Vol.+of+Distribution.+%5BUpdated+2020+Jul+27%5D.+In%3A+StatPearls+%5BInternet%5D.+StatPearls+Publishing%3A+Treasure+Island%2C+FL%2C+2020.+Available+from%3A+https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK545280%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMansoor%26aufirst%3DA.%26pub%3DStatPearls%2520Publishing%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pope, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewen, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkinson, A.</span></span> <span> </span><span class="NLM_article-title">Lysosomal sequestration (trapping) of lipophilic amine (cationic ampiphillic drugs) in immortalized human hepatocytes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">905</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.050054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1124%2Fdmd.112.050054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=23378628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkslSktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=897-905&author=F.+Kazmiauthor=T.+Hensleyauthor=C.+Popeauthor=R.+S.+Funkauthor=G.+J.+Loewenauthor=D.+B.+Buckleyauthor=A.+Parkinson&title=Lysosomal+sequestration+%28trapping%29+of+lipophilic+amine+%28cationic+ampiphillic+drugs%29+in+immortalized+human+hepatocytes&doi=10.1124%2Fdmd.112.050054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells)</span></div><div class="casAuthors">Kazmi, Faraz; Hensley, Tiffini; Pope, Chad; Funk, Ryan S.; Loewen, Greg J.; Buckley, David B.; Parkinson, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">897-905</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Lipophilic (logP > 1) and amphiphilic drugs (also known as cationic amphiphilic drugs) with ionizable amines (pKa > 6) can accumulate in lysosomes, a process known as lysosomal trapping.  This process contributes to presystemic extn. by lysosome-rich organs (such as liver and lung), which, together with the binding of lipophilic amines to phospholipids, contributes to the large vol. of distribution characteristic of numerous cardiovascular and central nervous system drugs.  Accumulation of lipophilic amines in lysosomes has been implicated as a cause of phospholipidosis.  Furthermore, elevated levels of lipophilic amines in lysosomes can lead to high organ-to-blood ratios of drugs that can be mistaken for active drug transport.  In the present study, we describe an in vitro fluorescence-based method (using the lysosome-specific probe LysoTracker Red) to identify lysosomotropic agents in immortalized hepatocytes (Fa2N-4 cells).  A diverse set of compds. with various physicochem. properties were tested, such as acids, bases, and zwitterions.  In addn., the partitioning of the nonlysosomotropic atorvastatin (an anion) and the lysosomotropics propranolol and imipramine (cations) were quantified in Fa2N-4 cells in the presence or absence of various lysosomotropic or nonlysosomotropic agents and inhibitors of lysosomal sequestration (NH4Cl, nigericin, and monensin).  Cellular partitioning of propranolol and imipramine was markedly reduced (by at least 40%) by NH4Cl, nigericin, or monensin.  Lysosomotropic drugs also inhibited the partitioning of propranolol by at least 50%, with imipramine partitioning affected to a lesser degree.  This study demonstrates the usefulness of immortalized hepatocytes (Fa2N-4 cells) for detg. the lysosomal sequestration of lipophilic amines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa8mAg9M-HcrVg90H21EOLACvtfcHk0ljFDaMtiiA14Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkslSktLs%253D&md5=ac5dc2bb69b754f004e2e2c92e1939f7</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.050054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.050054%26sid%3Dliteratum%253Aachs%26aulast%3DKazmi%26aufirst%3DF.%26aulast%3DHensley%26aufirst%3DT.%26aulast%3DPope%26aufirst%3DC.%26aulast%3DFunk%26aufirst%3DR.%2BS.%26aulast%3DLoewen%26aufirst%3DG.%2BJ.%26aulast%3DBuckley%26aufirst%3DD.%2BB.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DLysosomal%2520sequestration%2520%2528trapping%2529%2520of%2520lipophilic%2520amine%2520%2528cationic%2520ampiphillic%2520drugs%2529%2520in%2520immortalized%2520human%2520hepatocytes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D897%26epage%3D905%26doi%3D10.1124%2Fdmd.112.050054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Branigan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutshall, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarisky, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Vecchio, A. M.</span></span> <span> </span><span class="NLM_article-title">Use of a novel cell-based fusion reporter assay to explore the host range of human respiratory syncytial virus F protein</span>. <i>Virol. J.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1186/1743-422X-2-54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1186%2F1743-422X-2-54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=16014172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BD2MvlsVWquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=54-66&author=P.+J.+Braniganauthor=C.+Liuauthor=N.+D.+Dayauthor=L.+L.+Gutshallauthor=R.+T.+Sariskyauthor=A.+M.+Del+Vecchio&title=Use+of+a+novel+cell-based+fusion+reporter+assay+to+explore+the+host+range+of+human+respiratory+syncytial+virus+F+protein&doi=10.1186%2F1743-422X-2-54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a novel cell-based fusion reporter assay to explore the host range of human respiratory syncytial virus F protein</span></div><div class="casAuthors">Branigan Patrick J; Liu Changbao; Day Nicole D; Gutshall Lester L; Sarisky Robert T; Del Vecchio Alfred M</div><div class="citationInfo"><span class="NLM_cas:title">Virology journal</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human respiratory syncytial virus (HRSV) is an important respiratory pathogen primarily affecting infants, young children, transplant recipients and the elderly.  The F protein is the only virion envelope protein necessary and sufficient for virus replication and fusion of the viral envelope membrane with the target host cell.  During natural infection, HRSV replication is limited to respiratory epithelial cells with disseminated infection rarely, if ever, occurring even in immunocompromised patients.  However, in vitro infection of multiple human and non-human cell types other than those of pulmonary tract origin has been reported.  To better define host cell surface molecules that mediate viral entry and dissect the factors controlling permissivity for HRSV, we explored the host range of HRSV F protein mediated fusion.  Using a novel recombinant reporter gene based fusion assay, HRSV F protein was shown to mediate fusion with cells derived from a wide range of vertebrate species including human, feline, equine, canine, bat, rodent, avian, porcine and even amphibian (Xenopus).  That finding was extended using a recombinant HRSV engineered to express green fluorescent protein (GFP), to confirm that viral mRNA expression is limited in several cell types.  These findings suggest that HRSV F protein interacts with either highly conserved host cell surface molecules or can use multiple mechanisms to enter cells, and that the primary determinants of HRSV host range are at steps post-entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiHO62ol-EjIMcDoIzZtNkfW6udTcc2eZo82NhOU3x5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MvlsVWquw%253D%253D&md5=9acc3e3dddc04007308ccd5e127cc1d1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1186%2F1743-422X-2-54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1743-422X-2-54%26sid%3Dliteratum%253Aachs%26aulast%3DBranigan%26aufirst%3DP.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DDay%26aufirst%3DN.%2BD.%26aulast%3DGutshall%26aufirst%3DL.%2BL.%26aulast%3DSarisky%26aufirst%3DR.%2BT.%26aulast%3DDel%2BVecchio%26aufirst%3DA.%2BM.%26atitle%3DUse%2520of%2520a%2520novel%2520cell-based%2520fusion%2520reporter%2520assay%2520to%2520explore%2520the%2520host%2520range%2520of%2520human%2520respiratory%2520syncytial%2520virus%2520F%2520protein%26jtitle%3DVirol.%2520J.%26date%3D2005%26volume%3D2%26spage%3D54%26epage%3D66%26doi%3D10.1186%2F1743-422X-2-54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pickles, R. J.</span></span> <span> </span><span class="NLM_article-title">Human airway epithelial cell cultures for modeling respiratory syncytial virus infection</span>. <i>Curr. Top. Microbiol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1007/978-3-642-38919-1_19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1007%2F978-3-642-38919-1_19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=24362700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BC2c3psFWltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2013&pages=371-387&author=R.+J.+Pickles&title=Human+airway+epithelial+cell+cultures+for+modeling+respiratory+syncytial+virus+infection&doi=10.1007%2F978-3-642-38919-1_19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Human airway epithelial cell cultures for modeling respiratory syncytial virus infection</span></div><div class="casAuthors">Pickles Raymond J</div><div class="citationInfo"><span class="NLM_cas:title">Current topics in microbiology and immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">371-87</span>
        ISSN:<span class="NLM_cas:issn">0070-217X</span>.
    </div><div class="casAbstract">Respiratory syncytial virus (RSV) is an important human respiratory pathogen with narrow species tropism.  Limited availability of human pathologic specimens during early RSV-induced lung disease and ethical restrictions for RSV challenge studies in the lower airways of human volunteers has slowed our understanding of how RSV causes airway disease and greatly limited the development of therapeutic strategies for reducing RSV disease burden.  Our current knowledge of RSV infection and pathology is largely based on in vitro studies using nonpolarized epithelial cell-lines grown on plastic or in vivo studies using animal models semipermissive for RSV infection.  Although these models have revealed important aspects of RSV infection, replication, and associated inflammatory responses, these models do not broadly recapitulate the early interactions and potential consequences of RSV infection of the human columnar airway epithelium in vivo.  In this chapter, the pro et contra of in vitro models of human columnar airway epithelium and their usefulness in respiratory virus pathogenesis and vaccine development studies will be discussed.  The use of such culture models to predict characteristics of RSV infection and the correlation of these findings to the human in vivo situation will likely accelerate our understanding of RSV pathogenesis potentially identifying novel strategies for limiting the severity of RSV-associated airway disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSySEeEVfogvRLDWw4HIq2sfW6udTcc2eZo82NhOU3x5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3psFWltQ%253D%253D&md5=73e5843feb0686f2556ea317006c11e1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-38919-1_19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-38919-1_19%26sid%3Dliteratum%253Aachs%26aulast%3DPickles%26aufirst%3DR.%2BJ.%26atitle%3DHuman%2520airway%2520epithelial%2520cell%2520cultures%2520for%2520modeling%2520respiratory%2520syncytial%2520virus%2520infection%26jtitle%3DCurr.%2520Top.%2520Microbiol.%2520Immunol.%26date%3D2013%26volume%3D372%26spage%3D371%26epage%3D387%26doi%3D10.1007%2F978-3-642-38919-1_19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, G.</span></span> <span> </span><span class="NLM_article-title">Animal models of respiratory syncytial virus infection</span>. <i>Vaccine</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1016/j.vaccine.2016.11.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2Fj.vaccine.2016.11.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=27908639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKnurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=469-480&author=G.+Taylor&title=Animal+models+of+respiratory+syncytial+virus+infection&doi=10.1016%2Fj.vaccine.2016.11.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of respiratory syncytial virus infection</span></div><div class="casAuthors">Taylor, Geraldine</div><div class="citationInfo"><span class="NLM_cas:title">Vaccine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">469-480</span>CODEN:
                <span class="NLM_cas:coden">VACCDE</span>;
        ISSN:<span class="NLM_cas:issn">0264-410X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Human respiratory syncytial virus (hRSV) is a major cause of respiratory disease and hospitalisation of infants, worldwide, and is also responsible for significant morbidity in adults and excess deaths in the elderly.  There is no licensed hRSV vaccine or effective therapeutic agent.  However, there are a growing no. of hRSV vaccine candidates that have been developed targeting different populations at risk of hRSV infection.  Animal models of hRSV play an important role in the preclin. testing of hRSV vaccine candidates and although many have shown efficacy in preclin. studies, few have progressed to clin. trials or they have had only limited success.  This is, at least in part, due to the lack of animal models that fully recapitulate the pathogenesis of hRSV infection in humans.  This review summarises the strengths and limitations of animal models of hRSV, which include those in which hRSV is used to infect non-human mammalian hosts, and those in which non-human pneumoviruses, such as bovine (b)RSV and pneumonia virus of mice (PVM) are studied in their natural host.  Apart from chimpanzees, other non-human primates (NHP) are only semi-permissive for hRSV replication and exptl. infection with large doses of virus result in little or no clin. signs of disease, and generally only mild pulmonary pathol.  Other animal models such as cotton rats, mice, ferrets, guinea pigs, hamsters, chinchillas, and neonatal lambs are also only semi-permissive for hRSV.  Nevertheless, mice and cotton rats have been of value in the development of monoclonal antibody prophylaxis for infants at high risk of severe hRSV infection and have provided insights into mechanisms of immunity to and pathogenesis of hRSV.  However, the extent to which they predict hRSV vaccine efficacy and safety is unclear and several hRSV vaccine candidates that are completely protective in rodent models are poorly effective in chimpanzees and other NHP, such as African Green monkeys.  Furthermore, interpretation of findings from many rodent and NHP models of vaccine-enhanced hRSV disease has been confounded by sensitization to non-viral antigens present in the vaccine and challenge virus.  Studies of non-human pneumoviruses in their native hosts are more likely to reflect the pathogenesis of natural hRSV infection, and exptl. infection of calves with bRSV and of mice with PVM result in clin. disease and extensive pulmonary pathol.  These animal models have not only been of value in studies on mechanisms of immunity to and the pathogenesis of pneumovirus infections but have also been used to evaluate hRSV vaccine concepts.  Furthermore, the similarities between the epidemiol. of bRSV in calves and hRSV in infants and the high level of genetic and antigenic similarity between bRSV and hRSV, make the calf model of bRSV infection a relevant model for preclin. evaluation of hRSV vaccine candidates which contain proteins that are conserved between hRSV and bRSV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQGyFQHoxipLVg90H21EOLACvtfcHk0ljFDaMtiiA14Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKnurnF&md5=155d24a6e65fe5d30d8fc109243969cd</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.vaccine.2016.11.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vaccine.2016.11.054%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DG.%26atitle%3DAnimal%2520models%2520of%2520respiratory%2520syncytial%2520virus%2520infection%26jtitle%3DVaccine%26date%3D2017%26volume%3D35%26spage%3D469%26epage%3D480%26doi%3D10.1016%2Fj.vaccine.2016.11.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obst-Sander, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span> <span> </span><span class="NLM_article-title">Fluorine in medicinal chemistry</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1002/cbic.200301023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1002%2Fcbic.200301023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=15122635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=637-643&author=H.-J.+B%C3%B6hmauthor=D.+Bannerauthor=S.+Bendelsauthor=M.+Kansyauthor=B.+Kuhnauthor=K.+M%C3%BCllerauthor=U.+Obst-Sanderauthor=M.+Stahl&title=Fluorine+in+medicinal+chemistry&doi=10.1002%2Fcbic.200301023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in medicinal chemistry</span></div><div class="casAuthors">Bohm Hans-Joachim; Banner David; Bendels Stefanie; Kansy Manfred; Kuhn Bernd; Muller Klaus; Obst-Sander Ulrike; Stahl Martin</div><div class="citationInfo"><span class="NLM_cas:title">Chembiochem : a European journal of chemical biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">637-43</span>
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    </div><div class="casAbstract">Fluorinated compounds are synthesized in pharmaceutical research on a routine basis and many marketed compounds contain fluorine.  The present review summarizes some of the most frequently employed strategies for using fluorine substituents in medicinal chemistry.  Quite often, fluorine is introduced to improve the metabolic stability by blocking metabolically labile sites.  However, fluorine can also be used to modulate the physicochemical properties, such as lipophilicity or basicity.  It may exert a substantial effect on the conformation of a molecule.  Increasingly, fluorine is used to enhance the binding affinity to the target protein.  Recent 3D-structure determinations of protein complexes with bound fluorinated ligands have led to an improved understanding of the nonbonding protein-ligand interactions that involve fluorine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4zDG_wo1YGtts4TFFB11gfW6udTcc2eYYh9zicxIWobntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D&md5=fa5ca2cfc278b83c80d5c96b18dfe312</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200301023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200301023%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6hm%26aufirst%3DH.-J.%26aulast%3DBanner%26aufirst%3DD.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DObst-Sander%26aufirst%3DU.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DFluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DChemBioChem%26date%3D2004%26volume%3D5%26spage%3D637%26epage%3D643%26doi%3D10.1002%2Fcbic.200301023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crippen, G. M.</span></span> <span> </span><span class="NLM_article-title">Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions</span>. <i>Jourano of Chemical Information and Computing Science</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1021/ci00053a005</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci00053a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADyaL2sXotl2htg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1987&pages=21-35&author=A.+K.+Ghoseauthor=G.+M.+Crippen&title=Atomic+physicochemical+parameters+for+three-dimensional-structure-directed+quantitative+structure-activity+relationships.+2.+Modeling+dispersive+and+hydrophobic+interactions&doi=10.1021%2Fci00053a005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships.  2.  Modeling dispersive and hydrophobic interactions</span></div><div class="casAuthors">Ghose, Arup K.; Crippen, Gordon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-35</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    </div><div class="casAbstract">At. physicochem. properties for three-dimensional-structure-directed quant. structure-activity relationships were demonstrated, and at. parameters were developed to successfully evaluate the mol. water-octanol partition coeff., which is a measure of hydrophobicity.  The at. values of molar refractivity are reported.  C, H, O, N, S, and halogens are divided into 110 atom types of which 93 at. values are evaluated from 504 mols. by using a constrained least-squares technique.  These values gave a std. deviation of 1.269 and a correlation coeff. of 0.994.  The parameters were used to predict the molar refractivities of 78 compds.  The predicted values have a std. deviation of 1.614 and a correlation coeff. of 0.994.  The degree of closeness of the LFER between the at. water-octanol partition coeffs. and molar refractivities is checked by the correlation coeff. of 89 atom types used for both the properties.  The low correlation coeff. (0.322) suggests that both parameters can be used to model the intermol. interaction.  The origin of these physicochem. properties and the types of interaction that can be modeled by these properties are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK8YlSzH7fOrVg90H21EOLACvtfcHk0li1rQitGjJHbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXotl2htg%253D%253D&md5=a1c1f406e012ff0f059aa37d935ecc5c</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1021%2Fci00053a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci00053a005%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DCrippen%26aufirst%3DG.%2BM.%26atitle%3DAtomic%2520physicochemical%2520parameters%2520for%2520three-dimensional-structure-directed%2520quantitative%2520structure-activity%2520relationships.%25202.%2520Modeling%2520dispersive%2520and%2520hydrophobic%2520interactions%26jtitle%3DJourano%2520of%2520Chemical%2520Information%2520and%2520Computing%2520Science%26date%3D1987%26volume%3D27%26spage%3D21%26epage%3D35%26doi%3D10.1021%2Fci00053a005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combrink, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuring, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiello, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">4592</span>– <span class="NLM_lpage">4598</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.05.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2Fj.bmcl.2007.05.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=17576060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFSitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4592-4598&author=X.+A.+Wangauthor=C.+W.+Cianciauthor=K.+L.+Yuauthor=K.+D.+Combrinkauthor=J.+W.+Thuringauthor=Y.+Zhangauthor=R.+L.+Civielloauthor=K.+F.+Kadowauthor=J.+Roachauthor=Z.+Liauthor=D.+R.+Langleyauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Respiratory+syncytial+virus+fusion+inhibitors.+Part+5%3A+Optimization+of+benzimidazole+substitution+patterns+towards+derivatives+with+improved+activity&doi=10.1016%2Fj.bmcl.2007.05.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity</span></div><div class="casAuthors">Wang, Xiangdong Alan; Cianci, Christopher W.; Yu, Kuo-Long; Combrink, Keith D.; Thuring, Jan W.; Zhang, Yi; Civiello, Rita L.; Kadow, Kathleen F.; Roach, Julia; Li, Zhufang; Langley, David R.; Krystal, Mark; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4592-4598</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Extensive SAR studies and optimization of ADME properties of benzimidazol-2-one derivs. led to the identification of BMS-433771 (I) as an orally active RSV fusion inhibitor.  In order to extend the structure-activity relationships for this compd. series, substitution of the benzimidazole ring was examd. with a view to establishing addnl. productive interactions between the inhibitor and functionality present in the proposed binding pocket.  Amongst the compds. II (R1 = Br, CN, HO2C, HOCH2, H2NCH2, etc.; R2 = Me, Me2CH, H2C:CMe, Me3CO2CCH2) synthesized, the 5-aminomethyl analog II (R1 = 5-H2NCH2; R2 = Me2CH) demonstrated potent antiviral activity towards wild-type RSV and retained excellent inhibitory activity towards a virus that had been developed to express resistance to I, data consistent with an addnl. productive interaction between the inhibitor and the fusion protein target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0b3YCFITnK7Vg90H21EOLACvtfcHk0li1rQitGjJHbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFSitLc%253D&md5=90ec7b486a272dea239d0a3b0352fbb6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.05.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.05.102%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BA.%26aulast%3DCianci%26aufirst%3DC.%2BW.%26aulast%3DYu%26aufirst%3DK.%2BL.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DThuring%26aufirst%3DJ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DRoach%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DRespiratory%2520syncytial%2520virus%2520fusion%2520inhibitors.%2520Part%25205%253A%2520Optimization%2520of%2520benzimidazole%2520substitution%2520patterns%2520towards%2520derivatives%2520with%2520improved%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4592%26epage%3D4598%26doi%3D10.1016%2Fj.bmcl.2007.05.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span> For a discussion of
SAR in the benzimidazolone series, see:<span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiello, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trehan, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combrink, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulgeze, H.B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial inhibitors. Part 2: Benzimidazol-2-one derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1137</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.12.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2Fj.bmcl.2003.12.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=14980651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFemtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1133-1137&author=K.-L.+Yuauthor=Y.+Zhangauthor=R.+L.+Civielloauthor=A.+K.+Trehanauthor=B.+C.+Pearceauthor=Z.+Yinauthor=K.+D.+Combrinkauthor=H.B.+Gulgezeauthor=X.+A.+Wangauthor=K.+F.+Kadowauthor=C.+W.+Cianciauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Respiratory+syncytial+inhibitors.+Part+2%3A+Benzimidazol-2-one+derivatives&doi=10.1016%2Fj.bmcl.2003.12.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives</span></div><div class="casAuthors">Yu, Kuo-Long; Zhang, Yi; Civiello, Rita L.; Trehan, Ashok K.; Pearce, Bradley C.; Yin, Zhiwei; Combrink, Keith D.; Gulgeze, H. Belgin; Wang, Xiangdong Alan; Kadow, Kathleen F.; Cianci, Christopher W.; Krystal, Mark; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1133-1137</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Structure-activity relationships for a series of benzimidazol-2-one-based inhibitors of respiratory syncytial virus are described.  These studies focused on structural variation of the benzimidazol-2-one substituent, a vector inaccessible in a series of benzotriazole derivs. on which 2 is based, and revealed a broad tolerance for substituent size and functionality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK34s_9TMb7rVg90H21EOLACvtfcHk0lj2XvLADwqoSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFemtLk%253D&md5=5f3e8aa37f3d44511dc6209280fe2573</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.12.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.12.072%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DTrehan%26aufirst%3DA.%2BK.%26aulast%3DPearce%26aufirst%3DB.%2BC.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DGulgeze%26aufirst%3DH.B.%26aulast%3DWang%26aufirst%3DX.%2BA.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DCianci%26aufirst%3DC.%2BW.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DRespiratory%2520syncytial%2520inhibitors.%2520Part%25202%253A%2520Benzimidazol-2-one%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D1133%26epage%3D1137%26doi%3D10.1016%2Fj.bmcl.2003.12.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotthaus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetzer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Locht, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, B.</span></span> <span> </span><span class="NLM_article-title">Analysis of highly potent amidine containing inhibitors of serine proteases and their N-hydroxylated prodrugs (amidoximes)</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.3109/14756361003733647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.3109%2F14756361003733647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=20583861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFyrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2011&pages=115-122&author=J.+Kotthausauthor=T.+Steinmetzerauthor=A.+van+de+Lochtauthor=B.+Clement&title=Analysis+of+highly+potent+amidine+containing+inhibitors+of+serine+proteases+and+their+N-hydroxylated+prodrugs+%28amidoximes%29&doi=10.3109%2F14756361003733647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of highly potent amidine containing inhibitors of serine proteases and their N-hydroxylated prodrugs (amidoximes)</span></div><div class="casAuthors">Kotthaus, Joscha; Steinmetzer, Torsten; van de Locht, Andreas; Clement, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-122</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">The development of serine protease inhibitors often results in the discovery of new lead compds. contg. strong basic amidine functions that usually suffer from poor absorption from the intestine.  In order to improve oral bioavailability of these drugs, prodrug principles such as the conversion of amidines into amidoximes may be applied.  In this work, two HPLC-based sepn. methods of serine protease inhibitors (amidines) and their N-hydroxylated prodrugs have been developed and characterized.  This was performed by evaluating 11 distinct amidine-amidoxime pairs with different physicochem. parameters (clogP: -3 to 5.1).  The HPLC methods developed allowed excellent sepn. of the compd. pairs examd.  Also, the possible selection of different sepn. techniques (i.e. adsorption- and ion-pair-chromatog.) permits universal application.  Moreover, both techniques are compatible with mass spectrometry and are superior to the previously described methods.  In summary, both HPLC methods are suitable for the sepn. of most amidoxime-prodrugs currently in clin. or preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVKaHpBogg9LVg90H21EOLACvtfcHk0lj2XvLADwqoSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFyrsr4%253D&md5=ddd1372b994104f6740efed6300f62f2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3109%2F14756361003733647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F14756361003733647%26sid%3Dliteratum%253Aachs%26aulast%3DKotthaus%26aufirst%3DJ.%26aulast%3DSteinmetzer%26aufirst%3DT.%26aulast%3Dvan%2Bde%2BLocht%26aufirst%3DA.%26aulast%3DClement%26aufirst%3DB.%26atitle%3DAnalysis%2520of%2520highly%2520potent%2520amidine%2520containing%2520inhibitors%2520of%2520serine%2520proteases%2520and%2520their%2520N-hydroxylated%2520prodrugs%2520%2528amidoximes%2529%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2011%26volume%3D26%26spage%3D115%26epage%3D122%26doi%3D10.3109%2F14756361003733647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tahri, A.</span>; <span class="NLM_string-name">Vendeville, S. M. H.</span>; <span class="NLM_string-name">Jonckers, T. H. M.</span>; <span class="NLM_string-name">Raboisson, P. J.-M. B.</span>; <span class="NLM_string-name">Hu, L.</span>; <span class="NLM_string-name">Demin, S. D.</span>; <span class="NLM_string-name">Cooymans, L. P.</span></span> <span> </span><span class="NLM_article-title">RSV Antiviral Compounds</span>. <span class="NLM_patent">WO/2014/060411</span>, Apr 24, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=A.+Tahri&author=S.+M.+H.+Vendeville&author=T.+H.+M.+Jonckers&author=P.+J.-M.+B.+Raboisson&author=L.+Hu&author=S.+D.+Demin&author=L.+P.+Cooymans&title=RSV+Antiviral+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTahri%26aufirst%3DA.%26atitle%3DRSV%2520Antiviral%2520Compounds%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cockerill, G. S.</span>; <span class="NLM_string-name">Hanley, M. T.</span>; <span class="NLM_string-name">Mathews, N.</span>; <span class="NLM_string-name">Paradowski, M.</span>; <span class="NLM_string-name">Williams, G.</span>; <span class="NLM_string-name">Ward, S. E.</span></span> unpublished results. Reviral Ltd., Stevenage Bioscience Catalyst, Stevenage, Hertfordshire SG1 2FX, U.K.  Sussex Drug Discovery Centre, University of Sussex, Brighton, England BN1 9QJ, U.K. <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cockerill%2C+G.+S.%3B+Hanley%2C+M.+T.%3B+Mathews%2C+N.%3B+Paradowski%2C+M.%3B+Williams%2C+G.%3B+Ward%2C+S.+E.+unpublished+results.+Reviral+Ltd.%2C+Stevenage+Bioscience+Catalyst%2C+Stevenage%2C+Hertfordshire+SG1+2FX%2C+U.K.+Sussex+Drug+Discovery+Centre%2C+University+of+Sussex%2C+Brighton%2C+England+BN1+9QJ%2C+U.K.+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alber, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bithell, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chubb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockerill, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdell, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelsey, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luongo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najarro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickles, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmonds, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyms, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, K. L.</span></span> <span> </span><span class="NLM_article-title">RSV604, a novel inhibitor of respiratory syncytial virus replication</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3346</span>– <span class="NLM_lpage">3353</span>, <span class="refDoi"> DOI: 10.1128/AAC.00211-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1128%2FAAC.00211-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=17576833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVais7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=3346-3353&author=J.+Chapmanauthor=E.+Abbottauthor=D.+G.+Alberauthor=R.+C.+Baxterauthor=S.+K.+Bithellauthor=E.+A.+Hendersonauthor=M.+C.+Carterauthor=P.+Chambersauthor=A.+Chubbauthor=G.+S.+Cockerillauthor=P.+L.+Collinsauthor=V.+C.+Dowdellauthor=S.+J.+Keeganauthor=R.+D.+Kelseyauthor=M.+J.+Lockyerauthor=C.+Luongoauthor=P.+Najarroauthor=R.+J.+Picklesauthor=M.+Simmondsauthor=D.+Taylorauthor=S.+Tymsauthor=L.+J.+Wilsonauthor=K.+L.+Powell&title=RSV604%2C+a+novel+inhibitor+of+respiratory+syncytial+virus+replication&doi=10.1128%2FAAC.00211-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">RSV604, a novel inhibitor of respiratory syncytial virus replication</span></div><div class="casAuthors">Chapman, Joanna; Abbott, Elizabeth; Alber, Dagmar G.; Baxter, Robert C.; Bithell, Sian K.; Henderson, Elisa A.; Carter, Malcolm C.; Chambers, Phil; Chubb, Ann; Cockerill, G. Stuart; Collins, Peter L.; Dowdell, Verity C. L.; Keegan, Sally J.; Kelsey, Richard D.; Lockyer, Michael J.; Luongo, Cindy; Najarro, Pilar; Pickles, Raymond J.; Simmonds, Mark; Taylor, Debbie; Tyms, Stan; Wilson, Lara J.; Powell, Kenneth L.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3346-3353</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections worldwide, yet no effective vaccine or antiviral treatment is available.  Here we report the discovery and initial development of RSV604, a novel benzodiazepine with submicromolar anti-RSV activity.  It proved to be equipotent against all clin. isolates tested of both the A and B subtypes of the virus.  The compd. has a low rate of in vitro resistance development.  Sequencing revealed that the resistant virus had mutations within the nucleocapsid protein.  This is a novel mechanism of action for anti-RSV compds.  In a three-dimensional human airway epithelial cell model, RSV604 was able to pass from the basolateral side of the epithelium effectively to inhibit virus replication after mucosal inoculation.  RSV604, which is currently in phase II clin. trials, represents the first in a new class of RSV inhibitors and may have significant potential for the effective treatment of RSV disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofytd4GFiOgrVg90H21EOLACvtfcHk0lgaC1ZEjP2kZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVais7jE&md5=6c0937ea49d9ea7beaff40bc20d911d3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1128%2FAAC.00211-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00211-07%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DJ.%26aulast%3DAbbott%26aufirst%3DE.%26aulast%3DAlber%26aufirst%3DD.%2BG.%26aulast%3DBaxter%26aufirst%3DR.%2BC.%26aulast%3DBithell%26aufirst%3DS.%2BK.%26aulast%3DHenderson%26aufirst%3DE.%2BA.%26aulast%3DCarter%26aufirst%3DM.%2BC.%26aulast%3DChambers%26aufirst%3DP.%26aulast%3DChubb%26aufirst%3DA.%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DCollins%26aufirst%3DP.%2BL.%26aulast%3DDowdell%26aufirst%3DV.%2BC.%26aulast%3DKeegan%26aufirst%3DS.%2BJ.%26aulast%3DKelsey%26aufirst%3DR.%2BD.%26aulast%3DLockyer%26aufirst%3DM.%2BJ.%26aulast%3DLuongo%26aufirst%3DC.%26aulast%3DNajarro%26aufirst%3DP.%26aulast%3DPickles%26aufirst%3DR.%2BJ.%26aulast%3DSimmonds%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DTyms%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DL.%2BJ.%26aulast%3DPowell%26aufirst%3DK.%2BL.%26atitle%3DRSV604%252C%2520a%2520novel%2520inhibitor%2520of%2520respiratory%2520syncytial%2520virus%2520replication%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D3346%26epage%3D3353%26doi%3D10.1128%2FAAC.00211-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mirabelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaspers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorissen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koukni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardiot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaltin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jochmans, D.</span></span> <span> </span><span class="NLM_article-title">Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1823</span>– <span class="NLM_lpage">1829</span>, <span class="refDoi"> DOI: 10.1093/jac/dky089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1093%2Fjac%2Fdky089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=29596680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVait70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2018&pages=1823-1829&author=C.+Mirabelliauthor=M.+Jaspersauthor=M.+Boonauthor=M.+Jorissenauthor=M.+Koukniauthor=D.+Bardiotauthor=P.+Chaltinauthor=A.+Marchandauthor=J.+Neytsauthor=D.+Jochmans&title=Differential+antiviral+activities+of+respiratory+syncytial+virus+%28RSV%29+inhibitors+in+human+airway+epithelium&doi=10.1093%2Fjac%2Fdky089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium</span></div><div class="casAuthors">Mirabelli, Carmen; Jaspers, Martine; Boon, Mieke; Jorissen, Mark; Koukni, Mohamed; Bardiot, Dorothee; Chaltin, Patrick; Marchand, Arnaud; Neyts, Johan; Jochmans, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1823-1829</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">1460-2091</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: We report the use of reconstituted 3D human airway epithelium cells (HuAECs) of bronchial origin in an air-liq. interface to study respiratory syncytial virus (RSV) infection and to assess the efficacy of RSV inhibitors in (pre-)clin. development.  Methods: HuAECs were infected with RSV-A Long strain (0.01 CCID50/cell, where CCID50 represents 50% cell culture infectious dose in HEp2 cells) on the apical compartment of the culture.  At the time of infection or at 1 or 3 days post-infection, selected inhibitors were added and refreshed daily on the basal compartment of the culture.  Viral shedding was followed up by apical washes collected daily and quantifying viral RNA by RT-qPCR.  Results: RSV-A replicates efficiently in HuAECs and viral RNA is shed forweeks after infection.  RSV infection reduces the ciliary beat frequency of the ciliated cells as of 4 days post-infection, with complete ciliary dyskinesia obsd. by day 10.  Treatmentwith RSV fusion inhibitors resulted in an antiviral effect onlywhen added at the time of infection.  In contrast, the use of replication inhibitors (both nucleoside and non-nucleoside) elicited a marked antiviral effect evenwhen the start of treatmentwas delayed until 1 day or even 3 days after infection.  Levels of the inflammation marker RANTES (mRNA) increased ∼200-fold in infected, untreated cultures (at 3weeks post-infection), but levels were comparable to those of uninfected cultures in the presence of PC786, an RSV replication inhibitor, suggesting that an efficient antiviral treatment might inhibit virus-induced inflammation in thismodel.  Conclusions: Overall, HuAECs offer a robust and physiol. relevant model to study RSV replication and to assess the efficacy of antiviral compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPbiu5779F57Vg90H21EOLACvtfcHk0lgaC1ZEjP2kZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVait70%253D&md5=7c81e1c20009c4e8f25f02b31bf6b62e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdky089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdky089%26sid%3Dliteratum%253Aachs%26aulast%3DMirabelli%26aufirst%3DC.%26aulast%3DJaspers%26aufirst%3DM.%26aulast%3DBoon%26aufirst%3DM.%26aulast%3DJorissen%26aufirst%3DM.%26aulast%3DKoukni%26aufirst%3DM.%26aulast%3DBardiot%26aufirst%3DD.%26aulast%3DChaltin%26aufirst%3DP.%26aulast%3DMarchand%26aufirst%3DA.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DJochmans%26aufirst%3DD.%26atitle%3DDifferential%2520antiviral%2520activities%2520of%2520respiratory%2520syncytial%2520virus%2520%2528RSV%2529%2520inhibitors%2520in%2520human%2520airway%2520epithelium%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2018%26volume%3D73%26spage%3D1823%26epage%3D1829%26doi%3D10.1093%2Fjac%2Fdky089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKimm-Breschkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smout, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span> <span> </span><span class="NLM_article-title">Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1016/S0042-6822(03)00115-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2FS0042-6822%2803%2900115-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=12842618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFGmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2003&pages=275-288&author=C.+J.+Mortonauthor=R.+Cameronauthor=L.+J.+Lawrenceauthor=B.+Linauthor=M.+Loweauthor=A.+Luttickauthor=A.+Masonauthor=J.+McKimm-Breschkinauthor=M.+W.+Parkerauthor=J.+Ryanauthor=M.+Smoutauthor=J.+Sullivanauthor=S.+P.+Tuckerauthor=P.+R.+Young&title=Structural+characterization+of+respiratory+syncytial+virus+fusion+inhibitor+escape+mutants%3A+homology+model+of+the+F+protein+and+a+syncytium+formation+assay&doi=10.1016%2FS0042-6822%2803%2900115-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay</span></div><div class="casAuthors">Morton, Craig J.; Cameron, Rachel; Lawrence, Lynne J.; Lin, Bo; Lowe, Melinda; Luttick, Angela; Mason, Anthony; McKimm-Breschkin, Jenny; Parker, Michael W.; Ryan, Jane; Smout, Michael; Sullivan, Jayne; Tucker, Simon P.; Young, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-288</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a ubiquitous human pathogen and the leading cause of lower respiratory tract infections in infants.  Infection of cells and subsequent formation of syncytia occur through membrane fusion mediated by the RSV fusion protein (RSV-F).  A novel in vitro assay of recombinant RSV-F function has been devised and used to characterize a no. of escape mutants for three known inhibitors of RSV-F that have been isolated.  Homol. modeling of the RSV-F structure has been carried out on the basis of a chimera derived from the crystal structures of the RSV-F core and a fragment from the orthologous fusion protein from Newcastle disease virus (NDV).  The structure correlates well with the appearance of RSV-F in electron micrographs, and the residues identified as contributing to specific binding sites for several monoclonal antibodies are arranged in appropriate solvent-accessible clusters.  The positions of the characterized resistance mutants in the model structure identify two promising regions for the design of fusion inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriNHdqxZCrWrVg90H21EOLACvtfcHk0lgaC1ZEjP2kZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFGmtrw%253D&md5=90ae3069ed81de9ab431da6378e18743</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS0042-6822%2803%2900115-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0042-6822%252803%252900115-6%26sid%3Dliteratum%253Aachs%26aulast%3DMorton%26aufirst%3DC.%2BJ.%26aulast%3DCameron%26aufirst%3DR.%26aulast%3DLawrence%26aufirst%3DL.%2BJ.%26aulast%3DLin%26aufirst%3DB.%26aulast%3DLowe%26aufirst%3DM.%26aulast%3DLuttick%26aufirst%3DA.%26aulast%3DMason%26aufirst%3DA.%26aulast%3DMcKimm-Breschkin%26aufirst%3DJ.%26aulast%3DParker%26aufirst%3DM.%2BW.%26aulast%3DRyan%26aufirst%3DJ.%26aulast%3DSmout%26aufirst%3DM.%26aulast%3DSullivan%26aufirst%3DJ.%26aulast%3DTucker%26aufirst%3DS.%2BP.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26atitle%3DStructural%2520characterization%2520of%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitor%2520escape%2520mutants%253A%2520homology%2520model%2520of%2520the%2520F%2520protein%2520and%2520a%2520syncytium%2520formation%2520assay%26jtitle%3DVirology%26date%3D2003%26volume%3D311%26spage%3D275%26epage%3D288%26doi%3D10.1016%2FS0042-6822%2803%2900115-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovesi, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combrink, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span> <span> </span><span class="NLM_article-title">Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2448</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1128/AAC.48.7.2448-2454.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1128%2FAAC.48.7.2448-2454.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=15215093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFWmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=2448-54&author=C.+Cianciauthor=E.+V.+Genovesiauthor=L.+Lambauthor=I.+Medinaauthor=Z.+Yangauthor=L.+Zadjuraauthor=H.+Yangauthor=C.+D%E2%80%99Arienzoauthor=N.+Sinauthor=K.+L.+Yuauthor=K.+Combrinkauthor=Z.+Liauthor=R.+Colonnoauthor=N.+Meanwellauthor=J.+Clarkauthor=M.+Krystal&title=Oral+efficacy+of+a+respiratory+syncytial+virus+inhibitor+in+rodent+models+of+infection&doi=10.1128%2FAAC.48.7.2448-2454.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection</span></div><div class="casAuthors">Cianci, Christopher; Genovesi, Eugene V.; Lamb, Lucinda; Medina, Ivette; Yang, Zheng; Zadjura, Lisa; Yang, Hyekyung; D'Arienzo, Celia; Sin, Ny; Yu, Kuo-Long; Combrink, Keith; Li, Zhufang; Colonno, Richard; Meanwell, Nicholas; Clark, Junius; Krystal, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2448-2454</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">BMS-433771 is a potent inhibitor of respiratory syncytial virus (RSV) replication in vitro.  Mechanism of action studies have demonstrated that BMS-433771 halts virus entry through inhibition of F protein-mediated membrane fusion.  BMS-433771 also exhibited in vivo efficacy following oral administration in a mouse model of RSV infection.  In this report, the in vivo efficacy of BMS-433771 against RSV was further examd. in the BALB/c mouse and cotton rat host models of infection.  By using the Long strain of RSV, prophylactic efficacy via oral dosing was obsd. in both animal models.  A single oral dose, administered 1 h prior to intranasal RSV inoculation, was as effective against infection as a 4-day b.i.d. dosing regimen in which the first oral dose was given 1 h prior to virus inoculation.  Results of dose titrn. expts. suggested that RSV infection was more sensitive to inhibition by BMS-433771 treatment in the BALB/c mouse host than in the cotton rat.  This was reflected by the pharmacokinetic and pharmacodynamic anal. of the efficacy data, where the area under the concn.-time curve required to achieve 50% of the max. response was ∼7.5-fold less for mice than for cotton rats.  Inhibition of RSV by BMS-433771 in the mouse is the result of F1-mediated inhibition, as shown by the fact that a virus selected for resistance to BMS-433771 in vitro and contg. a single amino acid change in the F1 region was also refractory to treatment in the mouse host.  BMS-433771 efficacy against RSV infection was also demonstrated for mice that were chem. immunosuppressed by cyclophosphamide treatment, indicating that compd. inhibition of the virus did not require an active host immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBKvJm5WDYz7Vg90H21EOLACvtfcHk0ljP4PVSi47BaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFWmtrY%253D&md5=c57e810ebd46f01c6dd2da43c45f9248</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.7.2448-2454.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.7.2448-2454.2004%26sid%3Dliteratum%253Aachs%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DGenovesi%26aufirst%3DE.%2BV.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DK.%2BL.%26aulast%3DCombrink%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DOral%2520efficacy%2520of%2520a%2520respiratory%2520syncytial%2520virus%2520inhibitor%2520in%2520rodent%2520models%2520of%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D2448%26epage%3D54%26doi%3D10.1128%2FAAC.48.7.2448-2454.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alnajjar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battles, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitthicharoenchai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furmanova-Hollenstein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, J. V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwanten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginderen, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranckx, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaensch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorzaat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallup, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larios-Mora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabbe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntjens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raboisson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langedijk, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackermann, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendeville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span> <span> </span><span class="NLM_article-title">Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-00170-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1038%2Fs41467-017-00170-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=28761099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BC1cfivVyisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=167-182&author=D.+Roymansauthor=S.+S.+Alnajjarauthor=M.+B.+Battlesauthor=P.+Sitthicharoenchaiauthor=P.+Furmanova-Hollensteinauthor=P.+Rigauxauthor=J.+V.+D.+Bergauthor=L.+Kwantenauthor=M.+V.+Ginderenauthor=N.+Verheyenauthor=L.+Vranckxauthor=S.+Jaenschauthor=E.+Arnoultauthor=R.+Voorzaatauthor=J.+M.+Gallupauthor=A.+Larios-Moraauthor=M.+Crabbeauthor=D.+Huntjensauthor=P.+Raboissonauthor=J.+P.+Langedijkauthor=M.+R.+Ackermannauthor=J.+S.+McLellanauthor=S.+Vendevilleauthor=A.+Koul&title=Therapeutic+efficacy+of+a+respiratory+syncytial+virus+fusion+inhibitor&doi=10.1038%2Fs41467-017-00170-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor</span></div><div class="casAuthors">Roymans Dirk; Rigaux Peter; Berg Joke Van den; Kwanten Leen; Ginderen Marcia Van; Verheyen Nick; Vranckx Luc; Raboisson Pierre; Vendeville Sandrine; Koul Anil; Alnajjar Sarhad S; Sitthicharoenchai Panchan; Gallup Jack M; Larios-Mora Alejandro; Ackermann Mark R; Battles Michael B; McLellan Jason S; Furmanova-Hollenstein Polina; Voorzaat Richard; Langedijk Johannes P; Jaensch Steffen; Arnoult Eric; Crabbe Marjolein; Huntjens Dymphy</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">167</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Respiratory syncytial virus is a major cause of acute lower respiratory tract infection in young children, immunocompromised adults, and the elderly.  Intervention with small-molecule antivirals specific for respiratory syncytial virus presents an important therapeutic opportunity, but no such compounds are approved today.  Here we report the structure of JNJ-53718678 bound to respiratory syncytial virus fusion (F) protein in its prefusion conformation, and we show that the potent nanomolar activity of JNJ-53718678, as well as the preliminary structure-activity relationship and the pharmaceutical optimization strategy of the series, are consistent with the binding mode of JNJ-53718678 and other respiratory syncytial virus fusion inhibitors.  Oral treatment of neonatal lambs with JNJ-53718678, or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible.  Together, these data suggest that JNJ-53718678 is a promising candidate for further development as a potential therapeutic in patients at risk to develop respiratory syncytial virus acute lower respiratory tract infection.Respiratory syncytial virus causes lung infections in children, immunocompromised adults, and in the elderly.  Here the authors show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and ameliorating infection in rodents and neonatal lambs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBD68IhmKXha-9TkgmBqTqfW6udTcc2eavj5a25Wdau7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfivVyisg%253D%253D&md5=f3a5b7951500fbc8b42693818881c228</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00170-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00170-x%26sid%3Dliteratum%253Aachs%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DAlnajjar%26aufirst%3DS.%2BS.%26aulast%3DBattles%26aufirst%3DM.%2BB.%26aulast%3DSitthicharoenchai%26aufirst%3DP.%26aulast%3DFurmanova-Hollenstein%26aufirst%3DP.%26aulast%3DRigaux%26aufirst%3DP.%26aulast%3DBerg%26aufirst%3DJ.%2BV.%2BD.%26aulast%3DKwanten%26aufirst%3DL.%26aulast%3DGinderen%26aufirst%3DM.%2BV.%26aulast%3DVerheyen%26aufirst%3DN.%26aulast%3DVranckx%26aufirst%3DL.%26aulast%3DJaensch%26aufirst%3DS.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DVoorzaat%26aufirst%3DR.%26aulast%3DGallup%26aufirst%3DJ.%2BM.%26aulast%3DLarios-Mora%26aufirst%3DA.%26aulast%3DCrabbe%26aufirst%3DM.%26aulast%3DHuntjens%26aufirst%3DD.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DLangedijk%26aufirst%3DJ.%2BP.%26aulast%3DAckermann%26aufirst%3DM.%2BR.%26aulast%3DMcLellan%26aufirst%3DJ.%2BS.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DKoul%26aufirst%3DA.%26atitle%3DTherapeutic%2520efficacy%2520of%2520a%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitor%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D167%26epage%3D182%26doi%3D10.1038%2Fs41467-017-00170-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battles, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langedijk, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furmanova-Hollenstein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaiwatpongsakorn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwanten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranckx, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vink, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaensch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonckers, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeples, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, J. S.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of respiratory syncytial virus fusion inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1038%2Fnchembio.1982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=26641933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFemsbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=87-93&author=M.+B.+Battlesauthor=J.+P.+Langedijkauthor=P.+Furmanova-Hollensteinauthor=S.+Chaiwatpongsakornauthor=H.+M.+Costelloauthor=L.+Kwantenauthor=L.+Vranckxauthor=P.+Vinkauthor=S.+Jaenschauthor=T.+H.+Jonckersauthor=A.+Koulauthor=E.+Arnoultauthor=M.+E.+Peeplesauthor=D.+Roymansauthor=J.+S.+McLellan&title=Molecular+mechanism+of+respiratory+syncytial+virus+fusion+inhibitors&doi=10.1038%2Fnchembio.1982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of respiratory syncytial virus fusion inhibitors</span></div><div class="casAuthors">Battles, Michael B.; Langedijk, Johannes P.; Furmanova-Hollenstein, Polina; Chaiwatpongsakorn, Supranee; Costello, Heather M.; Kwanten, Leen; Vranckx, Luc; Vink, Paul; Jaensch, Steffen; Jonckers, Tim H. M.; Koul, Anil; Arnoult, Eric; Peeples, Mark E.; Roymans, Dirk; McLellan, Jason S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-93</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis in young children and the elderly.  Therapeutic small mols. have been developed that bind the RSV F glycoprotein and inhibit membrane fusion, yet their binding sites and mol. mechanisms of action remain largely unknown.  Here we show that these inhibitors bind to a three-fold-sym. pocket within the central cavity of the metastable prefusion conformation of RSV F.  Inhibitor binding stabilizes this conformation by tethering two regions that must undergo a structural rearrangement to facilitate membrane fusion.  Inhibitor-escape mutations occur in residues that directly contact the inhibitors or are involved in the conformational rearrangements required to accommodate inhibitor binding.  Resistant viruses do not propagate as well as wild-type RSV in vitro, indicating a fitness cost for inhibitor escape.  Collectively, these findings provide new insight into class I viral fusion proteins and should facilitate development of optimal RSV fusion inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowEnQ0xJnoFLVg90H21EOLACvtfcHk0lhEktQHvqnCQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFemsbrK&md5=c126990069d3f23d95d06693fe90a061</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1982%26sid%3Dliteratum%253Aachs%26aulast%3DBattles%26aufirst%3DM.%2BB.%26aulast%3DLangedijk%26aufirst%3DJ.%2BP.%26aulast%3DFurmanova-Hollenstein%26aufirst%3DP.%26aulast%3DChaiwatpongsakorn%26aufirst%3DS.%26aulast%3DCostello%26aufirst%3DH.%2BM.%26aulast%3DKwanten%26aufirst%3DL.%26aulast%3DVranckx%26aufirst%3DL.%26aulast%3DVink%26aufirst%3DP.%26aulast%3DJaensch%26aufirst%3DS.%26aulast%3DJonckers%26aufirst%3DT.%2BH.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DPeeples%26aufirst%3DM.%2BE.%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DMcLellan%26aufirst%3DJ.%2BS.%26atitle%3DMolecular%2520mechanism%2520of%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D87%26epage%3D93%26doi%3D10.1038%2Fnchembio.1982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cockerill, S.</span>; <span class="NLM_string-name">Mathews, N.</span>; <span class="NLM_string-name">Ward, S.</span>; <span class="NLM_string-name">Lunn, G.</span>; <span class="NLM_string-name">Paradowski, M.</span>; <span class="NLM_string-name">Gascon-Simorte, J. M.</span></span> <span> </span><span class="NLM_article-title">Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV)</span>. <span class="NLM_patent">WO 2016/055780</span>, Oct 6, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Cockerill&author=N.+Mathews&author=S.+Ward&author=G.+Lunn&author=M.+Paradowski&author=J.+M.+Gascon-Simorte&title=Spiro-indolines+for+the+treatment+and+prophylaxis+of+respiratory+syncytial+virus+infection+%28RSV%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCockerill%26aufirst%3DS.%26atitle%3DSpiro-indolines%2520for%2520the%2520treatment%2520and%2520prophylaxis%2520of%2520respiratory%2520syncytial%2520virus%2520infection%2520%2528RSV%2529%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cockerill, S.</span>; <span class="NLM_string-name">Pilkington, C.</span>; <span class="NLM_string-name">Lumley, J.</span>; <span class="NLM_string-name">Angell, R.</span>; <span class="NLM_string-name">Mathews, N.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical compounds</span>. <span class="NLM_patent">WO2013/068769</span>, May 16, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+Cockerill&author=C.+Pilkington&author=J.+Lumley&author=R.+Angell&author=N.+Mathews&title=Pharmaceutical+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCockerill%26aufirst%3DS.%26atitle%3DPharmaceutical%2520compounds%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">En, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.</span></span> <span> </span><span class="NLM_article-title">Zinc triflate-mediated cyclopropanation of oxindoles with vinyl diphenyl sulfonium triflate: a mild reaction with broad functional group compatibility</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3741</span>– <span class="NLM_lpage">3745</span>, <span class="refDoi"> DOI: 10.1039/C6RA24985J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1039%2FC6RA24985J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslOqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=3741-3745&author=M.+Zhouauthor=K.+Enauthor=Y.+Huauthor=Y.+Xuauthor=H.+C.+Shenauthor=X.+Qian&title=Zinc+triflate-mediated+cyclopropanation+of+oxindoles+with+vinyl+diphenyl+sulfonium+triflate%3A+a+mild+reaction+with+broad+functional+group+compatibility&doi=10.1039%2FC6RA24985J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc triflate-mediated cyclopropanation of oxindoles with vinyl diphenyl sulfonium triflate: a mild reaction with broad functional group compatibility</span></div><div class="casAuthors">Zhou, Mingwei; Ke, En; Hu, Yimin; Xu, Yufang; Shen, Hong C.; Qian, Xuhong</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3741-3745</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The first use of zinc triflate for the cyclopropanation of unprotected oxindoles with vinyl di-Ph sulfonium triflate salt to afford spiro[cyclopropane-1,3'-indoline]-2'-ones I [R = 5-OH, 6-F, 7-Cl, 4-Br, etc.] was reported.  The reaction proceeded under ambient conditions and consistently provided high yields with broad functional group tolerability.  The utility for the late-stage functionalization (LSF) of complex mols. was demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzhG-dUWIV0LVg90H21EOLACvtfcHk0lhEktQHvqnCQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslOqtw%253D%253D&md5=ef5135f3b8764bd196b8ddc542db5caf</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1039%2FC6RA24985J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6RA24985J%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DEn%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DQian%26aufirst%3DX.%26atitle%3DZinc%2520triflate-mediated%2520cyclopropanation%2520of%2520oxindoles%2520with%2520vinyl%2520diphenyl%2520sulfonium%2520triflate%253A%2520a%2520mild%2520reaction%2520with%2520broad%2520functional%2520group%2520compatibility%26jtitle%3DRSC%2520Adv.%26date%3D2017%26volume%3D7%26spage%3D3741%26epage%3D3745%26doi%3D10.1039%2FC6RA24985J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span> <span> </span><span class="NLM_article-title">A convenient cyclopropanation process of oxindoles via bromoethylsulfonium salt</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">6809</span>– <span class="NLM_lpage">6814</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2018.09.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2Fj.tet.2018.09.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCktb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2018&pages=6809-6814&author=H.+Qinauthor=Y.+Miaoauthor=K.+Zhangauthor=J.+Xuauthor=H.+Sunauthor=W.+Liuauthor=F.+Fengauthor=W.+Qu&title=A+convenient+cyclopropanation+process+of+oxindoles+via+bromoethylsulfonium+salt&doi=10.1016%2Fj.tet.2018.09.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A convenient cyclopropanation process of oxindoles via bromoethylsulfonium salt</span></div><div class="casAuthors">Qin, Hui; Miao, Yuanyuan; Zhang, Ke; Xu, Jian; Sun, Haopeng; Liu, Wenyuan; Feng, Feng; Qu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">6809-6814</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A practical convenient conversion of oxindoles into the corresponding spirocyclopropane-oxindoles, e.g., I, is achieved efficiently using bromoethylsulfonium salt, which is easily prepd. on a large scale and is stable cryst.  This reaction of bromoethylsulfonium salt with different substituted unprotected oxindoles proceeded under mild condition and provided moderate yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZy4OqanklqbVg90H21EOLACvtfcHk0lhEktQHvqnCQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCktb3P&md5=840213bf257d51e91d523e32db34e17d</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2018.09.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2018.09.042%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DH.%26aulast%3DMiao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DQu%26aufirst%3DW.%26atitle%3DA%2520convenient%2520cyclopropanation%2520process%2520of%2520oxindoles%2520via%2520bromoethylsulfonium%2520salt%26jtitle%3DTetrahedron%26date%3D2018%26volume%3D74%26spage%3D6809%26epage%3D6814%26doi%3D10.1016%2Fj.tet.2018.09.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andreassen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sletvold, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensen, H.</span></span> <span> </span><span class="NLM_article-title">Nucleophilic alkylations of 3-nitropyridines</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2671</span>– <span class="NLM_lpage">2676</span>, <span class="refDoi"> DOI: 10.1039/b408840a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1039%2Fb408840a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=15351832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnt1Grs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=2671-2676&author=E.+J.+Andreassenauthor=J.+M.+Bakkeauthor=I.+Sletvoldauthor=H.+Svensen&title=Nucleophilic+alkylations+of+3-nitropyridines&doi=10.1039%2Fb408840a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleophilic alkylations of 3-nitropyridines</span></div><div class="casAuthors">Andreassen, Einar J.; Bakke, Jan M.; Sletvold, Ingrid; Svensen, Harald</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2671-2676</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">3-Nitropyridine and 4-substituted-3-nitropyridines were reacted with chloroform, Me chloroacetate and Et 2-chloropropionate under vicarious nucleophilic substitution (VNS) conditions.  Substitution was obtained in the ortho or para position to the nitro group with acceptable to good yields and regioselectivity.  With potassium 5-nitropyridine-2-sulfonate the substitution took place in the 4-position.  Further substitution of the sulfonate group proved to be possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFNPxqNwvVa7Vg90H21EOLACvtfcHk0ljjjkVcw8EM7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnt1Grs7c%253D&md5=611c492e24f335ee1fc12ba58b98a68c</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1039%2Fb408840a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb408840a%26sid%3Dliteratum%253Aachs%26aulast%3DAndreassen%26aufirst%3DE.%2BJ.%26aulast%3DBakke%26aufirst%3DJ.%2BM.%26aulast%3DSletvold%26aufirst%3DI.%26aulast%3DSvensen%26aufirst%3DH.%26atitle%3DNucleophilic%2520alkylations%2520of%25203-nitropyridines%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2004%26volume%3D2%26spage%3D2671%26epage%3D2676%26doi%3D10.1039%2Fb408840a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Committee for Human Medicinal Products,
European Medicinces
Agency</span>.  <i>Guideline on the Clinical
Evaluation of Medicinal Products Indicated for the Prophylaxis or
Treatment of Respiratory Syncytial Virus (RSV)</i> Disease Draft
Guideline, EMA/CHMP/257022/2017; London, Oct 30, <span class="NLM_year">2017</span>. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-indicated-prophylaxis-treatment-respiratory_en.pdf" class="extLink">https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-indicated-prophylaxis-treatment-respiratory_en.pdf</a> (accessed October 21, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Committee+for+Human+Medicinal+Products%2C%0AEuropean+Medicinces%0AAgency&title=Guideline+on+the+Clinical%0AEvaluation+of+Medicinal+Products+Indicated+for+the+Prophylaxis+or%0ATreatment+of+Respiratory+Syncytial+Virus+%28RSV%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DGuideline%2520on%2520the%2520Clinical%250AEvaluation%2520of%2520Medicinal%2520Products%2520Indicated%2520for%2520the%2520Prophylaxis%2520or%250ATreatment%2520of%2520Respiratory%2520Syncytial%2520Virus%2520%2528RSV%2529%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">FDA, Center for Drug Evaluation and Research</span>.  <i>Respiratory Syncytial Virus Infection: Developing Antiviral
Drugs for Prophylaxis and Treatment Guidance for Industry</i> Draft Guidance, Silver Spring, MD; October 2017. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/respiratory-syncytial-virus-infection-developing-antiviral-drugs-prophylaxis-and-treatment-guidance" class="extLink">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/respiratory-syncytial-virus-infection-developing-antiviral-drugs-prophylaxis-and-treatment-guidance</a> (accessed October 22, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA%2C+Center+for+Drug+Evaluation+and+Research.+Respiratory+Syncytial+Virus+Infection%3A+Developing+Antiviral%0ADrugs+for+Prophylaxis+and+Treatment+Guidance+for+Industry+Draft+Guidance%2C+Silver+Spring%2C+MD%3B+October+2017.+https%3A%2F%2Fwww.fda.gov%2Fregulatory-information%2Fsearch-fda-guidance-documents%2Frespiratory-syncytial-virus-infection-developing-antiviral-drugs-prophylaxis-and-treatment-guidance+%28accessed+October+22%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DRespiratory%2520Syncytial%2520Virus%2520Infection%253A%2520Developing%2520Antiviral%250ADrugs%2520for%2520Prophylaxis%2520and%2520Treatment%2520Guidance%2520for%2520Industry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cehelsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nochur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeking, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pareek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studholme, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambkin-Williams, R.</span></span> <span> </span><span class="NLM_article-title">Viral load drives disease in humans experimentally infected with respiratory syncytial virus</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1164/rccm.201002-0221OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1164%2Frccm.201002-0221OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=20622030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1equg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2010&pages=1305-1314&author=J.+P.+DeVincenzoauthor=T.+Wilkinsonauthor=A.+Vaishnawauthor=J.+Cehelskyauthor=R.+Meyersauthor=S.+Nochurauthor=L.+Harrisonauthor=P.+Meekingauthor=A.+Mannauthor=E.+Moaneauthor=J.+Oxfordauthor=R.+Pareekauthor=R.+Mooreauthor=E.+Walshauthor=R.+Studholmeauthor=P.+Dorsettauthor=R.+Alvarezauthor=R.+Lambkin-Williams&title=Viral+load+drives+disease+in+humans+experimentally+infected+with+respiratory+syncytial+virus&doi=10.1164%2Frccm.201002-0221OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Viral load drives disease in humans experimentally infected with respiratory syncytial virus</span></div><div class="casAuthors">DeVincenzo, John P.; Wilkinson, Tom; Vaishnaw, Akshay; Cehelsky, Jeff; Meyers, Rachel; Nochur, Saraswathy; Harrison, Lisa; Meeking, Patricia; Mann, Alex; Moane, Elizabeth; Oxford, John; Pareek, Rajat; Moore, Ryves; Walsh, Ed; Studholme, Robert; Dorsett, Preston; Alvarez, Rene; Lambkin-Williams, Robert</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1305-1314</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is the leading cause of childhood lower respiratory infection, yet viable therapies are lacking.  Two major challenges have stalled antiviral development: ethical difficulties in performing pediatric proof-of-concept studies and the prevailing concept that the disease is immune-mediated rather than being driven by viral load.  The development of a human exptl. wild-type RSV infection model to address these challenges.  Healthy volunteers (n = 35), in five cohorts, received increasing quantities (3.0-5.4 log plaque-forming units/person) of wild-type RSV-A intranasally.  Overall, 77% of volunteers consistently shed virus.  Infection rate, viral loads, disease severity, and safety were similar between cohorts and were unrelated to quantity of RSV received.  Symptoms began near the time of initial viral detection, peaked in severity near when viral load peaked, and subsided as viral loads (measured by real-time polymerase chain reaction) slowly declined.  Viral loads correlated significantly with intranasal proinflammatory cytokine concns. (IL-6 and IL-8).  Increased viral load correlated consistently with increases in multiple different disease measurements (symptoms, phys. examn., and amt. of nasal mucus).  Viral load appears to drive disease manifestations in humans with RSV infection.  The obsd. parallel viral and disease kinetics support a potential clin. benefit of RSV antivirals.  This reproducible model facilitates the development of future RSV therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-DVpVkrytZ7Vg90H21EOLACvtfcHk0ljjjkVcw8EM7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1equg%253D%253D&md5=baadbf1735812bf00a63b9499a2fe3bd</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1164%2Frccm.201002-0221OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201002-0221OC%26sid%3Dliteratum%253Aachs%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26aulast%3DWilkinson%26aufirst%3DT.%26aulast%3DVaishnaw%26aufirst%3DA.%26aulast%3DCehelsky%26aufirst%3DJ.%26aulast%3DMeyers%26aufirst%3DR.%26aulast%3DNochur%26aufirst%3DS.%26aulast%3DHarrison%26aufirst%3DL.%26aulast%3DMeeking%26aufirst%3DP.%26aulast%3DMann%26aufirst%3DA.%26aulast%3DMoane%26aufirst%3DE.%26aulast%3DOxford%26aufirst%3DJ.%26aulast%3DPareek%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DWalsh%26aufirst%3DE.%26aulast%3DStudholme%26aufirst%3DR.%26aulast%3DDorsett%26aufirst%3DP.%26aulast%3DAlvarez%26aufirst%3DR.%26aulast%3DLambkin-Williams%26aufirst%3DR.%26atitle%3DViral%2520load%2520drives%2520disease%2520in%2520humans%2520experimentally%2520infected%2520with%2520respiratory%2520syncytial%2520virus%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D182%26spage%3D1305%26epage%3D1314%26doi%3D10.1164%2Frccm.201002-0221OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meals, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fok-Seang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntjens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariën, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remmerie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verloes, R.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: A placebo-controlled study</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>218</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1093/infdis/jiy227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1093%2Finfdis%2Fjiy227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=29684148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlCnt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=218&publication_year=2018&pages=748-756&author=M.+Stevensauthor=S.+Ruschauthor=J.+DeVincenzoauthor=Y.-I.+Kimauthor=L.+Harrisonauthor=E.+A.+Mealsauthor=A.+Boyersauthor=J.+Fok-Seangauthor=D.+Huntjensauthor=N.+Lounisauthor=K.+Mari%C3%ABnauthor=B.+Remmerieauthor=D.+Roymansauthor=A.+Koulauthor=R.+Verloes&title=Antiviral+activity+of+oral+JNJ-53718678+in+healthy+adult+volunteers+challenged+with+respiratory+syncytial+virus%3A+A+placebo-controlled+study&doi=10.1093%2Finfdis%2Fjiy227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: a placebo-controlled study</span></div><div class="casAuthors">Stevens, Marita; Rusch, Sarah; DeVincenzo, John; Kim, Young-In; Harrison, Lisa; Meals, Elizabeth A.; Boyers, Alison; Fok-Seang, Juin; Huntjens, Dymphy; Lounis, Nacer; Marien, Kris; Remmerie, Bart; Roymans, Dirk; Koul, Anil; Verloes, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">218</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">748-756</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">1537-6613</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  Respiratory syncytial virus (RSV) disease has no effective treatment.  JNJ-53718678 is a fusion inhibitor with selective activity against RSV.  After confirmation of RSV infection or 5 days after inoculation with RSV, participants (n = 69) were randomized to JNJ-53718678 75 mg (n = 15), 200 mg (n = 17), 500 mg (n = 18), or placebo (n = 17) orally once daily for 7 days.  Antiviral effects were evaluated by assessing RSV RNA viral load (VL) area under the curve (AUC) from baseline (before the first dose) until discharge, time-to-peak VL, duration of viral shedding, clin. symptoms, and quantity of nasal secretions.  Mean VL AUC was lower for individuals treated with different doses of JNJ-53718678 vs. placebo (203.8-253.8 vs 432.8 log10 PFUe.hour/mL).  Also, mean peak VL, time to peak VL, duration of viral shedding, mean overall symptom score, and nasal secretion wt. were lower in each JNJ-53718678-treated group vs. placebo.  No clear exposure-response relationship was obsd.  Three participants discontinued due to treatment-emergent adverse events of grade 2 and 1 ECG change (JNJ-53718678 75 mg and 200 mg, resp.) and grade 2 urticaria (placebo).  Conclusions.  JNJ-53718678 at all 3 doses substantially reduced VL and clin. disease severity, thus establishing clin. proof of concept and the compd.'s potential as a novel RSV treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9lct-FnOIM7Vg90H21EOLACvtfcHk0lijcSXW0XwyzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlCnt77J&md5=a7da58b73e29e9c06537292a14dc3408</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjiy227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjiy227%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%26aufirst%3DM.%26aulast%3DRusch%26aufirst%3DS.%26aulast%3DDeVincenzo%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.-I.%26aulast%3DHarrison%26aufirst%3DL.%26aulast%3DMeals%26aufirst%3DE.%2BA.%26aulast%3DBoyers%26aufirst%3DA.%26aulast%3DFok-Seang%26aufirst%3DJ.%26aulast%3DHuntjens%26aufirst%3DD.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DMari%25C3%25ABn%26aufirst%3DK.%26aulast%3DRemmerie%26aufirst%3DB.%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DVerloes%26aufirst%3DR.%26atitle%3DAntiviral%2520activity%2520of%2520oral%2520JNJ-53718678%2520in%2520healthy%2520adult%2520volunteers%2520challenged%2520with%2520respiratory%2520syncytial%2520virus%253A%2520A%2520placebo-controlled%2520study%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2018%26volume%3D218%26spage%3D748%26epage%3D756%26doi%3D10.1093%2Finfdis%2Fjiy227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span>GileadSciences.
Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV). <a href="http://Clintrials.gov" class="extLink">Clintrials.gov</a> <span class="NLM_year">2013</span>, NCT01797419. <a href="https://clinicaltrials.gov/ct2/show/NCT01797419" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01797419</a> (accessed October 22, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=GileadSciences.%0ASafety+Study+of+GS-5806+to+Treat+Respiratory+Syncytial+Virus+%28RSV%29.+Clintrials.gov+2013%2C+NCT01797419.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01797419+%28accessed+October+22%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chemaly, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadwal, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljungman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pipavath, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limaye, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winston, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiff, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuckerman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachance, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahav, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullane, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patron, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waghmare, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKevitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">German, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gossage, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckh, M.</span></span> <span> </span><span class="NLM_article-title">A phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">2777</span>– <span class="NLM_lpage">2786</span>, <span class="refDoi"> DOI: 10.1093/cid/ciz1166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1093%2Fcid%2Fciz1166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=31793991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnvFGgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2020&pages=2777-2786&author=R.+F.+Chemalyauthor=S.+S.+Dadwalauthor=A.+Bergeronauthor=P.+Ljungmanauthor=Y.-J.+Kimauthor=G.-S.+Chengauthor=S.+N.+Pipavathauthor=A.+P.+Limayeauthor=E.+Blanchardauthor=D.+J.+Winstonauthor=P.+J.+Stiffauthor=T.+Zuckermanauthor=S.+Lachanceauthor=G.+Rahavauthor=C.+B.+Smallauthor=K.+M.+Mullaneauthor=R.+L.+Patronauthor=D.-G.+Leeauthor=H.+H.+Hirschauthor=A.+Waghmareauthor=M.+McKevittauthor=R.+Jordanauthor=Y.+Guoauthor=P.+Germanauthor=D.+P.+Porterauthor=D.+L.+Gossageauthor=T.+R.+Watkinsauthor=F.+M.+Martyauthor=J.+W.+Chienauthor=M.+Boeckh&title=A+phase+2%2C+randomized%2C+double-blind%2C+placebo-controlled+trial+of+presatovir+for+the+treatment+of+respiratory+syncytial+virus+upper+respiratory+tract+infection+in+hematopoietic-cell+transplant+recipients&doi=10.1093%2Fcid%2Fciz1166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49aR"><div class="casContent"><span class="casTitleNuber">49a</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients</span></div><div class="casAuthors">Chemaly, Roy F.; Dadwal, Sanjeet S.; Bergeron, Anne; Ljungman, Per; Kim, Yae-Jean; Cheng, Guang-Shing; Pipavath, Sudhakar N.; Limaye, Ajit P.; Blanchard, Elodie; Winston, Drew J.; Stiff, Patrick J.; Zuckerman, Tsila; Lachance, Silvy; Rahav, Galia; Small, Catherine B.; Mullane, Kathleen M.; Patron, Roberto L.; Lee, Dong-Gun; Hirsch, Hans H.; Waghmare, Alpana; McKevitt, Matt; Jordan, Robert; Guo, Ying; German, Polina; Porter, Danielle P.; Gossage, David L.; Watkins, Timothy R.; Marty, Francisco M.; Chien, Jason W.; Boeckh, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">Suppl._4</span>),
    <span class="NLM_cas:pages">2777-2786</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Hematopoietic-cell transplant (HCT) recipients are at risk for severe respiratory syncytial virus (RSV) infection.  We evaluated the RSV fusion inhibitor presatovir in a randomized, double-blind, Phase II trial in HCT recipients with RSV upper respiratory tract infections.  Patients were stratified by lymphopenia (<200/μL) and ribavirin use; were randomized, stratified by lymphopenia (<200/μL) and ribavirin use, to receive oral presatovir at 200 mg or a placebo on Days 1, 5, 9, 13, and 17, and were followed through Day 28.  The coprimary efficacy endpoints were the time-weighted av. change in the nasal RSV viral load between Days 1 and 9 and the proportion of patients developing lower respiratory tract complications (LRTCs) through Day 28.  From 23 Jan. 2015 to 16 June 2017, 189 patients were randomly assigned to treatment (96 to presatovir and 93 to the placebo).  Presatovir treatment, compared with the placebo treatment, did not significantly affect (prespecified α = 0.01) a time-weighted av. decline in the RSV viral load from Day 1 to 9 (treatment difference, -0.33 log10 copies/mL; 95% confidence interval [CI] -.64 to -.02 log10 copies/mL; P = .040) or the progression to LRTC (11.2% vs 19.5%, resp.; odds ratio, 0.50; 95% CI, .22-1.18; P = .11).  In a post hoc anal. among patients with lymphopenia, presatovir decreased LRTC development by Day 28 (2/15 [13.3%] vs 9/14 [64.3%], resp.; P = .008), compared with the placebo.  Adverse events were similar for patients receiving presatovir and the placebo.  Presatovir had a favorable safety profile in adult HCT recipients with RSV but did not achieve the coprimary endpoints.  Exploratory analyses suggest an antiviral effect among patients with lymphopenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrYGSUXfnUMbVg90H21EOLACvtfcHk0lijcSXW0XwyzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnvFGgtQ%253D%253D&md5=ecf33034e40a2cf65d54c6879a2fd8ce</span></div><a href="/servlet/linkout?suffix=cit49a&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciz1166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciz1166%26sid%3Dliteratum%253Aachs%26aulast%3DChemaly%26aufirst%3DR.%2BF.%26aulast%3DDadwal%26aufirst%3DS.%2BS.%26aulast%3DBergeron%26aufirst%3DA.%26aulast%3DLjungman%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DY.-J.%26aulast%3DCheng%26aufirst%3DG.-S.%26aulast%3DPipavath%26aufirst%3DS.%2BN.%26aulast%3DLimaye%26aufirst%3DA.%2BP.%26aulast%3DBlanchard%26aufirst%3DE.%26aulast%3DWinston%26aufirst%3DD.%2BJ.%26aulast%3DStiff%26aufirst%3DP.%2BJ.%26aulast%3DZuckerman%26aufirst%3DT.%26aulast%3DLachance%26aufirst%3DS.%26aulast%3DRahav%26aufirst%3DG.%26aulast%3DSmall%26aufirst%3DC.%2BB.%26aulast%3DMullane%26aufirst%3DK.%2BM.%26aulast%3DPatron%26aufirst%3DR.%2BL.%26aulast%3DLee%26aufirst%3DD.-G.%26aulast%3DHirsch%26aufirst%3DH.%2BH.%26aulast%3DWaghmare%26aufirst%3DA.%26aulast%3DMcKevitt%26aufirst%3DM.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DGerman%26aufirst%3DP.%26aulast%3DPorter%26aufirst%3DD.%2BP.%26aulast%3DGossage%26aufirst%3DD.%2BL.%26aulast%3DWatkins%26aufirst%3DT.%2BR.%26aulast%3DMarty%26aufirst%3DF.%2BM.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DBoeckh%26aufirst%3DM.%26atitle%3DA%2520phase%25202%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520presatovir%2520for%2520the%2520treatment%2520of%2520respiratory%2520syncytial%2520virus%2520upper%2520respiratory%2520tract%2520infection%2520in%2520hematopoietic-cell%2520transplant%2520recipients%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2020%26volume%3D71%26spage%3D2777%26epage%3D2786%26doi%3D10.1093%2Fcid%2Fciz1166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit49b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemaly, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullane, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljungman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waghmare, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKevitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">German, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadwal, S. S.</span></span> <span> </span><span class="NLM_article-title">A phase 2b, randomized, double-blind, placebo-controlled multicenter study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus (RSV) infection of the lower respiratory tract</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">2787</span>– <span class="NLM_lpage">2795</span>, <span class="refDoi"> DOI: 10.1093/cid/ciz1167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1093%2Fcid%2Fciz1167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=31915807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnvFKisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2020&pages=2787-2795&author=F.+M.+Martyauthor=R.+F.+Chemalyauthor=K.+M.+Mullaneauthor=D.-G.+Leeauthor=H.+H.+Hirschauthor=C.+B.+Smallauthor=A.+Bergeronauthor=S.+Shohamauthor=P.+Ljungmanauthor=A.+Waghmareauthor=E.+Blanchardauthor=Y.-J.+Kimauthor=M.+McKevittauthor=D.+P.+Porterauthor=R.+Jordanauthor=Y.+Guoauthor=P.+Germanauthor=M.+Boeckhauthor=T.+R.+Watkinsauthor=J.+W.+Chienauthor=S.+S.+Dadwal&title=A+phase+2b%2C+randomized%2C+double-blind%2C+placebo-controlled+multicenter+study+evaluating+antiviral+effects%2C+pharmacokinetics%2C+safety%2C+and+tolerability+of+presatovir+in+hematopoietic+cell+transplant+recipients+with+respiratory+syncytial+virus+%28RSV%29+infection+of+the+lower+respiratory+tract&doi=10.1093%2Fcid%2Fciz1167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49bR"><div class="casContent"><span class="casTitleNuber">49b</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2b, randomized, double-blind, placebo-controlled multicenter study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus infection of the lower respiratory tract</span></div><div class="casAuthors">Marty, Francisco M.; Chemaly, Roy F.; Mullane, Kathleen M.; Lee, Dong-Gun; Hirsch, Hans H.; Small, Catherine B.; Bergeron, Anne; Shoham, Shmuel; Ljungman, Per; Waghmare, Alpana; Blanchard, Elodie; Kim, Yae-Jean; McKevitt, Matt; Porter, Danielle P.; Jordan, Robert; Guo, Ying; German, Polina; Boeckh, Michael; Watkins, Timothy R.; Chien, Jason W.; Dadwal, Sanjeet S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">Suppl._4</span>),
    <span class="NLM_cas:pages">2787-2795</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Presatovir significantly reduced nasal viral load, signs, and symptoms of respiratory syncytial virus (RSV) infection in a human challenge study.  We evaluated presatovir in hematopoietic-cell transplant (HCT) recipients with RSV lower respiratory tract infection (LRTI).  Patients with confirmed RSV in upper and lower respiratory tract and new chest X-ray abnormalities were randomized (1:1), stratified by supplemental oxygen and ribavirin use, to receive oral presatovir 200 mg or placebo every 4 days for 5 doses.  The primary endpoint was time-weighted av. change in nasal RSV viral load through day 9.  Secondary endpoints included supplemental oxygen-free days, incident respiratory failure requiring mech. ventilation, and all-cause mortality.  From Jan. 31, 2015, to March 20, 2017, 60 patients from 17 centers were randomized (31 presatovir, 29 placebo); 59 received study treatment (50 allogeneic, 9 autologous HCT).  In the efficacy population (29 presatovir, 28 placebo), presatovir treatment did not significantly reduce time-weighted av. change in viral load (-1.12 vs -1.09 log10 copies/mL; treatment difference -0.02 log10 copies/mL, 95% confidence interval: -.62, .57; P = .94), median supplemental oxygen-free days (26 vs 28 days, P = .84), incident respiratory failure (10.3 vs 10.7%, P = .98), or all-cause mortality (0 vs 7.1%, P = .19) vs. placebo.  Adverse events were similar between arms (presatovir 80%, placebo 79%).  Resistance-assocd. substitutions in RSV fusion protein emerged in 6/29 presatovir-treated patients.  Presatovir treatment was well tolerated in HCT patients with RSV LRTI but did not improve virol. or clin. outcomes vs. placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXu1F0E9LvMrVg90H21EOLACvtfcHk0li-IXNyngfTjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnvFKisw%253D%253D&md5=24e0b3c4c7602b70bcaac062a4512978</span></div><a href="/servlet/linkout?suffix=cit49b&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciz1167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciz1167%26sid%3Dliteratum%253Aachs%26aulast%3DMarty%26aufirst%3DF.%2BM.%26aulast%3DChemaly%26aufirst%3DR.%2BF.%26aulast%3DMullane%26aufirst%3DK.%2BM.%26aulast%3DLee%26aufirst%3DD.-G.%26aulast%3DHirsch%26aufirst%3DH.%2BH.%26aulast%3DSmall%26aufirst%3DC.%2BB.%26aulast%3DBergeron%26aufirst%3DA.%26aulast%3DShoham%26aufirst%3DS.%26aulast%3DLjungman%26aufirst%3DP.%26aulast%3DWaghmare%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DY.-J.%26aulast%3DMcKevitt%26aufirst%3DM.%26aulast%3DPorter%26aufirst%3DD.%2BP.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DGerman%26aufirst%3DP.%26aulast%3DBoeckh%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DT.%2BR.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DDadwal%26aufirst%3DS.%2BS.%26atitle%3DA%2520phase%25202b%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520multicenter%2520study%2520evaluating%2520antiviral%2520effects%252C%2520pharmacokinetics%252C%2520safety%252C%2520and%2520tolerability%2520of%2520presatovir%2520in%2520hematopoietic%2520cell%2520transplant%2520recipients%2520with%2520respiratory%2520syncytial%2520virus%2520%2528RSV%2529%2520infection%2520of%2520the%2520lower%2520respiratory%2520tract%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2020%26volume%3D71%26spage%3D2787%26epage%3D2795%26doi%3D10.1093%2Fcid%2Fciz1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dilling, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoop, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampolla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neurohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glanville, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKevitt, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">German, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamora, M.</span></span> <span> </span><span class="NLM_article-title">A phase 2b, randomized controlled trial of presatovir, an oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in lung transplant (LT) recipients</span>. <i>J. Heart Lung Transplant</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">S155</span>, <span class="refDoi"> DOI: 10.1016/j.healun.2018.01.375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2Fj.healun.2018.01.375" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=S155&author=J.+Gottliebauthor=F.+Torresauthor=T.+Haddadauthor=G.+Dhillonauthor=D.+F.+Dillingauthor=C.+Knoopauthor=R.+Rampollaauthor=R.+Waliaauthor=V.+Ahyaauthor=R.+Kesslerauthor=D.+P.+Masonauthor=M.+Budevauthor=C.+Neurohrauthor=A.+R.+Glanvilleauthor=R.+Jordanauthor=D.+Porterauthor=M.+T.+McKevittauthor=P.+Germanauthor=Y.+Guoauthor=J.+W.+Chienauthor=T.+R.+Watkinsauthor=M.+Zamora&title=A+phase+2b%2C+randomized+controlled+trial+of+presatovir%2C+an+oral+RSV+fusion+inhibitor%2C+for+the+treatment+of+respiratory+syncytial+virus+%28RSV%29+in+lung+transplant+%28LT%29+recipients&doi=10.1016%2Fj.healun.2018.01.375"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.healun.2018.01.375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.healun.2018.01.375%26sid%3Dliteratum%253Aachs%26aulast%3DGottlieb%26aufirst%3DJ.%26aulast%3DTorres%26aufirst%3DF.%26aulast%3DHaddad%26aufirst%3DT.%26aulast%3DDhillon%26aufirst%3DG.%26aulast%3DDilling%26aufirst%3DD.%2BF.%26aulast%3DKnoop%26aufirst%3DC.%26aulast%3DRampolla%26aufirst%3DR.%26aulast%3DWalia%26aufirst%3DR.%26aulast%3DAhya%26aufirst%3DV.%26aulast%3DKessler%26aufirst%3DR.%26aulast%3DMason%26aufirst%3DD.%2BP.%26aulast%3DBudev%26aufirst%3DM.%26aulast%3DNeurohr%26aufirst%3DC.%26aulast%3DGlanville%26aufirst%3DA.%2BR.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DPorter%26aufirst%3DD.%26aulast%3DMcKevitt%26aufirst%3DM.%2BT.%26aulast%3DGerman%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DWatkins%26aufirst%3DT.%2BR.%26aulast%3DZamora%26aufirst%3DM.%26atitle%3DA%2520phase%25202b%252C%2520randomized%2520controlled%2520trial%2520of%2520presatovir%252C%2520an%2520oral%2520RSV%2520fusion%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520respiratory%2520syncytial%2520virus%2520%2528RSV%2529%2520in%2520lung%2520transplant%2520%2528LT%2529%2520recipients%26jtitle%3DJ.%2520Heart%2520Lung%2520Transplant%26date%3D2018%26volume%3D37%26spage%3DS155%26doi%3D10.1016%2Fj.healun.2018.01.375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanfelt-Goade, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maimon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catherinot, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gafter-Gvili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napora, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeltser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moudgil, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limaye, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couturaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nseir, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKevitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">German, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gossage, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falsey, A. R.</span></span> <span> </span><span class="NLM_article-title">A Phase 2b, randomized, double-blind, placebo-controlled trial of presatovir (GS-5806), a novel oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in hospitalized adults</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">A4457</span>– <span class="NLM_lpage">A4457</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2018&pages=A4457-A4457&author=D.+Hanfelt-Goadeauthor=N.+Maimonauthor=A.+Nimerauthor=F.+Riviereauthor=E.+Catherinotauthor=M.+Isonauthor=S.+Jeongauthor=E.+Walshauthor=A.+Gafter-Gviliauthor=S.+Namaauthor=P.+Naporaauthor=M.+Chowersauthor=A.+Bergeronauthor=D.+Zeltserauthor=H.+Moudgilauthor=A.+P.+Limayeauthor=F.+Couturaudauthor=W.+Nseirauthor=M.+McKevittauthor=D.+Porterauthor=R.+Jordanauthor=Y.+Guoauthor=P.+Germanauthor=T.+R.+Watkinsauthor=D.+L.+Gossageauthor=J.+W.+Chienauthor=A.+R.+Falsey&title=A+Phase+2b%2C+randomized%2C+double-blind%2C+placebo-controlled+trial+of+presatovir+%28GS-5806%29%2C+a+novel+oral+RSV+fusion+inhibitor%2C+for+the+treatment+of+respiratory+syncytial+virus+%28RSV%29+in+hospitalized+adults"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHanfelt-Goade%26aufirst%3DD.%26aulast%3DMaimon%26aufirst%3DN.%26aulast%3DNimer%26aufirst%3DA.%26aulast%3DRiviere%26aufirst%3DF.%26aulast%3DCatherinot%26aufirst%3DE.%26aulast%3DIson%26aufirst%3DM.%26aulast%3DJeong%26aufirst%3DS.%26aulast%3DWalsh%26aufirst%3DE.%26aulast%3DGafter-Gvili%26aufirst%3DA.%26aulast%3DNama%26aufirst%3DS.%26aulast%3DNapora%26aufirst%3DP.%26aulast%3DChowers%26aufirst%3DM.%26aulast%3DBergeron%26aufirst%3DA.%26aulast%3DZeltser%26aufirst%3DD.%26aulast%3DMoudgil%26aufirst%3DH.%26aulast%3DLimaye%26aufirst%3DA.%2BP.%26aulast%3DCouturaud%26aufirst%3DF.%26aulast%3DNseir%26aufirst%3DW.%26aulast%3DMcKevitt%26aufirst%3DM.%26aulast%3DPorter%26aufirst%3DD.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DGerman%26aufirst%3DP.%26aulast%3DWatkins%26aufirst%3DT.%2BR.%26aulast%3DGossage%26aufirst%3DD.%2BL.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DFalsey%26aufirst%3DA.%2BR.%26atitle%3DA%2520Phase%25202b%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520presatovir%2520%2528GS-5806%2529%252C%2520a%2520novel%2520oral%2520RSV%2520fusion%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520respiratory%2520syncytial%2520virus%2520%2528RSV%2529%2520in%2520hospitalized%2520adults%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2018%26volume%3D197%26spage%3DA4457%26epage%3DA4457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brint, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meals, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cormier, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span> <span> </span><span class="NLM_article-title">Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants</span>. <i>Pediatr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">872</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1038/pr.2017.173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1038%2Fpr.2017.173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=28723886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BC1cjptFKhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2017&pages=872-880&author=M.+E.+Brintauthor=J.+M.+Hughesauthor=A.+Shahauthor=C.+R.+Millerauthor=L.+G.+Harrisonauthor=E.+A.+Mealsauthor=J.+Blanchauthor=C.+R.+Thompsonauthor=S.+A.+Cormierauthor=J.+P.+DeVincenzo&title=Prolonged+viral+replication+and+longitudinal+viral+dynamic+differences+among+respiratory+syncytial+virus+infected+infants&doi=10.1038%2Fpr.2017.173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants</span></div><div class="casAuthors">Brint Monica E; Harrison Lisa G; Meals Elizabeth A; Blanch Jacqueline; Cormier Stephania A; Hughes Joshua M; Shah Aditya; Miller Chelsea R; Thompson Charlotte R; DeVincenzo John P</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">872-880</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BackgroundLongitudinal respiratory syncytial virus (RSV) dynamics have not been well studied despite the existence of factors favoring prolonged RSV replication including high mutation rates allowing rapid evolution and potential escape from immune control.  We therefore measured viral load in previously RSV-naive infants over prolonged time spans.MethodsDuring 2014-2015, quantitative nasal aspirates were collected from 51 RSV-PCR+ infants.  Multiple parallel assessments of viral loads were quantified at each collected time point using a well-validated real-time quantitative reverse transcriptase polymerase chain reaction assay.  After observing viral load rebound phenomenon in some infants, the viral dynamics of 27 infants with sufficient longitudinal viral load data points were analyzed using the pre-defined criteria for viral rebound.  Additional analyses were performed comparing age with viral rebound, viral clearance rates, and viral load area-under-the-curve (AUCVL).ResultsThe 51 infants (303 nasal aspirate samples; mean of 5.9 per patient) exhibited slower than expected viral clearance.  Lower age trended toward slower viral clearance and greater AUCVL.  Six infants had detectable viral loads ≥1 month after symptom onset.  Ten of twenty-seven evaluable subjects exhibited viral rebound and this rebound was age-dependent (P=0.0259).  All but one rebounder were <70 days old.ConclusionInfants struggle to control primary RSV infections allowing prolonged viral replication and previously undescribed viral rebound; likely representing viral mutational immune escape.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDdN6tnGk9fXy-c-E1v-fmfW6udTcc2eZMQ9ewoLOYY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjptFKhsg%253D%253D&md5=0ebc9a6be5b1ff3d75e97b6f6da64630</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fpr.2017.173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fpr.2017.173%26sid%3Dliteratum%253Aachs%26aulast%3DBrint%26aufirst%3DM.%2BE.%26aulast%3DHughes%26aufirst%3DJ.%2BM.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DC.%2BR.%26aulast%3DHarrison%26aufirst%3DL.%2BG.%26aulast%3DMeals%26aufirst%3DE.%2BA.%26aulast%3DBlanch%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DC.%2BR.%26aulast%3DCormier%26aufirst%3DS.%2BA.%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26atitle%3DProlonged%2520viral%2520replication%2520and%2520longitudinal%2520viral%2520dynamic%2520differences%2520among%2520respiratory%2520syncytial%2520virus%2520infected%2520infants%26jtitle%3DPediatr.%2520Res.%26date%3D2017%26volume%3D82%26spage%3D872%26epage%3D880%26doi%3D10.1038%2Fpr.2017.173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tait, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efthimiou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockerill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littler, E.</span></span> <span> </span><span class="NLM_article-title">A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">e01884</span>– <span class="NLM_lpage">19</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=31712214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktFygs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2020&pages=e01884-19&author=J.+DeVincenzoauthor=D.+Taitauthor=J.+Efthimiouauthor=J.+Moriauthor=Y.-I.+Kimauthor=E.+Thomasauthor=L.+Wilsonauthor=R.+Harlandauthor=N.+Mathewsauthor=S.+Cockerillauthor=K.+Powellauthor=E.+Littler&title=A+randomized%2C+placebo-controlled%2C+respiratory+syncytial+virus+human+challenge+study+of+the+antiviral+efficacy%2C+safety%2C+and+pharmacokinetics+of+RV521%2C+an+inhibitor+of+the+RSV-F+protein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein</span></div><div class="casAuthors">DeVincenzo, John; Tait, Dereck; Efthimiou, John; Mori, Julie; Kim, Young-In; Thomas, Elaine; Wilson, Lynn; Harland, Rachel; Mathews, Neil; Cockerill, Stuart; Powell, Kenneth; Littler, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e01884</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Effective treatments for respiratory syncytial virus (RSV) infection are lacking.  Here, we report a human proof-of-concept study for RV521, a small-mol. antiviral inhibitor of the RSV-F protein.  In this randomized, double-blind, placebo-controlled trial, healthy adults were challenged with RSV-A Memphis-37b.  After infection was confirmed (or 5 days after challenge virus inoculation), subjects received RV521 (350 mg or 200 mg) or placebo orally every 12 h for 5 days.  The primary endpoint was area under the curve (AUC) for viral load, as assessed by reverse transcriptase quant. PCR (RT-qPCR) of nasal wash samples.  The primary efficacy anal. set included subjects successfully infected with RSV who received ≥1 dose of study drug.  A total of 66 subjects were enrolled (n = 22 per group); 53 were included in the primary anal. set (RV521 350 mg: n = 16; 200 mg: n = 18; placebo: n = 19).  The mean AUC of RT-qPCR-assessed RSV viral load (log10 PFU equiv. [PFUe]/mL.h) was significantly lower with RV521 350 mg (185.26; std. error [SE], 31.17; P = 0.002) and 200 mg (224.35; SE, 37.60; P = 0.007) vs. placebo (501.39; SE, 86.57).  Disease severity improved with RV521 350 mg and 200 mg vs. placebo (P = 0.002 and P = 0.009, resp., for AUC total symptom score [score × hours]).  Daily nasal mucus wt. was significantly reduced (P = 0.010 and P = 0.038 for RV521 350 mg and 200 mg, resp., vs. placebo).  All treatment-emergent adverse events were grade 1 or 2.  No subjects discontinued due to adverse events.  There was no evidence of clin. significant viral resistance, and only three variants were detected.  RV521 effectively reduced RSV viral load and disease severity in humans and was well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeVsGp1QWwVrVg90H21EOLACvtfcHk0lhJqey2NZ7cBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktFygs7g%253D&md5=9e3b634f6cca773406727b57776eea0d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeVincenzo%26aufirst%3DJ.%26aulast%3DTait%26aufirst%3DD.%26aulast%3DEfthimiou%26aufirst%3DJ.%26aulast%3DMori%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.-I.%26aulast%3DThomas%26aufirst%3DE.%26aulast%3DWilson%26aufirst%3DL.%26aulast%3DHarland%26aufirst%3DR.%26aulast%3DMathews%26aufirst%3DN.%26aulast%3DCockerill%26aufirst%3DS.%26aulast%3DPowell%26aufirst%3DK.%26aulast%3DLittler%26aufirst%3DE.%26atitle%3DA%2520randomized%252C%2520placebo-controlled%252C%2520respiratory%2520syncytial%2520virus%2520human%2520challenge%2520study%2520of%2520the%2520antiviral%2520efficacy%252C%2520safety%252C%2520and%2520pharmacokinetics%2520of%2520RV521%252C%2520an%2520inhibitor%2520of%2520the%2520RSV-F%2520protein%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2020%26volume%3D64%26spage%3De01884%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23a','cit23b'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27a','cit27b'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49a','cit49b'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Sisunatovir. </span><span class="cited-content_cbyCitation_journal-name">Synfacts</span><span> <strong>2021,</strong>,, 0722. <a href="https://doi.org/10.1055/s-0040-1720420" title="DOI URL">https://doi.org/10.1055/s-0040-1720420</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0040-1720420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0040-1720420%26sid%3Dliteratum%253Aachs%26jtitle%3DSynfacts%26atitle%3DSynthesis%252Bof%252BSisunatovir%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D07%26spage%3D0722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Clinical stage RSV fusion inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. A plot of numbers of compounds disclosed in three benzimidazole patents against clogP.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> clogP figures represent the central point of each bin covering clogP values ±0.25. clogP values were calculated using Biobyte version 5.4 (<a href="http://www.biobyte.com/index.html" class="extLink">http://www.biobyte.com/index.html</a>). Patent example data were extracted from Surechembl (<a href="https://www.surechembl.org/search/" class="extLink">https://www.surechembl.org/search/</a>). Examples with a molecular weight outside of the range 300–700 were removed, and structures were checked manually with reactive compounds removed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Summary of spirocyclic structural scan, with cores A–G used in the initial hit finding exercise. The five and six membered lactam cores are shown in red, and the proposed three to five membered spirocycles are shown in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Summary of metabolite ID study for compound <b>6</b> following incubation with microsomes derived from rat and human liver cells. The most likely sites of metabolism are indicated by arrows.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Project flowchart depicting the design, make, and test cycle for compounds prepared in the project. The design, make, and test cycle allowed a progression to <i>in vivo</i> evaluation in the mouse BalbC model. Detailed virology and toxicity analysis prior to progression into preclinical evaluation followed. Generalized progression criteria are shown in italics below or alongside each assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0006.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structural modification strategies employed in the lead optimization of hit <b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0007.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Spirocyclopropyl aza-oxindoles and heterocyclic spirocyclic oxindoles identified at Reviral Ltd.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0008.jpeg" id="rightTab-GRAPHIC-d7e2679-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (a) RV521 inhibition of RSV infection of HAE cells. Treatment of HAE cells with 10 nM RV521 2 h prior to infection (shaded bars) with recombinant luciferase-expressing RSV reduced the titer (as measured by luminescence) at 7 and 8 days postinfection versus untreated controls (white bars). Data are presented as mean ± SD (<i>n</i> = 3). (b) Representation of the inset cell system that allows viral infection to and sampling of the apical surface of the epithelial layer and compound administration (blue arrows) to the basolateral surface of the cells via the cell nutrient (salmon).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0009.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Crystal structure of RV521 bound to the F-protein (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KQD">7KQD</a>) in its trimeric prefusion conformation. Views are shown of the binding site created by the trimer. Amino acid residues are shown as gold, pink, or green filled sticks with the backbone shown as a ribbon in the corresponding color. Each colored region corresponds to each individual monomer. (a) Binding mode in a top-down view of RV521 depicting π-bonding interactions with phenylalanine 488 and 140 of the gold monomer. (b) Binding mode showing the orientation of the aminomethylene into a hydrophilic region created by Asp489 and Thr397 with the H bonding interaction with Threonine 397 backbone carbonyl indicated by the dotted line. The proximity of the mutable Asp489 is depicted most clearly in panel b. Amino acid residue labels are shown in the color of the monomer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0010.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. RV521 reduced lung virus titers in a Balb/C mouse model of RSV infection. Balb/C mice were treated with RV521 (1, 10, or 50 mg/kg) 2 h pre- and 24 h postintranasal inoculation with RSV strain A2. RSV viral titers in lung homogenates were measured 5 days postinfection. Data are expressed as a percentage of control group and shown as mean ± sd (<i>n</i> = 6 animals per group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0012.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Disconnection of Generalized Target Compound Structure into Chlorobenzimidazole and Spirocyclic Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Blue and red rings indicate variable sized spirocyclic ring systems. X = F, Cl, H. Y = H, CH<sub>2</sub>NHBoc, Cl, CN. R is a variable alkyl chain.</p></p></figure><figure data-id="sch2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Benzimidazole Intermediate for RV521<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 4,4,4-trifluorobutan-1-amine, NEt<sub>3</sub>, MeCN, rt, 16 h, 92%. (ii) Pd/C, H<sub>2</sub>, rt, 16 h, 88%. (iii) acetoxyacetyl chloride, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h, then AcOH, 80 °C, 16 h, 69%. (iv) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 1 h, 91%. (v) Pd(OH)<sub>2</sub>/C, HCl, H<sub>2</sub>, MeOH/THF, rt, 16 h, then BOC anhydride, DIPEA,CH<sub>2</sub>Cl<sub>2</sub>, rt, 3 h, 83%. (vi) MsCl, DIPEA, THF, rt, 16 h, 96%.</p></p></figure><figure data-id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0014.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Sequence Used in the Preparation of RV521<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <i>n</i>-BuLi, diisopropylamine, 1,2-dibromoethane, −40 to 18 °C, 47%. (ii) NaH, DMF, rt, 16 h, 75%. (iii) HCl (2 M in Et<sub>2</sub>O), CH<sub>2</sub>Cl<sub>2</sub>, rt, 6 h, then aq. NaHCO<sub>3</sub> workup, 63%. (iv) HCl (2 M in Et<sub>2</sub>O), CH<sub>2</sub>Cl<sub>2</sub>, 30 min, 81%.</p></p></figure><figure data-id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0015.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Spirocyclic Azaoxindole <b>49</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) ethylchoroacetate, KO<sup>t</sup>Bu, 0 °C to rt, 2.5 h, 80%. (ii) K<sub>2</sub>CO<sub>3</sub>, benzyltriethylammonium chloride, paraformaldehyde, toluene, 90 °C, 1.25 h, 77%. (iii) DBU, trimethylsulfoxonium chloride, CH<sub>3</sub>CN, 60 °C, 45 min, 59%. (iv) Pd/C, EtOH, H<sub>2</sub>, 16 h. (v) 1,5,7-Triazabicyclo[4.4.0]dec-5-ene, 80 °C, 1 h, 90%.</p></p></figure><figure data-id="sch5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0016.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 6-Aminomethylene Derivatives from 6-Cyanobenzimidazole <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Synthesis is described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_002.pdf" class="ext-link">Supporting Information</a>). Reagents and conditions: <b>25</b>: (i) acetyl chloride, EtOH, rt, 16 h. (ii) NH<sub>3</sub>, methanol, rt, 48 h, 21%. <b>26</b>: (iii) acetyl chloride, EtOH, rt, 16 h. (iv) EtNH<sub>2</sub>, methanol, rt, 16 h, 57%. <b>27</b>: (v) 5% Pd/C, H<sub>2</sub>, HCl/MeOH, 77%. vi) (BocN)<sub>2</sub>C═N(SO<sub>2</sub>CF<sub>3</sub>), Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 23 h. (vii) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 19 h, 78%. <b>28</b>: (viii) NaOH, dioxane, reflux, 36%. <b>31</b>: (ix) 5% Pd/C, H<sub>2</sub>, HCl/MeOH, 77%. (x) acetyl chloride, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 71%.</p></p></figure><figure data-id="fig11" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/medium/jm0c01882_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0011.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Mean viral load by nasal wash RT-qPCR (A) and by nasal wash cell-based infectivity assay (B) by day relative to dosing. Once RSV infection was confirmed, treatment was initiated at 200 or 350 mg BID. Viral load (RT-qPCR) appeared to rebound after day 8.5 in the placebo arm. However, this apparent increase resulted from the staggered randomization of subjects (the mean viral load at day 9 was calculated from just four subjects, three of whom had consistently high viral loads throughout the study). Figure reprinted under a Creative Commons Attribution 4.0 International License (CC BY 4.0).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Reprinted from DeVincenzo, J.; Tait, D.; Efthimiou, J.; Mori, J.; Kim, Y.-I.; Thomas, E.; Wilson, L.; Harland, R.; Mathews, N.; Cockerill, S.; Powell, K.; Littler, E. A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein. Antimicrob. Agents Chemother. 2020, 64, e01884–19. Copyright 2020 American Society of Microbiology.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c01882/20210331/images/large/jm0c01882_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01882&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01458" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01458" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 53 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falsey, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessey, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Formica, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, E. E.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus infection in the elderly and high-risk adults</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1749</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa043951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1056%2FNEJMoa043951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=15858184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1749-1759&author=A.+R.+Falseyauthor=P.+A.+Hennesseyauthor=M.+A.+Formicaauthor=C.+Coxauthor=E.+E.+Walsh&title=Respiratory+syncytial+virus+infection+in+the+elderly+and+high-risk+adults&doi=10.1056%2FNEJMoa043951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus infection in elderly and high-risk adults</span></div><div class="casAuthors">Falsey, Ann R.; Hennessey, Patricia A.; Formica, Maria A.; Cox, Christopher; Walsh, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1749-1759</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Respiratory syncytial virus (RSV) is an increasingly recognized cause of illness in adults.  Data on the epidemiol. and clin. effects in community-dwelling elderly persons and high-risk adults can help in assessing the need for vaccine development.  METHODS During four consecutive winters, we evaluated all respiratory illnesses in prospective cohorts of healthy elderly patients (≥65 years of age) and high-risk adults (those with chronic heart or lung disease) and in patients hospitalized with acute cardiopulmonary conditions.  RSV infection and influenza A were diagnosed on the basis of culture, reverse-transcriptase polymerase chain reaction, and serol. studies.  RESULTS A total of 608 healthy elderly patients and 540 high-risk adults were enrolled in prospective surveillance, and 1388 hospitalized patients were enrolled.  A total of 2514 illnesses were evaluated.  RSV infection was identified in 102 patients in the prospective cohorts and 142 hospitalized patients, and influenza A was diagnosed in 44 patients in the prospective cohorts and 154 hospitalized patients.  RSV infection developed annually in 3 to 7 percent of healthy elderly patients and in 4 to 10 percent of high-risk adults.  Among healthy elderly patients, RSV infection generated fewer office visits than influenza; however, the use of health care services by high-risk adults was similar in the two groups.  In the hospitalized cohort, RSV infection and influenza A resulted in similar lengths of stay, rates of use of intensive care (15 percent and 12 percent, resp.), and mortality (8 percent and 7 percent, resp.).  On the basis of the diagnostic codes of the International Classification of Diseases, 9th Revision, Clin. Modification at discharge, RSV infection accounted for 10.6 percent of hospitalizations for pneumonia, 11.4 percent for chronic obstructive pulmonary disease, 5.4 percent for congestive heart failure, and 7.2 percent for asthma.  CONCLUSIONS RSV infection is an important illness in elderly and high-risk adults, with a disease burden similar to that of nonpandemic influenza A in a population in which the prevalence of vaccination for influenza is high.  An effective RSV vaccine may offer benefits for these adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC4DLnaPCjP7Vg90H21EOLACvtfcHk0livJqxsQcCGvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsr8%253D&md5=84051565564c0794974fde0b28a0e887</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa043951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa043951%26sid%3Dliteratum%253Aachs%26aulast%3DFalsey%26aufirst%3DA.%2BR.%26aulast%3DHennessey%26aufirst%3DP.%2BA.%26aulast%3DFormica%26aufirst%3DM.%2BA.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DWalsh%26aufirst%3DE.%2BE.%26atitle%3DRespiratory%2520syncytial%2520virus%2520infection%2520in%2520the%2520elderly%2520and%2520high-risk%2520adults%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D1749%26epage%3D1759%26doi%3D10.1056%2FNEJMoa043951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simoes, E. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhi, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessner, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polack, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balsells, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acacio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguayo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alassani, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awori, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azziz-Baumgartner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggett, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmaseda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barahona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basnet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassat, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basualdo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigogo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bont, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breiman, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carosone-Link, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chipeta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clara, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Cuellar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, D.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash-yandag, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deloria-Knoll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dherani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eap, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebruke, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echavarria, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Freitas Lázaro Emediato, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasce, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feikin, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groome, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halasa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirve, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homaira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howie, S. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jara, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jroundi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartasasmita, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khuri-Bulos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotloff, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucero, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucion, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupisan, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcone, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCracken, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mejia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moisi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraleda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munywoki, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutyara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicol, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nokes, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nymadawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Costa Oliveira, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshitani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranhos-Baccalà, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picot, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakoto-Andrianarivelo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russomando, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salimi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawatwong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheltema, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweiger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidenberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strand, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutanto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapia, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamthitiwat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waicharoen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watthanaworawit, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, L.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zar, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, H.</span></span> <span> </span><span class="NLM_article-title">Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">946</span>– <span class="NLM_lpage">958</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)30938-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2FS0140-6736%2817%2930938-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=28689664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BC1cjlslKluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=946-958&author=T.+Shiauthor=D.+A.+McAllisterauthor=K.+L.+O%E2%80%99Brienauthor=E.+A.+F.+Simoesauthor=S.+A.+Madhiauthor=B.+D.+Gessnerauthor=F.+P.+Polackauthor=E.+Balsellsauthor=S.+Acacioauthor=C.+Aguayoauthor=I.+Alassaniauthor=A.+Aliauthor=M.+Antonioauthor=S.+Awasthiauthor=J.+O.+Aworiauthor=E.+Azziz-Baumgartnerauthor=H.+C.+Baggettauthor=V.+L.+Baillieauthor=A.+Balmasedaauthor=A.+Barahonaauthor=S.+Basnetauthor=Q.+Bassatauthor=W.+Basualdoauthor=G.+Bigogoauthor=L.+Bontauthor=R.+F.+Breimanauthor=W.+A.+Brooksauthor=S.+Broorauthor=N.+Bruceauthor=D.+Brudenauthor=P.+Buchyauthor=S.+Campbellauthor=P.+Carosone-Linkauthor=M.+Chadhaauthor=J.+Chipetaauthor=M.+Chouauthor=W.+Claraauthor=C.+Cohenauthor=E.+de+Cuellarauthor=D.-A.+Dangauthor=B.+Dash-yandagauthor=M.+Deloria-Knollauthor=M.+Dheraniauthor=T.+Eapauthor=B.+E.+Ebrukeauthor=M.+Echavarriaauthor=C.+C.+de+Freitas+L%C3%A1zaro+Emediatoauthor=R.+A.+Fasceauthor=D.+R.+Feikinauthor=L.+Fengauthor=A.+Gentileauthor=A.+Gordonauthor=D.+Goswamiauthor=S.+Goyetauthor=M.+Groomeauthor=N.+Halasaauthor=S.+Hirveauthor=N.+Homairaauthor=S.+R.+C.+Howieauthor=J.+Jaraauthor=I.+Jroundiauthor=C.+B.+Kartasasmitaauthor=N.+Khuri-Bulosauthor=K.+L.+Kotloffauthor=A.+Krishnanauthor=R.+Libsterauthor=O.+Lopezauthor=M.+G.+Luceroauthor=F.+Lucionauthor=S.+P.+Lupisanauthor=D.+N.+Marconeauthor=J.+P.+McCrackenauthor=M.+Mejiaauthor=J.+C.+Moisiauthor=J.+M.+Montgomeryauthor=D.+P.+Mooreauthor=C.+Moraledaauthor=J.+Moyesauthor=P.+Munywokiauthor=K.+Mutyaraauthor=M.+P.+Nicolauthor=D.+J.+Nokesauthor=P.+Nymadawaauthor=M.+T.+da+Costa+Oliveiraauthor=H.+Oshitaniauthor=N.+Pandeyauthor=G.+Paranhos-Baccal%C3%A0author=L.+N.+Phillipsauthor=V.+S.+Picotauthor=M.+Rahmanauthor=M.+Rakoto-Andrianariveloauthor=Z.+A.+Rasmussenauthor=B.+A.+Rathauthor=A.+Robinsonauthor=C.+Romeroauthor=G.+Russomandoauthor=V.+Salimiauthor=P.+Sawatwongauthor=N.+Scheltemaauthor=B.+Schweigerauthor=J.+A.+G.+Scottauthor=P.+Seidenbergauthor=K.+Shenauthor=R.+Singletonauthor=V.+Sotomayorauthor=T.+A.+Strandauthor=A.+Sutantoauthor=M.+Syllaauthor=M.+D.+Tapiaauthor=S.+Thamthitiwatauthor=E.+D.+Thomasauthor=R.+Tokarzauthor=C.+Turnerauthor=M.+Venterauthor=S.+Waicharoenauthor=J.+Wangauthor=W.+Watthanaworawitauthor=L.-M.+Yoshidaauthor=H.+Yuauthor=H.+J.+Zarauthor=H.+Campbellauthor=H.+Nair&title=Global%2C+regional%2C+and+national+disease+burden+estimates+of+acute+lower+respiratory+infections+due+to+respiratory+syncytial+virus+in+young+children+in+2015%3A+a+systematic+review+and+modelling+study&doi=10.1016%2FS0140-6736%2817%2930938-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study</span></div><div class="casAuthors">Shi Ting; Balsells Evelyn; Campbell Stuart; Campbell Harry; McAllister David A; O'Brien Katherine L; Deloria-Knoll Maria; Simoes Eric A F; Madhi Shabir A; Groome Michelle; Moore David P; Gessner Bradford D; Moisi Jennifer C; Polack Fernando P; Acacio Sozinho; Aguayo Claudia; Sotomayor Viviana; Alassani Issifou; Ali Asad; Antonio Martin; Ebruke Bernard E; Awasthi Shally; Pandey Nitin; Awori Juliet O; Azziz-Baumgartner Eduardo; Baggett Henry C; Baillie Vicky L; Balmaseda Angel; Barahona Alfredo; Basnet Sudha; Bassat Quique; Basualdo Wilma; Bigogo Godfrey; Bont Louis; Scheltema Nienke; Breiman Robert F; Brooks W Abdullah; Goswami Doli; Broor Shobha; Krishnan Anand; Bruce Nigel; Dherani Mukesh; Bruden Dana; Buchy Philippe; Carosone-Link Phyllis; Chadha Mandeep; Chipeta James; Chou Monidarin; Clara Wilfrido; Cohen Cheryl; Moyes Jocelyn; de Cuellar Elizabeth; Dang Duc-Anh; Dash-Yandag Budragchaagiin; Eap Tekchheng; Echavarria Marcela; Marcone Debora N; de Freitas Lazaro Emediato Carla Cecilia; da Costa Oliveira Maria Tereza; Fasce Rodrigo A; Feikin Daniel R; Feng Luzhao; Yu Hongjie; Gentile Angela; Lucion Florencia; Gordon Aubree; Goyet Sophie; Halasa Natasha; Hirve Siddhivinayak; Homaira Nusrat; Howie Stephen R C; Jara Jorge; McCracken John P; Jroundi Imane; Kartasasmita Cissy B; Mutyara Kuswandewi; Khuri-Bulos Najwa; Kotloff Karen L; Tapia Milagritos D; Libster Romina; Lopez Olga; Lucero Marilla G; Lupisan Socorro P; Mejia Mario; Montgomery Joel M; Moraleda Cinta; Munywoki Patrick; Nicol Mark P; Nokes D James; Nymadawa Pagbajabyn; Oshitani Histoshi; Paranhos-Baccala Glaucia; Picot Valentina Sanchez; Phillips Lia N; Rahman Mustafizur; Rakoto-Andrianarivelo Mala; Rasmussen Zeba A; Thomas Elizabeth D; Rath Barbara A; Robinson Annick; Romero Candice; Russomando Graciela; Salimi Vahid; Sawatwong Pongpun; Thamthitiwat Somsak; Schweiger Brunhilde; Scott J Anthony G; Seidenberg Phil; Shen Kunling; Singleton Rosalyn; Strand Tor A; Sutanto Agustinus; Sylla Mariam; Tokarz Rafal; Turner Claudia; Watthanaworawit Wanitda; Venter Marietjie; Waicharoen Sunthareeya; Wang Jianwei; Yoshida Lay-Myint; Zar Heather J; Nair Harish</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">390</span>
        (<span class="NLM_cas:issue">10098</span>),
    <span class="NLM_cas:pages">946-958</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  We have previously estimated that respiratory syncytial virus (RSV) was associated with 22% of all episodes of (severe) acute lower respiratory infection (ALRI) resulting in 55 000 to 199 000 deaths in children younger than 5 years in 2005.  In the past 5 years, major research activity on RSV has yielded substantial new data from developing countries.  With a considerably expanded dataset from a large international collaboration, we aimed to estimate the global incidence, hospital admission rate, and mortality from RSV-ALRI episodes in young children in 2015.  METHODS:  We estimated the incidence and hospital admission rate of RSV-associated ALRI (RSV-ALRI) in children younger than 5 years stratified by age and World Bank income regions from a systematic review of studies published between Jan 1, 1995, and Dec 31, 2016, and unpublished data from 76 high quality population-based studies.  We estimated the RSV-ALRI incidence for 132 developing countries using a risk factor-based model and 2015 population estimates.  We estimated the in-hospital RSV-ALRI mortality by combining in-hospital case fatality ratios with hospital admission estimates from hospital-based (published and unpublished) studies.  We also estimated overall RSV-ALRI mortality by identifying studies reporting monthly data for ALRI mortality in the community and RSV activity.  FINDINGS:  We estimated that globally in 2015, 33·1 million (uncertainty range [UR] 21·6-50·3) episodes of RSV-ALRI, resulted in about 3·2 million (2·7-3·8) hospital admissions, and 59 600 (48 000-74 500) in-hospital deaths in children younger than 5 years.  In children younger than 6 months, 1·4 million (UR 1·2-1·7) hospital admissions, and 27 300 (UR 20 700-36 200) in-hospital deaths were due to RSV-ALRI.  We also estimated that the overall RSV-ALRI mortality could be as high as 118 200 (UR 94 600-149 400).  Incidence and mortality varied substantially from year to year in any given population.  INTERPRETATION:  Globally, RSV is a common cause of childhood ALRI and a major cause of hospital admissions in young children, resulting in a substantial burden on health-care services.  About 45% of hospital admissions and in-hospital deaths due to RSV-ALRI occur in children younger than 6 months.  An effective maternal RSV vaccine or monoclonal antibody could have a substantial effect on disease burden in this age group.  FUNDING:  The Bill & Melinda Gates Foundation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT1wEfflojsmwxyojvcjibhfW6udTcc2eYuy2jAeKzJ6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjlslKluw%253D%253D&md5=e31889022b79f89577df68e5c4fa2788</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2930938-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252930938-8%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DT.%26aulast%3DMcAllister%26aufirst%3DD.%2BA.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DK.%2BL.%26aulast%3DSimoes%26aufirst%3DE.%2BA.%2BF.%26aulast%3DMadhi%26aufirst%3DS.%2BA.%26aulast%3DGessner%26aufirst%3DB.%2BD.%26aulast%3DPolack%26aufirst%3DF.%2BP.%26aulast%3DBalsells%26aufirst%3DE.%26aulast%3DAcacio%26aufirst%3DS.%26aulast%3DAguayo%26aufirst%3DC.%26aulast%3DAlassani%26aufirst%3DI.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DAntonio%26aufirst%3DM.%26aulast%3DAwasthi%26aufirst%3DS.%26aulast%3DAwori%26aufirst%3DJ.%2BO.%26aulast%3DAzziz-Baumgartner%26aufirst%3DE.%26aulast%3DBaggett%26aufirst%3DH.%2BC.%26aulast%3DBaillie%26aufirst%3DV.%2BL.%26aulast%3DBalmaseda%26aufirst%3DA.%26aulast%3DBarahona%26aufirst%3DA.%26aulast%3DBasnet%26aufirst%3DS.%26aulast%3DBassat%26aufirst%3DQ.%26aulast%3DBasualdo%26aufirst%3DW.%26aulast%3DBigogo%26aufirst%3DG.%26aulast%3DBont%26aufirst%3DL.%26aulast%3DBreiman%26aufirst%3DR.%2BF.%26aulast%3DBrooks%26aufirst%3DW.%2BA.%26aulast%3DBroor%26aufirst%3DS.%26aulast%3DBruce%26aufirst%3DN.%26aulast%3DBruden%26aufirst%3DD.%26aulast%3DBuchy%26aufirst%3DP.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DCarosone-Link%26aufirst%3DP.%26aulast%3DChadha%26aufirst%3DM.%26aulast%3DChipeta%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DM.%26aulast%3DClara%26aufirst%3DW.%26aulast%3DCohen%26aufirst%3DC.%26aulast%3Dde%2BCuellar%26aufirst%3DE.%26aulast%3DDang%26aufirst%3DD.-A.%26aulast%3DDash-yandag%26aufirst%3DB.%26aulast%3DDeloria-Knoll%26aufirst%3DM.%26aulast%3DDherani%26aufirst%3DM.%26aulast%3DEap%26aufirst%3DT.%26aulast%3DEbruke%26aufirst%3DB.%2BE.%26aulast%3DEchavarria%26aufirst%3DM.%26aulast%3Dde%2BFreitas%2BL%25C3%25A1zaro%2BEmediato%26aufirst%3DC.%2BC.%26aulast%3DFasce%26aufirst%3DR.%2BA.%26aulast%3DFeikin%26aufirst%3DD.%2BR.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DGentile%26aufirst%3DA.%26aulast%3DGordon%26aufirst%3DA.%26aulast%3DGoswami%26aufirst%3DD.%26aulast%3DGoyet%26aufirst%3DS.%26aulast%3DGroome%26aufirst%3DM.%26aulast%3DHalasa%26aufirst%3DN.%26aulast%3DHirve%26aufirst%3DS.%26aulast%3DHomaira%26aufirst%3DN.%26aulast%3DHowie%26aufirst%3DS.%2BR.%2BC.%26aulast%3DJara%26aufirst%3DJ.%26aulast%3DJroundi%26aufirst%3DI.%26aulast%3DKartasasmita%26aufirst%3DC.%2BB.%26aulast%3DKhuri-Bulos%26aufirst%3DN.%26aulast%3DKotloff%26aufirst%3DK.%2BL.%26aulast%3DKrishnan%26aufirst%3DA.%26aulast%3DLibster%26aufirst%3DR.%26aulast%3DLopez%26aufirst%3DO.%26aulast%3DLucero%26aufirst%3DM.%2BG.%26aulast%3DLucion%26aufirst%3DF.%26aulast%3DLupisan%26aufirst%3DS.%2BP.%26aulast%3DMarcone%26aufirst%3DD.%2BN.%26aulast%3DMcCracken%26aufirst%3DJ.%2BP.%26aulast%3DMejia%26aufirst%3DM.%26aulast%3DMoisi%26aufirst%3DJ.%2BC.%26aulast%3DMontgomery%26aufirst%3DJ.%2BM.%26aulast%3DMoore%26aufirst%3DD.%2BP.%26aulast%3DMoraleda%26aufirst%3DC.%26aulast%3DMoyes%26aufirst%3DJ.%26aulast%3DMunywoki%26aufirst%3DP.%26aulast%3DMutyara%26aufirst%3DK.%26aulast%3DNicol%26aufirst%3DM.%2BP.%26aulast%3DNokes%26aufirst%3DD.%2BJ.%26aulast%3DNymadawa%26aufirst%3DP.%26aulast%3Dda%2BCosta%2BOliveira%26aufirst%3DM.%2BT.%26aulast%3DOshitani%26aufirst%3DH.%26aulast%3DPandey%26aufirst%3DN.%26aulast%3DParanhos-Baccal%25C3%25A0%26aufirst%3DG.%26aulast%3DPhillips%26aufirst%3DL.%2BN.%26aulast%3DPicot%26aufirst%3DV.%2BS.%26aulast%3DRahman%26aufirst%3DM.%26aulast%3DRakoto-Andrianarivelo%26aufirst%3DM.%26aulast%3DRasmussen%26aufirst%3DZ.%2BA.%26aulast%3DRath%26aufirst%3DB.%2BA.%26aulast%3DRobinson%26aufirst%3DA.%26aulast%3DRomero%26aufirst%3DC.%26aulast%3DRussomando%26aufirst%3DG.%26aulast%3DSalimi%26aufirst%3DV.%26aulast%3DSawatwong%26aufirst%3DP.%26aulast%3DScheltema%26aufirst%3DN.%26aulast%3DSchweiger%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DJ.%2BA.%2BG.%26aulast%3DSeidenberg%26aufirst%3DP.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DSingleton%26aufirst%3DR.%26aulast%3DSotomayor%26aufirst%3DV.%26aulast%3DStrand%26aufirst%3DT.%2BA.%26aulast%3DSutanto%26aufirst%3DA.%26aulast%3DSylla%26aufirst%3DM.%26aulast%3DTapia%26aufirst%3DM.%2BD.%26aulast%3DThamthitiwat%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DE.%2BD.%26aulast%3DTokarz%26aufirst%3DR.%26aulast%3DTurner%26aufirst%3DC.%26aulast%3DVenter%26aufirst%3DM.%26aulast%3DWaicharoen%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWatthanaworawit%26aufirst%3DW.%26aulast%3DYoshida%26aufirst%3DL.-M.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DZar%26aufirst%3DH.%2BJ.%26aulast%3DCampbell%26aufirst%3DH.%26aulast%3DNair%26aufirst%3DH.%26atitle%3DGlobal%252C%2520regional%252C%2520and%2520national%2520disease%2520burden%2520estimates%2520of%2520acute%2520lower%2520respiratory%2520infections%2520due%2520to%2520respiratory%2520syncytial%2520virus%2520in%2520young%2520children%2520in%25202015%253A%2520a%2520systematic%2520review%2520and%2520modelling%2520study%26jtitle%3DLancet%26date%3D2017%26volume%3D390%26spage%3D946%26epage%3D958%26doi%3D10.1016%2FS0140-6736%2817%2930938-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Feltes, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondheimer, H. M.</span></span> <span> </span><span class="NLM_article-title">Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1471</span>– <span class="NLM_lpage">1480</span>, <span class="refDoi"> DOI: 10.1517/14712598.7.9.1471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1517%2F14712598.7.9.1471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=17727335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2sXps1Wnsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1471-1480&issue=9&author=T.+F.+Feltesauthor=H.+M.+Sondheimer&title=Palivizumab+and+the+prevention+of+respiratory+syncytial+virus+illness+in+pediatric+patients+with+congenital+heart+disease&doi=10.1517%2F14712598.7.9.1471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease</span></div><div class="casAuthors">Feltes, Timothy F.; Sondheimer, Henry M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1471-1480</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Respiratory syncytial virus (RSV) is a significant pathogen for infants and children with congenital heart disease.  Non-sustained immunity and failure to develop an effective vaccine has steered RSV management toward a passive immunotherapy strategy in at-risk children.  Palivizumab is a humanized murine monoclonal antibody targeting the RSV envelope F glycoprotein.  In a Phase III clin. trial palivizumab significantly reduced RSV hospitalization in children with significant congenital heart disease and was proven to be safe.  Palivizumab is one of the first monoclonal antibodies to significantly impact a pediatric disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYl03zv6kWuLVg90H21EOLACvtfcHk0liBkMWaIW3zIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXps1Wnsb8%253D&md5=48c600df4bf1fbd64e784d794e1af2a3</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1517%2F14712598.7.9.1471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.7.9.1471%26sid%3Dliteratum%253Aachs%26aulast%3DFeltes%26aufirst%3DT.%2BF.%26aulast%3DSondheimer%26aufirst%3DH.%2BM.%26atitle%3DPalivizumab%2520and%2520the%2520prevention%2520of%2520respiratory%2520syncytial%2520virus%2520illness%2520in%2520pediatric%2520patients%2520with%2520congenital%2520heart%2520disease%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2007%26volume%3D7%26issue%3D9%26spage%3D1471%26epage%3D1480%26doi%3D10.1517%2F14712598.7.9.1471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viboud, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringholz, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abedi, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brammer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shay, D. K.</span></span> <span> </span><span class="NLM_article-title">Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1427</span>– <span class="NLM_lpage">1436</span>, <span class="refDoi"> DOI: 10.1093/cid/cis211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1093%2Fcid%2Fcis211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=22495079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BC38rkt1GitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2012&pages=1427-1436&author=H.+Zhouauthor=W.+W.+Thompsonauthor=C.+G.+Viboudauthor=C.+M.+Ringholzauthor=P.-Y.+Chengauthor=C.+Steinerauthor=G.+R.+Abediauthor=L.+J.+Andersonauthor=L.+Brammerauthor=D.+K.+Shay&title=Hospitalizations+associated+with+influenza+and+respiratory+syncytial+virus+in+the+United+States%2C+1993%E2%80%932008&doi=10.1093%2Fcid%2Fcis211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008</span></div><div class="casAuthors">Zhou Hong; Thompson William W; Viboud Cecile G; Ringholz Corinne M; Cheng Po-Yung; Steiner Claudia; Abedi Glen R; Anderson Larry J; Brammer Lynnette; Shay David K</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1427-36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Age-specific comparisons of influenza and respiratory syncytial virus (RSV) hospitalization rates can inform prevention efforts, including vaccine development plans.  Previous US studies have not estimated jointly the burden of these viruses using similar data sources and over many seasons.  METHODS:  We estimated influenza and RSV hospitalizations in 5 age categories (<1, 1-4, 5-49, 50-64, and ≥65 years) with data for 13 states from 1993-1994 through 2007-2008.  For each state and age group, we estimated the contribution of influenza and RSV to hospitalizations for respiratory and circulatory disease by using negative binomial regression models that incorporated weekly influenza and RSV surveillance data as covariates.  RESULTS:  Mean rates of influenza and RSV hospitalizations were 63.5 (95% confidence interval [CI], 37.5-237) and 55.3 (95% CI, 44.4-107) per 100000 person-years, respectively.  The highest hospitalization rates for influenza were among persons aged ≥65 years (309/100000; 95% CI, 186-1100) and those aged <1 year (151/100000; 95% CI, 151-660).  For RSV, children aged <1 year had the highest hospitalization rate (2350/100000; 95% CI, 2220-2520) followed by those aged 1-4 years (178/100000; 95% CI, 155-230).  Age-standardized annual rates per 100000 person-years varied substantially for influenza (33-100) but less for RSV (42-77).  CONCLUSIONS:  Overall US hospitalization rates for influenza and RSV are similar; however, their age-specific burdens differ dramatically.  Our estimates are consistent with those from previous studies focusing either on influenza or RSV.  Our approach provides robust national comparisons of hospitalizations associated with these 2 viral respiratory pathogens by age group and over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzhkrglS1cIxWfpMXQLRstfW6udTcc2eaB6u48wQNxJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rkt1GitA%253D%253D&md5=0cd99de3701b6283121ecfcbdf49ce1e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcis211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcis211%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DW.%2BW.%26aulast%3DViboud%26aufirst%3DC.%2BG.%26aulast%3DRingholz%26aufirst%3DC.%2BM.%26aulast%3DCheng%26aufirst%3DP.-Y.%26aulast%3DSteiner%26aufirst%3DC.%26aulast%3DAbedi%26aufirst%3DG.%2BR.%26aulast%3DAnderson%26aufirst%3DL.%2BJ.%26aulast%3DBrammer%26aufirst%3DL.%26aulast%3DShay%26aufirst%3DD.%2BK.%26atitle%3DHospitalizations%2520associated%2520with%2520influenza%2520and%2520respiratory%2520syncytial%2520virus%2520in%2520the%2520United%2520States%252C%25201993%25E2%2580%25932008%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D54%26spage%3D1427%26epage%3D1436%26doi%3D10.1093%2Fcid%2Fcis211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Yarza, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mejias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramilo, O.</span></span> <span> </span><span class="NLM_article-title">The association between respiratory syncytial virus infection and the development of childhood asthma</span>. <i>Journal of Pediatric Infectious Disease</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1097/INF.0b013e3180618c42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1097%2FINF.0b013e3180618c42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=17848887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BD2srjvVSnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=733-739&author=E.+G.+Perez-Yarzaauthor=A.+Morenoauthor=P.+Lazaroauthor=A.+Mejiasauthor=O.+Ramilo&title=The+association+between+respiratory+syncytial+virus+infection+and+the+development+of+childhood+asthma&doi=10.1097%2FINF.0b013e3180618c42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature</span></div><div class="casAuthors">Perez-Yarza Eduardo G; Moreno Antonio; Lazaro Pablo; Mejias Asuncion; Ramilo Octavio</div><div class="citationInfo"><span class="NLM_cas:title">The Pediatric infectious disease journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">733-9</span>
        ISSN:<span class="NLM_cas:issn">0891-3668</span>.
    </div><div class="casAbstract">BACKGROUND:  The relation between early respiratory syncytial virus (RSV) infection and later emergence of episodes of wheezing/asthma remains a subject of debate.  We carried out a systematic review of studies of the association between RSV infection in the first 36 months of life and the subsequent development of asthma/bronchial hyperreactivity.  METHODS:  A literature search for original studies on RSV respiratory infection published in English or Spanish over the last 21 years was conducted in the bibliographic databases Medline, Embase, and Indice Medico Espanol, and in the Cochrane library.  Articles were included if they described original studies of confirmed RSV infection in children under 3 years of age, and had defined outcome variables.  The methodologic quality of articles included in the review was evaluated according to the Hadorn criteria.  RESULTS:  The review included 12 original articles that respond to the research question.  The studies evaluated showed that RSV lower respiratory tract infection is associated with an increased risk for subsequent development of asthma/recurrent wheezing, and that this association becomes progressively smaller with increasing age.  CONCLUSION:  On the basis of this systematic review of the literature, it can be concluded that a significant association exists between RSV infection in childhood and the long-term development of subsequent episodes of recurrent wheezing or asthma.  However, the methodologic quality of the articles evaluated is limited, and hence additional studies are needed, ideally, with specific therapeutic interventions aimed at reducing RSV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFb2bX3_5oohpyrDyM_m9cfW6udTcc2eaB6u48wQNxJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srjvVSnug%253D%253D&md5=e89f361d225f377e9ec63f9847f56262</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1097%2FINF.0b013e3180618c42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FINF.0b013e3180618c42%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Yarza%26aufirst%3DE.%2BG.%26aulast%3DMoreno%26aufirst%3DA.%26aulast%3DLazaro%26aufirst%3DP.%26aulast%3DMejias%26aufirst%3DA.%26aulast%3DRamilo%26aufirst%3DO.%26atitle%3DThe%2520association%2520between%2520respiratory%2520syncytial%2520virus%2520infection%2520and%2520the%2520development%2520of%2520childhood%2520asthma%26jtitle%3DJournal%2520of%2520Pediatric%2520Infectious%2520Disease%26date%3D2007%26volume%3D26%26spage%3D733%26epage%3D739%26doi%3D10.1097%2FINF.0b013e3180618c42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mac, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchesne-Belanger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, B.</span></span> <span> </span><span class="NLM_article-title">Cost-effectiveness of palivizumab for respiratory syncytial irus: a systematic review</span>. <i>Pediatrics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>143</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e20184064</span>, <span class="refDoi"> DOI: 10.1542/peds.2018-4064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1542%2Fpeds.2018-4064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=31040196" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2019&pages=e20184064&issue=5&author=S.+Macauthor=A.+Sumnerauthor=S.+Duchesne-Belangerauthor=R.+Stirlingauthor=M.+Tunisauthor=B.+Sander&title=Cost-effectiveness+of+palivizumab+for+respiratory+syncytial+irus%3A+a+systematic+review&doi=10.1542%2Fpeds.2018-4064"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1542%2Fpeds.2018-4064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1542%252Fpeds.2018-4064%26sid%3Dliteratum%253Aachs%26aulast%3DMac%26aufirst%3DS.%26aulast%3DSumner%26aufirst%3DA.%26aulast%3DDuchesne-Belanger%26aufirst%3DS.%26aulast%3DStirling%26aufirst%3DR.%26aulast%3DTunis%26aufirst%3DM.%26aulast%3DSander%26aufirst%3DB.%26atitle%3DCost-effectiveness%2520of%2520palivizumab%2520for%2520respiratory%2520syncytial%2520irus%253A%2520a%2520systematic%2520review%26jtitle%3DPediatrics%26date%3D2019%26volume%3D143%26issue%3D5%26spage%3De20184064%26doi%3D10.1542%2Fpeds.2018-4064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wainwright, C.</span></span> <span> </span><span class="NLM_article-title">Acute viral bronchiolitis in children – a very common condition with few therapeutic options</span>. <i>Paediatr. Respir. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.prrv.2009.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2Fj.prrv.2009.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=20113991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252Fotlyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=39-45&issue=1&author=C.+Wainwright&title=Acute+viral+bronchiolitis+in+children+%E2%80%93+a+very+common+condition+with+few+therapeutic+options&doi=10.1016%2Fj.prrv.2009.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Acute viral bronchiolitis in children- a very common condition with few therapeutic options</span></div><div class="casAuthors">Wainwright Claire</div><div class="citationInfo"><span class="NLM_cas:title">Paediatric respiratory reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-45; quiz 45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute viral bronchiolitis remains a cause of substantial morbidity and health care costs in young infants.  It is the most common lower respiratory tract condition and most common reason for admission to hospital in infants.  Many respiratory viruses have been associated with acute viral bronchiolitis although respiratory syncytial virus (RSV) remains the most frequently identified virus.  Most infants have a mild self limiting illness while others have more severe illness and require hospital admission and some will need ventilatory support.  Differences in innate immune function in response to the respiratory viral insult as well as differences in the geometry of the airways may explain some of the variability in clinical pattern.  Young age and history of prematurity remain the most important risk factors although male gender, indigenous status, exposure to tobacco smoke, poor socioeconomic factors and associated co-morbidities such as chronic lung disease and congenital heart disease increase the risks of more severe illness.  Supportive therapy remains the major treatment option as no specific treatments to date have been shown to provide clinically important benefits except for inhaled hypertonic saline.  Prophylaxis of high risk infants with palivizumab should be considered although the cost effectiveness is still unclear.  Many questions remain regarding optimal management approaches for infants requiring hospitalisation with bronchiolitis including use of nasogastric feeding, the optimal role of supplemental oxygen, optimal use of hypertonic saline and the role of combinations of therapies, the use of heliox or modern physiotherapy approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjYoMkmkNtP-Lt9HypzAgQfW6udTcc2eZKO1zH-O2Brrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252Fotlyhsw%253D%253D&md5=ef94d9327375911261d3d3cf730c66bd</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2Fj.prrv.2009.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prrv.2009.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DWainwright%26aufirst%3DC.%26atitle%3DAcute%2520viral%2520bronchiolitis%2520in%2520children%2520%25E2%2580%2593%2520a%2520very%2520common%2520condition%2520with%2520few%2520therapeutic%2520options%26jtitle%3DPaediatr.%2520Respir.%2520Rev.%26date%3D2010%26volume%3D11%26issue%3D1%26spage%3D39%26epage%3D45%26doi%3D10.1016%2Fj.prrv.2009.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Empey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peebles, R. S.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolls, J. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic advances in the treatment and prevention of respiratory syncytial virus</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1258</span>– <span class="NLM_lpage">1267</span>, <span class="refDoi"> DOI: 10.1086/651603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1086%2F651603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=20235830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVehtL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=1258-1267&issue=9&author=K.+M.+Empeyauthor=R.+S.+Peeblesauthor=J.+K.+Kolls&title=Pharmacologic+advances+in+the+treatment+and+prevention+of+respiratory+syncytial+virus&doi=10.1086%2F651603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic advances in the treatment and prevention of respiratory syncytial virus</span></div><div class="casAuthors">Empey, Kerry M.; Peebles, R. Stokes, Jr.; Kolls, Jay K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1258-1267</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">A review.  Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus (RSV).  Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children.  Ribavirin is approved for treatment of severe RSV disease; however, its effectiveness in improving outcomes is questionable.  During the past 40 years, many obstacles have delayed the development of safe and effective vaccines and treatment regimens.  This article reviews these obstacles and presents the novel development strategies used to overcome many of them.  Also discussed are promising new antiviral treatment candidates and their assocd. mechanism of action, the significant advances made in vaccine development, and exciting, new studies directed at improving outcomes through pharmacol. manipulation of the host response to RSV disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowVNHvx4G3Z7Vg90H21EOLACvtfcHk0ljoQiYVzUOvSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVehtL3N&md5=f5b23cc6db487b8e50ceb7379cdd107f</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1086%2F651603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F651603%26sid%3Dliteratum%253Aachs%26aulast%3DEmpey%26aufirst%3DK.%2BM.%26aulast%3DPeebles%26aufirst%3DR.%2BS.%26aulast%3DKolls%26aufirst%3DJ.%2BK.%26atitle%3DPharmacologic%2520advances%2520in%2520the%2520treatment%2520and%2520prevention%2520of%2520respiratory%2520syncytial%2520virus%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2010%26volume%3D50%26issue%3D9%26spage%3D1258%26epage%3D1267%26doi%3D10.1086%2F651603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collins, P. L.</span></span> <span> </span><span class="NLM_article-title">Respiratory Syncytial Virus—Human (Paramyxoviridae)</span>. In  <i>Encyclopedia of Virology</i>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, G.</span>, <span class="NLM_string-name">Robert, G. W.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Oxford, U.K.</span>, <span class="NLM_year">1999</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1006%2Frwvi.1999.0246" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&author=P.+L.+Collinsauthor=G.+Allan&author=G.+W.+Robert&title=Encyclopedia+of+Virology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1006%2Frwvi.1999.0246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1006%252Frwvi.1999.0246%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DP.%2BL.%26atitle%3DRespiratory%2520Syncytial%2520Virus%25E2%2580%2594Human%2520%2528Paramyxoviridae%2529%26btitle%3DEncyclopedia%2520of%2520Virology%26aulast%3DAllan%26aufirst%3DG.%26pub%3DElsevier%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hacking, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hull, J.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus--viral biology and the host response</span>. <i>J. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1053/jinf.2002.1015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1053%2Fjinf.2002.1015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=12217726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BD38vlvFKqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=18-24&author=D.+Hackingauthor=J.+Hull&title=Respiratory+syncytial+virus%2D%2Dviral+biology+and+the+host+response&doi=10.1053%2Fjinf.2002.1015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus--viral biology and the host response</span></div><div class="casAuthors">Hacking D; Hull J</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of infection</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-24</span>
        ISSN:<span class="NLM_cas:issn">0163-4453</span>.
    </div><div class="casAbstract">Respiratory syncytial virus (RSV) is the most important cause of respiratory tract infection in infants.  We have an incomplete understanding of the reasons why some infants are more severely affected by RSV than others.  There is no effective antiviral treatment for the infection.  Advances in our understanding of the biology of RSV, particularly in relation to the attachment protein G and the fusion protein F, have revealed potential targets for new antiviral therapies and vaccine development.  In response to RSV infection an intense inflammatory response is triggered, mediated initially by the infected airway epithelial cells.  Cell mediated responses are important in controlling the extent of infection and in viral clearance.  Humoral responses are important in protection.  There is early evidence that genetic variation of the host response can influence the outcome of RSV-induced bronchiolitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSLUItxgiDFScuCWE5mhx1RfW6udTcc2eZKO1zH-O2Brrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vlvFKqtw%253D%253D&md5=d6cb630e5400cdec66aca9d1b0026573</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1053%2Fjinf.2002.1015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fjinf.2002.1015%26sid%3Dliteratum%253Aachs%26aulast%3DHacking%26aufirst%3DD.%26aulast%3DHull%26aufirst%3DJ.%26atitle%3DRespiratory%2520syncytial%2520virus--viral%2520biology%2520and%2520the%2520host%2520response%26jtitle%3DJ.%2520Infect.%26date%3D2002%26volume%3D45%26spage%3D18%26epage%3D24%26doi%3D10.1053%2Fjinf.2002.1015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cockerill, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, J. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, N.</span></span> <span> </span><span class="NLM_article-title">State of the art in respiratory syncytial virus drug discovery and development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3206</span>– <span class="NLM_lpage">3227</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01361</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01361" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFeisrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3206-3227&author=G.+S.+Cockerillauthor=J.+A.+D.+Goodauthor=N.+Mathews&title=State+of+the+art+in+respiratory+syncytial+virus+drug+discovery+and+development&doi=10.1021%2Facs.jmedchem.8b01361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">State of the Art in Respiratory Syncytial Virus Drug Discovery and Development</span></div><div class="casAuthors">Cockerill, G. Stuart; Good, James A. D.; Mathews, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3206-3227</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Respiratory syncytial virus (RSV) is a globally prevalent viral infection with limited treatment options which hospitalizes millions each year.  Treatment options have been limited to palivizumab, a monoclonal antibody, approved for prophylaxis in high-risk infants and ribavirin with very limited efficacy and significant safety concerns.  This Perspective surveys the range of direct acting antiviral agents (DAAs) that target key steps in the viral life cycle.  A no. of approaches to DAAs have produced landmark clin. studies over the past few years, notably in fusion and nucleoside inhibitors, and an update of the clin. status of these compds. is provided.  Non-nucleoside inhibitors of replication are reviewed in addn. to inhibitors of other mechanisms, notably the RSV N and G proteins.  This article will provide an informative perspective of the current status of drug discovery targeted at providing an effective therapy for RSV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogooGT67MNJLVg90H21EOLACvtfcHk0lixkC0nP8GXNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFeisrnP&md5=b52538dbb8d747951846fc831eb67c1c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01361%26sid%3Dliteratum%253Aachs%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DGood%26aufirst%3DJ.%2BA.%2BD.%26aulast%3DMathews%26aufirst%3DN.%26atitle%3DState%2520of%2520the%2520art%2520in%2520respiratory%2520syncytial%2520virus%2520drug%2520discovery%2520and%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3206%26epage%3D3227%26doi%3D10.1021%2Facs.jmedchem.8b01361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, J.</span>; <span class="NLM_string-name">Cockerill, S. G.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of RSV604</span>. In  <i>Antiviral Drugs: From Basic Discovery Through Clinical Trials</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmierski, W. M.</span></span>, Ed.; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1002%2F9780470929353.ch26" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Chapman&author=S.+G.+Cockerillauthor=W.+M.+Kazmierski&title=Antiviral+Drugs%3A+From+Basic+Discovery+Through+Clinical+Trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2F9780470929353.ch26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470929353.ch26%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520RSV604%26btitle%3DAntiviral%2520Drugs%253A%2520From%2520Basic%2520Discovery%2520Through%2520Clinical%2520Trials%26aulast%3DKazmierski%26aufirst%3DW.%2BM.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaglioni-Weinlich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambkin-Williams, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Riordan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toback, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span> <span> </span><span class="NLM_article-title">Oral GS-5806 Activity in a respiratory syncytial virus challenge study</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1401184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1056%2FNEJMoa1401184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=25140957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Cjsb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=711-722&author=J.+P.+DeVincenzoauthor=R.+J.+Whitleyauthor=R.+L.+Mackmanauthor=C.+Scaglioni-Weinlichauthor=L.+Harrisonauthor=E.+Farrellauthor=S.+McBrideauthor=R.+Lambkin-Williamsauthor=R.+Jordanauthor=Y.+Xinauthor=S.+Ramanathanauthor=T.+O%E2%80%99Riordanauthor=S.+A.+Lewisauthor=X.+Liauthor=S.+L.+Tobackauthor=S.-L.+Linauthor=J.+W.+Chien&title=Oral+GS-5806+Activity+in+a+respiratory+syncytial+virus+challenge+study&doi=10.1056%2FNEJMoa1401184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Oral GS-5806 activity in a respiratory syncytial virus challenge study</span></div><div class="casAuthors">DeVincenzo, John P.; Whitley, Richard J.; Mackman, Richard L.; Scaglioni-Weinlich, Cecilia; Harrison, Lisa; Farrell, Eric; McBride, Stephen; Lambkin-Williams, Robert; Jordan, Robert; Xin, Yan; Ramanathan, Srini; O'Riordan, Thomas; Lewis, Sandra A.; Li, Xiaoming; Toback, Seth L.; Lin, Shao-Lee; Chien, Jason W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-722, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Respiratory syncytial virus (RSV) is a common cause of infant hospitalizations and is increasingly recognized as a cause of considerable morbidity and mortality.  No accepted antiviral treatment exists.  Methods: We conducted a double-blind, placebo-controlled study of GS-5806, an oral RSV-entry inhibitor, in healthy adults who received a clin. challenge strain of RSV intranasally.  Participants were monitored for 12 days.  At the time of a pos. test for RSV infection or 5 days after inoculation, whichever occurred first, participants were randomly assigned to receive GS-5806 or placebo in one of seven sequential cohorts.  Cohorts 1 to 4 received a first dose of 50 mg of GS-5806 and then 25 mg daily for the next 4 days, cohort 5 received a first dose of 50 mg and then 25 mg daily for the next 2 days, cohort 6 received one 100-mg dose, and cohort 7 received a first dose of 10 mg and then 5 mg daily for the next 4 days.  Dose selection for cohorts 5, 6, and 7 occurred after an interim anal. of data for cohorts 1 to 4.  The primary end point was the area under the curve (AUC) for the viral load, which was assessed after administration of the first dose through the 12th day after inoculation.  Secondary end points were mucus wt. and symptom scores.  Results: Among the 54 participants in cohorts 1 to 4 who were infected with RSV, active treatment was assocd. with a lower viral load (adjusted mean, 250.7 vs. 757.7 log10 plaque-forming-unit equiv. [PFUe] × hours per mL; P<0.001), lower total mucus wt. (mean, 6.9 g vs. 15.1 g; P = 0.03), and a lower AUC for the change from baseline in symptom scores (adjusted mean, -20.2 vs. 204.9 × hours; P = 0.005).  The results were similar in cohorts 5, 6, and 7.  Adverse events, including low neutrophil counts and increased levels of alanine aminotransferase, were more common among participants receiving GS-5806.  Conclusions: Treatment with GS-5806 reduced the viral load and the severity of clin. disease in a challenge study of healthy adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqxDrIVO5aQLVg90H21EOLACvtfcHk0lixkC0nP8GXNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Cjsb7O&md5=72276739a80d55a732269359e338fb95</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1401184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1401184%26sid%3Dliteratum%253Aachs%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26aulast%3DWhitley%26aufirst%3DR.%2BJ.%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DScaglioni-Weinlich%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DL.%26aulast%3DFarrell%26aufirst%3DE.%26aulast%3DMcBride%26aufirst%3DS.%26aulast%3DLambkin-Williams%26aufirst%3DR.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DXin%26aufirst%3DY.%26aulast%3DRamanathan%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DS.%2BA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DToback%26aufirst%3DS.%2BL.%26aulast%3DLin%26aufirst%3DS.-L.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26atitle%3DOral%2520GS-5806%2520Activity%2520in%2520a%2520respiratory%2520syncytial%2520virus%2520challenge%2520study%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D711%26epage%3D722%26doi%3D10.1056%2FNEJMoa1401184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinón-Torres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntjens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remmerie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vingerhoets, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrero, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epalza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, safety and antiviral effects of multiple doses of the respiratory syncytial virus fusion protein inhibitor, JNJ-53718678, in infants hospitalized with RSV infection: A randomized phase 1b study</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">e594</span>– <span class="NLM_lpage">e603</span>, <span class="refDoi"> DOI: 10.1093/cid/ciaa283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1093%2Fcid%2Fciaa283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=32201897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnvFCiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2020&pages=e594-e603&author=F.+Martin%C3%B3n-Torresauthor=S.+Ruschauthor=D.+Huntjensauthor=B.+Remmerieauthor=J.+Vingerhoetsauthor=K.+McFadyenauthor=F.+Ferreroauthor=E.+Baraldiauthor=P.+Rojoauthor=C.+Epalzaauthor=M.+Stevens&title=Pharmacokinetics%2C+safety+and+antiviral+effects+of+multiple+doses+of+the+respiratory+syncytial+virus+fusion+protein+inhibitor%2C+JNJ-53718678%2C+in+infants+hospitalized+with+RSV+infection%3A+A+randomized+phase+1b+study&doi=10.1093%2Fcid%2Fciaa283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics, safety, and antiviral effects of multiple doses of the respiratory syncytial virus (RSV) fusion protein inhibitor, JNJ-53718678, in infants hospitalized with RSV infection: a randomized phase 1b study</span></div><div class="casAuthors">Martinon-Torres, Federico; Rusch, Sarah; Huntjens, Dymphy; Remmerie, Bart; Vingerhoets, Johan; McFadyen, Katie; Ferrero, Fernando; Baraldi, Eugenio; Rojo, Pablo; Epalza, Cristina; Stevens, Marita</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e594-e603</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">This phase 1b study evaluated the pharmacokinetics, safety, and antiviral effects of the respiratory syncytial virus (RSV)-specific fusion inhibitor JNJ-53718678 (JNJ-8678) in hospitalized RSV-infected patients aged > 1 to ≤24 mo.  Patients categorized by age (cohort 1: ≥6 to ≤24 mo; cohort 2: ≥3 to < 6 mo; cohort 3: > 1 to < 3 mo) were randomized to oral JNJ-8678 or placebo once daily for 7 days.  Dose increases followed data review committee recommendations (cohort 1: 2/6/8/9 mg/kg; cohort 2: 1.5/4.5/6 mg/kg; cohort 3: 1/3/5 mg/kg).  Cohort 1 included a 9 mg/kg dose, as target exposures were not reached at lower doses.  Sparse pharmacokinetic samples were assessed using population pharmacokinetics modeling.  Safety was assessed by adverse events (AEs), lab. tests, and electrocardiograms.  To assess antiviral effects, RSV RNA viral load from nasal swabs was quantified over time using reverse-transcription quant. polymerase chain reaction.  Patients received JNJ-8678 (n = 37) or placebo (n = 7).  Pharmacokinetic parameters were similar at the highest doses for cohorts 1-3 (area under the plasma concn.-time curve from time of administration up to 24 h postdosing at day 7: 35 840, 34 980, and 39 627 ng × hour/mL, resp.).  Two grade 3 AEs were reported (both bronchiolitis; 1 JNJ-8678, 1 placebo), reported as serious AEs; all other AEs were grade 1 or 2.  Two addnl. serious AEs were reported (rhinitis [JNJ-8678]; pneumonia [placebo]).  No deaths, grade 4 AEs, or AEs leading to discontinuation were reported.  Median RSV viral load change from baseline in JNJ-8678 vs placebo by day 3 was -1.98 vs -0.32 log10 copies/mL.  In RSV-infected infants, JNJ-8678 was well tolerated.  Target exposures were reached and antiviral activity was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX-d7X2g1ye7Vg90H21EOLACvtfcHk0lgPZZZttFJZzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnvFCiug%253D%253D&md5=aa4018755fbc161c817b0abf56a2de8a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciaa283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciaa283%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%25C3%25B3n-Torres%26aufirst%3DF.%26aulast%3DRusch%26aufirst%3DS.%26aulast%3DHuntjens%26aufirst%3DD.%26aulast%3DRemmerie%26aufirst%3DB.%26aulast%3DVingerhoets%26aufirst%3DJ.%26aulast%3DMcFadyen%26aufirst%3DK.%26aulast%3DFerrero%26aufirst%3DF.%26aulast%3DBaraldi%26aufirst%3DE.%26aulast%3DRojo%26aufirst%3DP.%26aulast%3DEpalza%26aufirst%3DC.%26aulast%3DStevens%26aufirst%3DM.%26atitle%3DPharmacokinetics%252C%2520safety%2520and%2520antiviral%2520effects%2520of%2520multiple%2520doses%2520of%2520the%2520respiratory%2520syncytial%2520virus%2520fusion%2520protein%2520inhibitor%252C%2520JNJ-53718678%252C%2520in%2520infants%2520hospitalized%2520with%2520RSV%2520infection%253A%2520A%2520randomized%2520phase%25201b%2520study%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2020%26volume%3D71%26spage%3De594%26epage%3De603%26doi%3D10.1093%2Fcid%2Fciaa283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of ziresovir as a potent, selective, and orally bioavailable respiratory syncytial virus fusion protein inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6003</span>– <span class="NLM_lpage">6014</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00654</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00654" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKksb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6003-6014&author=X.+Zhengauthor=L.+Gaoauthor=L.+Wangauthor=C.+Liangauthor=B.+Wangauthor=Y.+Liuauthor=S.+Fengauthor=B.+Zhangauthor=M.+Zhouauthor=X.+Yuauthor=K.+Xiangauthor=L.+Chenauthor=T.+Guoauthor=H.+C.+Shenauthor=G.+Zouauthor=J.+Z.+Wuauthor=H.+Yun&title=Discovery+of+ziresovir+as+a+potent%2C+selective%2C+and+orally+bioavailable+respiratory+syncytial+virus+fusion+protein+inhibitor&doi=10.1021%2Facs.jmedchem.9b00654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor</span></div><div class="casAuthors">Zheng, Xiufang; Gao, Lu; Wang, Lisha; Liang, Chungen; Wang, Baoxia; Liu, Yongfu; Feng, Song; Zhang, Bo; Zhou, Mingwei; Yu, Xin; Xiang, Kunlun; Chen, Li; Guo, Tao; Shen, Hong C.; Zou, Gang; Wu, Jim Zhen; Yun, Hongying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6003-6014</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ziresovir (RO-0529, AK0529) is reported here for the first time as a promising respiratory syncytial virus (RSV) fusion (F) protein inhibitor that currently is in advanced clin. trials.  This article reports the discovery of ziresovir as a potent, selective and orally bioavailable RSV F protein inhibitor, and highlights the efforts of rational drug design, lead optimization, improvement of in vitro and in vivo anti-RSV activities and pharmacokinetics in animal species.  Ziresovir demonstrates single-digit nM EC50 potency against lab. strains as well as clin. isolates of RSV in cellular assays, and more than one log viral load redn. in BALB/c mouse model of RSV viral infection.  Ziresovir was proven to be a specific RSV F protein inhibitor by identification of drug resistant mutations of D486N, D489V, and D489Y in RSV F protein and the inhibition of RSV F protein-induced cell-cell fusion in cellular assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon6vNioogRRrVg90H21EOLACvtfcHk0lgPZZZttFJZzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKksb7K&md5=6d21370486436746fff2710b9a38b545</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00654%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DZou%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DYun%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520ziresovir%2520as%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520respiratory%2520syncytial%2520virus%2520fusion%2520protein%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6003%26epage%3D6014%26doi%3D10.1021%2Facs.jmedchem.9b00654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coakley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenhoor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eze, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noulin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvathova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adda, N.</span></span> <span> </span><span class="NLM_article-title">LB6. EDP-938, a novel RSV N-inhibitor, administered once or twice daily was safe and demonstrated robust antiviral and clinical efficacy in a healthy volunteer challenge study</span>. <i>Open Forum Infectious Diseases</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">S995</span>, <span class="refDoi"> DOI: 10.1093/ofid/ofz415.2489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1093%2Fofid%2Fofz415.2489" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=S995&author=E.+Coakleyauthor=A.+Ahmadauthor=K.+Larsonauthor=T.+McClureauthor=K.+Linauthor=K.+Linauthor=K.+Tenhoorauthor=K.+Ezeauthor=N.+Noulinauthor=V.+Horvathovaauthor=B.+Murrayauthor=M.+Bailletauthor=J.+Moriauthor=N.+Adda&title=LB6.+EDP-938%2C+a+novel+RSV+N-inhibitor%2C+administered+once+or+twice+daily+was+safe+and+demonstrated+robust+antiviral+and+clinical+efficacy+in+a+healthy+volunteer+challenge+study&doi=10.1093%2Fofid%2Fofz415.2489"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fofid%2Fofz415.2489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fofid%252Fofz415.2489%26sid%3Dliteratum%253Aachs%26aulast%3DCoakley%26aufirst%3DE.%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DLarson%26aufirst%3DK.%26aulast%3DMcClure%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DTenhoor%26aufirst%3DK.%26aulast%3DEze%26aufirst%3DK.%26aulast%3DNoulin%26aufirst%3DN.%26aulast%3DHorvathova%26aufirst%3DV.%26aulast%3DMurray%26aufirst%3DB.%26aulast%3DBaillet%26aufirst%3DM.%26aulast%3DMori%26aufirst%3DJ.%26aulast%3DAdda%26aufirst%3DN.%26atitle%3DLB6.%2520EDP-938%252C%2520a%2520novel%2520RSV%2520N-inhibitor%252C%2520administered%2520once%2520or%2520twice%2520daily%2520was%2520safe%2520and%2520demonstrated%2520robust%2520antiviral%2520and%2520clinical%2520efficacy%2520in%2520a%2520healthy%2520volunteer%2520challenge%2520study%26jtitle%3DOpen%2520Forum%2520Infectious%2520Diseases%26date%3D2019%26volume%3D6%26spage%3DS995%26doi%3D10.1093%2Fofid%2Fofz415.2489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combrink, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiello, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovesi, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venables, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulgeze, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trehan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span> <span> </span><span class="NLM_article-title">Orally active fusion inhibitor of respiratory syncytial virus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1128/AAC.48.2.413-422.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1128%2FAAC.48.2.413-422.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=14742189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFGls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=413-422&author=C.+Cianciauthor=K.+L.+Yuauthor=K.+Combrinkauthor=N.+Sinauthor=B.+Pearceauthor=A.+Wangauthor=R.+Civielloauthor=S.+Vossauthor=G.+Luoauthor=K.+Kadowauthor=E.+V.+Genovesiauthor=B.+Venablesauthor=H.+Gulgezeauthor=A.+Trehanauthor=J.+Jamesauthor=L.+Lambauthor=I.+Medinaauthor=J.+Roachauthor=Z.+Yangauthor=L.+Zadjuraauthor=R.+Colonnoauthor=J.+Clarkauthor=N.+Meanwellauthor=M.+Krystal&title=Orally+active+fusion+inhibitor+of+respiratory+syncytial+virus&doi=10.1128%2FAAC.48.2.413-422.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Orally active fusion inhibitor of respiratory syncytial virus</span></div><div class="casAuthors">Cianci, Christopher; Yu, Kuo-Long; Combrink, Keith; Sin, Ny; Pearce, Bradley; Wang, Alan; Civiello, Rita; Voss, Stacey; Luo, Guangxiang; Kadow, Kathy; Genovesi, Eugene V.; Venables, Brian; Gulgeze, Hatice; Trehan, Ashok; James, Jennifer; Lamb, Lucinda; Medina, Ivette; Roach, Julia; Yang, Zheng; Zadjura, Lisa; Colonno, Richard; Clark, Junius; Meanwell, Nicholas; Krystal, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">413-422</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">BMS-433771 was a potent inhibitor of respiratory syncytial virus (RSV) replication in vitro.  It exhibited excellent potency against multiple lab. and clin. isolates of both group A and B viruses, with an av. 50% effective concn. of 20 nM.  Mechanism-of-action studies demonstrated that BMS-433771 inhibits the fusion of lipid membranes during both the early virus entry stage and late-stage syncytium formation.  After isolation of resistant viruses, resistance was mapped to a series of single amino acid mutations in the F1 subunit of the fusion protein.  Upon oral administration, BMS-433771 was able to reduce viral titers in the lungs of mice infected with RSV.  This new class of orally active RSV fusion inhibitors offers potential for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR6fq_vRrsObVg90H21EOLACvtfcHk0lhi3xpIKOer0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFGls7Y%253D&md5=790547babc0dcd1a87b628897ac68663</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.2.413-422.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.2.413-422.2004%26sid%3Dliteratum%253Aachs%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DK.%2BL.%26aulast%3DCombrink%26aufirst%3DK.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DPearce%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DCiviello%26aufirst%3DR.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DKadow%26aufirst%3DK.%26aulast%3DGenovesi%26aufirst%3DE.%2BV.%26aulast%3DVenables%26aufirst%3DB.%26aulast%3DGulgeze%26aufirst%3DH.%26aulast%3DTrehan%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DRoach%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DOrally%2520active%2520fusion%2520inhibitor%2520of%2520respiratory%2520syncytial%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D413%26epage%3D422%26doi%3D10.1128%2FAAC.48.2.413-422.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vendeville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooymans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwanten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Berg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battles, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raboisson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonckers, T. H. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2- yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3- dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a potent and orally bioavailable fusion inhibitor of respiratory syncytial virus</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8046</span>– <span class="NLM_lpage">8058</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00226</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00226" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsVCqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8046-8058&author=S.+Vendevilleauthor=A.+Tahriauthor=L.+Huauthor=S.+Deminauthor=L.+Cooymansauthor=A.+Vosauthor=L.+Kwantenauthor=J.+Van+den%0ABergauthor=M.+B.+Battlesauthor=J.+S.+McLellanauthor=A.+Koulauthor=P.+Raboissonauthor=D.+Roymansauthor=T.+H.+M.+Jonckers&title=Discovery+of+3-%28%7B5-chloro-1-%5B3-%28methylsulfonyl%29propyl%5D-1H-indol-2-+yl%7Dmethyl%29-1-%282%2C2%2C2-trifluoroethyl%29-1%2C3-+dihydro-2H-imidazo%5B4%2C5-c%5Dpyridin-2-one+%28JNJ-53718678%29%2C+a+potent+and+orally+bioavailable+fusion+inhibitor+of+respiratory+syncytial+virus&doi=10.1021%2Facs.jmedchem.0c00226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus</span></div><div class="casAuthors">Vendeville, Sandrine; Tahri, Abdellah; Hu, Lili; Demin, Samuel; Cooymans, Ludwig; Vos, Ann; Kwanten, Leen; Van den Berg, Joke; Battles, Michael B.; McLellan, Jason S.; Koul, Anil; Raboisson, Pierre; Roymans, Dirk; Jonckers, Tim H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8046-8058</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a seasonal virus that infects the lungs and airways of 64 million children and adults every year.  It is a major cause of acute lower respiratory tract infection and is assocd. with significant morbidity and mortality.  Despite the large medical and economic burden, treatment options for RSV-assocd. bronchiolitis and pneumonia are limited and mainly consist of supportive care.  This publication covers the medicinal chem. efforts resulting in the identification of JNJ-53718678 (I), an orally bioavailable RSV inhibitor that was shown to be efficacious in a phase 2a challenge study in healthy adult subjects and that is currently being evaluated in hospitalized infants and adults.  Cocrystal structures of several new derivs. helped in rationalizing some of the structure-activity relationship (SAR) trends obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Q5vkPwsLFLVg90H21EOLACvtfcHk0lhi3xpIKOer0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsVCqtr0%253D&md5=cf57029d4262a269c1afeab3db55d4b2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00226%26sid%3Dliteratum%253Aachs%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DDemin%26aufirst%3DS.%26aulast%3DCooymans%26aufirst%3DL.%26aulast%3DVos%26aufirst%3DA.%26aulast%3DKwanten%26aufirst%3DL.%26aulast%3DVan%2Bden%2BBerg%26aufirst%3DJ.%26aulast%3DBattles%26aufirst%3DM.%2BB.%26aulast%3DMcLellan%26aufirst%3DJ.%2BS.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DJonckers%26aufirst%3DT.%2BH.%2BM.%26atitle%3DDiscovery%2520of%25203-%2528%257B5-chloro-1-%255B3-%2528methylsulfonyl%2529propyl%255D-1H-indol-2-%2520yl%257Dmethyl%2529-1-%25282%252C2%252C2-trifluoroethyl%2529-1%252C3-%2520dihydro-2H-imidazo%255B4%252C5-c%255Dpyridin-2-one%2520%2528JNJ-53718678%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520fusion%2520inhibitor%2520of%2520respiratory%2520syncytial%2520virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8046%26epage%3D8058%26doi%3D10.1021%2Facs.jmedchem.0c00226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-L.</span>; <span class="NLM_string-name">Civiello, R. L.</span>; <span class="NLM_string-name">Combrink, K. D.</span>; <span class="NLM_string-name">Gulgeze, H. B.</span>; <span class="NLM_string-name">Sin, N.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Meanwell, N.</span>; <span class="NLM_string-name">Venables, B. L.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Pearce, B. C.</span>; <span class="NLM_string-name">Yin, Z.</span>; <span class="NLM_string-name">Thuring, J. W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Substituted 2-Methyl-benzimidazole Antiviral Agents</span>. <span class="NLM_patent">WO/2002/062290</span>, Nov 21, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=K.-L.+Yu&author=R.+L.+Civiello&author=K.+D.+Combrink&author=H.+B.+Gulgeze&author=N.+Sin&author=X.+Wang&author=N.+Meanwell&author=B.+L.+Venables&author=Y.+Zhang&author=B.+C.+Pearce&author=Z.+Yin&author=J.+W.+Thuring&title=Heterocyclic+Substituted+2-Methyl-benzimidazole+Antiviral+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.-L.%26atitle%3DHeterocyclic%2520Substituted%25202-Methyl-benzimidazole%2520Antiviral%2520Agents%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-L.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Sun, Y.</span>; <span class="NLM_string-name">Cianci, C.</span>; <span class="NLM_string-name">Thuring, J. W.</span>; <span class="NLM_string-name">Combrink, K.</span>; <span class="NLM_string-name">Meanwell, N.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Civiello, R. L.</span></span> <span> </span><span class="NLM_article-title">Substituted 2-Methyl-benzimidazole Respiratory Syncytial Virus Antiviral Agents</span>. <span class="NLM_patent">WO/2003/053344</span>, July 03, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=K.-L.+Yu&author=X.+Wang&author=Y.+Sun&author=C.+Cianci&author=J.+W.+Thuring&author=K.+Combrink&author=N.+Meanwell&author=Y.+Zhang&author=R.+L.+Civiello&title=Substituted+2-Methyl-benzimidazole+Respiratory+Syncytial+Virus+Antiviral+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.-L.%26atitle%3DSubstituted%25202-Methyl-benzimidazole%2520Respiratory%2520Syncytial%2520Virus%2520Antiviral%2520Agents%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blade, H.</span>; <span class="NLM_string-name">Carron, E.</span>; <span class="NLM_string-name">Jackson, H.</span>; <span class="NLM_string-name">Lumley, J.</span>; <span class="NLM_string-name">Pilkington, C.</span>; <span class="NLM_string-name">Tomkinson, G.</span>; <span class="NLM_string-name">Thomas, A.</span>; <span class="NLM_string-name">Warne, J.</span></span> <span> </span><span class="NLM_article-title">Benzimidazole Derivatives and their use as Antiviral Agents</span>. <span class="NLM_patent">WO/2010/103306</span>, Sep 17, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=H.+Blade&author=E.+Carron&author=H.+Jackson&author=J.+Lumley&author=C.+Pilkington&author=G.+Tomkinson&author=A.+Thomas&author=J.+Warne&title=Benzimidazole+Derivatives+and+their+use+as+Antiviral+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlade%26aufirst%3DH.%26atitle%3DBenzimidazole%2520Derivatives%2520and%2520their%2520use%2520as%2520Antiviral%2520Agents%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0li7C_XRSiaeyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span>; <span class="NLM_string-name">Price, D. A.</span></span> <span> </span><span class="NLM_article-title">Chapter 23: Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks</span>. In  <i>Annu. Rep. Med. Chem.</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>, <span class="NLM_year">2010</span>; Vol.  <span class="NLM_volume">45</span>, pp  <span class="NLM_fpage">380</span>– <span class="NLM_lpage">391</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=380-391&author=M.+P.+Edwards&author=D.+A.+Priceauthor=J.+E.+Macor&title=Annu.+Rep.+Med.+Chem."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DChapter%252023%253A%2520Role%2520of%2520Physicochemical%2520Properties%2520and%2520Ligand%2520Lipophilicity%2520Efficiency%2520in%2520Addressing%2520Drug%2520Safety%2520Risks%26btitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26pub%3DAcademic%2520Press%26date%3D2010%26volume%3D45%26spage%3D380%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span> For a comparable study
in the benzimidazolone series of fusion inhibitors, see:<span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiello, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combrink, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulgeze, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venables, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalterio, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dando, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovesi, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.11.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2Fj.bmcl.2006.11.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=17169560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12rtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=895-901&author=K.-L.+Yuauthor=N.+Sinauthor=R.+L.+Civielloauthor=X.+A.+Wangauthor=K.+D.+Combrinkauthor=H.+B.+Gulgezeauthor=B.+L.+Venablesauthor=J.J.+K.+Wrightauthor=R.+A.+Dalterioauthor=L.+Zadjuraauthor=A.+Marinoauthor=S.+Dandoauthor=C.+D%E2%80%99Arienzoauthor=K.+F.+Kadowauthor=C.+W.+Cianciauthor=Z.+Liauthor=J.+Clarkeauthor=E.+V.+Genovesiauthor=I.+Medinaauthor=L.+Lambauthor=R.+J.+Colonnoauthor=Z.+Yangauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Respiratory+syncytial+virus+fusion+inhibitors.+Part+4%3A+Optimization+for+oral+bioavailability&doi=10.1016%2Fj.bmcl.2006.11.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability</span></div><div class="casAuthors">Yu, Kuo-Long; Sin, Ny; Civiello, Rita L.; Wang, X. Alan; Combrink, Keith D.; Gulgeze, H. Belgin; Venables, Brian L.; Wright, J. J. Kim; Dalterio, Richard A.; Zadjura, Lisa; Marino, Anthony; Dando, Sandra; D'Arienzo, Celia; Kadow, Kathleen F.; Cianci, Christopher W.; Li, Zhufang; Clarke, Junius; Genovesi, Eugene V.; Medina, Ivette; Lamb, Lucinda; Colonno, Richard J.; Yang, Zheng; Krystal, Mark; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-901</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of benzimidazole-based inhibitors of respiratory syncytial virus (RSV) fusion were optimized for antiviral potency, membrane permeability and metabolic stability in human liver microsomes.  1-Cyclopropyl-1,3-dihydro-3-[[1-(4-hydroxybutyl)-1H-benzimidazol-2-yl]methyl]-2H-imidazo[4,5-c]pyridin-2-one (I, BMS-433771) was identified as a potent RSV inhibitor demonstrating good bioavailability in the mouse, rat, dog and cynomolgus monkey that demonstrated antiviral activity in the BALB/c and cotton rat models of infection following oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwTTCqYL_6iLVg90H21EOLACvtfcHk0li7C_XRSiaeyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12rtLc%253D&md5=1df6d784bda1cabee0b57b799f1f165e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.11.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.11.063%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BA.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DGulgeze%26aufirst%3DH.%2BB.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DWright%26aufirst%3DJ.J.%2BK.%26aulast%3DDalterio%26aufirst%3DR.%2BA.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DDando%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DCianci%26aufirst%3DC.%2BW.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DClarke%26aufirst%3DJ.%26aulast%3DGenovesi%26aufirst%3DE.%2BV.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DRespiratory%2520syncytial%2520virus%2520fusion%2520inhibitors.%2520Part%25204%253A%2520Optimization%2520for%2520oral%2520bioavailability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D895%26epage%3D901%26doi%3D10.1016%2Fj.bmcl.2006.11.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mansoor, A.</span>; <span class="NLM_string-name">Mahabadi, N.</span></span> Vol. of Distribution. [Updated 2020 Jul 27]. In: StatPearls [Internet]. <span class="NLM_publisher-name">StatPearls Publishing</span>: <span class="NLM_publisher-loc">Treasure Island, FL</span>, <span class="NLM_year">2020</span>. Available from: <a href="https://www.ncbi.nlm.nih.gov/books/NBK545280/" class="extLink">https://www.ncbi.nlm.nih.gov/books/NBK545280/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Mansoor%2C+A.%3B+Mahabadi%2C+N.+Vol.+of+Distribution.+%5BUpdated+2020+Jul+27%5D.+In%3A+StatPearls+%5BInternet%5D.+StatPearls+Publishing%3A+Treasure+Island%2C+FL%2C+2020.+Available+from%3A+https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK545280%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMansoor%26aufirst%3DA.%26pub%3DStatPearls%2520Publishing%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pope, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loewen, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkinson, A.</span></span> <span> </span><span class="NLM_article-title">Lysosomal sequestration (trapping) of lipophilic amine (cationic ampiphillic drugs) in immortalized human hepatocytes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">905</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.050054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1124%2Fdmd.112.050054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=23378628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkslSktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=897-905&author=F.+Kazmiauthor=T.+Hensleyauthor=C.+Popeauthor=R.+S.+Funkauthor=G.+J.+Loewenauthor=D.+B.+Buckleyauthor=A.+Parkinson&title=Lysosomal+sequestration+%28trapping%29+of+lipophilic+amine+%28cationic+ampiphillic+drugs%29+in+immortalized+human+hepatocytes&doi=10.1124%2Fdmd.112.050054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells)</span></div><div class="casAuthors">Kazmi, Faraz; Hensley, Tiffini; Pope, Chad; Funk, Ryan S.; Loewen, Greg J.; Buckley, David B.; Parkinson, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">897-905</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Lipophilic (logP > 1) and amphiphilic drugs (also known as cationic amphiphilic drugs) with ionizable amines (pKa > 6) can accumulate in lysosomes, a process known as lysosomal trapping.  This process contributes to presystemic extn. by lysosome-rich organs (such as liver and lung), which, together with the binding of lipophilic amines to phospholipids, contributes to the large vol. of distribution characteristic of numerous cardiovascular and central nervous system drugs.  Accumulation of lipophilic amines in lysosomes has been implicated as a cause of phospholipidosis.  Furthermore, elevated levels of lipophilic amines in lysosomes can lead to high organ-to-blood ratios of drugs that can be mistaken for active drug transport.  In the present study, we describe an in vitro fluorescence-based method (using the lysosome-specific probe LysoTracker Red) to identify lysosomotropic agents in immortalized hepatocytes (Fa2N-4 cells).  A diverse set of compds. with various physicochem. properties were tested, such as acids, bases, and zwitterions.  In addn., the partitioning of the nonlysosomotropic atorvastatin (an anion) and the lysosomotropics propranolol and imipramine (cations) were quantified in Fa2N-4 cells in the presence or absence of various lysosomotropic or nonlysosomotropic agents and inhibitors of lysosomal sequestration (NH4Cl, nigericin, and monensin).  Cellular partitioning of propranolol and imipramine was markedly reduced (by at least 40%) by NH4Cl, nigericin, or monensin.  Lysosomotropic drugs also inhibited the partitioning of propranolol by at least 50%, with imipramine partitioning affected to a lesser degree.  This study demonstrates the usefulness of immortalized hepatocytes (Fa2N-4 cells) for detg. the lysosomal sequestration of lipophilic amines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa8mAg9M-HcrVg90H21EOLACvtfcHk0li7C_XRSiaeyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkslSktLs%253D&md5=ac5dc2bb69b754f004e2e2c92e1939f7</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.050054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.050054%26sid%3Dliteratum%253Aachs%26aulast%3DKazmi%26aufirst%3DF.%26aulast%3DHensley%26aufirst%3DT.%26aulast%3DPope%26aufirst%3DC.%26aulast%3DFunk%26aufirst%3DR.%2BS.%26aulast%3DLoewen%26aufirst%3DG.%2BJ.%26aulast%3DBuckley%26aufirst%3DD.%2BB.%26aulast%3DParkinson%26aufirst%3DA.%26atitle%3DLysosomal%2520sequestration%2520%2528trapping%2529%2520of%2520lipophilic%2520amine%2520%2528cationic%2520ampiphillic%2520drugs%2529%2520in%2520immortalized%2520human%2520hepatocytes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D897%26epage%3D905%26doi%3D10.1124%2Fdmd.112.050054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Branigan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutshall, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarisky, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Vecchio, A. M.</span></span> <span> </span><span class="NLM_article-title">Use of a novel cell-based fusion reporter assay to explore the host range of human respiratory syncytial virus F protein</span>. <i>Virol. J.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1186/1743-422X-2-54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1186%2F1743-422X-2-54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=16014172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BD2MvlsVWquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=54-66&author=P.+J.+Braniganauthor=C.+Liuauthor=N.+D.+Dayauthor=L.+L.+Gutshallauthor=R.+T.+Sariskyauthor=A.+M.+Del+Vecchio&title=Use+of+a+novel+cell-based+fusion+reporter+assay+to+explore+the+host+range+of+human+respiratory+syncytial+virus+F+protein&doi=10.1186%2F1743-422X-2-54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a novel cell-based fusion reporter assay to explore the host range of human respiratory syncytial virus F protein</span></div><div class="casAuthors">Branigan Patrick J; Liu Changbao; Day Nicole D; Gutshall Lester L; Sarisky Robert T; Del Vecchio Alfred M</div><div class="citationInfo"><span class="NLM_cas:title">Virology journal</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human respiratory syncytial virus (HRSV) is an important respiratory pathogen primarily affecting infants, young children, transplant recipients and the elderly.  The F protein is the only virion envelope protein necessary and sufficient for virus replication and fusion of the viral envelope membrane with the target host cell.  During natural infection, HRSV replication is limited to respiratory epithelial cells with disseminated infection rarely, if ever, occurring even in immunocompromised patients.  However, in vitro infection of multiple human and non-human cell types other than those of pulmonary tract origin has been reported.  To better define host cell surface molecules that mediate viral entry and dissect the factors controlling permissivity for HRSV, we explored the host range of HRSV F protein mediated fusion.  Using a novel recombinant reporter gene based fusion assay, HRSV F protein was shown to mediate fusion with cells derived from a wide range of vertebrate species including human, feline, equine, canine, bat, rodent, avian, porcine and even amphibian (Xenopus).  That finding was extended using a recombinant HRSV engineered to express green fluorescent protein (GFP), to confirm that viral mRNA expression is limited in several cell types.  These findings suggest that HRSV F protein interacts with either highly conserved host cell surface molecules or can use multiple mechanisms to enter cells, and that the primary determinants of HRSV host range are at steps post-entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiHO62ol-EjIMcDoIzZtNkfW6udTcc2ebLZRhpJNuAIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MvlsVWquw%253D%253D&md5=9acc3e3dddc04007308ccd5e127cc1d1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1186%2F1743-422X-2-54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1743-422X-2-54%26sid%3Dliteratum%253Aachs%26aulast%3DBranigan%26aufirst%3DP.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DDay%26aufirst%3DN.%2BD.%26aulast%3DGutshall%26aufirst%3DL.%2BL.%26aulast%3DSarisky%26aufirst%3DR.%2BT.%26aulast%3DDel%2BVecchio%26aufirst%3DA.%2BM.%26atitle%3DUse%2520of%2520a%2520novel%2520cell-based%2520fusion%2520reporter%2520assay%2520to%2520explore%2520the%2520host%2520range%2520of%2520human%2520respiratory%2520syncytial%2520virus%2520F%2520protein%26jtitle%3DVirol.%2520J.%26date%3D2005%26volume%3D2%26spage%3D54%26epage%3D66%26doi%3D10.1186%2F1743-422X-2-54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pickles, R. J.</span></span> <span> </span><span class="NLM_article-title">Human airway epithelial cell cultures for modeling respiratory syncytial virus infection</span>. <i>Curr. Top. Microbiol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1007/978-3-642-38919-1_19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1007%2F978-3-642-38919-1_19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=24362700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BC2c3psFWltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2013&pages=371-387&author=R.+J.+Pickles&title=Human+airway+epithelial+cell+cultures+for+modeling+respiratory+syncytial+virus+infection&doi=10.1007%2F978-3-642-38919-1_19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Human airway epithelial cell cultures for modeling respiratory syncytial virus infection</span></div><div class="casAuthors">Pickles Raymond J</div><div class="citationInfo"><span class="NLM_cas:title">Current topics in microbiology and immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">371-87</span>
        ISSN:<span class="NLM_cas:issn">0070-217X</span>.
    </div><div class="casAbstract">Respiratory syncytial virus (RSV) is an important human respiratory pathogen with narrow species tropism.  Limited availability of human pathologic specimens during early RSV-induced lung disease and ethical restrictions for RSV challenge studies in the lower airways of human volunteers has slowed our understanding of how RSV causes airway disease and greatly limited the development of therapeutic strategies for reducing RSV disease burden.  Our current knowledge of RSV infection and pathology is largely based on in vitro studies using nonpolarized epithelial cell-lines grown on plastic or in vivo studies using animal models semipermissive for RSV infection.  Although these models have revealed important aspects of RSV infection, replication, and associated inflammatory responses, these models do not broadly recapitulate the early interactions and potential consequences of RSV infection of the human columnar airway epithelium in vivo.  In this chapter, the pro et contra of in vitro models of human columnar airway epithelium and their usefulness in respiratory virus pathogenesis and vaccine development studies will be discussed.  The use of such culture models to predict characteristics of RSV infection and the correlation of these findings to the human in vivo situation will likely accelerate our understanding of RSV pathogenesis potentially identifying novel strategies for limiting the severity of RSV-associated airway disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSySEeEVfogvRLDWw4HIq2sfW6udTcc2ebLZRhpJNuAIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3psFWltQ%253D%253D&md5=73e5843feb0686f2556ea317006c11e1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-38919-1_19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-38919-1_19%26sid%3Dliteratum%253Aachs%26aulast%3DPickles%26aufirst%3DR.%2BJ.%26atitle%3DHuman%2520airway%2520epithelial%2520cell%2520cultures%2520for%2520modeling%2520respiratory%2520syncytial%2520virus%2520infection%26jtitle%3DCurr.%2520Top.%2520Microbiol.%2520Immunol.%26date%3D2013%26volume%3D372%26spage%3D371%26epage%3D387%26doi%3D10.1007%2F978-3-642-38919-1_19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, G.</span></span> <span> </span><span class="NLM_article-title">Animal models of respiratory syncytial virus infection</span>. <i>Vaccine</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1016/j.vaccine.2016.11.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2Fj.vaccine.2016.11.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=27908639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKnurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=469-480&author=G.+Taylor&title=Animal+models+of+respiratory+syncytial+virus+infection&doi=10.1016%2Fj.vaccine.2016.11.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of respiratory syncytial virus infection</span></div><div class="casAuthors">Taylor, Geraldine</div><div class="citationInfo"><span class="NLM_cas:title">Vaccine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">469-480</span>CODEN:
                <span class="NLM_cas:coden">VACCDE</span>;
        ISSN:<span class="NLM_cas:issn">0264-410X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Human respiratory syncytial virus (hRSV) is a major cause of respiratory disease and hospitalisation of infants, worldwide, and is also responsible for significant morbidity in adults and excess deaths in the elderly.  There is no licensed hRSV vaccine or effective therapeutic agent.  However, there are a growing no. of hRSV vaccine candidates that have been developed targeting different populations at risk of hRSV infection.  Animal models of hRSV play an important role in the preclin. testing of hRSV vaccine candidates and although many have shown efficacy in preclin. studies, few have progressed to clin. trials or they have had only limited success.  This is, at least in part, due to the lack of animal models that fully recapitulate the pathogenesis of hRSV infection in humans.  This review summarises the strengths and limitations of animal models of hRSV, which include those in which hRSV is used to infect non-human mammalian hosts, and those in which non-human pneumoviruses, such as bovine (b)RSV and pneumonia virus of mice (PVM) are studied in their natural host.  Apart from chimpanzees, other non-human primates (NHP) are only semi-permissive for hRSV replication and exptl. infection with large doses of virus result in little or no clin. signs of disease, and generally only mild pulmonary pathol.  Other animal models such as cotton rats, mice, ferrets, guinea pigs, hamsters, chinchillas, and neonatal lambs are also only semi-permissive for hRSV.  Nevertheless, mice and cotton rats have been of value in the development of monoclonal antibody prophylaxis for infants at high risk of severe hRSV infection and have provided insights into mechanisms of immunity to and pathogenesis of hRSV.  However, the extent to which they predict hRSV vaccine efficacy and safety is unclear and several hRSV vaccine candidates that are completely protective in rodent models are poorly effective in chimpanzees and other NHP, such as African Green monkeys.  Furthermore, interpretation of findings from many rodent and NHP models of vaccine-enhanced hRSV disease has been confounded by sensitization to non-viral antigens present in the vaccine and challenge virus.  Studies of non-human pneumoviruses in their native hosts are more likely to reflect the pathogenesis of natural hRSV infection, and exptl. infection of calves with bRSV and of mice with PVM result in clin. disease and extensive pulmonary pathol.  These animal models have not only been of value in studies on mechanisms of immunity to and the pathogenesis of pneumovirus infections but have also been used to evaluate hRSV vaccine concepts.  Furthermore, the similarities between the epidemiol. of bRSV in calves and hRSV in infants and the high level of genetic and antigenic similarity between bRSV and hRSV, make the calf model of bRSV infection a relevant model for preclin. evaluation of hRSV vaccine candidates which contain proteins that are conserved between hRSV and bRSV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQGyFQHoxipLVg90H21EOLACvtfcHk0lj4iCaem_5cPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKnurnF&md5=155d24a6e65fe5d30d8fc109243969cd</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.vaccine.2016.11.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vaccine.2016.11.054%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DG.%26atitle%3DAnimal%2520models%2520of%2520respiratory%2520syncytial%2520virus%2520infection%26jtitle%3DVaccine%26date%3D2017%26volume%3D35%26spage%3D469%26epage%3D480%26doi%3D10.1016%2Fj.vaccine.2016.11.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obst-Sander, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span> <span> </span><span class="NLM_article-title">Fluorine in medicinal chemistry</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1002/cbic.200301023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1002%2Fcbic.200301023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=15122635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=637-643&author=H.-J.+B%C3%B6hmauthor=D.+Bannerauthor=S.+Bendelsauthor=M.+Kansyauthor=B.+Kuhnauthor=K.+M%C3%BCllerauthor=U.+Obst-Sanderauthor=M.+Stahl&title=Fluorine+in+medicinal+chemistry&doi=10.1002%2Fcbic.200301023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in medicinal chemistry</span></div><div class="casAuthors">Bohm Hans-Joachim; Banner David; Bendels Stefanie; Kansy Manfred; Kuhn Bernd; Muller Klaus; Obst-Sander Ulrike; Stahl Martin</div><div class="citationInfo"><span class="NLM_cas:title">Chembiochem : a European journal of chemical biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">637-43</span>
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    </div><div class="casAbstract">Fluorinated compounds are synthesized in pharmaceutical research on a routine basis and many marketed compounds contain fluorine.  The present review summarizes some of the most frequently employed strategies for using fluorine substituents in medicinal chemistry.  Quite often, fluorine is introduced to improve the metabolic stability by blocking metabolically labile sites.  However, fluorine can also be used to modulate the physicochemical properties, such as lipophilicity or basicity.  It may exert a substantial effect on the conformation of a molecule.  Increasingly, fluorine is used to enhance the binding affinity to the target protein.  Recent 3D-structure determinations of protein complexes with bound fluorinated ligands have led to an improved understanding of the nonbonding protein-ligand interactions that involve fluorine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4zDG_wo1YGtts4TFFB11gfW6udTcc2ebG6jgwtfoLSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D&md5=fa5ca2cfc278b83c80d5c96b18dfe312</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200301023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200301023%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6hm%26aufirst%3DH.-J.%26aulast%3DBanner%26aufirst%3DD.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DObst-Sander%26aufirst%3DU.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DFluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DChemBioChem%26date%3D2004%26volume%3D5%26spage%3D637%26epage%3D643%26doi%3D10.1002%2Fcbic.200301023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crippen, G. M.</span></span> <span> </span><span class="NLM_article-title">Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions</span>. <i>Jourano of Chemical Information and Computing Science</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1021/ci00053a005</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci00053a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADyaL2sXotl2htg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1987&pages=21-35&author=A.+K.+Ghoseauthor=G.+M.+Crippen&title=Atomic+physicochemical+parameters+for+three-dimensional-structure-directed+quantitative+structure-activity+relationships.+2.+Modeling+dispersive+and+hydrophobic+interactions&doi=10.1021%2Fci00053a005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships.  2.  Modeling dispersive and hydrophobic interactions</span></div><div class="casAuthors">Ghose, Arup K.; Crippen, Gordon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-35</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    </div><div class="casAbstract">At. physicochem. properties for three-dimensional-structure-directed quant. structure-activity relationships were demonstrated, and at. parameters were developed to successfully evaluate the mol. water-octanol partition coeff., which is a measure of hydrophobicity.  The at. values of molar refractivity are reported.  C, H, O, N, S, and halogens are divided into 110 atom types of which 93 at. values are evaluated from 504 mols. by using a constrained least-squares technique.  These values gave a std. deviation of 1.269 and a correlation coeff. of 0.994.  The parameters were used to predict the molar refractivities of 78 compds.  The predicted values have a std. deviation of 1.614 and a correlation coeff. of 0.994.  The degree of closeness of the LFER between the at. water-octanol partition coeffs. and molar refractivities is checked by the correlation coeff. of 89 atom types used for both the properties.  The low correlation coeff. (0.322) suggests that both parameters can be used to model the intermol. interaction.  The origin of these physicochem. properties and the types of interaction that can be modeled by these properties are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK8YlSzH7fOrVg90H21EOLACvtfcHk0liN8XhdvtUldA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXotl2htg%253D%253D&md5=a1c1f406e012ff0f059aa37d935ecc5c</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1021%2Fci00053a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci00053a005%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DCrippen%26aufirst%3DG.%2BM.%26atitle%3DAtomic%2520physicochemical%2520parameters%2520for%2520three-dimensional-structure-directed%2520quantitative%2520structure-activity%2520relationships.%25202.%2520Modeling%2520dispersive%2520and%2520hydrophobic%2520interactions%26jtitle%3DJourano%2520of%2520Chemical%2520Information%2520and%2520Computing%2520Science%26date%3D1987%26volume%3D27%26spage%3D21%26epage%3D35%26doi%3D10.1021%2Fci00053a005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combrink, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuring, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiello, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">4592</span>– <span class="NLM_lpage">4598</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.05.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2Fj.bmcl.2007.05.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=17576060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFSitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4592-4598&author=X.+A.+Wangauthor=C.+W.+Cianciauthor=K.+L.+Yuauthor=K.+D.+Combrinkauthor=J.+W.+Thuringauthor=Y.+Zhangauthor=R.+L.+Civielloauthor=K.+F.+Kadowauthor=J.+Roachauthor=Z.+Liauthor=D.+R.+Langleyauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Respiratory+syncytial+virus+fusion+inhibitors.+Part+5%3A+Optimization+of+benzimidazole+substitution+patterns+towards+derivatives+with+improved+activity&doi=10.1016%2Fj.bmcl.2007.05.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity</span></div><div class="casAuthors">Wang, Xiangdong Alan; Cianci, Christopher W.; Yu, Kuo-Long; Combrink, Keith D.; Thuring, Jan W.; Zhang, Yi; Civiello, Rita L.; Kadow, Kathleen F.; Roach, Julia; Li, Zhufang; Langley, David R.; Krystal, Mark; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4592-4598</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Extensive SAR studies and optimization of ADME properties of benzimidazol-2-one derivs. led to the identification of BMS-433771 (I) as an orally active RSV fusion inhibitor.  In order to extend the structure-activity relationships for this compd. series, substitution of the benzimidazole ring was examd. with a view to establishing addnl. productive interactions between the inhibitor and functionality present in the proposed binding pocket.  Amongst the compds. II (R1 = Br, CN, HO2C, HOCH2, H2NCH2, etc.; R2 = Me, Me2CH, H2C:CMe, Me3CO2CCH2) synthesized, the 5-aminomethyl analog II (R1 = 5-H2NCH2; R2 = Me2CH) demonstrated potent antiviral activity towards wild-type RSV and retained excellent inhibitory activity towards a virus that had been developed to express resistance to I, data consistent with an addnl. productive interaction between the inhibitor and the fusion protein target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0b3YCFITnK7Vg90H21EOLACvtfcHk0liN8XhdvtUldA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFSitLc%253D&md5=90ec7b486a272dea239d0a3b0352fbb6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.05.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.05.102%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BA.%26aulast%3DCianci%26aufirst%3DC.%2BW.%26aulast%3DYu%26aufirst%3DK.%2BL.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DThuring%26aufirst%3DJ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DRoach%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DRespiratory%2520syncytial%2520virus%2520fusion%2520inhibitors.%2520Part%25205%253A%2520Optimization%2520of%2520benzimidazole%2520substitution%2520patterns%2520towards%2520derivatives%2520with%2520improved%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4592%26epage%3D4598%26doi%3D10.1016%2Fj.bmcl.2007.05.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span> For a discussion of
SAR in the benzimidazolone series, see:<span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civiello, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trehan, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combrink, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulgeze, H.B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Respiratory syncytial inhibitors. Part 2: Benzimidazol-2-one derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1137</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.12.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2Fj.bmcl.2003.12.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=14980651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFemtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=1133-1137&author=K.-L.+Yuauthor=Y.+Zhangauthor=R.+L.+Civielloauthor=A.+K.+Trehanauthor=B.+C.+Pearceauthor=Z.+Yinauthor=K.+D.+Combrinkauthor=H.B.+Gulgezeauthor=X.+A.+Wangauthor=K.+F.+Kadowauthor=C.+W.+Cianciauthor=M.+Krystalauthor=N.+A.+Meanwell&title=Respiratory+syncytial+inhibitors.+Part+2%3A+Benzimidazol-2-one+derivatives&doi=10.1016%2Fj.bmcl.2003.12.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives</span></div><div class="casAuthors">Yu, Kuo-Long; Zhang, Yi; Civiello, Rita L.; Trehan, Ashok K.; Pearce, Bradley C.; Yin, Zhiwei; Combrink, Keith D.; Gulgeze, H. Belgin; Wang, Xiangdong Alan; Kadow, Kathleen F.; Cianci, Christopher W.; Krystal, Mark; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1133-1137</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Structure-activity relationships for a series of benzimidazol-2-one-based inhibitors of respiratory syncytial virus are described.  These studies focused on structural variation of the benzimidazol-2-one substituent, a vector inaccessible in a series of benzotriazole derivs. on which 2 is based, and revealed a broad tolerance for substituent size and functionality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK34s_9TMb7rVg90H21EOLACvtfcHk0lhhsyG7g4HjCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFemtLk%253D&md5=5f3e8aa37f3d44511dc6209280fe2573</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.12.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.12.072%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.-L.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCiviello%26aufirst%3DR.%2BL.%26aulast%3DTrehan%26aufirst%3DA.%2BK.%26aulast%3DPearce%26aufirst%3DB.%2BC.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DGulgeze%26aufirst%3DH.B.%26aulast%3DWang%26aufirst%3DX.%2BA.%26aulast%3DKadow%26aufirst%3DK.%2BF.%26aulast%3DCianci%26aufirst%3DC.%2BW.%26aulast%3DKrystal%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DRespiratory%2520syncytial%2520inhibitors.%2520Part%25202%253A%2520Benzimidazol-2-one%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D1133%26epage%3D1137%26doi%3D10.1016%2Fj.bmcl.2003.12.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotthaus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetzer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Locht, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, B.</span></span> <span> </span><span class="NLM_article-title">Analysis of highly potent amidine containing inhibitors of serine proteases and their N-hydroxylated prodrugs (amidoximes)</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.3109/14756361003733647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.3109%2F14756361003733647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=20583861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFyrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2011&pages=115-122&author=J.+Kotthausauthor=T.+Steinmetzerauthor=A.+van+de+Lochtauthor=B.+Clement&title=Analysis+of+highly+potent+amidine+containing+inhibitors+of+serine+proteases+and+their+N-hydroxylated+prodrugs+%28amidoximes%29&doi=10.3109%2F14756361003733647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of highly potent amidine containing inhibitors of serine proteases and their N-hydroxylated prodrugs (amidoximes)</span></div><div class="casAuthors">Kotthaus, Joscha; Steinmetzer, Torsten; van de Locht, Andreas; Clement, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-122</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">The development of serine protease inhibitors often results in the discovery of new lead compds. contg. strong basic amidine functions that usually suffer from poor absorption from the intestine.  In order to improve oral bioavailability of these drugs, prodrug principles such as the conversion of amidines into amidoximes may be applied.  In this work, two HPLC-based sepn. methods of serine protease inhibitors (amidines) and their N-hydroxylated prodrugs have been developed and characterized.  This was performed by evaluating 11 distinct amidine-amidoxime pairs with different physicochem. parameters (clogP: -3 to 5.1).  The HPLC methods developed allowed excellent sepn. of the compd. pairs examd.  Also, the possible selection of different sepn. techniques (i.e. adsorption- and ion-pair-chromatog.) permits universal application.  Moreover, both techniques are compatible with mass spectrometry and are superior to the previously described methods.  In summary, both HPLC methods are suitable for the sepn. of most amidoxime-prodrugs currently in clin. or preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVKaHpBogg9LVg90H21EOLACvtfcHk0lhhsyG7g4HjCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFyrsr4%253D&md5=ddd1372b994104f6740efed6300f62f2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3109%2F14756361003733647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F14756361003733647%26sid%3Dliteratum%253Aachs%26aulast%3DKotthaus%26aufirst%3DJ.%26aulast%3DSteinmetzer%26aufirst%3DT.%26aulast%3Dvan%2Bde%2BLocht%26aufirst%3DA.%26aulast%3DClement%26aufirst%3DB.%26atitle%3DAnalysis%2520of%2520highly%2520potent%2520amidine%2520containing%2520inhibitors%2520of%2520serine%2520proteases%2520and%2520their%2520N-hydroxylated%2520prodrugs%2520%2528amidoximes%2529%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2011%26volume%3D26%26spage%3D115%26epage%3D122%26doi%3D10.3109%2F14756361003733647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tahri, A.</span>; <span class="NLM_string-name">Vendeville, S. M. H.</span>; <span class="NLM_string-name">Jonckers, T. H. M.</span>; <span class="NLM_string-name">Raboisson, P. J.-M. B.</span>; <span class="NLM_string-name">Hu, L.</span>; <span class="NLM_string-name">Demin, S. D.</span>; <span class="NLM_string-name">Cooymans, L. P.</span></span> <span> </span><span class="NLM_article-title">RSV Antiviral Compounds</span>. <span class="NLM_patent">WO/2014/060411</span>, Apr 24, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=A.+Tahri&author=S.+M.+H.+Vendeville&author=T.+H.+M.+Jonckers&author=P.+J.-M.+B.+Raboisson&author=L.+Hu&author=S.+D.+Demin&author=L.+P.+Cooymans&title=RSV+Antiviral+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTahri%26aufirst%3DA.%26atitle%3DRSV%2520Antiviral%2520Compounds%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cockerill, G. S.</span>; <span class="NLM_string-name">Hanley, M. T.</span>; <span class="NLM_string-name">Mathews, N.</span>; <span class="NLM_string-name">Paradowski, M.</span>; <span class="NLM_string-name">Williams, G.</span>; <span class="NLM_string-name">Ward, S. E.</span></span> unpublished results. Reviral Ltd., Stevenage Bioscience Catalyst, Stevenage, Hertfordshire SG1 2FX, U.K.  Sussex Drug Discovery Centre, University of Sussex, Brighton, England BN1 9QJ, U.K. <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cockerill%2C+G.+S.%3B+Hanley%2C+M.+T.%3B+Mathews%2C+N.%3B+Paradowski%2C+M.%3B+Williams%2C+G.%3B+Ward%2C+S.+E.+unpublished+results.+Reviral+Ltd.%2C+Stevenage+Bioscience+Catalyst%2C+Stevenage%2C+Hertfordshire+SG1+2FX%2C+U.K.+Sussex+Drug+Discovery+Centre%2C+University+of+Sussex%2C+Brighton%2C+England+BN1+9QJ%2C+U.K.+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alber, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bithell, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chubb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockerill, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdell, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelsey, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luongo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najarro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickles, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmonds, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyms, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, K. L.</span></span> <span> </span><span class="NLM_article-title">RSV604, a novel inhibitor of respiratory syncytial virus replication</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3346</span>– <span class="NLM_lpage">3353</span>, <span class="refDoi"> DOI: 10.1128/AAC.00211-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1128%2FAAC.00211-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=17576833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVais7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=3346-3353&author=J.+Chapmanauthor=E.+Abbottauthor=D.+G.+Alberauthor=R.+C.+Baxterauthor=S.+K.+Bithellauthor=E.+A.+Hendersonauthor=M.+C.+Carterauthor=P.+Chambersauthor=A.+Chubbauthor=G.+S.+Cockerillauthor=P.+L.+Collinsauthor=V.+C.+Dowdellauthor=S.+J.+Keeganauthor=R.+D.+Kelseyauthor=M.+J.+Lockyerauthor=C.+Luongoauthor=P.+Najarroauthor=R.+J.+Picklesauthor=M.+Simmondsauthor=D.+Taylorauthor=S.+Tymsauthor=L.+J.+Wilsonauthor=K.+L.+Powell&title=RSV604%2C+a+novel+inhibitor+of+respiratory+syncytial+virus+replication&doi=10.1128%2FAAC.00211-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">RSV604, a novel inhibitor of respiratory syncytial virus replication</span></div><div class="casAuthors">Chapman, Joanna; Abbott, Elizabeth; Alber, Dagmar G.; Baxter, Robert C.; Bithell, Sian K.; Henderson, Elisa A.; Carter, Malcolm C.; Chambers, Phil; Chubb, Ann; Cockerill, G. Stuart; Collins, Peter L.; Dowdell, Verity C. L.; Keegan, Sally J.; Kelsey, Richard D.; Lockyer, Michael J.; Luongo, Cindy; Najarro, Pilar; Pickles, Raymond J.; Simmonds, Mark; Taylor, Debbie; Tyms, Stan; Wilson, Lara J.; Powell, Kenneth L.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3346-3353</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections worldwide, yet no effective vaccine or antiviral treatment is available.  Here we report the discovery and initial development of RSV604, a novel benzodiazepine with submicromolar anti-RSV activity.  It proved to be equipotent against all clin. isolates tested of both the A and B subtypes of the virus.  The compd. has a low rate of in vitro resistance development.  Sequencing revealed that the resistant virus had mutations within the nucleocapsid protein.  This is a novel mechanism of action for anti-RSV compds.  In a three-dimensional human airway epithelial cell model, RSV604 was able to pass from the basolateral side of the epithelium effectively to inhibit virus replication after mucosal inoculation.  RSV604, which is currently in phase II clin. trials, represents the first in a new class of RSV inhibitors and may have significant potential for the effective treatment of RSV disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofytd4GFiOgrVg90H21EOLACvtfcHk0liFNGyWgm460Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVais7jE&md5=6c0937ea49d9ea7beaff40bc20d911d3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1128%2FAAC.00211-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00211-07%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DJ.%26aulast%3DAbbott%26aufirst%3DE.%26aulast%3DAlber%26aufirst%3DD.%2BG.%26aulast%3DBaxter%26aufirst%3DR.%2BC.%26aulast%3DBithell%26aufirst%3DS.%2BK.%26aulast%3DHenderson%26aufirst%3DE.%2BA.%26aulast%3DCarter%26aufirst%3DM.%2BC.%26aulast%3DChambers%26aufirst%3DP.%26aulast%3DChubb%26aufirst%3DA.%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DCollins%26aufirst%3DP.%2BL.%26aulast%3DDowdell%26aufirst%3DV.%2BC.%26aulast%3DKeegan%26aufirst%3DS.%2BJ.%26aulast%3DKelsey%26aufirst%3DR.%2BD.%26aulast%3DLockyer%26aufirst%3DM.%2BJ.%26aulast%3DLuongo%26aufirst%3DC.%26aulast%3DNajarro%26aufirst%3DP.%26aulast%3DPickles%26aufirst%3DR.%2BJ.%26aulast%3DSimmonds%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DTyms%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DL.%2BJ.%26aulast%3DPowell%26aufirst%3DK.%2BL.%26atitle%3DRSV604%252C%2520a%2520novel%2520inhibitor%2520of%2520respiratory%2520syncytial%2520virus%2520replication%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D3346%26epage%3D3353%26doi%3D10.1128%2FAAC.00211-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mirabelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaspers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorissen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koukni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardiot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaltin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jochmans, D.</span></span> <span> </span><span class="NLM_article-title">Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1823</span>– <span class="NLM_lpage">1829</span>, <span class="refDoi"> DOI: 10.1093/jac/dky089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1093%2Fjac%2Fdky089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=29596680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVait70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2018&pages=1823-1829&author=C.+Mirabelliauthor=M.+Jaspersauthor=M.+Boonauthor=M.+Jorissenauthor=M.+Koukniauthor=D.+Bardiotauthor=P.+Chaltinauthor=A.+Marchandauthor=J.+Neytsauthor=D.+Jochmans&title=Differential+antiviral+activities+of+respiratory+syncytial+virus+%28RSV%29+inhibitors+in+human+airway+epithelium&doi=10.1093%2Fjac%2Fdky089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium</span></div><div class="casAuthors">Mirabelli, Carmen; Jaspers, Martine; Boon, Mieke; Jorissen, Mark; Koukni, Mohamed; Bardiot, Dorothee; Chaltin, Patrick; Marchand, Arnaud; Neyts, Johan; Jochmans, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1823-1829</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">1460-2091</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: We report the use of reconstituted 3D human airway epithelium cells (HuAECs) of bronchial origin in an air-liq. interface to study respiratory syncytial virus (RSV) infection and to assess the efficacy of RSV inhibitors in (pre-)clin. development.  Methods: HuAECs were infected with RSV-A Long strain (0.01 CCID50/cell, where CCID50 represents 50% cell culture infectious dose in HEp2 cells) on the apical compartment of the culture.  At the time of infection or at 1 or 3 days post-infection, selected inhibitors were added and refreshed daily on the basal compartment of the culture.  Viral shedding was followed up by apical washes collected daily and quantifying viral RNA by RT-qPCR.  Results: RSV-A replicates efficiently in HuAECs and viral RNA is shed forweeks after infection.  RSV infection reduces the ciliary beat frequency of the ciliated cells as of 4 days post-infection, with complete ciliary dyskinesia obsd. by day 10.  Treatmentwith RSV fusion inhibitors resulted in an antiviral effect onlywhen added at the time of infection.  In contrast, the use of replication inhibitors (both nucleoside and non-nucleoside) elicited a marked antiviral effect evenwhen the start of treatmentwas delayed until 1 day or even 3 days after infection.  Levels of the inflammation marker RANTES (mRNA) increased ∼200-fold in infected, untreated cultures (at 3weeks post-infection), but levels were comparable to those of uninfected cultures in the presence of PC786, an RSV replication inhibitor, suggesting that an efficient antiviral treatment might inhibit virus-induced inflammation in thismodel.  Conclusions: Overall, HuAECs offer a robust and physiol. relevant model to study RSV replication and to assess the efficacy of antiviral compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPbiu5779F57Vg90H21EOLACvtfcHk0liFNGyWgm460Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVait70%253D&md5=7c81e1c20009c4e8f25f02b31bf6b62e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdky089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdky089%26sid%3Dliteratum%253Aachs%26aulast%3DMirabelli%26aufirst%3DC.%26aulast%3DJaspers%26aufirst%3DM.%26aulast%3DBoon%26aufirst%3DM.%26aulast%3DJorissen%26aufirst%3DM.%26aulast%3DKoukni%26aufirst%3DM.%26aulast%3DBardiot%26aufirst%3DD.%26aulast%3DChaltin%26aufirst%3DP.%26aulast%3DMarchand%26aufirst%3DA.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DJochmans%26aufirst%3DD.%26atitle%3DDifferential%2520antiviral%2520activities%2520of%2520respiratory%2520syncytial%2520virus%2520%2528RSV%2529%2520inhibitors%2520in%2520human%2520airway%2520epithelium%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2018%26volume%3D73%26spage%3D1823%26epage%3D1829%26doi%3D10.1093%2Fjac%2Fdky089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKimm-Breschkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smout, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span> <span> </span><span class="NLM_article-title">Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1016/S0042-6822(03)00115-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2FS0042-6822%2803%2900115-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=12842618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFGmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2003&pages=275-288&author=C.+J.+Mortonauthor=R.+Cameronauthor=L.+J.+Lawrenceauthor=B.+Linauthor=M.+Loweauthor=A.+Luttickauthor=A.+Masonauthor=J.+McKimm-Breschkinauthor=M.+W.+Parkerauthor=J.+Ryanauthor=M.+Smoutauthor=J.+Sullivanauthor=S.+P.+Tuckerauthor=P.+R.+Young&title=Structural+characterization+of+respiratory+syncytial+virus+fusion+inhibitor+escape+mutants%3A+homology+model+of+the+F+protein+and+a+syncytium+formation+assay&doi=10.1016%2FS0042-6822%2803%2900115-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay</span></div><div class="casAuthors">Morton, Craig J.; Cameron, Rachel; Lawrence, Lynne J.; Lin, Bo; Lowe, Melinda; Luttick, Angela; Mason, Anthony; McKimm-Breschkin, Jenny; Parker, Michael W.; Ryan, Jane; Smout, Michael; Sullivan, Jayne; Tucker, Simon P.; Young, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-288</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a ubiquitous human pathogen and the leading cause of lower respiratory tract infections in infants.  Infection of cells and subsequent formation of syncytia occur through membrane fusion mediated by the RSV fusion protein (RSV-F).  A novel in vitro assay of recombinant RSV-F function has been devised and used to characterize a no. of escape mutants for three known inhibitors of RSV-F that have been isolated.  Homol. modeling of the RSV-F structure has been carried out on the basis of a chimera derived from the crystal structures of the RSV-F core and a fragment from the orthologous fusion protein from Newcastle disease virus (NDV).  The structure correlates well with the appearance of RSV-F in electron micrographs, and the residues identified as contributing to specific binding sites for several monoclonal antibodies are arranged in appropriate solvent-accessible clusters.  The positions of the characterized resistance mutants in the model structure identify two promising regions for the design of fusion inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriNHdqxZCrWrVg90H21EOLACvtfcHk0liFNGyWgm460Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFGmtrw%253D&md5=90ae3069ed81de9ab431da6378e18743</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2FS0042-6822%2803%2900115-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0042-6822%252803%252900115-6%26sid%3Dliteratum%253Aachs%26aulast%3DMorton%26aufirst%3DC.%2BJ.%26aulast%3DCameron%26aufirst%3DR.%26aulast%3DLawrence%26aufirst%3DL.%2BJ.%26aulast%3DLin%26aufirst%3DB.%26aulast%3DLowe%26aufirst%3DM.%26aulast%3DLuttick%26aufirst%3DA.%26aulast%3DMason%26aufirst%3DA.%26aulast%3DMcKimm-Breschkin%26aufirst%3DJ.%26aulast%3DParker%26aufirst%3DM.%2BW.%26aulast%3DRyan%26aufirst%3DJ.%26aulast%3DSmout%26aufirst%3DM.%26aulast%3DSullivan%26aufirst%3DJ.%26aulast%3DTucker%26aufirst%3DS.%2BP.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26atitle%3DStructural%2520characterization%2520of%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitor%2520escape%2520mutants%253A%2520homology%2520model%2520of%2520the%2520F%2520protein%2520and%2520a%2520syncytium%2520formation%2520assay%26jtitle%3DVirology%26date%3D2003%26volume%3D311%26spage%3D275%26epage%3D288%26doi%3D10.1016%2FS0042-6822%2803%2900115-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cianci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovesi, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadjura, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combrink, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M.</span></span> <span> </span><span class="NLM_article-title">Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2448</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1128/AAC.48.7.2448-2454.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1128%2FAAC.48.7.2448-2454.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=15215093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFWmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=2448-54&author=C.+Cianciauthor=E.+V.+Genovesiauthor=L.+Lambauthor=I.+Medinaauthor=Z.+Yangauthor=L.+Zadjuraauthor=H.+Yangauthor=C.+D%E2%80%99Arienzoauthor=N.+Sinauthor=K.+L.+Yuauthor=K.+Combrinkauthor=Z.+Liauthor=R.+Colonnoauthor=N.+Meanwellauthor=J.+Clarkauthor=M.+Krystal&title=Oral+efficacy+of+a+respiratory+syncytial+virus+inhibitor+in+rodent+models+of+infection&doi=10.1128%2FAAC.48.7.2448-2454.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection</span></div><div class="casAuthors">Cianci, Christopher; Genovesi, Eugene V.; Lamb, Lucinda; Medina, Ivette; Yang, Zheng; Zadjura, Lisa; Yang, Hyekyung; D'Arienzo, Celia; Sin, Ny; Yu, Kuo-Long; Combrink, Keith; Li, Zhufang; Colonno, Richard; Meanwell, Nicholas; Clark, Junius; Krystal, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2448-2454</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">BMS-433771 is a potent inhibitor of respiratory syncytial virus (RSV) replication in vitro.  Mechanism of action studies have demonstrated that BMS-433771 halts virus entry through inhibition of F protein-mediated membrane fusion.  BMS-433771 also exhibited in vivo efficacy following oral administration in a mouse model of RSV infection.  In this report, the in vivo efficacy of BMS-433771 against RSV was further examd. in the BALB/c mouse and cotton rat host models of infection.  By using the Long strain of RSV, prophylactic efficacy via oral dosing was obsd. in both animal models.  A single oral dose, administered 1 h prior to intranasal RSV inoculation, was as effective against infection as a 4-day b.i.d. dosing regimen in which the first oral dose was given 1 h prior to virus inoculation.  Results of dose titrn. expts. suggested that RSV infection was more sensitive to inhibition by BMS-433771 treatment in the BALB/c mouse host than in the cotton rat.  This was reflected by the pharmacokinetic and pharmacodynamic anal. of the efficacy data, where the area under the concn.-time curve required to achieve 50% of the max. response was ∼7.5-fold less for mice than for cotton rats.  Inhibition of RSV by BMS-433771 in the mouse is the result of F1-mediated inhibition, as shown by the fact that a virus selected for resistance to BMS-433771 in vitro and contg. a single amino acid change in the F1 region was also refractory to treatment in the mouse host.  BMS-433771 efficacy against RSV infection was also demonstrated for mice that were chem. immunosuppressed by cyclophosphamide treatment, indicating that compd. inhibition of the virus did not require an active host immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBKvJm5WDYz7Vg90H21EOLACvtfcHk0lgZTaDBSCyIpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFWmtrY%253D&md5=c57e810ebd46f01c6dd2da43c45f9248</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.7.2448-2454.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.7.2448-2454.2004%26sid%3Dliteratum%253Aachs%26aulast%3DCianci%26aufirst%3DC.%26aulast%3DGenovesi%26aufirst%3DE.%2BV.%26aulast%3DLamb%26aufirst%3DL.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZadjura%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DK.%2BL.%26aulast%3DCombrink%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DMeanwell%26aufirst%3DN.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DKrystal%26aufirst%3DM.%26atitle%3DOral%2520efficacy%2520of%2520a%2520respiratory%2520syncytial%2520virus%2520inhibitor%2520in%2520rodent%2520models%2520of%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D2448%26epage%3D54%26doi%3D10.1128%2FAAC.48.7.2448-2454.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alnajjar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battles, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitthicharoenchai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furmanova-Hollenstein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, J. V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwanten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginderen, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranckx, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaensch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorzaat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallup, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larios-Mora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabbe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntjens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raboisson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langedijk, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackermann, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendeville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span> <span> </span><span class="NLM_article-title">Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-00170-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1038%2Fs41467-017-00170-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=28761099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BC1cfivVyisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=167-182&author=D.+Roymansauthor=S.+S.+Alnajjarauthor=M.+B.+Battlesauthor=P.+Sitthicharoenchaiauthor=P.+Furmanova-Hollensteinauthor=P.+Rigauxauthor=J.+V.+D.+Bergauthor=L.+Kwantenauthor=M.+V.+Ginderenauthor=N.+Verheyenauthor=L.+Vranckxauthor=S.+Jaenschauthor=E.+Arnoultauthor=R.+Voorzaatauthor=J.+M.+Gallupauthor=A.+Larios-Moraauthor=M.+Crabbeauthor=D.+Huntjensauthor=P.+Raboissonauthor=J.+P.+Langedijkauthor=M.+R.+Ackermannauthor=J.+S.+McLellanauthor=S.+Vendevilleauthor=A.+Koul&title=Therapeutic+efficacy+of+a+respiratory+syncytial+virus+fusion+inhibitor&doi=10.1038%2Fs41467-017-00170-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor</span></div><div class="casAuthors">Roymans Dirk; Rigaux Peter; Berg Joke Van den; Kwanten Leen; Ginderen Marcia Van; Verheyen Nick; Vranckx Luc; Raboisson Pierre; Vendeville Sandrine; Koul Anil; Alnajjar Sarhad S; Sitthicharoenchai Panchan; Gallup Jack M; Larios-Mora Alejandro; Ackermann Mark R; Battles Michael B; McLellan Jason S; Furmanova-Hollenstein Polina; Voorzaat Richard; Langedijk Johannes P; Jaensch Steffen; Arnoult Eric; Crabbe Marjolein; Huntjens Dymphy</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">167</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Respiratory syncytial virus is a major cause of acute lower respiratory tract infection in young children, immunocompromised adults, and the elderly.  Intervention with small-molecule antivirals specific for respiratory syncytial virus presents an important therapeutic opportunity, but no such compounds are approved today.  Here we report the structure of JNJ-53718678 bound to respiratory syncytial virus fusion (F) protein in its prefusion conformation, and we show that the potent nanomolar activity of JNJ-53718678, as well as the preliminary structure-activity relationship and the pharmaceutical optimization strategy of the series, are consistent with the binding mode of JNJ-53718678 and other respiratory syncytial virus fusion inhibitors.  Oral treatment of neonatal lambs with JNJ-53718678, or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible.  Together, these data suggest that JNJ-53718678 is a promising candidate for further development as a potential therapeutic in patients at risk to develop respiratory syncytial virus acute lower respiratory tract infection.Respiratory syncytial virus causes lung infections in children, immunocompromised adults, and in the elderly.  Here the authors show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and ameliorating infection in rodents and neonatal lambs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBD68IhmKXha-9TkgmBqTqfW6udTcc2ea-fuV9Jt3Ierntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfivVyisg%253D%253D&md5=f3a5b7951500fbc8b42693818881c228</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00170-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00170-x%26sid%3Dliteratum%253Aachs%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DAlnajjar%26aufirst%3DS.%2BS.%26aulast%3DBattles%26aufirst%3DM.%2BB.%26aulast%3DSitthicharoenchai%26aufirst%3DP.%26aulast%3DFurmanova-Hollenstein%26aufirst%3DP.%26aulast%3DRigaux%26aufirst%3DP.%26aulast%3DBerg%26aufirst%3DJ.%2BV.%2BD.%26aulast%3DKwanten%26aufirst%3DL.%26aulast%3DGinderen%26aufirst%3DM.%2BV.%26aulast%3DVerheyen%26aufirst%3DN.%26aulast%3DVranckx%26aufirst%3DL.%26aulast%3DJaensch%26aufirst%3DS.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DVoorzaat%26aufirst%3DR.%26aulast%3DGallup%26aufirst%3DJ.%2BM.%26aulast%3DLarios-Mora%26aufirst%3DA.%26aulast%3DCrabbe%26aufirst%3DM.%26aulast%3DHuntjens%26aufirst%3DD.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DLangedijk%26aufirst%3DJ.%2BP.%26aulast%3DAckermann%26aufirst%3DM.%2BR.%26aulast%3DMcLellan%26aufirst%3DJ.%2BS.%26aulast%3DVendeville%26aufirst%3DS.%26aulast%3DKoul%26aufirst%3DA.%26atitle%3DTherapeutic%2520efficacy%2520of%2520a%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitor%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D167%26epage%3D182%26doi%3D10.1038%2Fs41467-017-00170-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battles, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langedijk, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furmanova-Hollenstein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaiwatpongsakorn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwanten, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranckx, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vink, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaensch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonckers, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeples, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, J. S.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of respiratory syncytial virus fusion inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1038%2Fnchembio.1982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=26641933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFemsbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=87-93&author=M.+B.+Battlesauthor=J.+P.+Langedijkauthor=P.+Furmanova-Hollensteinauthor=S.+Chaiwatpongsakornauthor=H.+M.+Costelloauthor=L.+Kwantenauthor=L.+Vranckxauthor=P.+Vinkauthor=S.+Jaenschauthor=T.+H.+Jonckersauthor=A.+Koulauthor=E.+Arnoultauthor=M.+E.+Peeplesauthor=D.+Roymansauthor=J.+S.+McLellan&title=Molecular+mechanism+of+respiratory+syncytial+virus+fusion+inhibitors&doi=10.1038%2Fnchembio.1982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of respiratory syncytial virus fusion inhibitors</span></div><div class="casAuthors">Battles, Michael B.; Langedijk, Johannes P.; Furmanova-Hollenstein, Polina; Chaiwatpongsakorn, Supranee; Costello, Heather M.; Kwanten, Leen; Vranckx, Luc; Vink, Paul; Jaensch, Steffen; Jonckers, Tim H. M.; Koul, Anil; Arnoult, Eric; Peeples, Mark E.; Roymans, Dirk; McLellan, Jason S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-93</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis in young children and the elderly.  Therapeutic small mols. have been developed that bind the RSV F glycoprotein and inhibit membrane fusion, yet their binding sites and mol. mechanisms of action remain largely unknown.  Here we show that these inhibitors bind to a three-fold-sym. pocket within the central cavity of the metastable prefusion conformation of RSV F.  Inhibitor binding stabilizes this conformation by tethering two regions that must undergo a structural rearrangement to facilitate membrane fusion.  Inhibitor-escape mutations occur in residues that directly contact the inhibitors or are involved in the conformational rearrangements required to accommodate inhibitor binding.  Resistant viruses do not propagate as well as wild-type RSV in vitro, indicating a fitness cost for inhibitor escape.  Collectively, these findings provide new insight into class I viral fusion proteins and should facilitate development of optimal RSV fusion inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowEnQ0xJnoFLVg90H21EOLACvtfcHk0ljNoqKREXkG6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFemsbrK&md5=c126990069d3f23d95d06693fe90a061</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1982%26sid%3Dliteratum%253Aachs%26aulast%3DBattles%26aufirst%3DM.%2BB.%26aulast%3DLangedijk%26aufirst%3DJ.%2BP.%26aulast%3DFurmanova-Hollenstein%26aufirst%3DP.%26aulast%3DChaiwatpongsakorn%26aufirst%3DS.%26aulast%3DCostello%26aufirst%3DH.%2BM.%26aulast%3DKwanten%26aufirst%3DL.%26aulast%3DVranckx%26aufirst%3DL.%26aulast%3DVink%26aufirst%3DP.%26aulast%3DJaensch%26aufirst%3DS.%26aulast%3DJonckers%26aufirst%3DT.%2BH.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DPeeples%26aufirst%3DM.%2BE.%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DMcLellan%26aufirst%3DJ.%2BS.%26atitle%3DMolecular%2520mechanism%2520of%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D87%26epage%3D93%26doi%3D10.1038%2Fnchembio.1982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cockerill, S.</span>; <span class="NLM_string-name">Mathews, N.</span>; <span class="NLM_string-name">Ward, S.</span>; <span class="NLM_string-name">Lunn, G.</span>; <span class="NLM_string-name">Paradowski, M.</span>; <span class="NLM_string-name">Gascon-Simorte, J. M.</span></span> <span> </span><span class="NLM_article-title">Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV)</span>. <span class="NLM_patent">WO 2016/055780</span>, Oct 6, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Cockerill&author=N.+Mathews&author=S.+Ward&author=G.+Lunn&author=M.+Paradowski&author=J.+M.+Gascon-Simorte&title=Spiro-indolines+for+the+treatment+and+prophylaxis+of+respiratory+syncytial+virus+infection+%28RSV%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCockerill%26aufirst%3DS.%26atitle%3DSpiro-indolines%2520for%2520the%2520treatment%2520and%2520prophylaxis%2520of%2520respiratory%2520syncytial%2520virus%2520infection%2520%2528RSV%2529%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cockerill, S.</span>; <span class="NLM_string-name">Pilkington, C.</span>; <span class="NLM_string-name">Lumley, J.</span>; <span class="NLM_string-name">Angell, R.</span>; <span class="NLM_string-name">Mathews, N.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical compounds</span>. <span class="NLM_patent">WO2013/068769</span>, May 16, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+Cockerill&author=C.+Pilkington&author=J.+Lumley&author=R.+Angell&author=N.+Mathews&title=Pharmaceutical+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCockerill%26aufirst%3DS.%26atitle%3DPharmaceutical%2520compounds%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">En, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.</span></span> <span> </span><span class="NLM_article-title">Zinc triflate-mediated cyclopropanation of oxindoles with vinyl diphenyl sulfonium triflate: a mild reaction with broad functional group compatibility</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3741</span>– <span class="NLM_lpage">3745</span>, <span class="refDoi"> DOI: 10.1039/C6RA24985J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1039%2FC6RA24985J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslOqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=3741-3745&author=M.+Zhouauthor=K.+Enauthor=Y.+Huauthor=Y.+Xuauthor=H.+C.+Shenauthor=X.+Qian&title=Zinc+triflate-mediated+cyclopropanation+of+oxindoles+with+vinyl+diphenyl+sulfonium+triflate%3A+a+mild+reaction+with+broad+functional+group+compatibility&doi=10.1039%2FC6RA24985J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc triflate-mediated cyclopropanation of oxindoles with vinyl diphenyl sulfonium triflate: a mild reaction with broad functional group compatibility</span></div><div class="casAuthors">Zhou, Mingwei; Ke, En; Hu, Yimin; Xu, Yufang; Shen, Hong C.; Qian, Xuhong</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3741-3745</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The first use of zinc triflate for the cyclopropanation of unprotected oxindoles with vinyl di-Ph sulfonium triflate salt to afford spiro[cyclopropane-1,3'-indoline]-2'-ones I [R = 5-OH, 6-F, 7-Cl, 4-Br, etc.] was reported.  The reaction proceeded under ambient conditions and consistently provided high yields with broad functional group tolerability.  The utility for the late-stage functionalization (LSF) of complex mols. was demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzhG-dUWIV0LVg90H21EOLACvtfcHk0ljNoqKREXkG6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslOqtw%253D%253D&md5=ef5135f3b8764bd196b8ddc542db5caf</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1039%2FC6RA24985J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6RA24985J%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DEn%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DQian%26aufirst%3DX.%26atitle%3DZinc%2520triflate-mediated%2520cyclopropanation%2520of%2520oxindoles%2520with%2520vinyl%2520diphenyl%2520sulfonium%2520triflate%253A%2520a%2520mild%2520reaction%2520with%2520broad%2520functional%2520group%2520compatibility%26jtitle%3DRSC%2520Adv.%26date%3D2017%26volume%3D7%26spage%3D3741%26epage%3D3745%26doi%3D10.1039%2FC6RA24985J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span> <span> </span><span class="NLM_article-title">A convenient cyclopropanation process of oxindoles via bromoethylsulfonium salt</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">6809</span>– <span class="NLM_lpage">6814</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2018.09.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2Fj.tet.2018.09.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCktb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2018&pages=6809-6814&author=H.+Qinauthor=Y.+Miaoauthor=K.+Zhangauthor=J.+Xuauthor=H.+Sunauthor=W.+Liuauthor=F.+Fengauthor=W.+Qu&title=A+convenient+cyclopropanation+process+of+oxindoles+via+bromoethylsulfonium+salt&doi=10.1016%2Fj.tet.2018.09.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A convenient cyclopropanation process of oxindoles via bromoethylsulfonium salt</span></div><div class="casAuthors">Qin, Hui; Miao, Yuanyuan; Zhang, Ke; Xu, Jian; Sun, Haopeng; Liu, Wenyuan; Feng, Feng; Qu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">6809-6814</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A practical convenient conversion of oxindoles into the corresponding spirocyclopropane-oxindoles, e.g., I, is achieved efficiently using bromoethylsulfonium salt, which is easily prepd. on a large scale and is stable cryst.  This reaction of bromoethylsulfonium salt with different substituted unprotected oxindoles proceeded under mild condition and provided moderate yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZy4OqanklqbVg90H21EOLACvtfcHk0ljNoqKREXkG6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCktb3P&md5=840213bf257d51e91d523e32db34e17d</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2018.09.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2018.09.042%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DH.%26aulast%3DMiao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DQu%26aufirst%3DW.%26atitle%3DA%2520convenient%2520cyclopropanation%2520process%2520of%2520oxindoles%2520via%2520bromoethylsulfonium%2520salt%26jtitle%3DTetrahedron%26date%3D2018%26volume%3D74%26spage%3D6809%26epage%3D6814%26doi%3D10.1016%2Fj.tet.2018.09.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andreassen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sletvold, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensen, H.</span></span> <span> </span><span class="NLM_article-title">Nucleophilic alkylations of 3-nitropyridines</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2671</span>– <span class="NLM_lpage">2676</span>, <span class="refDoi"> DOI: 10.1039/b408840a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1039%2Fb408840a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=15351832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnt1Grs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=2671-2676&author=E.+J.+Andreassenauthor=J.+M.+Bakkeauthor=I.+Sletvoldauthor=H.+Svensen&title=Nucleophilic+alkylations+of+3-nitropyridines&doi=10.1039%2Fb408840a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleophilic alkylations of 3-nitropyridines</span></div><div class="casAuthors">Andreassen, Einar J.; Bakke, Jan M.; Sletvold, Ingrid; Svensen, Harald</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2671-2676</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">3-Nitropyridine and 4-substituted-3-nitropyridines were reacted with chloroform, Me chloroacetate and Et 2-chloropropionate under vicarious nucleophilic substitution (VNS) conditions.  Substitution was obtained in the ortho or para position to the nitro group with acceptable to good yields and regioselectivity.  With potassium 5-nitropyridine-2-sulfonate the substitution took place in the 4-position.  Further substitution of the sulfonate group proved to be possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFNPxqNwvVa7Vg90H21EOLACvtfcHk0lh3m2pl4TW3bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnt1Grs7c%253D&md5=611c492e24f335ee1fc12ba58b98a68c</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1039%2Fb408840a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb408840a%26sid%3Dliteratum%253Aachs%26aulast%3DAndreassen%26aufirst%3DE.%2BJ.%26aulast%3DBakke%26aufirst%3DJ.%2BM.%26aulast%3DSletvold%26aufirst%3DI.%26aulast%3DSvensen%26aufirst%3DH.%26atitle%3DNucleophilic%2520alkylations%2520of%25203-nitropyridines%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2004%26volume%3D2%26spage%3D2671%26epage%3D2676%26doi%3D10.1039%2Fb408840a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Committee for Human Medicinal Products,
European Medicinces
Agency</span>.  <i>Guideline on the Clinical
Evaluation of Medicinal Products Indicated for the Prophylaxis or
Treatment of Respiratory Syncytial Virus (RSV)</i> Disease Draft
Guideline, EMA/CHMP/257022/2017; London, Oct 30, <span class="NLM_year">2017</span>. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-indicated-prophylaxis-treatment-respiratory_en.pdf" class="extLink">https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-indicated-prophylaxis-treatment-respiratory_en.pdf</a> (accessed October 21, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Committee+for+Human+Medicinal+Products%2C%0AEuropean+Medicinces%0AAgency&title=Guideline+on+the+Clinical%0AEvaluation+of+Medicinal+Products+Indicated+for+the+Prophylaxis+or%0ATreatment+of+Respiratory+Syncytial+Virus+%28RSV%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DGuideline%2520on%2520the%2520Clinical%250AEvaluation%2520of%2520Medicinal%2520Products%2520Indicated%2520for%2520the%2520Prophylaxis%2520or%250ATreatment%2520of%2520Respiratory%2520Syncytial%2520Virus%2520%2528RSV%2529%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">FDA, Center for Drug Evaluation and Research</span>.  <i>Respiratory Syncytial Virus Infection: Developing Antiviral
Drugs for Prophylaxis and Treatment Guidance for Industry</i> Draft Guidance, Silver Spring, MD; October 2017. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/respiratory-syncytial-virus-infection-developing-antiviral-drugs-prophylaxis-and-treatment-guidance" class="extLink">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/respiratory-syncytial-virus-infection-developing-antiviral-drugs-prophylaxis-and-treatment-guidance</a> (accessed October 22, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA%2C+Center+for+Drug+Evaluation+and+Research.+Respiratory+Syncytial+Virus+Infection%3A+Developing+Antiviral%0ADrugs+for+Prophylaxis+and+Treatment+Guidance+for+Industry+Draft+Guidance%2C+Silver+Spring%2C+MD%3B+October+2017.+https%3A%2F%2Fwww.fda.gov%2Fregulatory-information%2Fsearch-fda-guidance-documents%2Frespiratory-syncytial-virus-infection-developing-antiviral-drugs-prophylaxis-and-treatment-guidance+%28accessed+October+22%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DRespiratory%2520Syncytial%2520Virus%2520Infection%253A%2520Developing%2520Antiviral%250ADrugs%2520for%2520Prophylaxis%2520and%2520Treatment%2520Guidance%2520for%2520Industry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishnaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cehelsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nochur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeking, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moane, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pareek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studholme, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambkin-Williams, R.</span></span> <span> </span><span class="NLM_article-title">Viral load drives disease in humans experimentally infected with respiratory syncytial virus</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1164/rccm.201002-0221OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1164%2Frccm.201002-0221OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=20622030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1equg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2010&pages=1305-1314&author=J.+P.+DeVincenzoauthor=T.+Wilkinsonauthor=A.+Vaishnawauthor=J.+Cehelskyauthor=R.+Meyersauthor=S.+Nochurauthor=L.+Harrisonauthor=P.+Meekingauthor=A.+Mannauthor=E.+Moaneauthor=J.+Oxfordauthor=R.+Pareekauthor=R.+Mooreauthor=E.+Walshauthor=R.+Studholmeauthor=P.+Dorsettauthor=R.+Alvarezauthor=R.+Lambkin-Williams&title=Viral+load+drives+disease+in+humans+experimentally+infected+with+respiratory+syncytial+virus&doi=10.1164%2Frccm.201002-0221OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Viral load drives disease in humans experimentally infected with respiratory syncytial virus</span></div><div class="casAuthors">DeVincenzo, John P.; Wilkinson, Tom; Vaishnaw, Akshay; Cehelsky, Jeff; Meyers, Rachel; Nochur, Saraswathy; Harrison, Lisa; Meeking, Patricia; Mann, Alex; Moane, Elizabeth; Oxford, John; Pareek, Rajat; Moore, Ryves; Walsh, Ed; Studholme, Robert; Dorsett, Preston; Alvarez, Rene; Lambkin-Williams, Robert</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1305-1314</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Respiratory syncytial virus (RSV) is the leading cause of childhood lower respiratory infection, yet viable therapies are lacking.  Two major challenges have stalled antiviral development: ethical difficulties in performing pediatric proof-of-concept studies and the prevailing concept that the disease is immune-mediated rather than being driven by viral load.  The development of a human exptl. wild-type RSV infection model to address these challenges.  Healthy volunteers (n = 35), in five cohorts, received increasing quantities (3.0-5.4 log plaque-forming units/person) of wild-type RSV-A intranasally.  Overall, 77% of volunteers consistently shed virus.  Infection rate, viral loads, disease severity, and safety were similar between cohorts and were unrelated to quantity of RSV received.  Symptoms began near the time of initial viral detection, peaked in severity near when viral load peaked, and subsided as viral loads (measured by real-time polymerase chain reaction) slowly declined.  Viral loads correlated significantly with intranasal proinflammatory cytokine concns. (IL-6 and IL-8).  Increased viral load correlated consistently with increases in multiple different disease measurements (symptoms, phys. examn., and amt. of nasal mucus).  Viral load appears to drive disease manifestations in humans with RSV infection.  The obsd. parallel viral and disease kinetics support a potential clin. benefit of RSV antivirals.  This reproducible model facilitates the development of future RSV therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-DVpVkrytZ7Vg90H21EOLACvtfcHk0lh3m2pl4TW3bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1equg%253D%253D&md5=baadbf1735812bf00a63b9499a2fe3bd</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1164%2Frccm.201002-0221OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201002-0221OC%26sid%3Dliteratum%253Aachs%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26aulast%3DWilkinson%26aufirst%3DT.%26aulast%3DVaishnaw%26aufirst%3DA.%26aulast%3DCehelsky%26aufirst%3DJ.%26aulast%3DMeyers%26aufirst%3DR.%26aulast%3DNochur%26aufirst%3DS.%26aulast%3DHarrison%26aufirst%3DL.%26aulast%3DMeeking%26aufirst%3DP.%26aulast%3DMann%26aufirst%3DA.%26aulast%3DMoane%26aufirst%3DE.%26aulast%3DOxford%26aufirst%3DJ.%26aulast%3DPareek%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DWalsh%26aufirst%3DE.%26aulast%3DStudholme%26aufirst%3DR.%26aulast%3DDorsett%26aufirst%3DP.%26aulast%3DAlvarez%26aufirst%3DR.%26aulast%3DLambkin-Williams%26aufirst%3DR.%26atitle%3DViral%2520load%2520drives%2520disease%2520in%2520humans%2520experimentally%2520infected%2520with%2520respiratory%2520syncytial%2520virus%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D182%26spage%3D1305%26epage%3D1314%26doi%3D10.1164%2Frccm.201002-0221OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meals, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fok-Seang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntjens, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariën, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remmerie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roymans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verloes, R.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: A placebo-controlled study</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>218</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1093/infdis/jiy227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1093%2Finfdis%2Fjiy227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=29684148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlCnt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=218&publication_year=2018&pages=748-756&author=M.+Stevensauthor=S.+Ruschauthor=J.+DeVincenzoauthor=Y.-I.+Kimauthor=L.+Harrisonauthor=E.+A.+Mealsauthor=A.+Boyersauthor=J.+Fok-Seangauthor=D.+Huntjensauthor=N.+Lounisauthor=K.+Mari%C3%ABnauthor=B.+Remmerieauthor=D.+Roymansauthor=A.+Koulauthor=R.+Verloes&title=Antiviral+activity+of+oral+JNJ-53718678+in+healthy+adult+volunteers+challenged+with+respiratory+syncytial+virus%3A+A+placebo-controlled+study&doi=10.1093%2Finfdis%2Fjiy227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: a placebo-controlled study</span></div><div class="casAuthors">Stevens, Marita; Rusch, Sarah; DeVincenzo, John; Kim, Young-In; Harrison, Lisa; Meals, Elizabeth A.; Boyers, Alison; Fok-Seang, Juin; Huntjens, Dymphy; Lounis, Nacer; Marien, Kris; Remmerie, Bart; Roymans, Dirk; Koul, Anil; Verloes, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">218</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">748-756</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">1537-6613</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  Respiratory syncytial virus (RSV) disease has no effective treatment.  JNJ-53718678 is a fusion inhibitor with selective activity against RSV.  After confirmation of RSV infection or 5 days after inoculation with RSV, participants (n = 69) were randomized to JNJ-53718678 75 mg (n = 15), 200 mg (n = 17), 500 mg (n = 18), or placebo (n = 17) orally once daily for 7 days.  Antiviral effects were evaluated by assessing RSV RNA viral load (VL) area under the curve (AUC) from baseline (before the first dose) until discharge, time-to-peak VL, duration of viral shedding, clin. symptoms, and quantity of nasal secretions.  Mean VL AUC was lower for individuals treated with different doses of JNJ-53718678 vs. placebo (203.8-253.8 vs 432.8 log10 PFUe.hour/mL).  Also, mean peak VL, time to peak VL, duration of viral shedding, mean overall symptom score, and nasal secretion wt. were lower in each JNJ-53718678-treated group vs. placebo.  No clear exposure-response relationship was obsd.  Three participants discontinued due to treatment-emergent adverse events of grade 2 and 1 ECG change (JNJ-53718678 75 mg and 200 mg, resp.) and grade 2 urticaria (placebo).  Conclusions.  JNJ-53718678 at all 3 doses substantially reduced VL and clin. disease severity, thus establishing clin. proof of concept and the compd.'s potential as a novel RSV treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9lct-FnOIM7Vg90H21EOLACvtfcHk0lgl4mbFMtgHmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlCnt77J&md5=a7da58b73e29e9c06537292a14dc3408</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjiy227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjiy227%26sid%3Dliteratum%253Aachs%26aulast%3DStevens%26aufirst%3DM.%26aulast%3DRusch%26aufirst%3DS.%26aulast%3DDeVincenzo%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.-I.%26aulast%3DHarrison%26aufirst%3DL.%26aulast%3DMeals%26aufirst%3DE.%2BA.%26aulast%3DBoyers%26aufirst%3DA.%26aulast%3DFok-Seang%26aufirst%3DJ.%26aulast%3DHuntjens%26aufirst%3DD.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DMari%25C3%25ABn%26aufirst%3DK.%26aulast%3DRemmerie%26aufirst%3DB.%26aulast%3DRoymans%26aufirst%3DD.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DVerloes%26aufirst%3DR.%26atitle%3DAntiviral%2520activity%2520of%2520oral%2520JNJ-53718678%2520in%2520healthy%2520adult%2520volunteers%2520challenged%2520with%2520respiratory%2520syncytial%2520virus%253A%2520A%2520placebo-controlled%2520study%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2018%26volume%3D218%26spage%3D748%26epage%3D756%26doi%3D10.1093%2Finfdis%2Fjiy227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span>GileadSciences.
Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV). <a href="http://Clintrials.gov" class="extLink">Clintrials.gov</a> <span class="NLM_year">2013</span>, NCT01797419. <a href="https://clinicaltrials.gov/ct2/show/NCT01797419" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01797419</a> (accessed October 22, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=GileadSciences.%0ASafety+Study+of+GS-5806+to+Treat+Respiratory+Syncytial+Virus+%28RSV%29.+Clintrials.gov+2013%2C+NCT01797419.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01797419+%28accessed+October+22%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chemaly, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadwal, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljungman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, G.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pipavath, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limaye, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winston, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiff, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuckerman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachance, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahav, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullane, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patron, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waghmare, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKevitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">German, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gossage, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckh, M.</span></span> <span> </span><span class="NLM_article-title">A phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">2777</span>– <span class="NLM_lpage">2786</span>, <span class="refDoi"> DOI: 10.1093/cid/ciz1166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1093%2Fcid%2Fciz1166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=31793991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnvFGgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2020&pages=2777-2786&author=R.+F.+Chemalyauthor=S.+S.+Dadwalauthor=A.+Bergeronauthor=P.+Ljungmanauthor=Y.-J.+Kimauthor=G.-S.+Chengauthor=S.+N.+Pipavathauthor=A.+P.+Limayeauthor=E.+Blanchardauthor=D.+J.+Winstonauthor=P.+J.+Stiffauthor=T.+Zuckermanauthor=S.+Lachanceauthor=G.+Rahavauthor=C.+B.+Smallauthor=K.+M.+Mullaneauthor=R.+L.+Patronauthor=D.-G.+Leeauthor=H.+H.+Hirschauthor=A.+Waghmareauthor=M.+McKevittauthor=R.+Jordanauthor=Y.+Guoauthor=P.+Germanauthor=D.+P.+Porterauthor=D.+L.+Gossageauthor=T.+R.+Watkinsauthor=F.+M.+Martyauthor=J.+W.+Chienauthor=M.+Boeckh&title=A+phase+2%2C+randomized%2C+double-blind%2C+placebo-controlled+trial+of+presatovir+for+the+treatment+of+respiratory+syncytial+virus+upper+respiratory+tract+infection+in+hematopoietic-cell+transplant+recipients&doi=10.1093%2Fcid%2Fciz1166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49aR"><div class="casContent"><span class="casTitleNuber">49a</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients</span></div><div class="casAuthors">Chemaly, Roy F.; Dadwal, Sanjeet S.; Bergeron, Anne; Ljungman, Per; Kim, Yae-Jean; Cheng, Guang-Shing; Pipavath, Sudhakar N.; Limaye, Ajit P.; Blanchard, Elodie; Winston, Drew J.; Stiff, Patrick J.; Zuckerman, Tsila; Lachance, Silvy; Rahav, Galia; Small, Catherine B.; Mullane, Kathleen M.; Patron, Roberto L.; Lee, Dong-Gun; Hirsch, Hans H.; Waghmare, Alpana; McKevitt, Matt; Jordan, Robert; Guo, Ying; German, Polina; Porter, Danielle P.; Gossage, David L.; Watkins, Timothy R.; Marty, Francisco M.; Chien, Jason W.; Boeckh, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">Suppl._4</span>),
    <span class="NLM_cas:pages">2777-2786</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Hematopoietic-cell transplant (HCT) recipients are at risk for severe respiratory syncytial virus (RSV) infection.  We evaluated the RSV fusion inhibitor presatovir in a randomized, double-blind, Phase II trial in HCT recipients with RSV upper respiratory tract infections.  Patients were stratified by lymphopenia (<200/μL) and ribavirin use; were randomized, stratified by lymphopenia (<200/μL) and ribavirin use, to receive oral presatovir at 200 mg or a placebo on Days 1, 5, 9, 13, and 17, and were followed through Day 28.  The coprimary efficacy endpoints were the time-weighted av. change in the nasal RSV viral load between Days 1 and 9 and the proportion of patients developing lower respiratory tract complications (LRTCs) through Day 28.  From 23 Jan. 2015 to 16 June 2017, 189 patients were randomly assigned to treatment (96 to presatovir and 93 to the placebo).  Presatovir treatment, compared with the placebo treatment, did not significantly affect (prespecified α = 0.01) a time-weighted av. decline in the RSV viral load from Day 1 to 9 (treatment difference, -0.33 log10 copies/mL; 95% confidence interval [CI] -.64 to -.02 log10 copies/mL; P = .040) or the progression to LRTC (11.2% vs 19.5%, resp.; odds ratio, 0.50; 95% CI, .22-1.18; P = .11).  In a post hoc anal. among patients with lymphopenia, presatovir decreased LRTC development by Day 28 (2/15 [13.3%] vs 9/14 [64.3%], resp.; P = .008), compared with the placebo.  Adverse events were similar for patients receiving presatovir and the placebo.  Presatovir had a favorable safety profile in adult HCT recipients with RSV but did not achieve the coprimary endpoints.  Exploratory analyses suggest an antiviral effect among patients with lymphopenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrYGSUXfnUMbVg90H21EOLACvtfcHk0lgl4mbFMtgHmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnvFGgtQ%253D%253D&md5=ecf33034e40a2cf65d54c6879a2fd8ce</span></div><a href="/servlet/linkout?suffix=cit49a&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciz1166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciz1166%26sid%3Dliteratum%253Aachs%26aulast%3DChemaly%26aufirst%3DR.%2BF.%26aulast%3DDadwal%26aufirst%3DS.%2BS.%26aulast%3DBergeron%26aufirst%3DA.%26aulast%3DLjungman%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DY.-J.%26aulast%3DCheng%26aufirst%3DG.-S.%26aulast%3DPipavath%26aufirst%3DS.%2BN.%26aulast%3DLimaye%26aufirst%3DA.%2BP.%26aulast%3DBlanchard%26aufirst%3DE.%26aulast%3DWinston%26aufirst%3DD.%2BJ.%26aulast%3DStiff%26aufirst%3DP.%2BJ.%26aulast%3DZuckerman%26aufirst%3DT.%26aulast%3DLachance%26aufirst%3DS.%26aulast%3DRahav%26aufirst%3DG.%26aulast%3DSmall%26aufirst%3DC.%2BB.%26aulast%3DMullane%26aufirst%3DK.%2BM.%26aulast%3DPatron%26aufirst%3DR.%2BL.%26aulast%3DLee%26aufirst%3DD.-G.%26aulast%3DHirsch%26aufirst%3DH.%2BH.%26aulast%3DWaghmare%26aufirst%3DA.%26aulast%3DMcKevitt%26aufirst%3DM.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DGerman%26aufirst%3DP.%26aulast%3DPorter%26aufirst%3DD.%2BP.%26aulast%3DGossage%26aufirst%3DD.%2BL.%26aulast%3DWatkins%26aufirst%3DT.%2BR.%26aulast%3DMarty%26aufirst%3DF.%2BM.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DBoeckh%26aufirst%3DM.%26atitle%3DA%2520phase%25202%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520presatovir%2520for%2520the%2520treatment%2520of%2520respiratory%2520syncytial%2520virus%2520upper%2520respiratory%2520tract%2520infection%2520in%2520hematopoietic-cell%2520transplant%2520recipients%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2020%26volume%3D71%26spage%3D2777%26epage%3D2786%26doi%3D10.1093%2Fcid%2Fciz1166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit49b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemaly, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullane, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljungman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waghmare, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKevitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">German, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadwal, S. S.</span></span> <span> </span><span class="NLM_article-title">A phase 2b, randomized, double-blind, placebo-controlled multicenter study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus (RSV) infection of the lower respiratory tract</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">2787</span>– <span class="NLM_lpage">2795</span>, <span class="refDoi"> DOI: 10.1093/cid/ciz1167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1093%2Fcid%2Fciz1167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=31915807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnvFKisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2020&pages=2787-2795&author=F.+M.+Martyauthor=R.+F.+Chemalyauthor=K.+M.+Mullaneauthor=D.-G.+Leeauthor=H.+H.+Hirschauthor=C.+B.+Smallauthor=A.+Bergeronauthor=S.+Shohamauthor=P.+Ljungmanauthor=A.+Waghmareauthor=E.+Blanchardauthor=Y.-J.+Kimauthor=M.+McKevittauthor=D.+P.+Porterauthor=R.+Jordanauthor=Y.+Guoauthor=P.+Germanauthor=M.+Boeckhauthor=T.+R.+Watkinsauthor=J.+W.+Chienauthor=S.+S.+Dadwal&title=A+phase+2b%2C+randomized%2C+double-blind%2C+placebo-controlled+multicenter+study+evaluating+antiviral+effects%2C+pharmacokinetics%2C+safety%2C+and+tolerability+of+presatovir+in+hematopoietic+cell+transplant+recipients+with+respiratory+syncytial+virus+%28RSV%29+infection+of+the+lower+respiratory+tract&doi=10.1093%2Fcid%2Fciz1167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49bR"><div class="casContent"><span class="casTitleNuber">49b</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2b, randomized, double-blind, placebo-controlled multicenter study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus infection of the lower respiratory tract</span></div><div class="casAuthors">Marty, Francisco M.; Chemaly, Roy F.; Mullane, Kathleen M.; Lee, Dong-Gun; Hirsch, Hans H.; Small, Catherine B.; Bergeron, Anne; Shoham, Shmuel; Ljungman, Per; Waghmare, Alpana; Blanchard, Elodie; Kim, Yae-Jean; McKevitt, Matt; Porter, Danielle P.; Jordan, Robert; Guo, Ying; German, Polina; Boeckh, Michael; Watkins, Timothy R.; Chien, Jason W.; Dadwal, Sanjeet S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">Suppl._4</span>),
    <span class="NLM_cas:pages">2787-2795</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Presatovir significantly reduced nasal viral load, signs, and symptoms of respiratory syncytial virus (RSV) infection in a human challenge study.  We evaluated presatovir in hematopoietic-cell transplant (HCT) recipients with RSV lower respiratory tract infection (LRTI).  Patients with confirmed RSV in upper and lower respiratory tract and new chest X-ray abnormalities were randomized (1:1), stratified by supplemental oxygen and ribavirin use, to receive oral presatovir 200 mg or placebo every 4 days for 5 doses.  The primary endpoint was time-weighted av. change in nasal RSV viral load through day 9.  Secondary endpoints included supplemental oxygen-free days, incident respiratory failure requiring mech. ventilation, and all-cause mortality.  From Jan. 31, 2015, to March 20, 2017, 60 patients from 17 centers were randomized (31 presatovir, 29 placebo); 59 received study treatment (50 allogeneic, 9 autologous HCT).  In the efficacy population (29 presatovir, 28 placebo), presatovir treatment did not significantly reduce time-weighted av. change in viral load (-1.12 vs -1.09 log10 copies/mL; treatment difference -0.02 log10 copies/mL, 95% confidence interval: -.62, .57; P = .94), median supplemental oxygen-free days (26 vs 28 days, P = .84), incident respiratory failure (10.3 vs 10.7%, P = .98), or all-cause mortality (0 vs 7.1%, P = .19) vs. placebo.  Adverse events were similar between arms (presatovir 80%, placebo 79%).  Resistance-assocd. substitutions in RSV fusion protein emerged in 6/29 presatovir-treated patients.  Presatovir treatment was well tolerated in HCT patients with RSV LRTI but did not improve virol. or clin. outcomes vs. placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXu1F0E9LvMrVg90H21EOLACvtfcHk0lhDuWKVWHCV0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnvFKisw%253D%253D&md5=24e0b3c4c7602b70bcaac062a4512978</span></div><a href="/servlet/linkout?suffix=cit49b&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciz1167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciz1167%26sid%3Dliteratum%253Aachs%26aulast%3DMarty%26aufirst%3DF.%2BM.%26aulast%3DChemaly%26aufirst%3DR.%2BF.%26aulast%3DMullane%26aufirst%3DK.%2BM.%26aulast%3DLee%26aufirst%3DD.-G.%26aulast%3DHirsch%26aufirst%3DH.%2BH.%26aulast%3DSmall%26aufirst%3DC.%2BB.%26aulast%3DBergeron%26aufirst%3DA.%26aulast%3DShoham%26aufirst%3DS.%26aulast%3DLjungman%26aufirst%3DP.%26aulast%3DWaghmare%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DY.-J.%26aulast%3DMcKevitt%26aufirst%3DM.%26aulast%3DPorter%26aufirst%3DD.%2BP.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DGerman%26aufirst%3DP.%26aulast%3DBoeckh%26aufirst%3DM.%26aulast%3DWatkins%26aufirst%3DT.%2BR.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DDadwal%26aufirst%3DS.%2BS.%26atitle%3DA%2520phase%25202b%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520multicenter%2520study%2520evaluating%2520antiviral%2520effects%252C%2520pharmacokinetics%252C%2520safety%252C%2520and%2520tolerability%2520of%2520presatovir%2520in%2520hematopoietic%2520cell%2520transplant%2520recipients%2520with%2520respiratory%2520syncytial%2520virus%2520%2528RSV%2529%2520infection%2520of%2520the%2520lower%2520respiratory%2520tract%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2020%26volume%3D71%26spage%3D2787%26epage%3D2795%26doi%3D10.1093%2Fcid%2Fciz1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dilling, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoop, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampolla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neurohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glanville, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKevitt, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">German, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamora, M.</span></span> <span> </span><span class="NLM_article-title">A phase 2b, randomized controlled trial of presatovir, an oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in lung transplant (LT) recipients</span>. <i>J. Heart Lung Transplant</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">S155</span>, <span class="refDoi"> DOI: 10.1016/j.healun.2018.01.375</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1016%2Fj.healun.2018.01.375" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=S155&author=J.+Gottliebauthor=F.+Torresauthor=T.+Haddadauthor=G.+Dhillonauthor=D.+F.+Dillingauthor=C.+Knoopauthor=R.+Rampollaauthor=R.+Waliaauthor=V.+Ahyaauthor=R.+Kesslerauthor=D.+P.+Masonauthor=M.+Budevauthor=C.+Neurohrauthor=A.+R.+Glanvilleauthor=R.+Jordanauthor=D.+Porterauthor=M.+T.+McKevittauthor=P.+Germanauthor=Y.+Guoauthor=J.+W.+Chienauthor=T.+R.+Watkinsauthor=M.+Zamora&title=A+phase+2b%2C+randomized+controlled+trial+of+presatovir%2C+an+oral+RSV+fusion+inhibitor%2C+for+the+treatment+of+respiratory+syncytial+virus+%28RSV%29+in+lung+transplant+%28LT%29+recipients&doi=10.1016%2Fj.healun.2018.01.375"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.healun.2018.01.375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.healun.2018.01.375%26sid%3Dliteratum%253Aachs%26aulast%3DGottlieb%26aufirst%3DJ.%26aulast%3DTorres%26aufirst%3DF.%26aulast%3DHaddad%26aufirst%3DT.%26aulast%3DDhillon%26aufirst%3DG.%26aulast%3DDilling%26aufirst%3DD.%2BF.%26aulast%3DKnoop%26aufirst%3DC.%26aulast%3DRampolla%26aufirst%3DR.%26aulast%3DWalia%26aufirst%3DR.%26aulast%3DAhya%26aufirst%3DV.%26aulast%3DKessler%26aufirst%3DR.%26aulast%3DMason%26aufirst%3DD.%2BP.%26aulast%3DBudev%26aufirst%3DM.%26aulast%3DNeurohr%26aufirst%3DC.%26aulast%3DGlanville%26aufirst%3DA.%2BR.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DPorter%26aufirst%3DD.%26aulast%3DMcKevitt%26aufirst%3DM.%2BT.%26aulast%3DGerman%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DWatkins%26aufirst%3DT.%2BR.%26aulast%3DZamora%26aufirst%3DM.%26atitle%3DA%2520phase%25202b%252C%2520randomized%2520controlled%2520trial%2520of%2520presatovir%252C%2520an%2520oral%2520RSV%2520fusion%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520respiratory%2520syncytial%2520virus%2520%2528RSV%2529%2520in%2520lung%2520transplant%2520%2528LT%2529%2520recipients%26jtitle%3DJ.%2520Heart%2520Lung%2520Transplant%26date%3D2018%26volume%3D37%26spage%3DS155%26doi%3D10.1016%2Fj.healun.2018.01.375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanfelt-Goade, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maimon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catherinot, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gafter-Gvili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napora, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeltser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moudgil, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limaye, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couturaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nseir, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKevitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">German, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gossage, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falsey, A. R.</span></span> <span> </span><span class="NLM_article-title">A Phase 2b, randomized, double-blind, placebo-controlled trial of presatovir (GS-5806), a novel oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in hospitalized adults</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">A4457</span>– <span class="NLM_lpage">A4457</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2018&pages=A4457-A4457&author=D.+Hanfelt-Goadeauthor=N.+Maimonauthor=A.+Nimerauthor=F.+Riviereauthor=E.+Catherinotauthor=M.+Isonauthor=S.+Jeongauthor=E.+Walshauthor=A.+Gafter-Gviliauthor=S.+Namaauthor=P.+Naporaauthor=M.+Chowersauthor=A.+Bergeronauthor=D.+Zeltserauthor=H.+Moudgilauthor=A.+P.+Limayeauthor=F.+Couturaudauthor=W.+Nseirauthor=M.+McKevittauthor=D.+Porterauthor=R.+Jordanauthor=Y.+Guoauthor=P.+Germanauthor=T.+R.+Watkinsauthor=D.+L.+Gossageauthor=J.+W.+Chienauthor=A.+R.+Falsey&title=A+Phase+2b%2C+randomized%2C+double-blind%2C+placebo-controlled+trial+of+presatovir+%28GS-5806%29%2C+a+novel+oral+RSV+fusion+inhibitor%2C+for+the+treatment+of+respiratory+syncytial+virus+%28RSV%29+in+hospitalized+adults"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHanfelt-Goade%26aufirst%3DD.%26aulast%3DMaimon%26aufirst%3DN.%26aulast%3DNimer%26aufirst%3DA.%26aulast%3DRiviere%26aufirst%3DF.%26aulast%3DCatherinot%26aufirst%3DE.%26aulast%3DIson%26aufirst%3DM.%26aulast%3DJeong%26aufirst%3DS.%26aulast%3DWalsh%26aufirst%3DE.%26aulast%3DGafter-Gvili%26aufirst%3DA.%26aulast%3DNama%26aufirst%3DS.%26aulast%3DNapora%26aufirst%3DP.%26aulast%3DChowers%26aufirst%3DM.%26aulast%3DBergeron%26aufirst%3DA.%26aulast%3DZeltser%26aufirst%3DD.%26aulast%3DMoudgil%26aufirst%3DH.%26aulast%3DLimaye%26aufirst%3DA.%2BP.%26aulast%3DCouturaud%26aufirst%3DF.%26aulast%3DNseir%26aufirst%3DW.%26aulast%3DMcKevitt%26aufirst%3DM.%26aulast%3DPorter%26aufirst%3DD.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DGerman%26aufirst%3DP.%26aulast%3DWatkins%26aufirst%3DT.%2BR.%26aulast%3DGossage%26aufirst%3DD.%2BL.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DFalsey%26aufirst%3DA.%2BR.%26atitle%3DA%2520Phase%25202b%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520presatovir%2520%2528GS-5806%2529%252C%2520a%2520novel%2520oral%2520RSV%2520fusion%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520respiratory%2520syncytial%2520virus%2520%2528RSV%2529%2520in%2520hospitalized%2520adults%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2018%26volume%3D197%26spage%3DA4457%26epage%3DA4457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brint, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meals, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cormier, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J. P.</span></span> <span> </span><span class="NLM_article-title">Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants</span>. <i>Pediatr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">872</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1038/pr.2017.173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=10.1038%2Fpr.2017.173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=28723886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A280%3ADC%252BC1cjptFKhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2017&pages=872-880&author=M.+E.+Brintauthor=J.+M.+Hughesauthor=A.+Shahauthor=C.+R.+Millerauthor=L.+G.+Harrisonauthor=E.+A.+Mealsauthor=J.+Blanchauthor=C.+R.+Thompsonauthor=S.+A.+Cormierauthor=J.+P.+DeVincenzo&title=Prolonged+viral+replication+and+longitudinal+viral+dynamic+differences+among+respiratory+syncytial+virus+infected+infants&doi=10.1038%2Fpr.2017.173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants</span></div><div class="casAuthors">Brint Monica E; Harrison Lisa G; Meals Elizabeth A; Blanch Jacqueline; Cormier Stephania A; Hughes Joshua M; Shah Aditya; Miller Chelsea R; Thompson Charlotte R; DeVincenzo John P</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">872-880</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BackgroundLongitudinal respiratory syncytial virus (RSV) dynamics have not been well studied despite the existence of factors favoring prolonged RSV replication including high mutation rates allowing rapid evolution and potential escape from immune control.  We therefore measured viral load in previously RSV-naive infants over prolonged time spans.MethodsDuring 2014-2015, quantitative nasal aspirates were collected from 51 RSV-PCR+ infants.  Multiple parallel assessments of viral loads were quantified at each collected time point using a well-validated real-time quantitative reverse transcriptase polymerase chain reaction assay.  After observing viral load rebound phenomenon in some infants, the viral dynamics of 27 infants with sufficient longitudinal viral load data points were analyzed using the pre-defined criteria for viral rebound.  Additional analyses were performed comparing age with viral rebound, viral clearance rates, and viral load area-under-the-curve (AUCVL).ResultsThe 51 infants (303 nasal aspirate samples; mean of 5.9 per patient) exhibited slower than expected viral clearance.  Lower age trended toward slower viral clearance and greater AUCVL.  Six infants had detectable viral loads ≥1 month after symptom onset.  Ten of twenty-seven evaluable subjects exhibited viral rebound and this rebound was age-dependent (P=0.0259).  All but one rebounder were <70 days old.ConclusionInfants struggle to control primary RSV infections allowing prolonged viral replication and previously undescribed viral rebound; likely representing viral mutational immune escape.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDdN6tnGk9fXy-c-E1v-fmfW6udTcc2eZ69GkaksO9Zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjptFKhsg%253D%253D&md5=0ebc9a6be5b1ff3d75e97b6f6da64630</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fpr.2017.173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fpr.2017.173%26sid%3Dliteratum%253Aachs%26aulast%3DBrint%26aufirst%3DM.%2BE.%26aulast%3DHughes%26aufirst%3DJ.%2BM.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DC.%2BR.%26aulast%3DHarrison%26aufirst%3DL.%2BG.%26aulast%3DMeals%26aufirst%3DE.%2BA.%26aulast%3DBlanch%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DC.%2BR.%26aulast%3DCormier%26aufirst%3DS.%2BA.%26aulast%3DDeVincenzo%26aufirst%3DJ.%2BP.%26atitle%3DProlonged%2520viral%2520replication%2520and%2520longitudinal%2520viral%2520dynamic%2520differences%2520among%2520respiratory%2520syncytial%2520virus%2520infected%2520infants%26jtitle%3DPediatr.%2520Res.%26date%3D2017%26volume%3D82%26spage%3D872%26epage%3D880%26doi%3D10.1038%2Fpr.2017.173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeVincenzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tait, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efthimiou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockerill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littler, E.</span></span> <span> </span><span class="NLM_article-title">A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">e01884</span>– <span class="NLM_lpage">19</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=31712214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktFygs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2020&pages=e01884-19&author=J.+DeVincenzoauthor=D.+Taitauthor=J.+Efthimiouauthor=J.+Moriauthor=Y.-I.+Kimauthor=E.+Thomasauthor=L.+Wilsonauthor=R.+Harlandauthor=N.+Mathewsauthor=S.+Cockerillauthor=K.+Powellauthor=E.+Littler&title=A+randomized%2C+placebo-controlled%2C+respiratory+syncytial+virus+human+challenge+study+of+the+antiviral+efficacy%2C+safety%2C+and+pharmacokinetics+of+RV521%2C+an+inhibitor+of+the+RSV-F+protein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein</span></div><div class="casAuthors">DeVincenzo, John; Tait, Dereck; Efthimiou, John; Mori, Julie; Kim, Young-In; Thomas, Elaine; Wilson, Lynn; Harland, Rachel; Mathews, Neil; Cockerill, Stuart; Powell, Kenneth; Littler, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e01884</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Effective treatments for respiratory syncytial virus (RSV) infection are lacking.  Here, we report a human proof-of-concept study for RV521, a small-mol. antiviral inhibitor of the RSV-F protein.  In this randomized, double-blind, placebo-controlled trial, healthy adults were challenged with RSV-A Memphis-37b.  After infection was confirmed (or 5 days after challenge virus inoculation), subjects received RV521 (350 mg or 200 mg) or placebo orally every 12 h for 5 days.  The primary endpoint was area under the curve (AUC) for viral load, as assessed by reverse transcriptase quant. PCR (RT-qPCR) of nasal wash samples.  The primary efficacy anal. set included subjects successfully infected with RSV who received ≥1 dose of study drug.  A total of 66 subjects were enrolled (n = 22 per group); 53 were included in the primary anal. set (RV521 350 mg: n = 16; 200 mg: n = 18; placebo: n = 19).  The mean AUC of RT-qPCR-assessed RSV viral load (log10 PFU equiv. [PFUe]/mL.h) was significantly lower with RV521 350 mg (185.26; std. error [SE], 31.17; P = 0.002) and 200 mg (224.35; SE, 37.60; P = 0.007) vs. placebo (501.39; SE, 86.57).  Disease severity improved with RV521 350 mg and 200 mg vs. placebo (P = 0.002 and P = 0.009, resp., for AUC total symptom score [score × hours]).  Daily nasal mucus wt. was significantly reduced (P = 0.010 and P = 0.038 for RV521 350 mg and 200 mg, resp., vs. placebo).  All treatment-emergent adverse events were grade 1 or 2.  No subjects discontinued due to adverse events.  There was no evidence of clin. significant viral resistance, and only three variants were detected.  RV521 effectively reduced RSV viral load and disease severity in humans and was well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeVsGp1QWwVrVg90H21EOLACvtfcHk0lg444MbtQb-qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktFygs7g%253D&md5=9e3b634f6cca773406727b57776eea0d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeVincenzo%26aufirst%3DJ.%26aulast%3DTait%26aufirst%3DD.%26aulast%3DEfthimiou%26aufirst%3DJ.%26aulast%3DMori%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.-I.%26aulast%3DThomas%26aufirst%3DE.%26aulast%3DWilson%26aufirst%3DL.%26aulast%3DHarland%26aufirst%3DR.%26aulast%3DMathews%26aufirst%3DN.%26aulast%3DCockerill%26aufirst%3DS.%26aulast%3DPowell%26aufirst%3DK.%26aulast%3DLittler%26aufirst%3DE.%26atitle%3DA%2520randomized%252C%2520placebo-controlled%252C%2520respiratory%2520syncytial%2520virus%2520human%2520challenge%2520study%2520of%2520the%2520antiviral%2520efficacy%252C%2520safety%252C%2520and%2520pharmacokinetics%2520of%2520RV521%252C%2520an%2520inhibitor%2520of%2520the%2520RSV-F%2520protein%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2020%26volume%3D64%26spage%3De01884%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KQD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KQD','PDB','7KQD'); return false;">PDB: 7KQD</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i45"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01882">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_88436"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01882?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01882</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular data strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_001.csv">CSV</a>)</p></li><li><p class="inline">Procedures for <i>in vitro</i> ADME assays, additional ADME data, metabolite identification data, virology data, crystallographic data, synthetic procedures, and characterization of all other compounds and key intermediates (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_001.csv">jm0c01882_si_001.csv (8.91 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01882/suppl_file/jm0c01882_si_002.pdf">jm0c01882_si_002.pdf (2.02 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01882&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01882%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01882" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67c7977d3a5e3dac","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
